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Abstract 
Extracellular membrane vesicles (EVs) are nano-scale cell lipid bilayer derived 
structures that have been described variously as apoptotic bodies (APs) (1µm - 5µm), 
microvesicles (MVs) (100nm - 1000nm) and exosomes (EXs) (40nm - 150nm). 
Previously, EVs were considered to be cell debris with little biological meaning. 
However, EVs are now believed to have significant biological function since they 
have been shown to contain functional molecules which they can deliver to target 
cells over some distance. Although knowledge of EV biogenesis and origin is 
limited, there are also significant knowledge gaps with regard to EV bio-molecular 
cargo, characterisation, and their capacity to alter the behaviour of recipient cells. Of 
interest to this author,  keratinocytes in 2D cultures were hypothesised to release 
three distinct populations of EVs which carry functional molecules (proteins and 
miRNAs). More importantly, it is possible that these EVs may influence the 
behaviour of recipient cells including dermal fibroblasts which have significant 
influence on wound healing processes.  
To address the above hypotheses, standard molecular and biochemical 
approaches and functional assays were applied. Isolation and characterisation of EVs 
were performed by a combination of differential ultracentrifugation and filtration, 
immunoblotting, electron microscopy and nanoparticle trafficking analysis. As 
expected three different EV populations including APs, MVs and EXs were able to 
be isolated from the conditioned media derived from keratinocytes in 2D cell culture. 
APs are the largest EV population, while MVs are smaller, and EXs are the smallest 
in size. The three different EV populations variously expressed the EV markers, 
HSP70, TSG101, AGO2, CD81, CD63 and CD9.  
In order to identify EV protein cargo, liquid chromatography tandem mass 
spectrometry (LC-MS/MS) measurement combined with database searching using 
the Paragon algorithm within ProteinPilot and Skyline software was utilised to 
generate and analyse peptide mass spectra. The analysis revealed and identified large 
numbers of proteins which varied in abundance and distribution across the three EV 
populations. Each EV population also contained their own subset of unique proteins 
in addition to a common protein cohort that was shared between the three EV 
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populations. Importantly, this study reports for the first time hundreds of novel 
exosomal proteins. Furthermore, bioinformatics analysis revealed that the EV 
proteins are associated with many biological processes and molecular functions (as 
determined by gene ontology enrichment analysis and Kyoto Encyclopedia of Genes 
and Genomes analysis), derived from various cellular components. Interestingly, 
there were a significant number of proteins associated with the extracellular matrix.  
With regard to the identification of EV miRNA cargo, miRNA Next-generation 
sequencing using the Illumia® Next Seq500 platform combined with the miRDeep2 
and the DESeq2 program package was used to identify and analyse the abundance 
levels of miRNAs in EVs. Similar to the protein analysis, numerous miRNAs were 
identified and expressed differently in the three EV populations. Strikingly, more 
than 150 exosomal miRNAs are reported for the first time herein. In addition, the 
most abundant EV miRNAs regulate many target genes encoding proteins involved 
in a range of biological processes. In addition, a number of these target genes are co-
regulated by several of the most abundant EV miRNAs. More in-depth 
bioinformatics data analysis also revealed that particular biological process terms 
which included ‘regulation’ was common to all EVs, while more specific terms such 
as: ‘cell death’; ‘cell cycle’; ‘regulation of transcription’; or molecular function terms 
such as  ‘transcription activities’ were more specific for individual EV populations.  
Importantly, molecular profile data from both proteins and miRNAs (EV cargo) were 
able to discriminate or distinguish EXs from APs and MVs. 
With the aim of investigating the potential function of keratinocyte-derived 
EVs, a scratch wound assay was utilised to evaluate the ability of EV-treated 
fibroblasts to elicit a migration response, while miRNA-21 abundance levels was 
examined in EV-treated fibroblasts by qRT-PCR. It was demonstrated that EVs 
released from primary keratinocytes promoted fibroblast migration, whereas EVs 
released from HaCaT did not promote fibroblast migration. Despite this difference in 
the capacity of HaCaT-derived EVs and primary keratinocyte-derived EVs to 
enhance dermal fibroblast migration, the EVs did not alter the abundance levels of 
miRNA-21 in treated primary dermal fibroblasts.  
To summarise, this PhD project has characterised and analysed the cargo of 
three EV populations from keratinocyte cultures for the first time. In addition, 
protein and miRNA signatures were analysed synchronously in all three EV 
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populations and compared to reveal the common and unique components of each EV 
population. Many EV molecules are associated with important biological events; and 
hundreds of exosomal proteins and miRNAs were reported for the first time herein. 
Furthermore, the keratinocyte-derived EV capacity for the promotion of fibroblast 
migration has been illustrated and this response seems to be associated with the 
cellular origin of EVs. Together, the outcomes of this project have significantly 
contributed to the body of knowledge surrounding EV biology especially with regard 
to keratinocyte-derived EVs and keratinocyte – fibroblast interaction via EVs. This 
information will have utility for future research directions in wound and skin 
biology. 
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1.1 INTRODUCTION 
Extracellular vesicles (EVs) are membrane-enclosed vesicles that are released 
into extracellular environments by various cell types, such as platelets, tumour cells, 
dendritic cells, epithelial cells, stem cells and neural cells under normal physiological 
or pathological conditions (Baietti et al., 2012; Fauré et al., 2006; Hao et al., 2006; 
Lee et al., 2011; Marzesco et al., 2005; Meister et al., 2005; Valadi et al., 2007; 
Vlassov et al., 2012). EVs have also been identified in body fluids such as breast 
milk, plasma, urine, amniotic fluids and saliva (Hao et al., 2006; Huang et al., 2013; 
Keller et al., 2007; Michael et al., 2010; Zonneveld et al., 2014). Although the 
classification of EVs is complicated and usually confusing, in general, EVs can be 
classified into 3 populations: apoptotic bodies (APs) which are products of apoptosis; 
microvesicles (MVs) which are shed directly from the cellular membrane; and, 
exosomes (EXs) which have endocytotic origins and are released by exocytosis 
(Akers et al., 2013; Muralidharan-Chari et al., 2010). The EVs consist of a 
phospholipid bilayer similar to a cell membrane and have diameters ranging from 40 
nm to 5 µm (Akers et al., 2013). During the formation and release process, EVs 
enclose a number of functional molecules, including DNA, small RNAs, proteins and 
lipids, derived from the cells of origin (Kalra et al., 2012; Lee et al., 2011; Rossella 
et al., 2013). According to Vesiclepedia (version 3.1 released 9/01/2015), the EV 
databases contain a catalogue of 82,987 proteins, 27,642 mRNA, 4934 miRNA and 
584 lipid entries from 538 independent studies in 33 species. Some individual 
biomolecules are common to most EVs, but different EV populations exhibit 
variation in their biomolecular composition (Rossella et al., 2013). Some proteins are 
unique for a particular population of vesicle and could be considered as markers of 
that EV population. For example, annexin V is a marker of apoptotic bodies and 
microvesicles (Akers et al., 2013; Bilyy et al., 2012). Similarly, transmembrane 
proteins of the tetraspanin family are known to be markers for exosomes (Smith et 
al., 2015). Moreover, the vesicle’s cargo largely depends on the parental cell type 
and physiological conditions. Microvesicles from tumors and neutrophils are 
enriched with metaloproteinases and other proteolytic enzymes that have functions in 
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the digestion of the extracellular matrix necessary for the progress of cancer growth 
and for inflammation (Dolo et al., 1998; Gasser et al., 2003). In addition to proteins, 
RNAs, including mRNA and microRNAs (miRNAs), have been found in EVs. 
Valadi et al. (2007) detected 121 miRNAs in exosomes released from mast cells, 
while Hunter et al. (2008) found 33 miRNAs in exosomes isolated from plasma 
(Hunter et al., 2008; Valadi et al., 2007). Recently, a diverse range of miRNAs was 
detected in all three EV populations (Ji et al., 2014; Lunavat et al., 2015). 
Interestingly, exosomes from body fluids such as human saliva, plasma and breast 
milk contain RNAs, but little or no ribosomal RNAs (18S and 28S) (Lasser et al., 
2011). Ribosomal RNA has also been detected in apoptotic bodies, in addition to 
exosomes, but these ribosomal RNAs were either very rarely detected in 
microvesicles or not detected at all (Rossella et al., 2013). In addition to proteins and 
RNAs, EVs also possess a characteristic lipid composition, which includes 
cholesterol, sphingomyelin, ceramide and phosphatidylserine, providing additional 
traits for identification (Février et al., 2004; Keller et al., 2006; Logozzi et al., 2009; 
Vlassov et al., 2012). Interestingly, the logical consequence arising from the specific 
combination of components present in EVs is that they are likely to have bioactivity. 
Although EVs contain functional molecules, how EVs affect cellular function 
is a critical question. Recently, the ability of EVs to facilitate cell-to-cell 
communication has been reported (Pegtel et al., 2014). Moreover, it is now thought 
that EVs represent a universal means for cells to interact with each other from a 
distance and alter the behaviour of target cells by exchanging materials and 
information (Ratajczak et al., 2006). Depending on the type of EV and the biological 
context, different mechanisms of interaction between EVs and target cells have been 
described, including ligand-receptor interactions, internalisation and direct 
membrane fusion (Smith et al., 2015). As a result, questions about the specific 
biological roles of EVs have been raised (Thery et al., 2002). Indeed, a number of 
studies have focused on the investigation of the role of EVs in cancer, immune 
responses and wound healing (Anna et al., 2001; De La Taille et al., 1999; 
Janowska‐Wieczorek et al., 2005; Li et al., 2006; Piccina et al., 2007; Shabbir et 
al., 2015; Wysoczynski et al., 2009; Zhuang et al., 2012).  
EVs are evidently associated with the wound healing process through the 
facilitation of cell differentiation, migration and angiogenesis (Cheng et al., 2008a; 
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Keerthikumar et al., 2015; Nazarenko et al., 2010). However, different EVs 
populations may not have the same level of influence on cell function due to 
differences in vesicle biomolecular cargo (Keerthikumar et al., 2015). Indeed, 
changes in the content of vesicles, especially protein and miRNA expression, in 
common disease states, could be either a mediator or a consequence of the disease 
and may reveal information regarding the physiological state or relative health of the 
cells of origin. Thus, when a change in the biomolecular cargo is a consequence of 
the disease state, the expression or abundance patterns of protein or miRNA might 
offer diagnostic information. Conversely, when a change in biomolecular cargo is 
associated with the facilitation of disease processes, inhibition or supplementation of 
specific protein and / or miRNA, may offers potentially novel therapeutic options. 
Taken together therefore, it is necessary to understand more completely how EV 
cargo may be exploited for diagnostic and / or therapeutic purposes. The following 
literature review will more deeply examine the scope of current EV research and 
knowledge of the biological effects of EV derived biomolecules, especially in the 
context of skin and wound healing, before summarising key knowledge gaps and 
outlining the aims of this project. 
 
1.2 OVERVIEW OF EXTRACELLULAR MEMBRANE VESICLES 
EVs are membrane-enclosed vesicles that are released by various cells under 
specific physiological conditions (Baietti et al., 2012; Hao et al., 2006; Lee et al., 
2011; Meister et al., 2005; Valadi et al., 2007; Vlassov et al., 2012). EVs have a 
phospholipid bilayer similar to the cell membrane with diameters ranging from 40 
nm to 5 µm. In general, EVs can be classified into 3 populations: apoptotic bodies 
(also known as apoptotic vesicles); microvesicles (also known as shedding vesicles); 
and, exosomes. 
 
1.2.1 Apoptotic bodies 
Apoptotic bodies (APs) are membrane-enclosed vesicles that have a 
heterogeneous morphology with a diameter range between 1 µm – 5 µm (György et 
al., 2011). Apoptotic bodies are released when cells undergo apoptosis and they often 
carry cytoplasmic biomolecules such as protein and RNA, and can contain organelles 
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and fragmented DNA derived from parental cells, as a result of nuclear 
fragmentation (Elmore, 2007). However, not all APs contain nuclear fragments 
(Elmore, 2007). 
Apoptotic or dying cells release APs into the extracellular environment through 
several stages. During the early and intermediate stages, the cell membrane 
undergoes contraction; the cytoplasm is condensed; and, the cells become smaller in 
size (Elmore, 2007). Simultaneously, nuclear chromatin condenses and the plasma 
membrane deteriorates such that its permeability increases in the late stage (Elmore, 
2007). As a result, the plasma membrane undergoes a process that is commonly 
known as blebbing (Kerr, 1972); and the cellular content is separated into distinct 
membrane enclosed vesicles known as APs (Kerr, 1972). APs, therefore, include 
cytoplasm but may or may not include tightly packed organelles or nuclear 
fragments. Interestingly, however, where organelles are included in the APs, the 
organelle integrity is maintained (Elmore, 2007). During the formation process, 
phosphatidylserine (PS) residues that are normally located on the internal surface of 
the plasma membrane, then translocate to the external surface. This process presents 
extracellular signals that attract macrophages to clear the apoptotic products via 
phagocytosis. A summary of the AP formation process is illustrated in Figure 1.1. 
 
Figure 1.1: Formation of apoptotic bodies and clearance by phagocytosis 
 
Formation of apoptotic bodies includes processes of condensation and segregation of 
nucleus, and deteriorates and blebing of the plasma membrane. The result of these 
processes is a separation of cellular contents into membrane-enclosed vesicles which 
can be cleared by phagocytic cells. 
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Necrosis, like apoptosis, is a major mechanism of cell death, which produces 
cellular debris and is initiated by diverse biological stimuli (Edinger et al., 2004; 
Elmore, 2007; Kerr, 1972). In contrast to apoptosis, which is programed cell death; 
necrosis is passive, uncontrolled and initiated by mechanical damage, or disease 
(Edinger et al., 2004). Cell necrosis is characterised by major morphological changes 
including: cell swelling; formation of cytoplasmic vacuoles and cytoplasmic blebs; 
enlarged endoplasmic reticulum; condensed, swollen or ruptured mitochondria; 
disaggregation and detachment of ribosomes; disrupted organelle membranes; 
swollen and ruptured lysosomes; and eventual disruption of the cell membrane 
(Elmore, 2007; Kerr, 1972). Unlike apoptosis in which the products are cleared 
locally by macrophages via phagocytosis (Kerr, 1972), necrosis may cause 
inflammatory responses through the release of cytosolic constituents directly into the 
extracellular space following damage to the plasma membrane (Proskuryakov et al., 
2003).  
 
1.2.2 Microvesicles 
Microvesicles (MVs) are large membranous vesicles with a diameter range of 
100 nm to 1 µm; are formed by the outward budding and fission of the plasma 
membrane; and arise from a wide variety of cell types (Kalra et al., 2012; Simpson et 
al., 2012b). Although there is still a limited understanding about the formation and 
shedding mechanisms at the cell surface, the formation of MVs may be a result of the 
dynamic interplay between phospholipid redistribution and cytoskeletal protein 
contraction (Akers et al., 2013). This process is regulated by several enzymes, such 
as calpain, flippase, floppase, scramblase, and gelsolin (Piccina et al., 2007). 
Flippases transfer phospholipids from the outer-membrane leaﬂet to the inner leaﬂet, 
while ﬂoppases transfer phospholipids from the inner-membrane leaﬂet to the outer 
leaﬂet (Clark, 2011). The translocation of phosphatidylserine to the outer-membrane 
leaﬂet is a signal that induces membrane budding / vesicle formation (Figure 1.2) 
(Akers et al., 2013). In addition, MV formation was associated with ADP-
ribosylation factor 6 (ARF6), which is a small GTPase protein that activates myosin 
light chain kinase (Muralidharan-Chari et al., 2010). The budding process is 
completed through the contraction of cytoskeletal structures via actin and myosin 
interactions (Akers et al., 2013). 
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Figure 1.2: Formation of microvesicles 
 
When floppase translocates phospholipid, especially phosphatidylserine, to the outer 
of cell membrane, flippase translocates others to the inner of cell membrane. These 
translocations induce the forming and budding microvesicles 
 
 
1.2.3 Exosomes 
Exosomes, which are the smallest class of EVs, have a diameter range between 
40 nm and 100 nm and exhibit a cup shaped morphology according to previous 
studies using electron microscopy (Théry et al., 2009).  
Although the mechanism of exosome biogenesis is not fully understood, it is 
accepted that exosomes have an endocytic origin, are formed and developed via the 
endosome system and are released to the extracellular environment through 
exocytosis (Raposo et al., 1996). The formation and release process begins when 
fluids, solutes, macromolecules, plasma components and particles are internalised by 
various endocytic trafficking pathways into transport vesicles (Harrison, 2014; 
Huotari et al., 2011). Once created these transport vesicles fuse with one another or 
with an existing sorting endosome to form larger ‘early endosomes’. During the 
following developmental stage sorting endosomes either: 1) accumulate proteins and 
other components for recycling back to the plasma membrane or degradation by 
lysosomes (Harrison, 2014; Thery et al., 2002); or 2) become multi-vesicular bodies 
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(MVBs) that carry and release exosomes when they fuse with the cellular membrane 
(Thery et al., 2002) (Figure 1.3). Although the exact mechanisms of exosome 
biogenesis and sorting components into exosome lumen are not fully understood, 
exosome formation and release are tightly regulated by multiple signalling 
mechanisms (Thery et al., 2002). For instance, it may require the involvement of the 
Endosomal Sorting Complexes Required for Transport (ESCRT) mechanism (Thery 
et al., 2002; Wang et al., 2012b). Moreover, the MVB endosome pathway and 
exosome formation and release are correlated with cellular background, activation 
and differentiation state and local environment (Harrison, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Exosome biogenesis  
 
Beginning from internalization of membrane proteins and lipid complexes by 
endocytosis, endocytotic vesicles are delivered to the early endosomes, which fuse 
with each other resulting in formation of multivesicular endosomes / multivesicular 
bodies (MVB). MVBs release exosomes by fusion with the cellular membrane, or 
their contents are degraded if they develop into lysosomes.  
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1.3 CELL-TO-CELL COMMUNICATION VIA EXTRACELLULAR 
VESICLES 
Cell-to-cell communication is a pivotal mechanism that enables the transfer of 
selected cellular components from one cell to another in multicellular organisms. The 
mechanism which facilitate cell-to-cell communication, which are very complex and 
involve intercellular and intracellular signals, are mediated by a number of cellular 
and extracellular structures including cell junctions, adhesion contacts and soluble 
factors (Camussi et al., 2010; Majka et al., 2001). Cells can form bridges to connect 
to and exchange surface-associated cargo with neighbouring cells based on direct 
adhesion mechanisms (Sherer et al., 2008). In addition, they can form tunnelling 
nanotubes or filopodia called cytonemes to contact and transfer both cell surface 
molecules and cytoplasmic components to other cells (Rustom et al., 2004; Sherer et 
al., 2008). In the last decade, EVs have been found to function as an additional 
means of communication because they carry functional molecules and can 
horizontally transfer these to neighbouring cells without direct cell to cell contact 
(Cocucci et al., 2009; Del Conde et al., 2005; Morelli et al., 2004).  
Once EVs were detected in the circulation and other body fluids or found in 
tissue microenvironments, EV mediated cell-to-cell communication was described as 
a way for cells to interact with neighbouring or other cells over long distances 
(Camussi et al., 2010). The binding of EVs to target cells is specific, for example: 
platelet-derived EVs have been found to bind to neutrophils (Lösche, 2004); 
neutrophil-derived EVs have been found to bind to dendritic cells (Eken et al., 2008), 
monocytes and endothelial cells (Gasser et al., 2003); and leukocyte-derived EVs 
have been found to bind to platelets (Pluskota et al., 2008). The interaction between 
EVs and target cells are thought to require the coordinated action of the recipient cell 
cytoskeleton and vesicle fusion machinery (Akers et al., 2013). Despite the limited 
understanding about EV transport, different mechanisms of interaction between EVs 
and recipient cells including ligand-receptor interactions, internalisation and direct 
membrane fusion have been studied in more detail (Figure 1.4).  
Examples of ligand-receptor interaction mechanisms have been studied in EVs 
released from dendritic cells, T-cells and platelets (Hoen et al., 2009; Janowska-
Wieczorek et al., 2001) (Figure 1.4 A). The dendritic cell-derived exosomes, which 
contain MHC class II and CD9 on their membrane, were found to bind to the surface 
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of activated T-cells (Hoen et al., 2009). This binding could be an interaction between 
MHC II molecules on exosome membranes and T-cell receptors on T-cell 
membranes (Hoen et al., 2009). Interestingly, the exosomes which bound to T-cells 
through this mechanism remained bound to the surface of the plasma membrane 
without fusing or were not internalised (Hoen et al., 2009). Similarly, microvesicles 
released from platelets and which contained CD41 antigen, were found to bind to the 
membrane of human bone marrow CD34+ cells and stimulate the adhesion of these 
cells to the endothelium. They also facilitated the direction of these CD34+ cells from 
the peripheral blood back to the bone marrow (Janowska-Wieczorek et al., 2001).  
With regard to the direct membrane fusion mechanism of cell-to-cell 
communication, Del Conde et al. (2005) illustrated that microvesicles fused directly 
with platelets and transferred their contents to the platelet membrane (Del Conde et 
al., 2005) (Figure 1.4 B). It seems that the fusion of EVs to the plasma membrane is 
also dependant on SNARE proteins, which regulate the fusion and target specificity 
in intracellular vesicle trafficking (Fader et al., 2009). Such direct membrane fusion 
transferred membrane components and receptors to recipient cells could lead to a 
change in recipient behaviour. For example, an increased risk of HIV infection 
together with resistance to apoptosis in case of macrophages receiving chemokine 
receptors was observed (Brühl et al., 2000). Additionally, enhancement of apoptosis 
was increased in the case of T lymphocytes receiving the Fas ligand (a death-receptor 
ligand) (Kim et al., 2005). 
Morelli et al. (2004) found evidence of the internalisation of circulating EVs 
into dendritic cells, phagocytes of spleen, and Kupffer cells in the liver via clathrin-
dependent endocytosis and in a calcium and temperature dependent manner (Morelli 
et al., 2004) (Figure 1.4 C). This internalisation of EVs by dendritic cells requires 
participation of the dendritic cell cytoskeleton as well as surface molecules such as 
externalised phosphatidylserine, CD11a, CD54, CD9 and CD81 (Morelli et al., 
2004). Additionally, cellular maturity also influences the internalisation ability of 
EVs by dendritic cells, since immature dendritic cells exhibited a higher endocytic 
capability than mature dendritic cells (Morelli et al., 2004). This internalisation of 
EVs carry allo-antigens (cell surface Ags) into dendritic cells could induce peripheral 
T-cell tolerance (Morelli et al., 2004), or internalisation of EVs into fibroblasts could 
stimulate cell proliferation and migration (Shabbir et al., 2015).  
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Figure 1.4: Interaction of EVs with target cells 
 
A) Ligand-receptor interactions which induce cell function via ligands on EV 
membrane; B) Direct membrane fusion which induces cell function via release of EV 
cargo into target cells; and C) Internalisation of EVs into target cells, then release of 
their cargo into the cytoplasm and induction of cell functional effects. 
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1.4 FUNCTIONAL COMPONENTS OF EXTRACELLULAR MEMBRANE 
VESICLES 
Proteins 
In general, all populations of mammalian EVs share common characteristics 
such as structure (lipid bi-layer) and common cargo such as protein, lipid or genetic 
material. However, these characteristics may be distinct depending on the manner of 
formation as well as the nature of their parental cells. Molecules which are unique to 
each vesicle population, can be used to distinguish between them. For example, 
annexin V is an apoptosis and MV marker, as it has high affinity to 
phosphatidylserine, which is externalised when cells are undergoing apoptosis 
(Akers et al., 2013; Bilyy et al., 2012). In another example, the tetraspanin family, 
which forms a complex network of interacting molecules that play a role in 
trafficking of transmembrane proteins (Berditchevski et al., 2007), including CD9, 
CD63, and CD81 are known as exosome markers since they are often involved in 
exosome biogenesis pathways (Escola et al., 1998; Keller et al., 2007; Smith et al., 
2015). Interestingly, CD24 could be considered as a marker of exosomes from urine, 
amniotic fluids, and cancer since it has been found to be over-expressed in ovarian, 
breast, non-small cell lung, prostate and pancreatic carcinomas; however, this protein 
is not involved in exosome formation and release (Keller et al., 2007; Kristiansen et 
al., 2004). In terms of other functional proteins, Dujarin et al. (2014) reported that 
Tau, a microtubule-associated, and matrix metalloproteinase (MMP) -1 (MMP-1) 
proteins, were enriched in MVs compared to exosomes (Dujardin et al., 2014; 
Keerthikumar et al., 2015). However, no studies have reported the enrichment level 
of Tau and MMP1 proteins in APs.  
Importantly, specific EV biomolecular cargo has previously been related to 
cancer and tumour development (Anna et al., 2001; Dolo et al., 1998; Gasser et al., 
2003). For example, APs, which contained DNA encoding the oncogenes H-rasV12 
and c-myc, derived from H-rasV12 and c-myc-transfected rat embryonic fibroblasts 
were found to induce tumour formation and growth in severe combined 
immunodeficient (SCID) mice (Anna et al., 2001). Furthermore, MVs carrying 
MMP-9 released from breast carcinoma cells, fibrosarcoma cells and 
polymorphonuclear leucocytes functioned in the digestion of the extracellular matrix, 
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necessary for the progress of cancer growth and inflammation (Dolo et al., 1998; 
Gasser et al., 2003).  
EVs have also been found to play a role in angiogenesis and coagulation 
processes (Del Conde et al., 2005; Heijnen et al., 1999; Taraboletti et al., 2002). For 
instance, endothelial cell-derived MVs, which are enriched with MMPs, including: 
MMP-1; MMP-2; and, MMP-9, could stimulate the invasion of human umbilical 
vein endothelial cells (HUVECs) through filters treated with a basement membrane 
Matrigel and the formation of capillary-like structures (Taraboletti et al., 2002). 
Indeed, MMPs have been identified as important mediators of angiogenesis 
(Giavazzi et al., 2001; Hidalgo et al., 2001), but exactly how the EV MMPs 
contribute to the angiogenic process has not yet been revealed. Interestingly, the 
level to which MMPs accumulated within MVs was shown to be stimulated by 
angiogenic factors, including, fibroblast growth factor (FGF) - 2 and vascular 
endothelial growth factor (VEGF) (Taraboletti et al., 2002). Moreover, EVs are also 
associated with coagulation since MVs originated from platelets and monocytes, 
which contained tissue factor (TF), were involved in the initiation of the coagulation 
process (Del Conde et al., 2005; Heijnen et al., 1999).  
EVs also seem to function in the regulation of immune responses since 
exosomes have been found to contain major histocompatibility complex (MHC) class 
I and II molecules and may transfer these molecules to dendritic cells (Blanchard et 
al., 2002; Hao et al., 2006; Wolfers et al., 2001). The transferral of MHC I molecules 
from melanoma cell line-derived exosomes to dendritic cells, triggered the 
production of IFN- γ in the dendritic cells (Wolfers et al., 2001). Furthermore, MHC 
I molecules carried by dendritic cell-derived exosomes could activate CD8+ T cell 
responses (Hao et al., 2006; Wolfers et al., 2001). These studies indicate that 
exosomes can potentially act as extracellular antigen sources, which could help to 
develop immune-interventions. In addition to having roles in the immune system, 
preliminary studies indicate that EVs also have important roles in the nervous 
system, however, the exact mechanisms mediating these EV functions in the nervous 
system is still an active area of research (Zappulli et al., 2016).  
Finally, cytoplasmic proteins, such as tubulin, actin, actin-binding proteins, 
annexins and Rab proteins, which are involved in intracellular membrane fusion and 
transport, and ESCRT machinery complex proteins are also found in exosomes 
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(Thery et al., 2001; Théry et al., 1999; Thery et al., 2002; Wang et al., 2012b). In 
addition, molecules responsible for signal transduction, such as protein kinases, 14-3-
3 and heterotrimeric G proteins, are enveloped during exosome formation and release 
(Bard et al., 2004; Thery et al., 2001; Thery et al., 2002; Wang et al., 2012a). Those 
EV-sorted components could be delivered to other cells and may have their function 
in recipient cells. Taken together these studies indicate that EVs and their cargo are 
functional and could influence recipient cell behaviour.  
Lipids 
Interestingly, EV lipid composition, which includes cholesterol, 
sphingomyelin, ceramide, phospholipids and glucans can be characteristic of 
exosomes from various origins and thus provide an additional means of identification 
(Batista et al., 2011; Laulagnier et al., 2004; Subra et al., 2007; Trajkovic et al., 
2008). Indeed, exosomes have been found to be enriched with higher amounts of 
cholesterol and sphingolipids, including sphingomyelin and hexosylceramide, 
compared to parent cell membrane (Trajkovic et al., 2008). In contrast, exosomes 
have been found to contain lower amounts of accumulated phosphatidylcholine, 
compared to parent cell membrane (Trajkovic et al., 2008). More importantly, the 
high enrichment of ceramide in exosomes raises the question of whether or not this 
lipid contributes to vesicle biogenesis. This was partly addressed by Trajkovic et al. 
(2008) where the authors showed that high concentrations of ceramide exist in the 
micro-domains where multi-vesicular endosomes are formed leading to a suggestion 
that ceramide can be useful for enlarging micro-domains, facilitating the inducement 
of domain budding (Trajkovic et al., 2008). Consequently, these studies indicate that 
lipids can partly regulate the formation and release of vesicles (Batista et al., 2011; 
Trajkovic et al., 2008). 
MicroRNAs (miRNAs) 
As mentioned somewhere, genetic material has also detected in EVs (Ji et al., 
2014; Lasser et al., 2011; Valadi et al., 2007). Interestingly, numbers of EV miRNAs 
have been increasingly identified and detected to have function in recipient cells 
(Hunter et al., 2008; Lunavat et al., 2015; Rossella et al., 2013). More details of EV 
miRNA are discussed in section 1.5.4. 
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1.5 MICRORNAS 
Of particular interest, RNAs (including mRNA and miRNAs) have also been 
found in EVs (Lasser et al., 2011; Rossella et al., 2013; Thery et al., 2002; Valadi et 
al., 2007). MicroRNAs (miRNAs) are small non-coding RNAs, generally 19-24 
nucleotides long, that have been shown to target mRNAs for cleavage or translational 
repression (Bartel, 2004). It is estimated that miRNAs regulate more than 60% of the 
translation of protein-coding genes (Esteller, 2011; Krol et al., 2010).  
 
1.5.1 Biogenesis and structure of miRNAs 
MiRNAs are processed from the introns of protein coding host genes under the 
activity of RNA polymerase II (RNA pol II). Initially, a primary-miRNA can be 
quite long, at more than 1 kb, but then a ∼ 60-70 nucleotide stem-loop is liberated to 
become a precursor-miRNA (pre-miRNA) (Lee et al., 2002). This truncation is 
performed by the Drosha RNase III endonuclease that cleaves the nucleotide chain at 
sites near the base of the primary stem loop (Gorenchtein et al., 2012). Pre-miRNAs 
are then exported to the cytoplasm via a complex between RAs-related Nuclear 
protein - Guanosine-5’-triphosphate (RAN-GTP) and Exportin 5. In the cytoplasm, 
the double-stranded portion of the pre-miRNA are recognised by the enzyme Dicer. 
Dicer has affinity for a 5’ phosphate and 3’ overhang at the base of the stem loop, 
which it then excises from the loop (Bartel, 2004). The resultant double-stranded 
miRNAs are next loaded into the RNA induced silencing complex (RISC) where one 
strand of miRNA duplex is peeled away and degraded. The remaining strand then 
regulates their target genes by inducing cleavage of mRNA or blocking its translation 
(Gorenchtein et al., 2012). A summary of miRNA biogenesis is illustrated in Figure 
1.5. 
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Figure 1.5: miRNA biogenesis and functions 
  
miRNAs are transcribed from DNA to form primary miRNA (pri-miRNA) by RNA 
polymerase II (Pol II). They are then converted to a precursor miRNA (pre-miRNA) 
before transportation to the cytoplasm by the GTP-dependent exportin-5 complex. 
Within the cytoplasm Dicer processes the pre-miRNA to become a double stranded 
miRNA. Following one miRNA strand is degraded and the complementary strand 
becomes mature miRNA. The mature miRNA and its complementary strand are then 
complexed with a RNA induced silencing complex (RISC), whereby individual 
miRNAs regulate mRNA stability (degradation) or translational (repression).  
 
 
1.5.2 Regulation of miRNAs 
There are several proposed regulatory mechanisms that describe the way 
miRNAs are guided to their target mRNAs, however, the exact mechanisms remain 
controversial (Bartel, 2009). However, it is accepted that miRNAs form partial 
duplexes with their targets through 3’UTR interactions (Bartel, 2009). Normally, this 
is facilitated by a pairing between nucleotides 2 and 7 at the 5’ end of the miRNA 
and the 3’ UTR of the target site (Pasquinelli, 2012; Rigoutsos, 2009). Pairing of a 
miRNA with its target site supports endonucleolytic cleavage of the mRNA by 
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Argonaute proteins, which are the main components of the miRNA-induced silencing 
complex (RISC) (Meister et al., 2004). Additionally, some other proteins have been 
shown to regulate the ability of the miRISC to bind or regulate specific targets, 
however, most of these proteins themselves are targets of miRNA regulation 
(Huntzinger, 2011). Thus, miRNAs can silence their target genes through facilitation 
of RNA degradation as well as translational repression pathways (Huntzinger, 2011) 
(Figure 1.5). Regulation of gene targets by miRNAs is subject to various levels of 
control, and gene targets can reciprocally control the level and function of miRNAs 
(Bartel, 2009).  
With a potential to recognise multiple mRNA targets by sequence 
complementarity and RNA-binding proteins, miRNA functions are becoming 
recognised in most biological processes. These include tissue proliferation, 
differentiation, apoptosis and development (Amaral et al., 2008). In concordance, 
evidence for miRNA involvement in the regulation of skin function and homeostasis 
has increased steadily (Banerjee et al., 2011; Sen et al., 2008; Shilo et al., 2007). 
 
1.5.3 miRNA function 
As pivotal regulators of cellular processes, such as proliferation, differentiation 
as well as development and cell death, miRNAs can, post-transcriptionally, regulate 
their target mRNAs depending on the level of miRNA abundance relative to the 
abundance of their target mRNA (Mercer et al., 2009). This has led to the association 
of various miRNAs with many human diseases including: cancer, cardiovascular 
disease, neurological dysfunction, and immune responses (Gorenchtein et al., 2012; 
O'Neill et al., 2011; Romaine et al., 2015; Zhou et al., 2011). Studies have shown 
that particular miRNAs (miR-181a and miR-155) have a role in immune regulation 
(Hao et al., 2006; Kosaka et al., 2010; Sen et al., 2008). For instance, miR-181 and 
miR-155, which are recognised stimulators of B cell differentiation (Chen et al., 
2004; Vigorito et al., 2007), were found to be enriched in human milk (Kosaka et al., 
2010). Interestingly, Kosaka et al. (2010) and Zhou et al. (2012) demonstrated that 
exosomal miRNAs from breast milk modulated the development of the infant 
immune system (Kosaka et al., 2010; Zhou et al., 2012). Furthermore, miRNAs in 
breast milk were stable even under strong acidic conditions (pH 1), suggesting that 
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these molecules could tolerate the infant gastrointestinal environment to then be 
absorbed across the intestine and influence the immune system (Kosaka et al., 2010).   
 
MiRNAs in wound healing 
As mentioned, miRNAs are thought to regulate more than 60% of the 
translation of protein-coding genes, and thus play an important role in many human 
diseases (Esteller, 2011), as well as skin development (Banerjee et al., 2011). Of 
particular interest to this author, it has been demonstrated that miRNAs are also 
important in the wound healing process (Sen et al., 2008) in that, specific miRNA 
expression was associated with different stages of the cutaneous wound healing 
process (Shilo et al., 2007).  
For instance, evidence has suggested that miRNAs are involved in 
angiogenesis during the inflammatory phase of the healing process, by affecting the 
migration, capillary sprouting and tubulogenesis of endothelial cells (Kuehbacher et 
al., 2007; Shilo et al., 2008; Suárez et al., 2007).  
With regard to the regulation of skin cell migration and proliferation, miR-205, 
miR-184 and miR-210 are all expressed during the proliferative phase of wound 
healing (Biswas et al., 2010; Yu et al., 2010; Yu et al., 2008). Specifically, miR-205 
repressed SHIP2 (SH2-containing phosphoinositide 5-phosphatase) leading to 
interfere ATK signalling pathways via SHIP2 induction, which then decreased 
remarkably keratinocyte apoptosis and promote keratinocyte migration (Yu et al., 
2010; Yu et al., 2008). In contrast, miR-184 antagonised the repression of SHIP2 by 
miRNA-205, possibly due to competition for the same set of complementary 
nucleotides in the binding site on the SHIP2 gene, and also repressed ATK 
expression (Yu et al., 2010; Yu et al., 2008). Interestingly, miR-210 is hypoxia 
sensitive and has been shown to profoundly affect keratinocyte migration and wound 
closure (Biswas et al., 2010; Pasquale et al., 2009).  
In terms of miRNA regulation of the remodelling phase of wound healing, 
miRNA-29a was demonstrated to be under the control of TGF-β, PDGF-B and IL-4 
and to regulate collagen expression in normal skin fibroblasts (Maurer et al., 2010).. 
Reportedly, several important proteins, such as COL (type I, III, IV and V); TGF-β; 
Smads; and, β-catenin, which are involved in the signalling pathways for healing, 
 18 Chapter 1: Literature review 
were repressed by miRNA-29b and miRNA-29c (Li et al., 2009; Rooij et al., 2008). 
Also of importance during remodelling, collagen 1α2 expression was enhanced by 
through the suppression of miRNA-192 to Smad-interacting protein 1 (SIP1) (Kato et 
al., 2007). While some miRNAs enhanced cutaneous wound healing, others such as 
miR-21 and miR-130a were reported to inhibit the wound healing process (Pastar et 
al., 2012). Taken together the results of these studies indicate that miRNA may 
mediate directly or indirectly wound healing processes through their target genes. 
Interestingly, miRNA have been detected in EVs which may suggest a new study 
strategy for miRNA investigation. 
 
1.5.4 miRNAs in EVs 
The discovery of miRNAs as regulators of gene expression has opened new 
options for the design of therapeutic agents that could modify gene expression in 
disease and biological processes. After Valadi et al. (2007) detected 121 miRNAs in 
exosomes released from mast cells (Valadi et al., 2007) and Hunter et al. (2008) 
detected 33 expressed miRNAs in exosomes isolated from blood (Hunter et al., 
2008), many other studies have also reported the detection of miRNAs in EVs 
(Goldie et al., 2014; Keller et al., 2011; Kosaka et al., 2010; Lasser et al., 2011; 
Lunavat et al., 2015; Mittelbrunn et al., 2011; Montecalvo et al., 2012; Taylor et al., 
2008; Wang et al., 2010). It was found that miRNAs carried by EVs (including 
exosomes, microvesicles and apoptotic bodies), secreted from different types of cells, 
were protected from degradation (Keller et al., 2011). It was also shown that EV 
miRNAs could be transferred between cells at a distance and are speculated to be 
involved in many exosome-mediated biological functions (Feliciano et al., 2014; 
Hunter et al., 2008; Keller et al., 2011; Montecalvo et al., 2012; Wang et al., 2010). 
The majority of miRNAs, which were identified in exosomes isolated from blood, 
regulated the cellular differentiation of blood cells and metabolic pathways (Hunter 
et al., 2008). In addition, T cell-derived exosomal miRNA were transferred to 
antigen-presenting cells at the immune synapse (Mittelbrunn et al., 2011). They are 
functional and alter gene expression in target cells (Mittelbrunn et al., 2011). 
Moreover, neuronal exosomal miRNA-124a was shown to regulate the expression 
level of astroglial GLT1, which is a glutamate transporter involved in extracellular 
glutamate concentration (Morel et al., 2013). Normally, miRNAs regulate the protein 
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expression by binding directly to target mRNA transcripts at 3’UTRs to mediate 
mRNA translation (Bartel, 2009). However, the miRNA-124a sequence was not 
matched directly with the mRNA-124a transcript and did not bind to the 3’UTR of 
any mRNA transcript (Morel et al., 2013). This indicated that miRNA-124a 
regulated the expression of GLT1 protein in an indirect manner. 
EV miRNAs were also suggested to be diagnostic biomarkers of cancers 
(Nilsson et al., 2009; Rabinowits et al., 2009; Taylor et al., 2008). For instance, 218 
miRNAs were identified in ovarian tumour cell-derived exosomes (Taylor et al., 
2008), only 8 of which, were expressed at the same level between cells and 
exosomes (Taylor et al., 2008). Specifically, the cancer-derived exosomal miRNAs 
could not be identified in non-cancer controls (Taylor et al., 2008) and suggests that 
exosome-derived miRNAs could act as potential diagnostic biomarkers of ovarian 
cancer (Taylor et al., 2008). Similarly, Rabinowits et al. (2009) reported the 
concentration of exosomal miRNA was 158.6 ng / ml in plasma from patients with 
lung adenocarcinoma versus 68.1 ng / ml in the control group without known lung 
cancer, suggesting exosomal miRNA might be useful as a screening test for lung 
adenocarcinoma (Rabinowits et al., 2009). Taken together, the above data suggests 
that EV miRNAs have a role as mediators of cell function, and biomarkers of 
disease. 
Because miRNAs are often functional and EVs have the ability to transfer 
these functional molecules to target cells, EV miRNAs could be developed to 
become a potential source of efficient diagnostic and disease-specific therapy 
(Gusachenko et al., 2013; Rana et al., 2013).  
 
1.6 THE ROLES OF EVS IN WOUND HEALING 
Wound healing is an essential process to restore the structure and function of 
damaged or injured tissues. For most tissues, the process requires multiple cell types 
from several distinct lineages where each responds to and generates different signals 
at different times (Singer et al., 1999). The wound healing process involves a series 
of overlapping phases including haemostasis, inflammation, migration and tissue 
remodelling (Guo et al., 2010). During these phases, a series of precise biological 
events occur including: coagulation; inflammation; cell migration into the wound 
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site, cell proliferation and differentiation to form granulation tissue; angiogenesis; 
and extracellular-matrix reorganisation (Singer et al., 1999). Initial evidence for the 
involvement of EVs in wound healing in vitro has been described for coagulation, 
cell proliferation, cell migration and angiogenesis (Cocucci et al., 2009; 
Keerthikumar et al., 2015; Moulin et al., 2010; Shabbir et al., 2015).  
 
1.6.1 Coagulation 
The blood clotting process is complex and regulated by coagulation factors 
such as calcium ions, phosphatidylserine (PS) and tissue factor (TF). TF is an 
initiator of coagulation activation that was found to be present on the plasma 
membrane of EVs (including microvesicles and exosomes) which were derived from 
cell types such as monocytes/macrophages and platelets and isolated from body fluid 
such as saliva (Biró et al., 2003; Del Conde et al., 2005; Sturk et al., 2011). Platelets, 
neutrophils and macrophages, the first cells to arrive in the wound site after tissues 
are damaged, help to stop bleeding and clean and sterilise the injured tissue (Koh et 
al., 2011). The control of coagulation processes by these inflammatory cells may be 
functioned through the release of EVs, such as platelet-derived microvesicles, which 
contain factor X and prothrombin and have procoagulation activity (Del Conde et al., 
2005). Similarly, monocyte-derived microvesicles are enriched with TF and P-
selectin glycoprotein ligand-1 (PSDL-1) and can bind, fuse and transfer their content 
to collagen-activated platelets (Del Conde et al., 2005). In an in vitro study, salivary 
EVs that contained TF significantly reduced the clotting time of human wound blood 
and this process was influenced by coagulation factor VII (Sturk et al., 2011). 
Similarly, EVs carrying TF from pericardial blood of cardiac surgery patients 
induced coagulation in vitro and stimulated thrombogenicity in rats (Biró et al., 
2003). Conversely, EVs from venous blood of healthy individuals also carrying TF 
did not reduce clotting time and were not influenced by coagulation factor VII (Biró 
et al., 2003; Del Conde et al., 2005; Sturk et al., 2011). This may be due to soluble 
inhibitors including Tissue Factor Pathway Inhibitor (TFPI) or conformational 
regulation of TF in plasma that impedes the binding of coagulation factor VII and 
inhibits its activity (Del Conde et al., 2005). Interestingly, the cellular origins of EVs 
in body fluids, which contain TF, are different. For instance, in saliva, EVs originate 
from various cell types such as epithelial cells and granulocytes (Sturk et al., 2011); 
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meanwhile, EVs, which are isolated from blood, largely originate from platelets, 
erythrocytes and granulocytes (Biró et al., 2003). 
Although EVs contribute to coagulation, the precise mechanism of this 
contribution remains unclear. Currently, there is no evidence to support EV-exposed 
phosphatidylserine (PS), and PS-carrying EV’s influence on coagulation. Moreover, 
few studies have investigated the role of EVs in haemostasis and other processes in 
the initial phases of the inflammatory response to wounding. 
 
1.6.2 Cell proliferation 
Cell proliferation, which is a pivotal cellular activity underpinning the wound 
healing process, has been shown to respond to EV treatment (Bhatwadekar et al., 
2009; Du et al., 2014; Jeong et al., 2014; Moulin et al., 2010; Shabbir et al., 2015; 
Zhang et al., 2015). For instance, EVs released from mesenchymal stem cells (MSC) 
greatly enhanced fibroblast cell proliferation (Du et al., 2014; Shabbir et al., 2015; 
van Koppen et al., 2012). This enhancement occurred through the internalisation of 
EVs into recipient fibroblasts and delivery of EV contents such as RNAs. MSC-
derived EVs induced hepatocyte growth factor (HGF) synthesis; HGF then bound to 
c-MET protein and phosphorylated two tyrosine residues at the C-terminus of MET, 
which subsequently resulted in the activation of the AKT and ERK1/2 effector 
pathway (Du et al., 2014). These activated pathways induced the expression of a 
number of genes involved in cell cycle progression such as c-myc, cyclin A1 and 
cyclin D2 and promoted the production of growth factors, including insulin-like 
growth factor-1 (IGF-1), stromal-derived growth factor-1 (SDF-1) and cytokine 
interleukin-6 (IL- 6) (Du et al., 2014; Shabbir et al., 2015).  
Apart from MSC-derived EVs, the ability of EVs derived from embryonic cells 
and myofibroblasts to improve proliferation of skin fibroblasts has been investigated 
previously (Du et al., 2014; Moulin et al., 2010; Zhang et al., 2015). Embryonic cell-
derived MVs enhanced cell viability and proliferation of skin fibroblasts in a dose-
dependent manner (Jeong et al., 2014). In accordance with the enhanced 
proliferation, the levels of gene and protein expression related to cell proliferation, 
including VEGF-α and TGF-β were promoted by treatment with EVs (Jeong et al., 
2014; Moulin et al., 2010). The mechanism by which embryonic cell-derived EVs 
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may facilitate fibroblast proliferation is speculated through the mitogen-activated 
protein kinase (MAPK) pathway, which controls cellular functions such as 
proliferation, differentiation, gene expression, mitosis, cell survival and apoptosis 
(Pearson et al., 2001). When EVs contact fibroblasts, EV membrane proteins trigger 
MAPK pathway signalling by inducing the phosphorylation of the activation loops of 
MAPK, leading to promotion of fibroblast proliferation (Jeong et al., 2014).  
Although it has been demonstrated that EVs play a role in cell proliferation 
through induction of the production of growth factors and activation of signalling 
pathways, detailed evidence is limited. While a few studies have been conducted into 
the role of EVs, released from MSCs, embryonic cells and myofibroblasts on 
fibroblast proliferation, no studies have reported on the effects of EVs on other cells 
involved in cutaneous wound healing such as keratinocytes. 
 
1.6.3 Cell migration 
After clotting, immune cells including neutrophils and macrophages are 
recruited to the wound site to remove necrotic tissues, debris, and bacteria from the 
wound. Concomitantly, other cells including epithelial cells and fibroblasts migrate 
into the wound site to perform specific tasks such as to induce the secretion of 
growth factors, synthesis of extracellular matrix, angiogenesis and wound closure 
(Singer et al., 1999). The involvement of EVs in the migration of epithelial cells and 
fibroblasts in vitro has been the subject of limited investigation (Cheng et al., 2008a; 
Zhang et al., 2015). 
The migration of endothelial cells, which are crucial for vascular repair and 
regeneration, has been shown to be influenced by EVs released from cells such as 
keratinocytes; MSCs; and other endothelial cells (Bhatwadekar et al., 2009; Leoni et 
al., 2015; van Koppen et al., 2012; Zhang et al., 2015). For instance, the expression 
of ICAM1 and VCAM1, which are involved in cell recruitment and adhesion (Sans 
et al., 1999), was also found to be increased in cells treated with apoptotic bodies 
derived from retinal micro-vascular endothelial cells (Bhatwadekar et al., 2009). An 
increase in the expression of these two proteins leads to a growth of endothelial 
progenitor cell recruitment and a promotion of the adhesion of these cells at the 
wound site (Bhatwadekar et al., 2009). In addition, embryonic MSC-derived 
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exosomes consistently enabled induction of human microvascular endothelial cell 
migration in a wound scratch assay and resulted in more rapid wound closure (van 
Koppen et al., 2012).  
Rapid epithelial cell migration to wound edge is necessary for re-establishing 
the integrity of the endothelium, reducing the healing time and limiting other 
damages from bleeding and contamination (Evans et al., 2013; Sturm et al., 2008). 
Interestingly, the migration of epithelial cells was enhanced by annexin-containing 
EVs (Leoni et al., 2015). Members of the annexin protein family, including annexin 
A1 (ANXA1) and annexin A5 (ANXA5), have been detected in EVs released from 
intestinal epithelial cells (Leoni et al., 2015). ANXA1 in epithelial cell-derived EVs 
was found to bind and activate formyl peptide receptors on the cell membrane of 
migrating epithelial cells and accelerate wound closure in a scratch wound model 
(Leoni et al., 2015). In contrast, ANXA5 in intestinal epithelial cell-derived EVs did 
not promote epithelial cell migration and wound closure (Leoni et al., 2015). This 
was possibly due to the formyl peptide receptors on the epithelial cell membranes not 
being the receptor for ANXA5; therefore EV ANXA5 could not influence the 
epithelial cell migration as the way EV ANXA1 did (Leoni et al., 2015).  
In wound healing, fibroblasts release growth factors, which induce other cells 
to proliferate and migrate, and produce collagen that provides structure to the wound 
(Gospodarowicz, 1991; Guo et al., 2010). Interestingly, the migration of fibroblasts 
toward the wound site has been found to involve EVs. Cheng et al. (2008) suggested 
that TGFα stimulates heat-shock protein (HSP)-90α (HSP90α) secretion from human 
keratinocytes via the exosome pathway. Most exosomes contain some HSP family 
members, such as HSP70 and HSP90 (Bard et al., 2004; Gastpar et al., 2005; Thery 
et al., 2002), which support folding of nascent peptides, prevent aggregation of 
proteins and assist the transportation of proteins across the cell membrane (Atalay et 
al., 2009). They can also induce cell motility (Gastpar et al., 2005; McCready et al., 
2010). When conditioned media of human keratinocyte cultures, containing 
exosomes with HSP90α cargo, was added into cell migration assays, it resulted in the 
rapid migration of dermal fibroblasts (Cheng et al., 2008a). HSP90α is comprised of 
4 domains, including an N-terminal domain, a charged sequence connected to the N-
terminal domain, a middle domain and a C-terminal domain (Pearl et al., 2000). It is 
thought that HSP90α may promote cell migration through binding interactions of its 
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middle and charged sequences with the cell surface receptor LRP-1/CD91 (Cheng et 
al., 2008a; McCready et al., 2010). In addition, HSP70, another member of the heat 
shock protein family, has also been shown to induce migration of natural killer cells 
(Gastpar et al., 2005). 
EVs seem to enhance cell migration in a dose-dependant manner. Exosomes, 
which were released from human induced pluripotent stem cells-derived MSCs, were 
applied to primary fibroblasts at 2 different concentrations with the higher dose 
stimulating a more rapid migration rate in a wound scratch assay (Zhang et al., 
2015). However, the disease state of cells may influence their migration capability in 
response to EVs in addition to the dose-dependency described above. For instance, 
MSC-derived exosomes enhanced the migration of both normal and diabetic 
fibroblasts to close a wound scratch in vitro (Shabbir et al., 2015). However, diabetic 
fibroblasts were more sensitive to MSC-derived exosomes, with migration and 
wound closure induced at low MSC-derived exosome concentration (1 µg / ml), 
while normal fibroblasts responded well to higher concentrations of MSCs-derived 
exosomes (10 µg / ml) (Shabbir et al., 2015).  
With regard to keratinocyte migration, which is responsible for wound re-
epithelialization, it can be inhibited or promoted by EVs released from different cell 
types. CoCl2-treated tumor cell-derived exosomes which contained C4.4A, Intergrin 
α6β4 and MMP14 inhibited keratinocyte migration through focalised laminin 332 
degradation resulting in a delay in wound closure (Ngora et al., 2012). Conversely, 
HSP90α-bearing exosomes released from keratinocyte culture significantly enhanced 
the migration of keratinocytes at a younger passage in a wound scratch (Cheng et al., 
2008b). 
 
1.6.4 Angiogenesis 
New blood vessel formation is critical for wound healing in order to supply 
nutrients and oxygen to newly formed tissues. The formation of new blood vessels 
requires the proliferation of endothelial cells and the interaction between endothelial 
cells, angiogenic factors (such as VEGF and FGF) and surrounding ECM proteins 
(Liekens et al., 2001). Under chemotaxis, endothelial cells penetrate the underlying 
vascular basement membrane, invade ECM stroma and form tube-like structures that 
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continue to extend, branch, and create networks (Hughes, 2008; Liekens et al., 
2001). Recently, EVs have been found to contribute to these events (Bhatwadekar et 
al., 2009; Hughes, 2008; Jeong et al., 2014; Shabbir et al., 2015; Zhang et al., 2015).  
All three populations of EVs (APs, MVs and exosomes) are thought to 
contribute to the regulation of vessel formation as they have been found to enhance 
the expression of VEGF (Bhatwadekar et al., 2009; Jeong et al., 2014). VEGF is a 
strong angiogenic factor that is involved in endothelial cell growth and vessel 
formation (Coultas et al., 2005), therefore, changes in the expression of this growth 
factor lead to changes in vessel formation in wound healing. 
In addition, MSC-derived EVs have been found to play a role in angiogenesis 
via some different mechanisms (Hughes, 2008; Zhang et al., 2015). Van Kopper et 
al. (2012) showed that following internalisation embryonic MSC-derived exosomes 
enhanced angiogenesis by promotion of endothelial cell migration towards wound 
sites (van Koppen et al., 2012). These internalised exosomes then enhanced the 
differentiation of endothelial cells to form a tubular network in a dose-dependent 
manner in vitro (Shabbir et al., 2015). MSC-exosomes increased the formation of 
new tubes and enhanced their maturation at wound sites in a rat model (Zhang et al., 
2015). 
Most studies focus on EV influence on the expression of growth factors (VEGF 
and FGF) and the recruitment of endothelial cells towards wounded sites. Since the 
growth of endothelial cells is critical for tube formation, any influence on these cells 
from EVs may influence the angiogenic process.  
 
1.7 KNOWLEDGE GAP AND HYPOTHESIS 
A review of the EV field as described above revealed that the functional role of 
EVs and their contents, including proteins and miRNAs, are poorly understood. A 
more complete understanding of these EVs associated with their origins in 
morphology, components and their contents may lead to novel therapeutic strategies 
and additionally allow the identification of biomarkers for applications in 
personalised medicine. Importantly, wound healing is a complex biological process 
where understanding, especially in the field of EV function, is lacking and may 
greatly benefit from research in this niche.  
 26 Chapter 1: Literature review 
Therefore, the hypothesis is that keratinocytes release three EV subpopulations, 
including APs, MVs and EXs, that differ in protein and miRNA content and possible 
function. Indeed, those EV components may be functional and involved in various 
biological events, especially in wound healing process.  
 
1.8 AIMS 
To address the hypotheses, the aims of this PhD project are: 
Aim 1: To isolate and morphologically and molecularly characterise EVs, 
including: apoptotic bodies; microvesicles; and exosomes derived from the 
conditioned media of HaCaT cell and human primary keratinocyte cultures.  
Aim 2: To characterise the EVs proteome and postulate potential EV protein 
mediated function using bioinformatics analysis of the identified proteins. 
Aim 3: To characterise the EV microRNA profile and postulate potential EV 
miRNA mediated function using bioinformatics analysis of EV miRNA target genes.  
Aim 4: To determine the functional affect of three keratinocyte-derived EV 
populations on fibroblast migration in vitro. 
 
1.9 SIGNIFICANCE OF THE PROJECT 
The results of this project contributes to the understanding of the biomolecular 
cargo of keratinocyte derived EVs, specifically the proteins and microRNAs, which 
are not fully understood. The results illustrate which components are common across 
each EV population and those that are specific to each EV sub-population. In 
addition, the project reveals a large number of exosomal proteins and miRNAs that 
are reported for the first time. 
Moreover, the results of the bioinformatics analysis of the biomolecular 
composition of each EV sub-population infer the involvement of EVs in cell 
migration and other important processes which, in the case of influence of cell 
migration, is supported by experimental data. Importantly, the data herein reveal 
epidermal keratinocyte-dermal fibroblast interactions via EVs, which has not yet 
revealed experimentally, that is critical to cutaneous wound healing studies.  
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Finally, this project, utilised and confirmed the methods of isolation and 
characterization of EVs from cell culture media, which are still under development. 
The data confirm that EVs are released from many different cell types, especially 
from skin cells in this project.  
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Chapter 2: Materials and methodology 
2.1 MATERIALS 
Primary keratinocytes and fibroblasts were isolated in the primary cell culture 
laboratories at the Institute of Health and Biomedical Innovation (IHBI) from 
discarded skin collected from informed and consenting adult patients undergoing 
elective cosmetic breast reduction (BRR) or abdominoplasty (ABDO) surgeries at 
the Brisbane Private Hospital, Princess Alexandra Hospital (PAH), or St Andrews 
Hospital. Patient (donor) samples were numbered according to the order in which 
they were collected. The individual sample numbers used for cell isolation for this 
project include: 288 (BRR), 289 (ABDO), 290 (BRR), 296 (BRR), 299 (ABDO), 300 
(ABDO), 304 (ABDO), 306 ((BRR), 307 (ABDO), 325 (ABDO), 361 (ABDO), 363 
(BRR), 366 (ABDO), 367 (BRR), 377 (ABDO), 378 (BRR), 386 (ABDO), 387 
(ABDO), 389 (ABDO) and 400 (BRR). Ethical approval for all skin collection and 
subsequent research detailed herein was obtained from: Queensland University of 
Technology (QUT) and the Pacific Day Surgery / Brisbane Private Hospital 
(approval # 1300000063/QUT); the PAH (approval # HREC/06/QPAH/91); and the 
United Health Care hospitals, St. Andrews Hospital & the Wesley Hospital (approval 
# 2003/46).  
HaCaT cells, an immortal human keratinocyte cell line commonly utilised for 
epidermal investigations, were ordered from Cell Lines Service (Eppenheim, 
Germany). NIH 3T3 fibroblast cells, originally derived from mouse embryos, were 
used as feeder cells for primary keratinocyte cultures in this study and were 
purchased from the ATCC. 
Primary antibodies against CD9 (ab92726), CD63 (ab8219), CD81 
(ab128202), HSP70 (ab47455), AGO2 (ab135025), and TSG101 (ab92726) in 
addition to the AnnexinV-FITC Apoptosis Detection Kit were purchased from 
Abcam® (Cambridge, UK). The HRP conjugated - chicken anti-rabbit IgG 
secondary antibody (HAP 008) was purchased from R&D Systems (Noble Park, 
Victoria, Australia). The Pierce™ BCA protein Assay Kit, Pierce™ Silver Stain Kit, 
Pierce™ ECL Western Blotting Substrate and Restore™ PLUS Western Blot 
Stripping Buffer were purchased from Thermo Scientific (Rockford, USA). The 
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miScript II RT kit including miScript Reverse Transcriptase Mix, 5X miScript 
Hispec Buffer and 10X miScript Nucleixs was purchased from QIAGEN (Maryland, 
USA). Similarly, oligonucleotide primers for mature miRNA (hsa-miR 205; hsa-miR 
146a; hsa-miR 29a; hsa-miR let 7b; hsa-miR 21; hsa-miR 141; hsa-miR 199a; and 
hsa-miR 203) were also purchased from QIAGEN (QIAGEN). SYBR Green® 
Master Mix was purchased from Applied Biosystems™ (Austin, TX, USA) and 
RNAse-free water was purchased from Invitrogen™ (Carlsbad, CA, USA). TrizolTM 
reagent was purchased from Thermo Fisher Scientific (Carlsbad, CA, USA). 
Isopropanol, MgCl2 and Glycogen azure solution were purchased from Sigma-
Aldrich (St Louis, MO, USA). 
Sequencing Grade Modified Trypsin was purchased from Promega (Madison, 
WI, USA). Ammonium bicarbonate, acetonitrile, formic acid, iodoacetamide, 
tetraethylammonium bromide were purchased from Sigma-Aldrich (Sydney, NSW, 
Australia). A TruSeq® Small RNA Library Preparation kit, including ligation buffer, 
stop solution, RNase inhibitor, RNA ligase, 10 mM ATP, 25 mM dNTP mix, PCR 
mix, high resolution ladder, custom RNA ladder, ultrapure water, RNA adapter and 
PCR primer, was purchased from Illumina (San Diego, CA, USA). Novex 6% TBE 
10 well gels were purchased from Invitrogen™ (Carlsbad, CA, USA). 
The reagents for cell culture including Phosphate Buffered Saline (PBS), 
Dulbecco's Modified Eagle Medium (DMEM), Foetal Bovine Serum (FCS), Trypsin 
0.05 %, trypsin 0.25 %, pen/strep, Ham’s F12, L-glutamine, Collagenase Type 1, 
non-essential amino acids, and human recombinant EGF were purchased from 
Gibco® by Life Technology (Melbourne, Victoria, Australia). Cholera toxin, Insulin, 
adenine, transferrin, triiodothronine, hydrocortisone, and dimethyl sulfoxide 
(DMSO) were purchased from Sigma (Sydney, NSW, Australia).  
The NuPAGE® LDS sample buffer 4x and SDS-PAGE 4-12 % polyacrylamide 
were purchased from Invitrogen - Life Technologies (Brisbane, QLD, Australia). 
Durapore® 5 µm / 1.2 µm / 0.1 µm pore membrane filters were purchased from 
Millipore Australia Pty (Bayswater, Victoria, Australia). MicroAmp® Fast optical 96 
well plates were purchased from Invitrogen (Invitrogen, Melbourne, Australia), and 
MicroAmp Optical Adhesive Film was purchased from Applied Biosystems 
(Melbourne, Victoria, Australia). Formvar-carbon coated grids were purchased from 
TED PELLA (Redding, CA, USA). Microcon-30kDa Centrifugal Filter Units were 
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purchased from Merck (Bayswater, Victoria, Australia). Polypropylene mass 
spectrometry vial inserts (250 µl) were purchased from Agilent Technologies 
(Melbourne, Victoria, Australia). Low-bind microtubes were purchased from 
Eppendorf AG (Hamburg, Germany). 
 
2.2 CELL CULTURES 
Extracellular vesicles (EVs) were harvested from HaCaT cells and primary 
keratinocyte cultures in vitro. The harvested EVs were used for the investigation of 
skin cell derived EV molecular biology and their functional effect on dermal 
fibroblast and keratinocyte migration in vitro. Mycoplasma infection was evaluated 
by PCR for HaCaT passage 47 in order to ensure that all cells which were expanded 
from the HaCaT passage 47 used for all experiments detailed in this study were not 
contaminated. The PCR reaction was performed twice with the following 
mycoplasma specific primers purchased from Sigma. 
1st forward primer: ACACCATGGGAGCTGGTAAT 
1st reverse primer: CTTCATCGACTTTCAGACCCA 
2nd forward primer: GTTCTTTGAAAACTGAAT 
2nd reverse primer: GCATCCACGAAAAACTCT  
The PCR reactions were performed in 4 steps: (1): 94 ºC for 5 minutes for 
initialisation; (2): 94 ºC for 30 seconds for denaturation; (3): 55 ºC for 1 minute for 
annealing; (4): 72 ºC for 1 minute for elongation (steps from 2 to 4 were run for 30 
cycles); and then the reaction was held at 4 ºC. Subsequently, 10 µL of the resulting 
PCR product was run on a 2 % agarose gel at 110 V for 25 minutes and examined. 
Gels were post-stained with Ethidium bromide and then examined under UV light. A 
band at 700 bp indicated that samples were positive with mycoplasma. And the 
HaCaT cells used for this project were negative with mycoplasma. 
 
2.2.1 HaCaT cultures 
Frozen HaCaT cells were removed from liquid nitrogen storage thawed and 
seeded at a concentration of 1 x 106 cells / T75 flask or 2 x 106 cells / T175 flask in 
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88 % DMEM, 10 % FCS, 1 % pen/strep and 1 % glutamine (HaCaT media) and 
incubated at 37 ºC and 5 % CO2 until 80 % confluent. The cells were then sub-
cultured up to passage 53 for use in EV production experiments, after which, the 
cultures were prepared for incubation in serum free media for generation of EV 
containing conditioned media as described in section 2.2.3 below.  
 
2.2.2 Primary keratinocyte culture 
Human epidermal primary keratinocytes were cultured according to the method 
described by Rheinwald and Green et al. (1975) and referred to as Full Green’s 
media (DMEM, Ham’s F12 (3 DMEM : 1 Ham’s F12), 10 % foetal calf serum, 2mM 
L-glutamine, 1 % v / v penicillin-streptomycin, 180 µM adenine, 0.5 µM insulin, 
0.05 µM cholera toxin, 0.01 % v / v non-essential amino acid solution, 2.5 µg 
transferrin, 0.1 µM triiodothyronine, 0.16 µg hydrocortisone and 0.05 ng human 
recombinant EGF) (Rheinwald et al., 1975). This keratinocyte culture method also 
incorporates the use of a fibroblast feeder layer. Thus, NIH 3T3 fibroblast cells, 
derived from mouse embryo tissue and purchased from ATCC, were seeded in T75 
or T175 cm2 cell culture flasks in 93 % DMEM, 5 % FCS, 1% v / v pen/strep and 2 
mM glutamine and cultured at 37 °C and 5 % CO2 until approximately 80 % 
confluent. Next, the 3T3 cells were harvested using 0.05% Trypsin-EDTA and then 
centrifuged at 1000 x g for 5 minutes. The 3T3 cell pellets were resuspended in a 
volume of new culture media to reach a desired concentration (1 – 2 x 106 cells / 
mL), and mitotically inactivated by exposure to 2 cycles of gamma-irradiation at 50 
Grays at the Australian Red Cross Blood Services (Brisbane, QLD, Australia). The 
irradiated 3T3 (i3T3) cells were centrifuged at 1000 x g for 5 minutes to remove 
media, and resuspended again in 10 % DMSO in FCS to final concentration of 2 x 
106 cells / mL and transferred to 1.5 mL ice cold cryo-tubes and subsequently frozen 
at -80 °C for 24 hours before storage in liquid nitrogen. As required frozen i3T3 were 
thawed and seeded at 1 x 106 cells / T75 tissue culture flask at least 2 hours prior to 
seeding with primary keratinocytes as described below. On occasion freshly 
irradiated 3T3 cells were seeded directly into T75 flasks in preparation for primary 
keratinocyte culture. 
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For primary keratinocyte isolation and culture, donor surgical discard skin 
collected from theatre was placed into containers containing PBS and transported to 
the tissue culture laboratories at IHBI. The skin was then transferred to fresh petri 
dishes with PBS, subsequently cut into small pieces (0.3 – 0.5 cm2) and transferred 
into a 50 mL falcon tube containing 0.125 % Trypsin-EDTA and incubated for 12 - 
24 h at 4 °C. The incubation was deemed to be complete when the epidermis could 
be peeled from the dermis. The skin (epidermis and dermis) was then washed in PBS 
and temporarily transferred into normal culture media containing 10 % FCS to 
negate the action of any residual trypsin. Keratinocytes were scraped from the 
underside of the epidermis and the upper surface of the de-epidermised dermis into 
normal culture media containing 10 % FCS, using a scalpel and the long part of a No 
22 blade. The harvested keratinocytes were then filtered using a 100 µm cell strainer 
(Greiner Bio-One, Frickenhausen, Germany) to remove tissue debris, concentrated 
by centrifugation at 300 x g for 5 min, resuspend as a single cell suspension in 1 mL 
of Full Green’s media and transferred to tissue culture flasks containing i3T3 cells 
and Full Green’s media (Xie et al., 2010a), and cultured at 37 ºC / 5 % CO2 with 
media changes every 2 days.  
Once the primary keratinocyte cells reached approximately 80 % confluent the 
i3T3 cells were removed using 0.05 % Trypsin-EDTA. Subsequent, incubation with 
a second addition of 0.05 % Trypsin-EDTA allowed the harvest of the primary 
keratinocyte cells from the culture flasks prior to, centrifugation at 1000 x g for 5 
minutes, resuspension and subculture to fresh flasks containing new i3T3 feeder cells 
prepared as described above.  
 
2.2.3 Preparation of keratinocyte EV conditioned media 
The expired media was removed from HaCaT cell cultures which were then 
subjected to a single wash with PBS and two washes with DMEM to remove dead 
cells and cellular debris. Next, the HaCaT cells were incubated in 10 mL (T75 flasks) 
or 20 mL serum-free media for 48 hours at 37 ºC and 5 % CO2 to allow for the 
release of EVs from the cells.  
The primary human keratinocytes were sub-cultured until passage 2, and 
allowed to reach approximately 80 % confluent before removal of the expired media 
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and washing with PBS. After removal of all PBS, the culture was incubated with 1 
mL of 0.05 % Trypsin-EDTA for approximately 2 minutes (T75 flask) to remove the 
i3T3 cells. The remaining keratinocyte cultures were then washed twice with fresh 
DMEM to remove any remaining i3T3 and other dead cells or cellular debris. 
Finally, 10 mL of serum-free Full Greens media was added to the keratinocyte 
cultures and incubated for 48 hours at 37 ºC and 5 % CO2 to allow for the release of 
EVs from the cells. 
After 48 hours of incubation, the CM, from either the HaCaT cell or primary 
keratinocyte cell cultures, containing EVs and any other secreted components was 
collected into fresh falcon tubes and centrifuged at 300 x g for 10 minutes to remove 
cells and cellular debris prior to proceeding with EV isolation (Chiba et al., 2012) or 
storage at 4 ºC for maximum of 4 days. 
 
2.2.4 Primary fibroblast isolation 
Following the collection of the primary human keratinocytes primary dermal 
fibroblasts were isolated from the de-epidermised dermis by mincing the dermis into 
small pieces in 1 mL of 0.05 % collagenase solution. The minced pieces were then 
transferred to a new petri dish and incubated in 9 mL of 0.05% collagenase solution 
at 37 °C for 24 hours. The following day, the collagenase solution containing the 
minced dermis was centrifuged at 300 x g for 10 minutes. The supernatant was 
discarded and the pellet resuspended in 1 mL fibroblast culture media (88 % DMEM, 
10 % FCS, 1 % pen/strep and 1 % glutamine) and transferred into a new culture flask 
already containing fibroblast culture media and allowed to incubate at 37 °C and 5 % 
CO2. After 24 hours of culture, the media containing unattached minced dermis was 
removed, and new fibroblast culture media was added to the flask and incubated at 
37 °C and 5 % CO2. The expired media was replaced every 2 days and sub-cultured, 
when they reached approximately 80% confluent. Briefly, the expired media was 
removed and the cells washed with PBS and harvested with using 0.05 % Trypsin-
EDTA. The released fibroblasts were collected into a fresh falcon tube and 
centrifuged at 1000 x g for 5 minutes. The supernatant was removed and cell pellet 
was resuspended in a volume of culture media and seeded into a new culture flask 
with cell concentration of 1 - 5 x 105 cells / 1 T75 flask. 
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2.3 EV ISOLATION 
A number of extracellular membrane vesicle (EV) isolation methods are 
available, which are typically chosen based on EV sources. For example, the method 
applied for isolation of EVs from plasma sources may be inappropriate to apply for 
EVs from urine or cell culture media. Size and density of the EVs are key factors that 
affect the choice of EV isolation method. Other than the size and density of EVs, the 
isolation efficiency can depend on: EV shape; solution viscosity; temperature; 
centrifugation time; and the type of rotor used for the centrifugation. Currently, 
differential centrifugation is the most widely utilised technique for EV isolation 
(Rossella et al., 2013; Théry et al., 2006). This approach was utilised to separate 
keratinocyte-derived EVs in this project. In addition, a series of filtering steps were 
added to the differential centrifugation protocol to reduce potential contamination 
from large vesicles in each subsequent centrifugation step. 
 
2.3.1 Differential ultracentrifugation 
Differential ultracentrifugation is a centrifugation approach that separates EVs 
based on their density and size distribution; whereas filtration is a step used to further 
remove contaminating EVs by size from smaller EV populations. Therefore, a 
sequential combination method involving filtration and differential 
ultracentrifugation-based protocols was applied in the separation of EVs (Heinemann 
et al., 2014; Hessvik et al., 2012; Keerthikumar et al., 2015; Rossella et al., 2013; 
Turiák et al., 2011). All centrifugation and filtration steps were performed at 4 °C 
and described in detail for each EV population below.  
 
2.3.1.1 Apoptotic body (AP) isolation 
Each CM sample, collected as described in section 2.2.3, containing the total 
EV population was gravity filtered through a Durapore® 5 µm membrane filter 
(Millipore) to remove intact cells, cell debris and particles greater than 5 µm. 
Afterwards, each CM sample was centrifuged at 3,000 x g for 40 minutes prior to 
removal of the supernatant for subsequent MV collection (below). The pellets 
containing APs were resuspended with PBS before re-centrifugation at 3,500 x g for 
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1 hour to harvest clean AP pellets (Rossella et al., 2013; Valadi et al., 2007). These 
clean AP pellets were subsequently resuspended in 100 µL PBS and stored at either -
20 ºC for 4 weeks or -80 ºC for longer time storage until required for further analysis. 
 
2.3.1.2 Microvesicle (MV) isolation 
The supernatants collected prior to the AP-harvest described above (section 
2.3.1.1) were gravity filtered through a Hydrophilic Nylon 1.2 µm membrane filter 
(Millipore). The filtrates were centrifuged at 16,500 x g for 1 hour at 4 ºC to harvest 
microvesicles (MVs) (Rossella et al., 2013; Valadi et al., 2007). The supernatants 
were collected in preparation for exosome harvest (below). The pellets containing the 
MVs were washed in PBS and then re-centrifuged at 16,500 x g for 1 hour at 4 ºC. 
The clean MV pellets were resuspended in 100 µL PBS and stored at -20 ºC for 4 
weeks or -80 ºC for longer time storage until required for further analysis. 
 
2.3.1.3 Exosome (EX) isolation 
The remaining supernatants collected prior to the MV - harvest described 
above in section 2.3.1.2 were gravity filtered through a Durapore® 0.1 µm 
membrane filter (Millipore). The resulting filtrates were centrifuged at 100,000 x g 
for 1.5 hours at 4 ºC in order to harvest exosomes (EXs) (Rossella et al., 2013; Théry 
et al., 2006; Valadi et al., 2007). Post-centrifugation the supernatant was collected 
into micro-tubes as a negative control of the post-EV collection. The resulting EX 
pellet was resuspended in PBS and re-centrifuged at 100,000 x g for 2 hours at 4 ºC. 
The clean EX pellets were resuspended in PBS and stored at -20 ºC for 4 weeks or -
80 ºC for longer term storage until required for further analysis. 
 
2.3.2 Sucrose gradient centrifugation 
Sucrose gradient centrifugation is a technique that enables the reduction of 
contaminants from EV preparations such as nonspecific exosomal proteins and larger 
protein aggregates, and was utilised in this study as an additional step to enhance the 
isolation of relatively pure populations of EXs. The protocol described by (Théry et 
al., 2006) was followed with little modification. Briefly, 4 mL of 30 % sucrose 
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solution was loaded into a centrifuge tube (Thinwall, ultra-clear, 14 x 95 mm, 
Beckman Coulter) prior to the addition of 6 mL of EX suspension (collected as 
described in section 2.3.1.3) to the top of the sucrose cushion and centrifuged at 
120,000 x g for 1.5 hours at 4 ºC. A 10 mL syringe fitted with a 19 gauge needle was 
used to collect 3.5 mL of sucrose cushion, from the side of the tube, containing the 
EXs which were transferred into a new centrifuge tube. The extracted EXs were 
diluted with 15 mL PBS and re-centrifuged at 120,000 x g for 2 hours at 4 ºC. 
Finally, the resulting EX pellets were resuspended with 50 µL of PBS and stored at -
20 ºC for 2 weeks or -80 ºC for longer periods prior to subsequent analysis. 
 
2.4 TOTAL PROTEIN EXTRACTION AND QUANTITATION 
A volume of vesicle suspension was mixed with the same volume of extract 
buffer (4 % SDS, 100 mM Tris / HCl pH 7.6) in a Protein Lo-Bind tube and 
incubated for 3 minutes at 95 ºC to disrupt the membrane structure. DNA was 
sheered by sonication for 5 minutes at room temperature. The mixture was 
centrifuged at 14,000 x g for 15 minutes at 4 ºC, prior to transfer of the supernatant 
into a fresh tube for further processing or storage at -20 ºC until required. The pellets 
containing vesicle debris and DNA were discarded. 
Total protein concentration was determined using the bicinchoninic acid 
(BCA) protein assay kit (Thermo Scientific™) according to the manufacturer’s 
instructions. Briefly, bovine serum albumin (BSA) standards, included in the kit, 
were diluted with MilliQ water into the desired concentrations (2000 µg / mL, 1500 
µg / mL, 1000 µg / mL, 750 µg / mL, 500 µg / mL, 250 µg / mL, 125 µg / mL, 25 µg 
/ mL and 0 µg / mL). A working solution was then prepared by mixing 50 parts of 
BCA Reagent A with 1 part of BCA Reagent B. After this, triplicate 25 µL aliquots 
of each standard or sample were transferred into individual wells of a 96 well 
microplate (NUNCTM, Roskilde, Denmark) prior to addition of 200 µL working 
solution into each well and incubation for 30 minutes at 37 ºC. The plate was then 
cooled at room temperature and the absorbance was measured at 562 nm on a 
Microplate Spectrophotometer (Benchmark Plus™, Bio Rad). A standard curve was 
used to determine the protein concentration of each sample. 
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2.5 SILVER STAIN 
For general protein visualisation, EV proteins were resolved by SDS-PAGE 
and stained using a Pierce® Silver Stain Kit (Thermo Scientific). Briefly, two 10 µl 
biological replicates of the exosomal protein preparations from each cell type were 
loaded into separate lanes of 4-12 % polyacrylamide SDS-PAGE gels (Invitrogen) 
and run at 200 V for 35 minutes at 4 ºC to separate proteins based on molecular 
weight. After protein separation, the gels were washed with MilliQ water twice for 5 
minutes per wash and then fixed with 30 % ethanol : 10 % acetic acid solution for 15 
minutes. The solution was then removed and the gels were fixed again with 30 % 
ethanol : 10 % acetic acid solution for another 15 minutes followed by 2 x 5 minute 
washes in 10 % ethanol solution and then 2 x 5 minute washes with MilliQ water. 
Subsequently, the gels were incubated with Sensitizer Working Solution (20 µL 
Silver Stain Sensitizer in 10 mL H2O) for 1 minute prior to 2 x 1 minute washes with 
H2O. Following removal of the sensitizer solution, the gels were incubated with 
silver stain working solution (200 µL Silver Stain Enhancer in 10 mL Silver Stain 
solution) for 30 minutes, and then washed with MilliQ water twice for 20 seconds 
each. The gels were the exposed to Developer Working Solution (200 µL Silver 
Stain Enhancer in 10 mL Silver Developer solution) and incubated until protein 
bands appeared (2 - 3 minutes). When desired resolution was reached, the reaction 
was stopped by adding a 5 % acetic acid solution. Finally, the gels were incubated 
with MilliQ water for 10 minutes before image capture using a BioRad – 
ChemidocTM XRS system (BioRad Universal Hood II, BioRad, USA); or scanning 
on a flatbed scanner (CanoScan 8600F, Cannon, USA).  
 
2.6 IMMUNOBLOTTING 
To detect EV biomarkers, an immunoblotting approach was utilised to detect 
the presence of six proteins known to be enriched in EVs, including HSP70, 
TSG101, AGO2, CD9, CD63 and CD81. Briefly, 20 µg of EV protein, 4.25 µL of 
LDS sample buffer 4x (NOVEX) and 1.7 µL of 1 M DTT were mixed and heated at 
70 °C for 15 minutes. CD9, CD63 and CD81 electrophoresis was conducted under 
non-reducing conditions since the reducing reagent (DTT) prevents the recognition 
of the relevant epitopes by the antibodies to these proteins. EV proteins were 
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separated on 4-12 % SDS-PAGE gels (Invitrogen) at 200 V for 35 minutes. The 
separated EV proteins were then transferred to a Pure Nitrocellulose Blotting 
Membrane (BioTrace™ NT, PALL Life Technology, Mexico) at 200 mA for 2 hours 
in chilled transfer buffer (Transfer Buffer: 25 mM Tris Base, 192 mM Glycine and 
20 % (v/v) Methanol). Next, the membrane was blocked with 5 % skim milk in Tris 
Buffered Saline / 0.01 % Tween (TBST) pH 7.4 for 30 minutes. The membrane was 
probed overnight at 4 °C with primary antibodies, against the specific target proteins, 
diluted in 0.5 % skim milk in TBST. The primary and secondary antibody working 
dilutions are detailed in the method section of chapter 3. The membranes were 
washed 5 times for 5 minutes per wash before incubation with an appropriate 
secondary antibody for 30 minutes at room temperature. The membranes were again 
washed 5 times for 5 minutes per wash and incubated with the ECL detection 
solution (Pierce™ ECL Western Blotting Substrate, Thermo Scientific) as per 
manufacturer’s instructions for 5 minutes. Images of the resulting blots were 
captured on Curix Ultra UV-G Medical X-ray film (along with fixer and developer 
reagents are designed for film developer equipment CP 1000 from AGFA) (AFGA; 
Mortsel, Belgium).  
Membranes that were to be subjected to the stripping protocol were stored at 4 
ºC until required.  
 
2.7 STRIPPING PROTOCOL 
Stripping, was used to remove primary and secondary antibodies from western 
blot membrane, in order to detect more than one target protein on the same 
membrane.   
The previously developed membranes were washed with TBST 5 times for 5 
minutes per wash at room temperature prior to being washed in Restore™ PLUS 
Western Blot Stripping Buffer (Thermo Scientific) for 15 minutes at room 
temperature with gentle shaking. Determination of the efficacy of the stripping wash 
was conducted by exposing the stripped membranes to Curix Ultra UV-G Medical 
X-ray film (AFGA; Mortsel, Belgum). The stripping protocol was deemed to have 
worked effectively if there was no signal captured on the film. The membranes were 
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then re-blocked with 5 % skim milk in TBST pH 7.4 for 30 minutes prior to being re-
probed with a different primary antibody as described above.  
 
2.8 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
Transmission electron microscopy (TEM) was used to analyse the individual 
morphology and morphological homogeneity of each EV population. In this regard, 
EV pellets were resuspended gently in PBS or frozen EVs were thawed and kept at 
room temperature. An equal volume of EVs solution was mixed with a volume of 4 
% paraformaldehyde, after which 5 µL of the fixed EV-containing suspension was 
deposited on Formvar-carbon coated grids (TED PELLA Inc., CA, USA) and 
allowed to stand for 20 minutes in a dry environment. The grids were then washed 
with PBS before incubating in 1 % glutaraldehyde for 5 minutes followed by 8 x 2 
minute washes in MilliQ water. Subsequently, the samples were stained with uranyl-
oxalate, pH 7 (4 % uranyl acetate (w / v), pH 4 in 0.15 M oxalic acid with ratio 1 : 1, 
pH adjustment using 25 %  NH4OH (w / v)) for 5 minutes at room temperature 
before being transferred to methyl cellulose-uranyl acetate (4 % uranyl acetate (w / 
v) , pH 4 in 2 % methyl cellulose (w / v), ratio 1 : 9, respectively) for 10 minutes on 
ice. At each step, the side of the grid, containing the adsorbed EVs, was kept wet, 
however the opposite side of the grid was kept dry. Finally, the grids were allowed to 
dry at room temperature (Tauro et al., 2012; Théry et al., 2006). Imaging was 
performed using a JEOL 1400 TEM for different magnification levels at 80 kV. 
 
2.9 CONFOCAL MICROSCOPY 
Confocal microscopy was utilised to detect fragmented DNA of APs, which 
could be used to separate APs from MVs. APs obtained from pellets following 
centrifugation (as detailed in section 2.3.1.1) were resuspended in 100 µL of 1 x 
binding buffer (Annexin V-FITC Apoptosis Detection Kit, Abcam) to make a vesicle 
suspension. Then 1 µL of Annexin V-FITC and 1 µL of PI (Propidium iodide) (50 
mg / mL) (AnnexinV-FITC Apoptosis Detection Kit, Abcam) were added to the 
vesicle suspension. The mixture was incubated in the dark for 5 minutes at room 
temperature. Approximately 5 µL of the AP suspension was applied to a glass slide 
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and covered with a coverslip prior to being sealed by clear nail polish. Stained 
vesicles were observed and photographed (60x objective) using a Confocal Leica 
TSC SP5 (Leica Microsystems, Germany) using a dual filter set for FITC and 
rhodamine (Hristov et al., 2004). 
 
2.10 NANOPARTICLE TRACKING ANALYSIS 
Nanoparticle Tracking Analysis (NTA) is an approach that can measure the 
size and calculate the concentration of particles in a liquid (Filipe et al., 2010; 
Gardiner et al., 2013; Jeppesen et al., 2014b). A volume of 50 µL of EX suspension 
(as described in part 2.3) was diluted into 450 µL of MilliQ water to make a total 
volume of 500 µL in a 1 mL Lobind tube (Eppendorf). The EX suspension then was 
loaded into the NanoSight NS500 sample chamber (Malvern, Worcestershire, UK) 
which was subsequently illuminated by a laser source. A control bead (100 nm) 
suspension was initially analysed in order to establish the size parameters for EX 
analysis. The EXs were tracked and analysed by a high-resolution camera and 
accompanying NTA 3.0 software. The parameters established were optimal for 
exosome analysis, specifically, a camera level setting of 5; the number of captures 
was set to 5; capture duration was set at 60 seconds; the screen gain of 1.0; and a 
detection threshold set to 10. The raw data was exported to an excel file and 
subsequently imported into GraphPad Prism 6 for further statistical analysis and 
graphing.  
Apoptotic bodies and microvesicles are large vesicles, which are not in the 
detection range of the NanoSight equipment, therefore APs and MVs were not 
analysed by this technique. 
 
2.11 PROTEIN ANALYSIS 
In order to analyse the protein composition of each EV sub-population from 
HaCaT and primary keratinocytes, a liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) proteomics based approach was utilised. 
 
 42 Chapter 2: Materials and methodology 
2.11.1 Sample preparation 
To analyse the proteome of different populations of EVs, equivalent volumes 
of vesicle suspension and extraction buffer (4 % SDS, 100 mM Tris / HCl pH 7.6) 
were mixed in a Protein LoBind tube (Eppendorf) and incubated for 3 minutes at 95 
ºC. The samples were then sonicated to disrupt the EV membrane structure and shear 
DNA thus reducing the viscosity of the sample. The mixture was centrifuged at 
14,000 x g for 15 minutes at 4 ºC, prior to transfer of the supernatant into a fresh tube 
for further processing or storage at -20 ºC until required. The pellets containing 
vesicle debris and DNA were discarded.   
The protein content of each sample was quantified using the Pierce™ BCA 
Protein Assay Kit (Thermo Fisher Scientific, USA) as described in section 2.4. 
 
2.11.2 Sample processing and peptide digestion 
The samples were processed and subjected to protein digestion using the Filter 
Aided Sample Preparation (FASP) method (Zougman et al., 2009). A volume of 30 
µL of protein extract (from section 2.11.1) was mixed with 200 µL 8 M urea (Chem-
Supply) in a microcon-30 kDa Centrifugal Filter Unit (Merck) in order to denature 
the proteins. The samples were then mixed by vortex and centrifuged at 14,000 x g 
for 15 minutes at room temperature. Next, disulphide bonds were reduced by the 
addition of 200 µL of 25 mM DTT (Sigma Aldrich), and 8 M urea to the filter unit 
followed by incubation at room temperature for 30 minutes before centrifugation at 
14,000 x g for 15 minutes. A volume of 100 µL of 50 mM iodoacetamide (Sigma 
Aldrich) in urea buffer, was added into the filter unit and incubated at room 
temperature for 15 minutes in order to alkylate the free sulfhydryl group on the 
exposed cysteine residues, prior to centrifugation at 14,000 x g for 15 minutes. The 
retained proteins were washed twice with 100 µL of 8 M urea, centrifuged at 14,000 
x g for 15 minutes and washed with 100 µL of 50 mM ammonium bicarbonate buffer 
(Sigma Aldrich) before centrifugation again at 14,000 x g for 15 minutes to remove 
the urea buffer. The retained proteins were then washed in 50 mM ammonium 
bicarbonate buffer and centrifuged at 14,000 x g for 15 minutes. The ammonium 
bicarbonate buffer flow-through was discarded prior to the addition of 40 µL of 
sequencing grade modified trypsin (Promega) (0.01 µg / mL in ammonium 
bicarbonate buffer) to the retained protein for digestion. The filter units were then 
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placed into an air-tight humidified container at 37 ºC and allowed to digest for 4 - 8 
hours (overnight). The following day, the insert portion of the filter units, containing 
the digested protein were transferred to new collection tubes and centrifuged at 
14000 x g for 15 minutes. An additional 10 µL of 0.1 % formic acid (Sigma Aldrich) 
was added into the filter unit and centrifuged at 14,000 x g for 15 minutes in order to 
wash the filter membrane. The tryptic peptides were captured in the fresh collection 
tubes and were subsequently subjected to a desalting protocol. 
 
2.11.3 Stop-and-go-extraction tips (StageTips) preparation 
To ensure high quality proteomic analysis by mass spectrometry, the retained 
tryptic peptides were concentrated and cleaned to remove contaminants using Stop-
and-go-extraction tips (Stage Tips) (Rappsilber et al., 2007). Ready-to-use StageTips 
were produced by members of our research team, Dr. James Broadbent and Dr. 
Daniel Broszczak, as follows. An Empore Octadecyl C18 47 mm diameter Extraction 
disk (66883U, Sigma) was placed in a sterile petri dish. A blunt-ended needle (18 
gauge) attached to a 1 mL syringe was used to produce a small plug of Empore 
Octadecyl C18, by gently pressing the blunt-ended needle completely through the 
disk. The Empore disk plug remained inside the cutter and was deposited into a 200 
µL pipette tip by depressing the syringe plunger, which forced the plug to the bottom 
of the tip. The cutter was removed and the tips containing the new Empore plugs 
(StageTips) were stored in a tip box.  
 
2.11.4 Tryptic peptide desalting using StageTips 
The hand-made C18 StageTips prepared as described above (2.11.3) were used 
to desalt, decontaminate and concentrate the tryptic peptides. Firstly, the plug was 
pre-wetted by addition of 20 µL of 100 % acetonitrile (ACN) (Sigma Aldrich) to the 
proximal end of the stage tip followed by gentle pressurisation of the tip with 
compressed air to force the ACN through the C18 plug. In order to equilibrate the 
disk, 20 µL of 0.1 % formic acid (Sigma Aldrich) was added into the proximal end of 
the StageTips and passed through the C18 plug with filtered compressed air as 
described above. Next, 50 µL of sample was loaded into the proximal end of the tip 
and passed through the plug with filtered compressed air as described above prior to 
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washing with 20 µL of 0.1 % formic acid in the same manner. Finally, the peptides 
were eluted from the plug, into a 250 µL polypropylene vial insert (Agilent 
Technologies, USA) within a fresh 1.5 mL LoBind Eppendorf tube (Eppendorf), by 
the addition of 20 µL of 80 % acetonitrile, 1 % formic acid to the proximal end of the 
stage tip, prior to pressurisation with filtered compressed air as described above. 
 
2.11.5 Final peptide concentration for LC-MS/MS  
The peptides within the eluate in the MS vial insert were concentrated using a 
vacuum centrifuge SpeedVac (Eppendorf Concentrator 5301, Eppendorf AG, 
Hamburg, Germany). The progress was checked every 15 minutes to ensure that 
almost all of the elution buffer had evaporated, but that the peptides were not 
completely dried. The peptides were then resuspended in 20 µL of 0.1 % formic acid, 
2 % acetonitrile and stored at 4 ºC for 1 day maximum prior to LC-MS/MS or stored 
at -20 ºC for longer storage times. 
 
2.11.6 LC-MS/MS and database search  
Tryptic peptides were analysed by LC-MS/MS using an ekspert nanoLC 400 
(Eksigent, CA, US) coupled to a Triple TOF5600+ mass spectrometer (SCIEX, CA, 
US) in standard injection mode (1µL autosample). After injection, the tryptic 
peptides were de-salted (5 µL for 5 minutes) in a trap column (particle size, 3 µm; 
diameter, 150 µm; length, 10 cm; Eksigent Technologies), then resolved on an 
analytical column (particle size, 3 µm; diameter, 150 µm; length, 10 cm; Eksigent 
Technologies) at total flow rate 0.3 µL / minute using the following gradient: 2 - 40 
% buffer B (80 % acetonitrile, 0.1 % formic acid) over 60 minutes; up to 65 % buffer 
B over 5 minutes; and up to 95 % buffer B over 5 minutes; the column was then 
flushed with 95 % buffer B for 10 minutes and finally re-equilibrated with 2 % buffer 
B for 10 minutes. MS/MS spectra were acquired under Data Dependent Acquisition 
(DDA) top-40 mode in rolling collision mode with a maximum accumulation time of 
50 milliseconds within the mass range of 100 – 2000 Da. All spectra were acquired 
in positive ion mode inclusive of charge states 2 - 5 with full scan MS spectra 
scanning from 350 Da – 1350 Da. Procedures of peptide sequencing were performed 
by Dr Pawel Sadoski and Dr Rajesh Gupta (CARF, QUT). 
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The mass spectral data were analysed with ProteinPilot software (SCIEX, CA, 
US) that uses the Paragon™ algorithm to perform protein identifications. All MS/MS 
spectra were searched against UniProt-Human-Reviewed database (accessed 
6/8/2015), which was appended with the common repository adventitious protein 
database. The parameters were set at: Sample type: Identification; Cys Alkylation: 
Iodoacetamide; Digestion: Trypsin; Instrument: TripleTOF5600; Species: Homo 
sapiens; ID focus: Biological modification and Amino acid substitutions; Search 
Effort: Thorough ID; Detected protein threshold: 0.05; Run FDR Analysis: yes. Only 
proteins identified with at least 95 % confidence and at least 2 peptides were 
reported. 
 
2.11.7 Combining data from different biological replicates 
Data–dependant acquisition (DDA) mass spectrometry experiments can often 
suffer from poor reproducibility due to the stochastic nature of precursor ion 
selection throughout LC-MS/MS analyses. In order to generate a protein list 
representative of the samples, three independent biological replicates were analysed 
by DDA mass spectrometry. Protein identifications from the three biological samples 
of parental cells or each individual EV population were analysed separately to 
determine the analytical concordance as shown using Venn diagrams. Data were also 
searched together to generate a comprehensive spectral library for quantitative 
analysis using Skyline software. This analysis was not limited to only the proteins 
common to all three biological samples. The reason for this is that the total list of 
proteins indicates the variance in identified proteins in different biological replicates 
(rather than technical variation) and as such this biological variance should be 
captured for consideration and further analysis. Finally, using a total list of proteins 
improved the sensitivity of protein significance analysis, reduced the required sample 
size, and improved the precision and accuracy of protein quantification (Clough et 
al., 2012).  
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2.11.8 Skyline MS1 Filtering  
In order to reveal different abundance levels of proteins in three EV 
population, peptide quantification was performed using Skyline software. In this 
regard raw MS/MS spectra, as well as the database search results generated by 
Proteins Pilot (section 2.11.6) were imported into Skyline software (64-bit, v3.1, 
release 16/3/2015, MacCoss Lab) to quantify peptide precursor MS1 signal. Skyline 
software is a freely available open source application for creating and analysing 
targeted proteomics experiments (https://skyline.gs.washington.edu) (Abbatiello et 
al., 2015). In general, a comprehensive spectral library was generated from the raw 
data containing MS/MS spectra. The resulting database was used to direct MS1 peak 
picking and integration and peak identification. Skyline will select a constant time 
interval to use for peak picking and ion intensity integration of peptide isotopes over 
the entire measured range. Step by step instructions for peak picking were followed 
using the online protocol published on Skyline website at:  
https://skyline.gs.washington.edu/labkey/webdav/home/software/Skyline/%40files/tu
torials/PeakPicking_2-5.pdf  
Skyline provides graphical tools to visually assess multiple precursors during 
MS1 filtering and then calculates the intensity of selected peaks and their multiple 
precursor isotopes.  
MS1 Filtering started with importing the database search results to generate a 
spectral library from the Import Peptide Search wizard. The results were then aligned 
with the UniProt-Human-Reviewed database (accessed 6/8/2015). Parameters were 
then set up for Transition Settings of Full Scan for MS1 filtering (Isotope peaks 
included: None) and MS/MS filtering (Acquisition method: None) before adding raw 
data files (WIFF files; peptide confidence cut-off score at 0.95). The Add 
Modifications tool was set up for ‘Oxidation (M)’ modifications. The Configure 
MS1 Full-Scan Settings was adjusted for Precursor charges field (at ‘2, 3, 4’), MS1 
Filtering (Isotope peaks included: Counts, Precursor mass analyzer: TOF, Peaks: 3 
which are M, M+1 and M+2, and Resolving power: 10,000), Retention time filtering 
(Use only scan within 5 minutes of MS/MS IDs). Skyline then added targets for all 
of the peptides from the FASTA file and imported the raw WIFF files to generate 
extracted ion chromatograms. The peak picking model within Skyline software was 
set up to refine the MS1 peak picking. Each peptide was then manually reviewed for 
 Chapter 2: Materials and methodology 47 
retention time and intensity and any mass error. After inspection of all peptides, 
peptide quantification data was exported as an Excel file. 
The resulting relative protein abundance data were compared between three EV 
populations and the statistical difference was analysed by one-way ANOVA using 
Statistical Analysis System program (SAS v9.3).  
 
2.11.9 Enrichment analysis using DAVID Bioinformatics Resources 
A list of the UniProt protein accession IDs for the identified proteins were 
uploaded into the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) Bioinformatics Resources 6.7 (https://david.ncifcrf.gov/home.jsp) and 
converted to DAVID IDs prior to enrichment analysis based on the whole Homo 
Sapiens genome background (Huang et al., 2009a; Huang et al., 2009b). The Gene 
Functional Classification Tool, Gene Ontology (Biological Process, Cellular 
Components, and Molecular Function), and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) were used to structurally and functionally classify the EV proteins 
identified. 
Analysis conditions of the Gene Functional Classification were performed 
using the following parameters: classification stringency set to medium; Kappa 
similarity overlap set to 4 and threshold set to 0.35; and classification threshold set to 
0.5. Gene Ontology (GO) analysis of identified EV proteins was performed for 
categories of Biological process (BP), Cellular component (CC) and Molecular 
function (MF) using FAT (BP_FAT, CC_FAT and MF_FAT) with a threshold count 
set to 2, EASE set to 0.1 and Benjamini-Hochberg for comparison correction. FAT 
(indicates the filter algorithm applied by DAVID) level was selected as this analysis 
provides very broad filtered-GO terms (specific GO terms are not overshadowed) 
compared to other level. The data were exported and graphed using GraphPad Prism 
6. Only GO terms with p-value < 0.05 were reported and accepted as significant. 
 
2.11.10 ExoCarta comparison  
Utilisation of the ExoCarta database, a manually curated database of exosomal 
proteins and their detection and isolation methods, provides an opportunity to detect 
the most frequent expression of exosomal markers, compare identified proteins and 
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reveal novel exosomal proteins in new studies (Simpson et al., 2012a). To reveal if 
there was a correlation between the identified exosomal proteins with previous 
studies, a comparison of the identified proteins reported herein with human proteins 
from the ExoCarta database (http://www.exocarta.org, released 29/07/2015) was 
performed. The ExoCarta database is comprised of human proteins which were 
detected by various methods, therefore many of the proteins listed were duplicated. 
Duplicate proteins were removed using Microsoft Excel to obtain a final database 
containing non-duplicated exosomal proteins. In addition, the entries within the 
database are curated using gene names, therefore the current list of 948 identified 
proteins from HaCaT-derived EXs were converted from UniProt-accession numbers 
to 751 gene names, and the list of 790 protein identifiers from primary keratinocyte-
derived EXs were converted successfully to 563 gene names, using the Retrieve/ID 
mapping tool from the UniProt website (http://www.uniprot.org). The lists of gene 
names were then used for comparison with the refined ExoCarta entries to reveal 
novel EX proteins using a Venn diagram program online 
(http://www.bioinformatics.lu/venn.php). 
The refinement process is summarised in Figure 2.1.  
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Figure 2.1: Summary of the refinement process to obtain a list of proteins from the 
ExoCarta protein database to allow comparison of ExoCarta protein database with 
identified exosomal proteins. 
 
2.12 MICRORNA ANALYSIS 
Quantitative real-time polymerase chain reaction (qRT-PCR) was used herein 
to compare the expression level of mature miRNAs among different populations of 
EVs. This approach has been used previously to determine changes in the expression 
level of mature miRNAs isolated from cells and cell culture media before and after 
treatment with EVs (Pritchard et al., 2012). Additionally, miRNA sequencing is a 
high throughput approach to detect the presence of large numbers of miRNA. Both 
qRT-PCR and miRNA sequencing were used to identify the presence and abundance 
of miRNAs in EVs in this chapter. 
 
2.12.1 Total RNA extraction 
Total RNA was extracted using the Trizol™ method following the 
manufacturer’s protocol (Chomczynski et al., 2006; Zhou et al., 2012). Trizol™ 
reagent (Thermo Fisher Scientific) was added to a 2 mL Eppendorf tube containing 
suspensions of whole cells, APs, MVs, EXs in a volume ratio of 9 : 1 (900 µL Trizol 
: 100 µL vesicles). The Trizol™-vesicle solution was triturated or vortexed to ensure 
Primary ExoCarta database 
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vesicle lysis. MgCl2 solution (Sigma) was added to each Trizol™ - vesicle mixture to 
a final concentration of 50 mM in order to stabilize RNA structures. For better 
precipitation yield, Glycogen Azure (Sigma) was added to the Trizol™-vesicle 
mixture to produce a final concentration of no more than 8 µg / mL in the final RNA 
solution prior to the addition of 180 µL of chloroform to the sample for every 900 µL 
of TrizolTM added. The mixture was vortexed vigorously for 10 seconds, and 
incubated at room temperature for 10 minutes prior to centrifugation at 12,000 x g 
for 5 minutes, and subsequent aspiration and transfer of the aqueous phase to a fresh 
2 mL eppendorf tube. Then, 0.9 mL of isopropanol for each 1 mL of original Trizol 
was added and samples were inverted 30 times each, incubated at RT for 10 minutes 
and then incubated at -20 °C for 1 hour (or overnight). Following incubation, the 
samples were centrifuged at 12,000 x g for 10 minutes at 4 °C. The resulting 
supernatants were aspirated being careful not to disturb the pellets. Then, 1 mL of 
RNAse-free 75 % ethanol was added to each sample and inverted to dislodge the 
RNA pellets and to wash the inner surface of the tube. The samples containing the 
dislodged pellets were centrifuged at 7,500 x g for 5 minutes at 4 °C and washed 
again with RNAse-free 75 % ethanol. Again the supernatants were removed and the 
RNA pellets were allowed to air dry. Finally, the RNA within the dried pellets was 
resuspended in 10 – 20 µL RNase-free water (Invitrogen) (depending on the size of 
the RNA pellets). 
 
2.12.2 Total RNA quantification and qualification 
Total RNA concentration was determined at A260 following application of 1.5 
µL of RNA suspension onto a Nanodrop® ND-1000 (Thermo Scientific) 
spectrometer. The A260 / A280 ratio was used to indicate the purity of samples with 
a ratio of above 1.8 being considered suitably pure.  
After vesicle-derived RNA had been quantified and evaluated for quality, RNA 
samples of appropriate quality were subjected to initial qRT-PCR experiments to 
confirm the presence of miRNAs prior to subjecting RNA to next generation 
sequencing. 
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2.12.3 cDNA synthesis 
Extracted total RNAs (described above) were used as template RNAs to 
prepare complementary deoxyribonucleic acid (cDNA) using miScript II RT kit 
(QIAGEN) following the manufacturer’s instructions. Briefly, template RNAs and 
miScript Reverse Transcriptase Mix were thawed and kept on ice. The 5x miScript 
Hispec Buffer, 10x miScript Nucleics Mix were thawed and kept at room 
temperature. All reagents and template RNA were mixed to create a 10 µL - half 
reaction (a full reaction is 20 µL). The 10 µL mixture of 2 µL 5x miScript Hispec 
Buffer, 1 µL 10x miScript Nucleics Mix, 1 µL miScript Reverse Transcriptase Mix 
and 6 µL template RNA were incubated in a Bio-Rad T100™ Thermal Cycler (Bio-
Rad) at 37 ºC for 1 hour, 95 ºC for 5 minutes and then 6 ºC to protect cDNA from 
degradation. 
 
2.12.4 Quantitative reverse transcription polymerase chain reaction 
The quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
has been used in order to validate the presence of miRNAs in cell derived EVs. 
Preliminary analysis by our research team revealed that miRNAs, including hsa-miR 
146a, hsa-miR 29a, hsa-miR let7b, hsa-miR 21, hsa-miR 141, and hsa-miR 203, had 
been identified in keratinocytes (Mr Dominic Guanzon, personal communication and 
(Than et al., 2015)). Therefore, they were used as candidate miRNAs in order to 
determine if these were possibly trafficked from keratinocytes to EVs.  
Initially, SYBR Green PCR Master Mix (Applied BiosystemTM), 10x miScript 
Universal Primer (QIAGEN), 10x miScript Primer Assay (QIAGEN) and RNAse-
free water (InvitrogenTM) were thawed and kept at room temperature. cDNA 
templates prepared as described above were thawed and kept on ice, prior to dilution 
with RNAse-free water to a final concentration of 0.67 ng / µL cDNA. The specific 
commercial primer sequences were designed for mature miRNA (post-
transcriptionally modified) sequences detailed in Table 2.1. 
All samples were prepared in triplicate in a reaction mix with a total volume of 
10 µL, where each well in a MicroAmp® Fast optical 96 well plate (Invitrogen) 
received 5 µL SYBR Green, 1 µL 10X miScript Universal Primer, 1 µL 10x miScript 
Primer Assay, 1.5 µL RNAse-free water and 1.5 µL cDNA template (1 ng of cDNA). 
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The plate was sealed tightly with a MicroAmp Optical Adhesive Film prior to 
centrifugation for 1 minute at 1,000 x g at room temperature. Subsequently, qRT-
PCR of samples was performed using an Applied Biosystems 7500 Fast Block 
(Applied Biosystems™) under the following conditions: holding stage (95 ºC for 15 
minutes); 3 step-cycling stage (94 °C denaturation for 15 seconds; 55 °C annealing 
for 30 seconds; 70 °C extension for 34 seconds); and melt curve stage (95 ºC for 15 
seconds, 60 ºC for 1 minute, 95 ºC for 30 seconds and 60 ºC for 15 seconds) and 40 
cycles. The condition was set up in a similar way for all genes. 
Table 2.1: Mature miRNA sequences of miRNAs of interest 
 
miRNA name miRNA sequence miScript Assay ID 
hsa-miR-203  5’GUGAAAUGUUUAGGACCACUAG MS00003766 
hsa-miR-29a 5’UAGCACCAUCUGAAAUCGGUUA MS00003262 
hsa-miR-141 5’UAACACUGUCUGGUAAAGAUGG  MS00003507 
hsa-miR21 5’UAGCUUAUCAGACUGAUGUUGA MS00009079 
hsa-let-7b 5’UGAGGUAGUAGGUUGUAUGGUU MS00003129 
hsa-146a 5’UGAGAACUGAAUUCCAUGGGUU MS00003535 
RNU6 (no information of the sequence from the 
company) 
MS00033740 
 
QIAGEN miScript II HiFlex Universal Primer (3’primer) and miScript assay sequence (5’ primer) are proprietary 
information. 
 
The qRT-PCR data was analysed for cycle threshold (Ct) values which are 
inversely proportional to the amount of nucleic acid that is in the sample (Dvinge et 
al., 2009). The lower Ct value indicates high amounts of targeted nucleic acid, while 
the higher Ct values indicates lower amounts of the target nucleic acid. 
 
2.12.5 Sequencing microRNAs using Illumina ® Next Seq500  
An RNA library was prepared using the Illumina®TruSeq®Small RNA 
Library Prep Kit as per the manufacturer’s instructions by Mr Dominic Guanzon. 
Firstly, 1 µL of RNA 3’ adapters were mixed with 5 µL of total RNA in a 200 µL 
eppendorf tube (Eppendorf) on ice to a total volume of 6 µL. Next, the tube was 
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incubated at 70 ºC for 2 minutes and then immediately placed on ice. To start the 
ligation reaction, 4 µL of reagent mix (2 µL Ligation Buffer, 1 µL RNase Inhibitor 
and 1 µL T4 RNA Ligase 2) was added into the reaction tube prior to incubation in a 
thermal cycler (BIO-RAD T100TM Thermal Cycler) at 28 ºC for 1 hour. Next, 1 µL 
of stop solution was added to the reaction tube prior to incubation at 28 ºC for a 
further 15 minutes. The reaction was subsequently placed on ice prior to the addition 
of 3 µL of RNA 5’ adapter mix (1 µL RNA 5’ adapter, 1 µL 10mM ATP and 1 µL 
T4 RNA Ligase), gentle mixing by trituration, incubation in a thermal cycler at 28 ºC 
for 1 hour and placement on ice. Reverse transcription was conducted by the addition 
of 1 µL of RNA RT primer to each 6 µL of 3’ and 5’ adapter-ligated total RNA prior 
to incubation at 70 ºC for 2 minutes. Next, 5.5 µL of reagent mix (2 µL 5X First 
Strand Buffer, 0.5 µL 12.5 mM dNTP, 1 µL 100 mM DTT, 1 µL RNase Inhibitor 
and 1 µL SuperScript II Reverse Transcriptase) was added and incubated at 50 ºC for 
1 hours to facilitate the  reverse transcription reaction. The resulting cDNA was 
amplified by PCR using primers designed to anneal to the ends of the adapters. A 
37.5 µL volume of PCR master mix (8.5 µL Ultra Pure Water, 25 µL PCR Mix, 2 µL 
RNA PCR Primer and 2 µL RNA PCR Primer Index) was added to the reaction tube 
and the PCR conditions were set as follows: thermal cycler lid was preheated to 100 
ºC; then the block was heated to 98 ºC for 30 seconds; 11 cycles of 98 ºC for 10 
seconds, 60 ºC for 30 seconds and 72 ºC for 15 seconds; 72 ºC for 10 minutes; and 
holding stage at 4 ºC. The amplified products from PCR from this stage are referred 
to as the small RNA library. Following the amplification step, the small RNA library 
was purified using gel electrophoresis by mixing a maximum of 50 µL of the small 
RNA library with 10 µL of Novex® Hi-Density TBE Sample Buffer and then 
loading into two lanes of a Novex 6 % TBE 10-well gel, flanked by custom RNA 
ladder (CRL) and high-resolution DNA ladder (HRL) (supplied with the Illumina 
TruSeq small RNA prep kit). The gel was run at 145 V for 60 minutes prior to 
staining with SYBR gold solution (1X concentration in 50 mL TBE running buffer) 
and subsequent visualisation in a UV transilluminator. The bands containing 
miRNAs between 145 bp and 160 bp were excised using a gel breaker tube and 
collected into a 1 mL LoBind eppendorf tube. The small RNA library was eluted in 
200 µL pure water by incubation overnight with shaking and then validated using a 
Bioanalyzer. The cDNA library was diluted to 2 nM using a solution of Tris – HCl 
10 nM, pH 8.5 and 0.1 % Tween 20 prior to loading onto an Illumina chip and 
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sequencing using an Illumina® Next Seq500. miRNA sequencing was performed by 
Ms Sahana Manoli using Illumina® Next Seq500, according to the manufactures 
protocol (Central Analytical Research Facility, Institute for Future Environments, 
QUT). 
 
2.12.6 miRNA identification and statistics 
The raw data generated from the Illumina® Next Seq500 were exported into a 
FASTQ file. Index and adaptor sequences were removed using the TagCleaner 
program (http://tagcleaner.sourceforge.net/index.html, version 0.16) and trimmed to 
28 nucleotides using the FASTX-Toolkit program 
(http://hannonlab.cshl.edu/fastx_toolkit/index.html, version 0.0.13) prior to 
submission of the cleaned nucleotide data to the miRDeep2 software for subsequent 
analysis. 
The miRDeep2 software is a specific tool used for the detection and discovery 
of known and novel miRNAs with high accuracy and time efficiency (Friedländer et 
al., 2012). The miRDeep2 program used for the miRNA identification in this study 
was version 2.0.0.7 (https://www.mdc-berlin.de/8551903/en/). The databases 
required for this analysis included the human genome (hg19) indexed by Bowtie 
(downloaded from http://bowtie-bio.sourceforge.net/index.shtml) and miRNA 
databases “mature.fa” and “hairpin.fa” (downloaded from 
http://www.mirbase.org/index.shtml). The human mature and hairpin miRNAs (from 
mature.fa and hairpin.fa databases) were extracted and the sequences were aligned to 
the humane genome using the mapper module in miRDeep2. Next the quantifier 
module in miRDeep2 was used to quantify miRNAs and finally generate a file which 
contained a summary of identified and quantified miRNAs for each sample. 
The identified miRNAs and their raw counts were further analysed using a 
DESeq2 software (version 1.10.1) for filtering, normalisation and to test the 
differential expression of miRNA levels using a negative binomial generalised linear 
model (Love et al., 2014). A Wald test was used to calculate statistical significance 
and was adjusted for multiple testing using the Benjamini and Hochberg procedure 
(Love et al., 2014). Results were considered statistically different where there was an 
adjusted p-value < 0.01 between groups. Graphs and heat maps were produced using 
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the online R statistical environment (R version 3.2.2, last update 14/8/2015) and 
gplots package (version 2.17.0) (R Development Core Team, 2011). These processes 
were performed with guidance from Mr. Dominic Guanzon (Tissue Repair and 
Regeneration (TRR) Program, Institute of Health and Biomedical Innovation 
(IHBI)). 
In order to examine the relative abundance levels of identified miRNAs in each 
EV population, the raw read counts were normalised using the Read Per Million 
(RPM) method (Mortazavi et al., 2008). The formula used to normalise the data is 
detailed as follows: 
 
 
 
 
 
 
 
2.12.7 Analysis of miRNA targets 
The miRbase ID for each of the five most abundant identified miRNAs was 
obtained from the miRBase website (www.mirbase.org). These were subsequently 
analysed using Cytoscape (version 3.2.1) to create an interaction network of the 
identified miRNAs and their target genes. The target database (version 6.0) was 
downloaded from the miRTarBase website (accessed 5/1/2016, 
http://mirtarbase.mbc.nctu.edu.tw). miRTarbase is an experimentally validated 
miRNA-target interaction database which was updated recently (released 15/9/2015 
for version 6). The data were exported as an image of the target gene-miRNA 
interaction network and as an excel file of target genes. A target gene list, was then 
used for the analysis of potential miRNA functional roles using the DAVID 
Bioinformatics Resources version 6.7 (https://david-d.ncifcrf.gov/) based on the 
whole Homo sapiens genome background (Huang et al., 2009a; Huang et al., 2009b). 
Gene Ontology (GO) analysis of the identified EV miRNA target genes was 
performed for Biological process (BP), Cellular component (CC) and Molecular 
Sum of total read counts (all miRNAs)  
1,000,000 
A = 
RPM  =    
A  
Raw counts of the miRNA of interest  
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function (MF) using FAT (BP_FAT, CC_FAT and MF_FAT) with a threshold count 
set to 2, EASE set to 0.1 and Benjamini-Hochberg for comparison correction. Only 
GO terms with a p-value < 0.05 were reported and accepted as significant. The 
resulting Gene Ontology and biological pathways were evaluated to reveal the 
potential functions of miRNAs, and therefore the potential biological influence of the 
relevant EV population. 
 
2.12.8 ExoCarta database comparison 
To determine if any of the detected exosomal miRNAs were unique and had 
not been previously reported, the lists of common and exosomal miRNAs were 
compared with the ExoCarta miRNA database. The miRNA database was 
downloaded from the ExoCarta website (exocarta.org, version 5, released on 29 July 
2015) which contained a total of 2766 miRNAs (Homo sapiens). Since not all of the 
miRNA names in the database contain the stem loop component of the full miRNA 
name, these were added manually following retrieval from the miRTarbase website 
through matching of the Entrez Gene ID with the miRNA name information. Next, 
the annotated miRNA list was sorted to remove duplicates (miRNAs detected by 
different methods) followed by removal of the lettered suffixes which indicate 5’ arm 
or 3’ arm of the precursor miRNAs in order to retrieve miRNA names for only 
mature sequences. This produced a final list of 926 miRNAs for the comparison. The 
empirical exosomal miRNA lists (with at least two counts) were used to search the 
DAVID database to obtain the Entrez Gene ID for each identified miRNA 
(https://david.ncifcrf.gov/). Similarly, exosomal miRNA names were then adjusted 
(removal of the lettered suffixes indicating 5’ arm or 3’ arm of the precursor 
miRNAs to retrieve miRNA name for only mature sequence) to the Entrez Gene ID 
to ensure compatibility with the ExoCarta database. A summary of the procedure is 
illustrated in figure 2.2. 
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Figure 2.2: Schematic representing the process of refining ExoCarta miRNA 
database and adjusting the name of the identified miRNAs to enable comparison with 
miRNAs within the ExoCarta miRNA database. 
Note: * denotes removal of -5p or -3p from miRNA names. 
 
2.13 MIGRATION ASSAY  
In order to investigate how EVs influence the migration ability of cells, a 
wound scratch migration assay using the IncuCyte™ system (Essen Bioscience) was 
employed. 
 
2.13.1 Media preparation 
The fibroblast culture media used for scratch assay cultures was comprised of 
similar components to normal fibroblast culture media (NM) which included 
DMEM, 10% FCS, 1% Pen/Strep and 1% L-glutamine. Since FCS may contain 
endogenous EVs which might influence cell function, 10 mL FCS was centrifuged in 
a centrifuge tube (Thinwall, ultra-clear, 14 x 95 mm, Beckman Coulter) at 120,000 x 
g for 24 h at 4 ºC to remove EVs (EV-free FCS) (Shelke et al., 2014). The EV-
Primary ExoCarta database 
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depleted media (DM) was prepared in a similar fashion to normal media, only using 
EV-free FCS. The culture media for wound scratch assays was prepared by the 
addition of keratinocyte-derived EVs to DM to a final concentration of 1 µg, 10 µg 
and 20 µg per 100 µL (as described in section 2.13.2). Prior to conducting the wound 
scratch assay, control analysis was performed to compare three types of media, 
including NM, DM and conditioned media (CM). CM was prepared from HaCaT or 
primary keratinocyte conditioned culture media that was collected after the final EX 
isolation described above in section 2.3.1.3. The CM served as the negative control 
for this optimisation experiment since its nutrients were previously used for 
keratinocyte cultures and EVs had already been isolated. 
 
2.13.2 Wound scratch  
Primary human dermal fibroblasts at passage 4 (patient number 300) were 
seeded in 96 well ImageLock plates (Essen BioScience) at 2.4 x 104 cells / well in 
order to establish a 100 % confluent culture. Cells were placed in the incubator at 5 
% CO2 and 37 ºC for 6 hours then treated with Mitomycin C (Sigma Aldrich) at 10 
µg in 50 µL NM / well to inhibit cell proliferation. After 2 hours, the media 
containing the Mitomycin C was discarded and the cells were washed with 2 x 100 
µL of fresh DMEM (GibcoTM). Next, 100 µL NM media was added into each well 
and the cells were incubated at 5 % CO2, 37 ºC for 10 - 12 hours before 
simultaneously creating a scratch wound in each well using a WoundMaker™ device 
(Essen Bioscience). 
Prior to creating the scratch wounds, the pins of the WoundMaker™ device 
(Essen Bioscience) were soaked in sterilised water (autoclave) for 5 minutes then 
sterilised in 70 % ethanol for 5 minutes. The WoundMaker™ device was then 
allowed to air dry prior to placement of the cell culture plate (with cells and media) 
into the WoundMaker™ device pocket. Subsequently, the cell culture plate cover 
was removed and the WoundMaker™ device was operated as per manufacturer’s 
instructions to create a wound in each culture. The cell culture plate is then removed 
from the WoundMaker™ device and the cell layers were washed twice with fresh 
DMEM to remove cellular debris. 
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After the wounds were created, triplicate wells were treated with EVs at 
protein concentrations of either 1 µg, 10 µg or 20 µg per well (in 100 mL DM). The 
protein concentration was calculated using BCA assay as described in section 2.4. 
Each assay was repeated with at least 3 biological repeats. For control experiments, 
following wound creation cells in triplicate control wells were cultured in DM. The 
DM was selected as the control media for testing the capacity of EVs to influence the 
migration of primary dermal fibroblasts. Subsequently, cells were incubated in the 
same conditions as EV treated-cell cultures (as described above). 
 
2.13.3 IncuCyte 
The 96 well plates with the wounded cell cultures were placed into an 
IncuCyte™ Zoom instrument (Essen Bioscience) to measure the wound-closure rate. 
Step by step setup of IncuCyte™ Zoom is described briefly below. Firstly, a “vessel” 
of the EV-treated cell culture plate was selected followed by selection of plate type 
(Essen Bioscience). Processing definition parameters were set at: ‘scratch wound’ for 
job type and ‘fibroblasts’ for cell type. At the ‘image collection” proper, the 
“required image channels” parameter was set the phases of Green up to 400 and Red 
up to 800. The images were then previewed and the background was set to 50 µm to 
remove all debris smaller than 50 µm. Next, “Blend Mode”, “Mask”, “Brightness” 
and “Contrast” were set to best view selected images (existing images selected as 
model for setting parameters) (depended on the operator). The scan mode was set at 
1 image / well at 2 hourly intervals for the 24 hours of the experiment. Analysis was 
launched on the selected vessels and observed over the 24 hour period under 
IncuCyte™ Zoom, and images were acquired and registered automatically by the 
IncuCyte™ software system. Processing definition parameters were saved and used 
for further experiments. The data was expressed as the Wound Relative Density and 
was exported to an excel file in order to calculate the wound-closure rate at particular 
time points during the experiment. Images and videos were also used to observe the 
cell migration process. 
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2.13.4 Analysis of relative wound closure using Imagej 
Due to the poor data quality, wound relative density measured by IncuCyteTM 
was exported to an excel file (in section 2.14.2), images of migrating fibroblasts were 
subjected to manual re-calculation of wound closure using ImageJ analysis. ImageJ 
(version 1.48, https://imagej.nih.gov/ij), a public domain Java-based image 
processing program developed by Wayne Rasband from National Institutes of Health 
(NIH, USA), was used to measure closed areas of wound scratches at different time 
points. Initially, individual images were opened in ImageJ, prior to conversion to a 
32-bit type image. The wound edges were identified by the ‘find edges’ tool. Next, 
an adjustment of threshold was necessary to clearly demarcate the wound area and 
area accommodated by cells. A ‘pen’ tool was then used to draw a frame that 
covered the wound area prior to using a wand tool to pick and export the wound area 
to an excel file.  For each cell culture, images of different time points at 0 hour, 6 
hours, 12 hours and 24 hours were measured. 
 
2.14 GRAPH AND STATISTICS  
Each experiment was conducted at least 3 times in order to obtain data from 3 
biological replicates (3 separate cell donors). Graphs and statistical analysis were 
performed with GraphPad Prism 6 version 6.00 for MacBook (GraphPad Software, 
La Jolla California USA, www.graphpad.com), the R Environment for Statistical 
Computing version 3.2.2 or Statistical Analysis System program version 9.3. The 
significance of the results were analysed using two tailed t-test, one-way ANOVA or 
two-way ANOVA. Statistical significance was accepted at a p-value of < 0.05. 
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Chapter 3: Characterisation of extracellular 
membrane vesicles 
3.1 INTRODUCTION 
Extracellular membrane vesicles (EVs) are secreted by various cell types, 
including both normal and cancer cells. In addition, these EVs have been found in 
body fluids such as breast milk, urine, amniotic fluids, plasma and saliva, as well as 
in cell culture media (Hao et al., 2006; Keller et al., 2007; Lasser et al., 2011; 
Michael et al., 2010; Than et al., 2015; Zonneveld et al., 2014). Typically, EVs are 
classified as apoptotic bodies (APs) (1000 – 5000 nm), microvesicles (MVs) (100 – 
1000 nm) or exosomes (EXs) (40 – 100 nm) (György et al., 2011). While APs are 
products of apoptosis, MVs and EXs are shed and released from cells during normal 
physiological conditions or diseases. During the formation and release process, EVs 
which are composed of a lipid bilayer similar in structure to a cell membrane, is 
furnished with components such as proteins, lipids, organelles and genetic materials 
(Lee et al., 2011; Rossella et al., 2013; Valadi et al., 2007).  
According to Vesiclepedia (version 3.1 released 9/01/2015), an EV database, 
there have been 82,987 proteins, 27,642 mRNAs, 4,934 miRNAs and 584 lipids 
described from 538 independent EV studies in 33 species. An EV’s specific cargo 
largely depends on their cell of origin and physiological conditions. Moreover, 
different populations of EVs exhibit a variety of compositions (Rossella et al., 2013), 
which could be unique to a particular population of EV and therefore could be 
considered to be markers of that EV population. For instance, annexin V protein is 
marker of APs and MVs, whereas, transmembrane proteins of the tetraspanin family 
(including CD9, CD63 and CD81) are markers of EXs (Escola et al., 1998; Keller et 
al., 2007; Smith et al., 2015). Additionally, CD24 is a marker of exosomes isolated 
from urine and amniotic fluids, especially cancer-derived exosomes, because this 
protein has been found to be over-expressed in many human carcinomas, including 
ovarian cancer, breast cancer, non-small cell lung cancer, prostate cancer and 
pancreatic cancer (Keller et al., 2007; Kristiansen et al., 2010). Furthermore, MVs 
released from tumours and neutrophils are enriched with metaloproteinases and other 
proteolytic enzymes that have functions in the digestion of the extracellular matrix, 
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which is necessary for the progress of inflammation and for cancer growth (Dolo et 
al., 1998; Gasser et al., 2003). Functional components, which are present in EVs, not 
only provide additional means of identification but also confer the vesicles with 
select bioactivity, and thus consequently they have emerged as potential candidates 
for biomedical studies. Indeed, the significance of EV biology may be in their 
capacity to shuttle functional molecules into and alter the behaviour of recipient 
cells. Recently, investigations have focused on EXs for their potential to mediate 
health and disease (Harrison, 2014). However, there is a lack of studies investigating 
MVs and APs and their potential biological roles. Indeed, current knowledge is 
focussed on three populations of EV biogenesis mechanisms, but there remains a 
limited understanding of their cargo and their traits for characterisation. Importantly, 
due to the EV study area are young and being developed, there is no individual 
standard method to isolate and characterise EVs and as a consequence it is very 
difficult to classify subclasses of EVs due to the overlap of size and the lack of 
reliable protein markers. With this limited understanding of the characteristics of 
each EV population, it is difficult to further investigate EV function.  
Keratinocytes are the major cell type of stratified epithelia and spatially occupy 
the most basal to the most superficial layers of the epidermis. In skin, keratinocytes 
serve as barrier between an organism’s interior and the external environment. The 
major functions of the skin are to: prevent the loss of moisture and heat; stimulate 
inflammation in response to injury; provide a water resistant barrier to abrasive 
injury and defence against pathogen invasion (Di Meglio et al., 2009; Raghavan et 
al., 2002). Keratinocytes also secret growth factors and cytokines to attract other cell 
types into wounded areas (Armour et al., 2007; Gauglitz et al., 2012). Importantly, 
there has not been any study of potential EVs, which may carry functional molecules, 
released from keratinocytes. Thus the hypothesis for this study was that keratinocyte 
cultures release all three EV populations, and each EV population will express a 
different suite of physical and biochemical characteristics. Therefore, in order to 
address this hypothesis this study aimed to firstly, isolate APs, MVs and EXs, 
released from keratinocyte cultures in vitro using traditional isolation methods with 
minor modification; and secondly to characterise EVs via analysis of size distribution 
and cellular membrane and intracellular biomarkers.  
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3.2 METHODS 
The following is a brief summary of the materials and methods used to 
generate data for this chapter. Full details of materials and methods are described in 
Chapter 2 (cell cultures and EV production in sections 2.2.1, 2.2.2, 2.2.4, and 2.2.5; 
EV isolation in section 2.3; protein distribution analysis in section 2.4; EV 
characterisation in sections 2.6, 2.7, 2.8, 2.9, and 2.10). 
 
3.2.1  Materials 
HaCaT cells subcultured for this study were utilised in experiments at passages 
49 to 53 as independent replicates. 
Primary epidermal keratinocytes were isolated from discarded skin collected 
from adult patients undergoing elective cosmetic breast reduction or abdominoplasty 
surgeries. Primary keratinocytes were isolated from different donor skin samples for 
individual experiments, including donor numbers: 288, 296, 300, 306, 325, 361, 363, 
364, and 366. Information related to each patient is also detailed in each 
experimental result.  
Reagents used for procedures in this chapter are detailed in section 2.1 of 
chapter 2. 
 
3.2.2  HaCaT cell culture 
Initially, HaCaT cells were expanded in 88 % DMEM, 10 % FCS, 1 % 
pen/strep and 1 % glutamine (HaCaT media) at 37 °C and 5 % CO2. Following sub-
culture for several passages a stock of cells were prepared. The HaCaT cells, which 
are at passage 49 to 53, were seeded at a concentration of 1 x 106 cells / T75 flask or 
2 x 106 cells / T175 flask in HaCaT media and incubated at 37 ºC / 5 % CO2 until 80 
% confluent. Subsequently, HaCaT cultures were incubated in serum-free media for 
EV production (as detailed in Section 2.2.3 and outlined in Section 3.2.4 below). 
 
3.2.3 Primary keratinocyte culture 
Human epidermal primary keratinocytes were cultured using the method 
described by Rheinwald and Green et al. (1975) (called Full Green’s media including 
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DMEM, Ham’s F12 (3 DMEM : 1 Ham’s F12), 10 % fetal calf serum, 2mM L-
glutamine, 1 % v / v penicillin-streptomycin, 180 µM adenine, 0.5 µM insulin, 0.05 
µM cholera toxin, 0.01 % v / v non-essential amino acids solutions, 2.5 µg 
transferrin, 0.1 µM triiodothyronine, 0.16 µg hydrocortisone and 0.05 ng human 
recombinant EGF) (Rheinwald et al., 1975). Initially, epidermal keratinocytes were 
isolated from donor skin (as detailed in section 2.2.2) and cultured at 37 ºC / 5 % 
CO2 with i3T3 feeder cells (as detailed in section 2.2.4). The media was changed 
every 2 days until the cultures were 80 % confluent prior to the removal of i3T3 cells 
using 0.05 % Trypsin-EDTA. A subsequent incubation in 0.05 % Trypsin-EDTA 
was performed to de-attach the primary cells from the culture flask. The detached 
cells were transferred to new falcon tubes and centrifuged at 1000 x g for 5 minutes. 
The primary human keratinocytes were sub-cultured until passage 2 prior to 
incubation in serum-free culture media. The serum-free culture media includes all the 
components of full Green’s media, but no FCS (Full details of serum-free culture 
conditions are described in section 2.2.5) (Lässer et al., 2012). 
 
3.2.4 EV production 
The expired media was removed from HaCaT cells prior to washing twice with 
fresh DMEM. Next, serum-free media (10 mL for T75 flask and 20 mL for T175 
flask) was added to each culture flask and incubated for 48 hours at 37 ºC and 5 % 
CO2 to allow for the release of EVs from the cells. 
For primary keratinocytes, the expired Full Green’s media was removed from 
cultures prior to washing one time the cells with PBS (Figure 3.1 A). After removal 
of all PBS, the culture was incubated with 1 mL of 0.05 % Trypsin-EDTA (T75 
flask) to remove the i3T3 (Figure 3.1 B). The cells then were washed twice with 
fresh DMEM to remove dead cells, cell debris and any remaining i3T3s. Finally, 10 
mL of serum-free media was added to each T75 cell culture flask prior to incubation 
at for 48 hours at 37 ºC, 5 % CO2 for the EV release from cells. 
After 48 hours incubation (Figure 3.1 C), the CM (serum-free culture media 
containing EVs released from cells) from HaCaT and primary keratinocyte cultures 
were collected into falcon tubes and centrifuged at 300 x g / 10 minutes to remove 
cells and cell debris prior to proceeding with EV isolation (Chiba et al., 2012) or 
storage at 4 ºC for a maximum of 4 days. 
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Figure 3.1: Examples of epidermal primary keratinocytes in 2D cultures 
  
A) Cells reached approximately 80 % confluence. B) Removal of i3T3 (feeder layer) 
before subjecting cells to serum-free media. C) Cells after 48 hours of incubation 
with serum-free media to release EVs. Images were captured within Nikon Eclipse 
TS 1000, objective 20X. 
 
 
3.2.5 EV isolation 
The CM containing EVs were gravity filtered through a Durapore® 5 µm 
membrane filter (Millipore) to remove cell debris and particles greater than 5 µm. 
Next, the CM was transferred to a Falcon 50 mL centrifuge tube (Sigma Aldrich) and 
centrifuged at 3,000 x g for 40 minutes using a prior to collection of the supernatant 
for subsequent MV collection. The pellet containing APs was resuspended with PBS 
before re-centrifugation at 3,500 x g for 1 hour to harvest clean AP pellets (Rossella 
et al., 2013; Valadi et al., 2007).  
The supernatant collected prior to the AP-harvest, described above, was gravity 
filtered through a 1.2 µm Hydrophilic Nylon membrane filter (Millipore). Filtrates 
were collected into a centrifuge tube (Thinwall, ultra-clear, 14 x 95 cm, Beckman 
Coulter) and centrifuged at 16,500 x g for 1 hour at 4 ºC (Rotor SW70, Beckman 
Coulter) to harvest MVs (Rossella et al., 2013; Valadi et al., 2007). The supernatant 
was collected in preparation for EX harvest while the pellet was washed in PBS and 
then re-centrifuged at 16,500 x g for 1 hour at 4 ºC.  
The remaining supernatant collected prior to the MV-harvest described above 
was gravity filtered through a 0.1 µm Durapore® membrane filter (Millipore). The 
resulting filtrates were transferred to a centrifuge tube (Thinwall, ultra-clear, 14 x 95 
cm, Beckman Coulter) and centrifuged at 100,000 x g for 1.5 hours at 4 ºC (Rotor 
Before trypsinization 
  (~ 80% confluence) 
After trypsinization 
   (removal of i3T3) 
Before collecting CM 
(48 hours incubation) 
A" B" C"
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SW70, Beckman Coulter) to harvest EXs (Rossella et al., 2013; Théry et al., 2006; 
Valadi et al., 2007). Post-centrifugation the supernatant was collected into micro-
tubes to be used as a control of the post-EV collection.  
The clean AP, MV and EX pellets were resuspended in PBS and stored at -20 
ºC for 2 weeks or -80 ºC for longer term storage until required for further analysis. 
In order to test the purity of isolated EVs using differential centrifugation and 
filtration, sucrose (30 % sucrose cushion) centrifugation was also employed for 
comparison. Briefly, 4 mL of 30 % sucrose solution was loaded into a centrifuge 
tube (Thinwall, ultra-clear, 14 x 95 mm, Beckman Coulter) prior to the addition of 6 
mL of EX suspension was subsequently loaded on top of the sucrose cushion and 
centrifuged at 120,000 x g for 1.5 hours at 4 ºC. A 10 mL syringe fitted with a 19 
gauge needle was used to collect 3.5 mL of the sucrose cushion, from the side of the 
tube, containing the exosomes which were transferred into a new centrifuge tube. 
The extracted exosomes were diluted with 15 mL PBS and re-centrifuged at 120,000 
x g for 2 hours at 4 ºC. Finally, the resulting exosome pellets were resuspended with 
50 µL of PBS and stored at -20 ºC for 2 weeks or -80 ºC for longer periods prior to 
subsequent analysis. 
 
3.2.6 Protein distribution using Silver stain 
Total protein was extracted as described in section 2.4. The total protein 
concentration was then determined using the bicinchoninic acid assay (BCA) (full 
details in section 2.4).  
For general visualisation, EV proteins were resolved by SDS-PAGE and silver 
stained. Details of the protein visualisation by silver stain can be found in section 2.5. 
Two biological repeats were performed for each cell type with the same volume of 
protein extract for each lane in one gel. 
 
3.2.7 Immunoblotting 
To detect EV biomarkers, an immunoblotting approach was used to detect six 
proteins known to be enriched in EVs, including HSP70, TSG101, AGO2, CD9, 
CD63 and CD81. Those proteins also were tested their enrichment in parental cells 
as control in addition to their enrichment in EVs (Lo¨tvall, 2014). Step by step of this 
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immunoblotting was performed as described in section 2.6. The membrane was 
probed overnight at 4 °C with primary antibodies, against the specific target proteins 
diluted in 0.5 % skim milk or albumin in TBST as follows: HSP70 1/10000; TSG 
101 1/10000; AGO2 1/5000; CD9 1/100; CD63 1/100; CD81 1/2000. The 
membranes were then subjected to 5 x 5 minute washes before incubation in a 
1/5000 dilution of appropriate secondary antibody for 30 minutes at room 
temperature. The membranes were again subjected to 5 x 5 minute washes and 
incubated with the ECL detection solution (Pierce™ ECL Western Blotting 
Substrate, Thermo Scientific) as per manufacturer’s instructions for 5 minutes. 
Images of the resulting blots were captured on Curix Ultra UV-G Medical X-ray film 
(AFGA; Mortsel, Belgium).  
The membranes to be subjected to the stripping protocol (as described in 
section 2.7) were stored at 4 ºC until required. 
 
3.2.8 Microscopy 
Transmission electron microscopy (TEM) was utilised to analyse the 
homogeneity and morphology of each EV population. Details of EV fixation, the 
step-by-step protocol and reagents can be found in section 2.8. At each step, the side 
of the grid, containing the adsorbed EVs, was kept wet, however the opposite side of 
the grid was kept dry. Finally, the grids were allowed to dry at room temperature 
(Théry et al., 2006). Imaging was performed using a JEOL 1400 TEM for different 
magnification levels at 80 kV. 
In addition to TEM, confocal microscopy was used to analyse DNA and 
apoptosis signatures of APs, which are used to distinguish APs from MVs. Details of 
the preparation and protocol can be found in section 2.9. Stained vesicles were 
observed and photographed (objective 60X) using a Confocal Leica TSC SP5 
microscope (Leica Microsystems, Germany) with the dual filter set for FITC and 
rhodamine (Hristov et al., 2004). 
 
3.2.9 Nanoparticle tracking analysis 
Concentration, size, aggregation and zeta potential of individual EX samples 
were acquired and analysed using a NanoSight NS500 and Nanoparticle Tracking 
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Analysis (NTA) 3.0 software (Malvern, Worcestershire, UK). More details of the 
NTA procedures can be found in section 2.10. The raw data was exported to an excel 
file and subsequently imported into GraphPad Prism 6 for further statistical analysis 
and graphing. 
APs and MVs are large vesicles, which are not specifically within the detection 
range of the NanoSight equipment, therefore APs and MVs were not analysed by this 
technique. 
 
3.3 RESULTS 
3.3.1 Evaluation of EV isolation 
In order to determine if the EV isolation strategy was effective it was necessary 
to perform a preliminary examination of EV contents. Others have previously found 
that differences in EV content are associated with specific EV populations. For 
example some tetraspanin family members are enriched in EXs, while MMP2 has 
been found to be enriched in MVs (Keerthikumar et al., 2015; Vlassov et al., 2012). 
Therefore, different EV populations may be distinguished by their furnished 
components. 
 
3.3.1.1 Protein distribution in isolated EVs 
In order to examine the general distribution of proteins in each EV population 
and their parent cells (cell lysates), aliquots of total protein was subjected to SDS-
PAGE and silver stain. There were clear differences in the distribution of proteins 
across the three isolated EV populations using both differential centrifugation only 
(Figure 3.2 A) and a combination method which included differential centrifugation 
and filtration (Figure 3.2 B). Upon closer examination of the protein distribution 
across the three EV populations, there was a greater amount of proteins present in the 
cell lysate, with fewer proteins distributed to the AP, MV and EX fractions. The 
pattern of protein distribution for each EV population was quite similar from both 
differential centrifugation and combination of differential centrifugation and 
filtration. As expected, these data indicate that total EV proteins are less varied than 
those of their parental cells.  
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Taken together, these data have indicated that there was a difference in protein 
distribution between three EV populations. Moreover, the differences in the signals 
of proteins (protein bands) present in the cell lysates, three EV populations and 
depleted CM suggest that each EV population was successfully isolated. 
Furthermore, the EV populations appear to have both common and potentially 
unique sets of proteins. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Protein distribution in parental cell lysate and EV populations.  
 
(A) EVs were isolated using differential ultra-centrifugation prior to loading of 10 µl 
of total protein extract into each lane. SDS-PAGE and silver stain was completed for 
parental cells and EV released from passage 49 HaCaT, passage 50 HaCaT, and 
passage 1 primary keratinocytes from patient 361. The silver stain image is 
representative for EVs released from passage 50 HaCaT cells. (B) EVs were isolated 
using a combination method of differential ultra-centrifugation and filtration. Briefly, 
10 µl of total protein extract was loaded into each lane. SDS-PAGE and silver stain 
was performed for parental cells and EVs released from passage 51 HaCaT cells and 
passage 1 primary keratinocytes originated from patient 361. The image is 
representative for EVs released from passage 1 primary keratinocytes (patient 361). 
M: Molecular weight marker; CL: Cell lysate; AP: Apoptotic bodies; MV: 
Microvesicles; EX: Exosomes; Media: Depleted conditioned media following 
isolation and collection of the three EV populations.  
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3.3.1.2 Purification of EVs 
To test purity, each EV population was subjected to an extra purification step 
following the collection of the EX pellets from the differential centrifugation 
combined with filtration (DC) using a sucrose density centrifugation (SC) approach. 
The comparative EX size distribution between the DC isolation and the SC 
approaches were determined using NTA analysis. The data revealed that there were 
few differences in the size distribution of EVs isolated by either approach (Figure 3.3 
A). The EX sizes ranged from 80 nm to 230 nm, with most vesicles concentrated in 
the 90 nm – 160 nm range for both isolation approaches (Figure 3.3 A). 
Unexpectedly, there were some EVs with a peak distribution detected at around 320 
nm in the SC samples and 330 nm for the DC samples (Figure 3.3 A). Further 
comparative analysis revealed that there was no statistically significant difference 
between the DC and SC approaches in terms of the particle concentration (Figure 3.3 
B); the particle size mode (Figure 3.3 C); and the mean particle size (Figure 3.3 D).  
According to the principles of DC and SC, the EX population isolated by SC 
should be purer than the EX population isolated from DC (Momen-Heravi et al., 
2013; Théry et al., 2006). In addition, due to the unknown buoyant density of APs 
and MVs, it is very difficult to apply gradient density centrifugation to isolate these 
vesicle populations compared to EXs. Therefore, DC was used to isolate all three EV 
populations for further analysis. 
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Figure 3.3: Analysis of exosome purity using Nanoparticle Tracking Analysis (NTA) 
 
Exosomes were isolated using differential centrifugation (DC) and sucrose density 
centrifugation (SC). A) The size distribution of exosomes isolated by DC and SC. B) 
The average number of exosomes per mL collected by DC and SC isolation methods. 
C) The size mode of exosomes; and D) The size mean of exosomes. DC: Differential 
centrifugation; SC: Sucrose density centrifugation. Bar errors indicate SD, three 
biological replicates (EVs released from HaCaT cells at passage 50, 51 and 53). T-
test (two tails) was employed to determine statistical significance, NS = not 
significant (p-value > 0.05).  
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3.3.2  Vesicle morphology 
The information from literature suggests that the three EV populations have 
different sizes and morphology (Cocucci et al., 2007; Rossella et al., 2013). 
Therefore, transmission electron microscopy (TEM) was utilised to analyse the 
morphological characteristics of individual vesicles in each EV preparation. Initial 
examination of the AP fraction revealed vesicles larger than 1 µm (Figure 3.4 A and 
B). However, there were also a number of particles smaller than 1µm observed in 
this. Examination of the MV fraction revealed a population of vesicles with irregular 
morphology and about 300 nm – 700 nm in diameter (Figure 3.4 C and D), which is 
consistent with MV characteristics. Lastly, examination of the EX fraction revealed a 
relatively homogenous population of smaller vesicles, 50 nm - 200 nm in diameter, 
and importantly, exhibited the characteristic cup shape typical of exosomes (Figure 
3.4 E and F). Most of the EXs were distributed in the size range between 50 nm to 
120 nm. There were also a few large, approximately 200 nm diameter, cup-shaped 
vesicles observed (Figure 3.4 E). 
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Figure 3.4: Morphological analysis of EV populations 
 
A & B) AP: Apoptotic bodies; C & D) MV: Microvesicles; E & F) EX: Exosomes. 
EVs were fixed with 4% paraformaldehyde and deposited on Formvar-carbon coated 
grids. The EV structure was stabilised with 1% glutaraldehyde prior to staining with 
unranyl-oxalate and transfer to methyl cellulose-unranyl acetate solution. The 
mounted EVs were then examined using a JEOL 1400 TEM with a magnification 
range of 50 X - 2,000,000 X. Four independent biological samples were analysed 
(HaCaT cells passage 49, 50, primary keratinocytes isolated from patient # 288, 
300). Images are representative for EVs released from HaCaT passage 50. Arrows 
indicate large vesicles (>200 nm) detected in the EX fraction. 
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APs are different from MVs and EXs as they contain nuclear fragments and 
express phosphatidylserine (PS), which is translocated to the external cell membrane 
(Bratton et al., 1997) and has high affinity for Annexin V. Therefore, 
immunofluorescence staining with PI and Annexin V followed by confocal 
microscopy were performed to examine if the putative APs in the AP fraction 
possessed these traits. Immunofluorescence revealed the presence of Annexin V 
(green) and DNA fragments (red) on and in APs (Figure 3.5). While, some vesicles 
were positive for both DNA and Annexin V staining, others only exhibited positive 
staining for Annexin V. In addition, the vesicles in the AP preparation which were 
positive for both PI and Annexin V, appeared approximately spherical in shape with 
a diameter of around 1 µm (Figure 3.5 B) morphology of Annexin V positive only 
vesicles appeared smaller and irregular in shape (Figure 3.5 B). As a control staining 
was performed on the MV fraction and the result showed that MVs were positive for 
Annexin V (green) but had no nuclear fragment signal (Appendix figure 3.1). These 
data suggest that the AP fraction may contain some MVs, or as reviewed in the 
literature that some APs do not contain DNA fragments. Furthermore, the data 
presented here is consistent with the findings from TEM and the different traits of the 
isolated AP population compared to MVs and EXs. 
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Figure 3.5: Detection of PS-Annexin V and nucleic acid fragments in APs  
 
(A 1 - 3) APs were stained with PI (red) and AnnexinV (green) to reveal the presence 
of nucleic acid fragments and expression of PS - Annexin V respectively. (B 1 - 3) 
Some APs were positive with both nucleic acid fragments and Annexin V signatures 
(arrow 1), but some AP were only positive for Annexin V (arrow 2). Three 
independent biological replicates (HaCaT passage 50, HaCaT passage 53, primary 
keratinocytes isolated from donor # 288); Images are representative for APs released 
from HaCaT passage 53. The stained APs were examined and photographed using 
Leica TSC SP5 Confocal microscopy, objective 60X. 
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3.3.3 Size distribution of exosomes 
A challenge for the accurate characterization of EVs is their nano-scale size. 
Therefore, to determine the size distribution of keratinocyte-derived EXs, EXs were 
analysed using NTA which revealed that both HaCaT-derived and primary 
keratinocyte-derived EXs ranged from approximately 60 to approximately 220 nm in 
size (Figure 3.6 A and B). More specifically, the mean size of HaCaT derived EXs 
was 124 nm (Figure 3.6 C), while the size of primary keratinocyte derived EXs was 
129 nm. The size mode was almost identical between the HaCaT derived EXs and 
primary keratinocyte derived EXs at 104 nm and 103 nm respectively (Figure 3.6 D). 
There were no significant differences between EXs isolated from HaCaT cultures 
and primary keratinocyte cultures regarding to size distribution. 
In addition, an estimation of exosome number per parental cell and to µg 
protein was calculated for exosomes released from both HaCaT and primary 
keratinocytes. An estimate of 31 exosomes were produced per HaCaT cell and 
approximately 95 exosomes per primary keratinocyte over 48 hours of incubation. 
Similarly, there are 58083,6 HaCaT-derived exosomes per 1 µg protein and 241170 
primary keratinocyte-derived exosomes per 1 µg protein (Appendix figure 3.2). 
There was no significant difference between HaCaT and primary keratinocyte-
derived exosome number released per cell, but the number of exosomes per µg of 
protein was significantly different between HaCaT and primary keratinocyte 
preparations (p < 0.05). 
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Figure 3.6: The size distribution analysis of exosomes released from the HaCaT cell 
line and primary keratinocytes in 2D culture 
 
50 µL frozen EX suspension was thawed and diluted in 450 µL PBS to make a total 
volume of 500 µL prior to analysing size distribution using NanoSight NS 500 
(Malvern, Worcestershire, UK). A) Size distribution of EXs which were released 
from HaCaT cultures. B) Size distribution of EXs which were released from primary 
keratinocyte cultures. C) Size mean of EXs. D) Size mode of EXs. Three biological 
repeats were performed for each experiment (HaCaT cell line at passage 49, 50, and 
51; primary keratinocyte patient numbers: 296 passage 1, 325 passage 1, and 366 
passage 2). Error bars indicate SD, T-test was used to examine statistical difference. 
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3.3.4 Differential expression of vesicle markers 
Transmembrane proteins such as the tetraspanins, including CD9, CD63 and 
CD81; cytosolic proteins with membrane binding capacity, such as TSG101; and 
intracellular proteins, such as Argonaute and Heat shock proteins have all been 
previously investigated as EV biomarkers (Lee et al., 2011; Lo¨tvall, 2014; Logozzi 
et al., 2009). Importantly, total protein from the cell lysates were utilised as controls 
of protein enrichment since some proteins may be expressed in parental cells, but are 
not expressed in the corresponding EVs and vice versa and some proteins maybe 
expressed in both parental cells and EVs (Lo¨tvall, 2014). As expected, the data 
showed that four out of 6 studied markers, including HSP70, TSG101, AGO2 and 
CD81 (primary keratinocytes only), were detected in parental cells and the 
corresponding EVs originating from those cells. However, CD9 and CD63 were 
detected in EXs, but not detected in their parental cells (Figure 3.7). As alluded to 
above, CD81 was not detected in HaCaT cell lysate but was detected in primary 
keratinocyte cell lysate, however, it was detected in both HaCaT and primary 
keratinocyte EXs (Figure 3.7). 
Upon closer examination of these proteins in each EV population, HSP70 is the 
only marker that was detected in all three EV populations regardless of cellular 
origin i.e. HaCaT cells or primary keratinocytes. On the other hand, TSG101 and 
CD9 were expressed exclusively in EXs released from both HaCaT and primary 
keratinocytes. Unexpectedly, other proteins, including AGO2 and CD81, were 
expressed differently between the EVs which were released from HaCaT and 
primary keratinocytes. Interestingly, while AGO2 was detected in all HaCaT 
derived-EVs, this marker was only clearly detected in APs originating from primary 
keratinocytes. However, there was a very faint immunoreactive band detected in the 
EXs originating from primary keratinocytes. Conversely, CD81 was detected in all 
primary keratinocyte-derived EVs but only detected in HaCaT-derived EXs. These 
data may be influenced by EV cross contamination since it was not completely pure 
EV fractions (Figure 3.4). However, these data generally indicate that the expression 
of EV markers is dependent on the EV cell of origin. 
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Figure 3.7: EV biomarkers were expressed in EVs derived from HaCaT cells and 
primary keratinocytes 
 
Total protein (20 µg) from parental cell lysate and each EV population were 
separated by SDS-PAGE under reducing conditions for the detection of HSP70, 
TSG101 and AGO2, and non-reducing conditions for the detection of CD9, CD63 
and CD81. All detections were repeated three times with the exception of CD81, 
which was only subjected to a single detection experiment. Primary antibodies were 
diluted in 5 % skim milk or albumin in TBST (HSP70: 1/10000; TSG 101: 1/10000; 
AGO2: 1/5000; CD9: 1/100; CD63: 1/100; and CD81: 1/2000). CL: Cell lysate; AP: 
Apoptotic bodies; MV: Microvesicles; EX: Exosomes. Cell lysate served as a 
positive control to reveal the protein enrichment in EVs and parental cells. Images 
are representative for EVs released from HaCaT passage 50 and primary 
keratinocytes passage 1 from patient 306 (TSG 101, AGO2, CD9, CD63 and CD81) 
and 363 (HSP70). 
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In order to validate the Western Blot, these six protein markers (HSP70, 
TSG101, AGO2, CD9, CD63 and CD81) will be examined for the peak areas which 
indicates the protein expression levels in three EV populations in the next chapter.  
 
3.4 DISCUSSION 
The number of studies investigating EV biology has significantly increased 
over the past few years due to the belief that they contribute to many biological 
processes (Ya´n˜ez-Mo´ et al., 2015). The differences in biogenesis, physical 
characteristics such as size, weight, content and buoyancy overlap between EV 
populations and this makes them difficult to isolate and characterise. There is some 
controversy regarding the standardisation of methods for the isolation and analysis of 
EVs (György et al., 2011; Witwer et al., 2013). As such, it is accepted that there is a 
need to combine several analytic approaches to collect and analyse EVs (Lo¨tvall, 
2014). Therefore, this study utilised a range of previously reported methods, 
including nanoparticle tracking analysis (NTA), electron microscopy, confocal 
microscopy, and immunoblotting, in an attempt to characterise different EV 
populations isolated by differential centrifugation with or without filtration. The 
initial results showed the general protein distributions for the different EV fractions 
and parental cells (Figure 3.2). This general analysis of EV proteins provided 
preliminary evidence of differential protein composition between each EV 
population. Reportedly, differential centrifugation is a simple and reliable method 
which is mostly used to isolate EVs from culture media (Raposo et al., 1996; Théry 
et al., 2006). However, this approach requires modification depending on the specific 
purpose of the investigation. Differential centrifugation can separate EV populations 
based on their relative size and weight (Rossella et al., 2013). In an attempt to obtain 
extremely pure EVs, an additional sucrose centrifugation (sucrose cushion) step, 
which separates EVs based on buoyancy, was implemented (Raposo et al., 1996; 
Théry et al., 2006). However, this type of gradient centrifugation can only be applied 
to purify EXs, which float on the sucrose gradient which has a density of 1.19 g / ml 
– 1.23 g / ml (Théry et al., 2009). Unfortunately, it does not seem possible to purify 
other EVs, such as APs and MVs, using this approach because there is little 
information regarding their buoyancy. Furthermore, their size and potentially 
therefore their weight exists within a very broad range (from 1 - 5 µm for apoptotic 
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bodies and from 0.1 - 1 µm for microvesicles) (Tauro et al., 2012; Théry et al., 
2009). In addition, fewer amount of exosomes and proteins collected in this present 
study is consistent with the results from Lamparski et al. since the sucrose gradient 
density centrifugation can remove particles and protein aggregates contaminated in 
exosome population (Lamparski et al., 2002). Moreover, utilisation of a sucrose 
gradient failed to isolate EXs and MVs from HIV – 1 particles which have similar 
buoyancy to EXs and tend to remain within the EX fraction. Recently, an iodixanol 
gradient density centrifugation approach was used to purify EXs (Van Deun et al., 
2014). This solution may overcome some of the limitations of sucrose density 
gradient centrifugation, however, it still isolates particles based on buoyant density 
which, as mentioned above, remains unclear for APs and MVs (Cantin et al., 2008; 
Dettenhofer et al., 1999). In an attempt to obtain pure EXs, a sucrose cushion 
approach was utilised and compared to differential centrifugation with incorporated 
filtration and PBS wash steps. Consequently, there were no differences in EXs 
regarding the size distribution and concentration (Figure 3.3). This result suggests 
that the effectiveness of the sucrose gradient method compared to differential 
ultracentrifugation followed by filtration and washing in PBS in an attempt to purify 
EXs are essentially equivalent. Therefore, based on the literature and results 
presented in Figure 3.2 and 3.3 it was decided to not isolate EXs using sucrose 
density centrifugation, thus, for the purpose of this study differential centrifugation 
was deemed appropriate to isolate APs, MVs and EXs. 
Notwithstanding the decision to not utilise buoyant density gradient, especially 
sucrose density centrifugation, in order to try to limit cross contamination of EV 
populations, a series of filtrations steps were implemented in between each 
differential centrifugation step in order to deplete populations of larger vesicles from 
each EV population fraction (Heinemann et al., 2014; Valadi et al., 2007). Despite 
this additional level of rigour, it still proved difficult to completely eliminate cross 
contamination of one EV population with another (Witwer et al., 2013). As reported 
in this chapter, there was some contamination of larger vesicles in the EX population, 
and smaller vesicles in the AP population (Figure 3.4 A and E). The contamination 
of small EVs in the large EV population collected may due to the small EVs staying 
near the bottom of the centrifuge tubes were pelleted at low g forces together with 
the large EVs. The problem with EV sub-fraction purity has been previously 
discussed in some reviews of the literature, in which it is recognised that it is very 
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difficult to discriminate EV populations due to the apparent size overlap (György et 
al., 2011; Raposo et al., 2013; Witwer et al., 2013). The application of filtration in 
this current study is also limited in that the filtration approach could result in a loss 
of EVs as a consequence of EV adhesion to the filter membrane and not completely 
addressed the cross contamination of EV size. However, the filtration step can be 
applied for all three EV populations, especially APs and MVs since their very broad 
range of size and unclear buoyancy, and it may need more optimisation for EX 
isolation and purification.  
While the morphology of APs seemed to be relatively spherical (Figure 3.4 and 
3.5), confocal microscopy and propidium iodide staining indicated that they might 
also contain DNA fragments (Figure 3.5 A and B). These are consistent with other 
observations that APs showed or not showed the condensed chromatin substance in 
roughly round shaped structures as APs (Elmore, 2007; Kerr, 1972; Rossella et al., 
2013). In addition, the membrane of APs in this study were Annexin V positive 
which is also consistent with that reported previously about APs isolated from human 
umbilical vein endothelial cell cultures (Hristov et al., 2004). Annexin V is a protein 
with high affinity to PS which is initially located on the cytoplasmic side of the 
plasma membrane but is translocated to the extracellular surface of the cell 
membrane during cellular apoptosis and MV shedding (Heijnen et al., 1999; Hristov 
et al., 2004). Importantly, however, MVs do not contain DNA fragments (Appendix 
figure 3.1), hence the expression of the Annexin V marker on vesicles with 
accompanying DNA signatures indicated that these vesicles were products of the 
apoptotic process. The morphology of MVs and EXs in this study (Figure 3.4D) are 
also consistent with previous investigations that report an irregular morphology for 
MVs and a round or cup-shape morphology for EXs (Keerthikumar et al., 2015; 
Rossella et al., 2013; Théry et al., 2006). Although, this cup-shape can be a result of 
membrane collapse during the drying process for TEM, it is often considered as a 
typical feature of EXs (Raposo et al., 1996). Taken together, these TEM and 
confocal microscopy data indicates information regarding EV morphology which are 
consistent with previous investigations. 
NTA showed that the EXs population described herein ranged from 60 nm to 
220 nm in diameter, with most EXs around 100 nm (Figure 3.6) which was relatively 
consistent with the TEM data (Figure 3.4). Unexpectedly, a small proportion of the 
EX population was measured at around 200 nm (Figure 3.6 A and B). EX 
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populations which contain a small proportion of larger vesicles (>150 nm), have also 
been reported previously (Dragovic et al., 2011; Jeppesen et al., 2014b; 
Keerthikumar et al., 2015). These larger EVs could be a clump of several small 
vesicles due to inadequate manual pipetting of vesicle suspension prior to NTA 
analysis. Evidently, different techniques, such as electron microscopy, flow 
cytometry or NTA, can give different size distributions (Dragovic et al., 2011; Filipe 
et al., 2010; Pol et al., 2014). Here, variation in EV size distribution as evaluated by 
TEM and NTA again confirm the inconsistency with determining size distribution 
using different approaches. Since one of the limitations of NTA is that it is inaccurate 
in characterising particles greater than 1 µm such as APs, and tends to miss small 
particles when it measures larger particles such as MVs (100 nm to 1000 nm) (Filipe 
et al., 2010) NTA was not applied to analyse the specific size distribution of MVs 
and APs in this study. Instead, NTA was utilised to measure the EX size distribution 
and count the number of EXs in suspension (Filipe et al., 2010), while TEM was 
used to analyse individual EV morphological characteristics. TEM analysis revealed 
the size of APs to be approximately 1 µm, while MVs appeared to exist in the 300 to 
700 nm range and EXs within the 50 nm to 150 nm range (Figure 3.4 A-F). A 
previous study on keratinocyte-derived EXs by Chavez-Muñoz et al. (2008) reported 
that EXs isolated by sucrose gradient centrifugation and visualised by TEM had a 
cup-shape and were 50 - 100 nm diameter (Chavez-Muñoz et al., 2008). The 
difference in EX size range observed in this current study and in the study by 
Chavez-Muñoz et al. (2008) could be due to the use of different isolation methods. 
Immunoblotting was also utilised in this current study to examine EV markers 
CD9, CD63, CD81, TSG101, HSP70 and AGO2. However, the expression of these 
markers varied depending on the cells of origin and some markers were expressed in 
the EVs but not in the EV secreting cells (Figure 3.7). Typically, these markers are 
detected in EVs and their parental cells; however, previous evidence has shown that 
some markers may only be detected in EVs but not in parental cells (Jeppesen et al., 
2014b; Mineo et al., 2012; Yoshioka et al., 2013). Additionally, some markers only 
expressed in a specific population of EV, for example, CD63 was only detected in 
the HaCaT derived EX population which is similar to previous results that CD63 
enriched in EXs but not in MVs originated from activated platelets (Heijnen et al., 
1999). However, the expression of CD63 was inconsistent since this marker was not 
detected in primary keratinocyte-derived EXs. The inconsistent expression of CD63 
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has been reported previously in EXs released from several human cancer cell lines. 
For example, the marker was expressed extremely high in EXs released from prostate 
cancer cell line (PC3) but very low in EXs released from prostate non-cancer cell 
line (PNT2) or in a breast cancer cell line (MCF7) (Yoshioka et al., 2013). 
Additionally, CD63 has been detected in only 82 % of experiments reported in the 
ExoCarta database (http://exocarta.org/download). However, even though CD63 was 
not detected in EXs released from primary cells by immunoblotting, this protein was 
detected in the same sample by mass spectrometry (Chapter 4). The lack of positive 
control for the immunoblot experiment in this current study makes it difficult to state 
why CD63 was detected in HaCaT-derived EXs but not detected in primary 
keratinocyte-derived EXs. This may indicate that the immunoblot experiment 
employed in this current study is not ideal for the CD63 detection. Similarly, CD9 
and TSG101 were also only detected in EXs derived from both HaCaT cells and 
primary keratinocytes (Figure 3.7). However, these two proteins were previously 
detected in both MVs and EXs released from human LIM 1863 Colon cancer cell 
line and SH-SY5Y neuroblastoma cell cultures (Keerthikumar et al., 2015). 
Furthermore, CD81, AGO2 and HSP70 described herein were expressed in all three 
EV populations (Figure 3.7). The expression of CD81 and HSP70 in EXs has been 
reported previously as its markers (Lasser et al., 2011; Segura et al., 2005; Wolfers 
et al., 2001; Yoshioka et al., 2013), however, to the best of this authors knowledge 
they have not be previously described as protein markers to detect MVs and APs. 
The marker HSP70 is a membranous and cytosolic protein (Kampinga et al., 2010; 
Multhoff et al., 1996), so this could be enveloped into any membrane-enclosed 
vesicles, not only EXs. Similarly, AGO2 could be detected in all three EV 
populations, as this marker is an intracellular protein and incorporated with other 
proteins to form a RNA-Induced Silencing Complex (RISC) in the cytoplasm 
(Meister et al., 2004). Reportedly, top 100 frequently identified exosomal proteins 
summarised in ExoCarta (http://exocarta.org/download or Appendix table 3.1, 
accessed 12/10/2016) indicates that those proteins were not always detected.  
 
3.5 CONCLUSION 
The three different EV populations, including APs, MVs and EXs, were 
separated successfully from 2D keratinocyte culture media. This allowed the 
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demonstration that each EV population exhibited their own, but sometime 
overlapping markers, size and morphological characteristics. In general, APs are the 
biggest vesicles which have irregular shapes; MVs are second largest vesicle 
population which also exhibited an irregular morphology; and EXs were the smallest 
vesicle population which exhibited a characteristic cup shape with a size distribution 
between 60 nm to 200 nm. Moreover, various combinations of the biological EV 
markers expressed differently in the three EV populations. These data infer general 
differences in each EV population which form the basis characteristics that enabled 
the further characterisation of their components, described in the following chapters. 
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Chapter 4: Identification of proteins present 
in extracellular membrane 
vesicles 
4.1 INTRODUCTION 
Intercellular interaction is an important process by which cells exchange 
signals. Several means of cell-to-cell communication have been described, such as 
cell junctions, adhesion contacts and soluble factors (Camussi et al., 2010; Majka et 
al., 2001). Recently, a new mode of cell-to-cell communication via extracellular 
membrane vesicles (EVs) has been recognised (Cocucci et al., 2009). These 
membranous EVs, including apoptotic bodies (APs), microvesicles (MVs) and 
exosomes (EXs), are secreted by various cell types (reviewed in (Akers et al., 2013; 
Thery et al., 2002)), and have been detected in cell culture media and bodily fluids, 
such as breast milk, urine, plasma, amniotic fluids and saliva (Hao et al., 2006; 
Huang et al., 2013; Keller et al., 2007; Michael et al., 2010; Thery et al., 2001; 
Zonneveld et al., 2014).  
In recent years, progress has been made in understanding the protein cargo of 
EVs. EV proteins have been detected using SDS-PAGE followed by protein staining, 
immunoblotting or using protein sequencing approaches. Investigation of EV cargo 
is crucial in order to understand their biogenesis and their functions. To date, there is 
limited knowledge of the protein components among different populations of EVs. 
Studies have been performed to profile proteins in EVs released from cancer cells 
(Keerthikumar et al., 2015; Mathivanan et al., 2010; Park et al., 2013) or body fluids 
(Chiasserini et al., 2014; Kalraa et al., 2013). However, those studies investigated 
only one individual population of vesicle. Furthermore, few investigations have 
made pairwise comparisons between vesicles such as APs and MVs or MVs and EXs 
(Keerthikumar et al., 2015; Turiák et al., 2011). Critically, no study has compared 
the proteins from three populations of EV released from a single source of parental 
cell type. In addition, there is a lack of studies reporting on the proteomics of primary 
cell-derived EVs, especially keratinocytes. As such a deeper understanding of the 
differences in protein composition between EV populations, and the links between 
EV cargo with their cellular origins and their respective biological functions is 
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required. Consequently the study described herein used an LC-MS/MS approach to 
profile proteins in three keratinocyte-derived EV populations, followed by 
bioinformatics analysis to examine the associated Gene Ontologies of the EV 
proteins.  
 
4.2 MATERIALS AND METHODS 
The following is a summary of the materials and methods used for the studies 
described in this chapter. Full details can be found in chapter 2. 
 
4.2.1 Materials 
Vesicles used for protein extraction and investigations reported in this chapter 
included HaCaT cells (passage 49, 50 and 51) and primary epidermal keratinocytes 
isolated from patients # 363 (passage 2), 364 (passage 1) and 366 (passage 1). 
Detailed information of reagents and chemicals can be found in section 2.1 of 
chapter 2. 
 
4.2.2 Cell culture and EV isolation 
HaCaT cells and primary keratinocytes were cultured as described in section 
2.2 to until 80 % confluent. The cells were then prepared and incubated in serum-free 
media for 48 hours for EV production (more details in section 2.2.5). Subsequently, 
conditioned media (CM), which contained EVs, was harvested and centrifuged at 
300 x g to remove cell debris before being subjected to differential centrifugation and 
filtration steps to isolate APs, MVs and EXs as described in section 2.3. EV pellets 
were resuspended in 100 µL PBS which were then stored at -20 ºC for 2 weeks or -
80 ºC for longer periods prior to protein extraction. 
 
4.2.3 Protein extraction 
To analyse the proteome of different EV populations (APs, MVs and EXs), a 
volume of each vesicle suspension was mixed with an equivalent volume of 
extraction buffer (4 % SDS, 100 mM Tris / HCl pH 7.6) in individual Protein LoBind 
tubes and incubated for 3 minutes at 95 ºC. The samples were sonicated to disrupt the 
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membrane structure and shear DNA thus reducing the viscosity of the sample. The 
mixture was centrifuged at 14,000 x g for 15 minutes at 4 ºC, prior to transfer of the 
supernatant into a fresh tube for further processing or storage at -20 ºC until required. 
The pellets containing vesicle debris and DNA were discarded.   
The protein content of each sample was quantified using the Pierce™ BCA 
Protein Assay Kit as described in section 2.4. 
 
4.2.4 Sample processing and peptide digestion 
The samples were processed and subjected to protein digestion using the Filter 
Aided Sample Preparation (FASP) method (Zougman et al., 2009). Briefly, a volume 
of 30 µL of protein extract was mixed with 200 µL of 8 M urea in a microcon-30 
kDa Centrifugal Filter Unit, mixed by vortex and then centrifuged at 14,000 x g for 
15 minutes at room temperature. Next, in order to reduce disulphide bonds, 200 µL 
of 25 mM DTT, and 8 M urea was added to the filter unit and incubated at room 
temperature for 30 minutes prior to centrifugation at 14,000 x g for 15 minutes. A 
volume of 100 µL of 50 mM iodoacetamide in urea buffer was added into the filter 
unit, in order to alkylate the free sulfhydryl group on the cysteine residues, and 
subsequently incubated at room temperature for 15 minutes prior to centrifugation at 
14,000 x g for 15 minutes. The retained proteins were washed twice with 100 µL of 8 
M urea, centrifuged again at 14,000 x g for 15 minutes and washed again with 100 
µL of 50 mM ammonium bicarbonate buffer before centrifugation again at 14,000 x 
g for 15 minutes to remove the urea buffer. The retained proteins were then washed 
again in 50 mM ammonium bicarbonate buffer and centrifuged at 14,000 x g for 15 
minutes. The ammonium bicarbonate buffer flow through was discarded prior to the 
addition of 40 µL of sequencing grade modified trypsin (0.01 µg / mL in ammonium 
bicarbonate buffer) to the retained protein for digestion. The filter units were then 
placed into an air-tight humidified container at 37 ºC and allowed to digest for 4 - 8 
hours (overnight). The following day, the top portion of the filter units, containing 
the digested protein were transferred to new collection tubes and centrifuged at 
14000 x g for 15 minutes. An additional 10 µL of 0.1 % formic acid was added into 
the filter unit and centrifuged at 14,000 x g for 15 minutes in order to wash the filter 
membrane. The tryptic peptides were captured in the fresh collection tubes and were 
subsequently subjected to a desalting protocol. 
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4.2.5 Tryptic peptide desalting using StageTip 
Stop-and-go-extraction-tips (StageTips) used for tryptic peptide desalting were 
prepared as described in section 2.11.3. The step by step procedure for desalting and 
washing of tryptic peptides is summarised below. Firstly, the C18 membrane plug 
was pre-wetted by addition of 20 µL of 100 % acetonitrile (ACN) to the proximal 
end of the stage tip and then pressurising the tip with compressed air to force the 
ACN through the C18 plug. In order to equilibrate the plug, 20 µL of 0.1 % formic 
acid was added into the proximal end of the StageTips and passed through the C18 
plug as described above. Next, 50 µL of sample was loaded into the proximal end of 
the tip and passed through the plug with filtered compressed air as described above 
prior to washing with 20 µL of 0.1 % formic acid in the same manner. Finally, the 
peptides were eluted from the plug, into a 250 µL Agilent MS polypropylene vial 
insert within a fresh 1.5 mL Lo-Bind tube, by the addition of 20 µL of 80 % 
acetonitrile, 1 % formic acid to the proximal end of the stage tip, and pressurisation 
with filtered compressed air as described above. 
Following desalting the peptides were transferred to the MS vial insert and 
subsequently concentrated by vacuum centrifuge. The almost dry peptides were then 
resuspended in 20 µL of 0.1 % formic acid, 2 % acetonitrile and stored at 4 ºC for a 
maximum of one day prior to liquid chromatography – tandem mass spectrometry 
(LC-MS/MS) or stored at -20 ºC for longer storage times. 
 
4.2.6 LC-MS/MS and database search 
Tryptic peptides were analysed by LC-MS/MS using an Eksigent ekspert 
nanoLC 400 coupled to a SCIEX Triple TOF5600+ mass spectrometer in standard 
injection mode. After injection, the tryptic peptides were again de-salted in a trap 
column, with 98 % Buffer A (0.1 % formic acid), then resolved on an analytical 
column at total flow rate 0.3 µL / minute across a 60 minute gradient consisting of 2 
% – 40 % buffer B (80 % acetonitrile in 0.1 % formic acid) (v/v). The concentration 
of buffer B was then increased to 65 % over 5 minutes, then increased again to 95 % 
over 15 minutes, prior to decreasing to 2 % buffer B for 10 minutes. MS/MS spectra 
were acquired using Data Dependent Acquisition (DDA) top-40 mode, in rolling 
collision mode with a maximum accumulation time of 50 milliseconds within the 
mass range of 100 – 2000 Da. All spectra were acquired in positive ion mode 
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inclusive of charge states 2 - 5 with full scan MS spectra scanning from 350 – 1350 
Da. More details of this procedure can be found in section 2.11.6. 
The mass spectral data were analysed with ProteinPilot software using the 
Paragon™ algorithm to perform protein identifications. All MS/MS spectra were 
searched against the UniProt-Human-Reviewed database (accessed 6/8/2015), which 
was appended with the common repository adventitious protein (CRAP) database. 
The search parameters were set as follows:  
• Sample type - Identification;  
• Cys Alkylation - Iodoacetamide;  
• Digestion - Trypsin;  
• Instrument - TripleTOF5600;  
• Species - Homo sapiens;  
• ID focus - Biological modification and Amino acid substitutions;  
• Search Effort - Thorough ID;  
• Detected protein threshold - 0.05;  
• Run False Discovery Rate (FDR) Analysis - yes.  
Only proteins identified with at least 95 % confidence, a FDR of < 5% and 
with at least 2 peptides detected were reported. 
The resulting data were imported into the open source Skyline software (64-bit, 
v3.1, release 16/3/2015, MacCoss Lab) to quantify peptide precursor MS1 signal. 
(https://skyline.gs.washington.edu/labkey/project/home/software/Skyline/begin.view), 
(Abbatiello et al., 2015). Details regarding the input parameters for each step can be 
found in section 2.11.8. Following development of an advanced peak picking model 
within the software, the peak area for each peptide was calculated. The resulting 
relative protein abundance data were analysed by one-way ANOVA using the 
Statistical Analysis System program (SAS v9.3). 
 
4.2.7 Combining data from independent biological replicates 
DDA MS experiments can often suffer from poor reproducibility due to the 
stochastic nature of precursor ion selection throughout the LC-MSMS analyses. In 
order to generate a protein list representative of the samples, three independent 
biological replicates were analysed by DDA MS. Protein identifications from the 
three biological samples of parental cells or each individual EV population were 
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analysed separately to determine the analytical concordance for further analysis. This 
analysis was not limited to only the proteins common to all three biological samples. 
The reason for this is that the total list of proteins indicates the variance in identified 
proteins in different biological replicates (rather than technical variation) and as such 
this biological variance should be captured for further analysis.  
 
4.2.8 Enrichment analysis using David Bioinformatics Resources 
In order to analyse potential functional enrichment of identified proteins, a list 
of UniProt protein accession IDs for each EV population were individually uploaded 
to the DAVID Bioinformatics Resource 6.7 (https://david.ncifcrf.gov/home.jsp) and 
converted to DAVID IDs before being analysed based on a whole genome (Homo 
sapiens) background. The Gene Functional Classification (GFC) tool, Gene Ontology 
(Biological Process (BP), Cellular Components (CC), and Molecular Function 
(MF)), and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to 
analyse EV proteins for their potential involvement in various bioactivities (Huang et 
al., 2009a). 
 The GFC tool was used to classify proteins into groups with shared functions. 
Analysis conditions of the Gene Functional Classification were performed using the 
following parameters: medium classification stringency; Kappa similarity overlap at 
4; and threshold at 0.35; and classification threshold at 0.5. Gene Ontology (GO) 
analysis of EV proteins was performed for the categories: BP-FAT, CC-FAT and 
MF-FAT at threshold count 2, where FAT is the filter algorithm applied by DAVID. 
The threshold count level was selected as this analysis provides very broad filtered-
GO terms (specific GO terms are not over-shadowed) compared to ALL levels. 
Background used for GO enrichment analysis was the Homo sapiens whole genome 
(DAVID default) (https://david.ncifcrf.gov/). The modified Fisher’s exact test 
(EASE) was set at 0.1; and Benjamini-Hochberg for comparison correction. The data 
were exported and graphed using GraphPad Prism 6. Only GO terms with p-value < 
0.05 were reported and considered significant. 
 
4.2.9 ExoCarta comparison 
To examine the potential correlation of identified exosomal proteins with 
previous studies, a comparison of the identified exosomal proteins reported herein 
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with human proteins from the ExoCarta database (http://www.exocarta.org), released 
29/07/2015) was performed. The initial database was adjusted to remove duplicated 
proteins detected by different methods, and the identified exosomal proteins were 
converted to gene symbols. The details of this refinement process can be found in 
section 2.11.10. The lists of gene names were then used for comparison with the 
refined ExoCarta entries to reveal previously un-reported EX proteins identified in 
this current study using a Venn diagram program online 
(http://bioinformatics.psb.ugent.be/webtools/Venn/). 
 
4.3 RESULTS 
The aims of this study were to: identify and explore the different expression 
levels of proteins present in the three EV populations; reveal un-reported exosomal 
proteins; and, to examine the potential EV function through analysis of significant 
GO terms and KEGG pathways associated with EV proteins. The data reported in 
this chapter constitute an overview and are focused on groups of proteins associated 
specifically with EV formation and with wound healing aspects. 
 
4.3.1 Global distribution analysis of identified EV proteins revealed the 
common and unique protein profiles for each EV populations  
Directly after completion of the protein identification and accounting for a 
FDR of < 5%, the data were summarised to reveal the global distribution of proteins 
between the separate EV populations. The data showed differences in the protein 
distributions between the three EV populations released from HaCaT and primary 
keratinocytes (Figure 4.1 A and B). With regard to HaCaT cells, there were 1831 
proteins identified in HaCaT parental cells. In addition, 1152, 470, and 948 proteins 
were identified in HaCaT-derived, APs, MVs and EXs respectively (Figure 4.1 A). 
Moreover, comparison of the three EV populations revealed that there were 223 
proteins that were shared between APs, MVs and EXs (Figure 4.1 A, in red text). 
Importantly, there were 371 proteins unique to EXs; 160 proteins unique to MVs; 
and, 546 proteins unique to APs. Additionally, APs and MVs shared 58 proteins, 
MVs and EXs shared 29 proteins, and APs and EXs shared 325 proteins (Figure 4.1 
A or more clearly in Appendix figure 4.1 A).  
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With regard to the primary keratinocyte-derived EVs, there were 1472 proteins 
identified in parental primary keratinocytes. Furthermore, 644, 415 and 790 proteins 
were identified in primary keratinocyte-derived APs, MVs and EXs, respectively 
(Figure 4.1 B). Additionally, a total of 242 identified proteins were shared between 
APs, MVs and EXs (Figure 4.1 B, in red text). There were 390 unique exosomal 
proteins, 55 proteins unique to MVs and 226 proteins unique to APs. Moreover, APs 
and MVs shared 68 proteins, MVs and EXs shared 50 proteins, and APs and EXs 
shared 108 proteins (Figure 4.1 B or more clearly in Appendix figure 4.1 B). It was 
clear that the number of proteins identified in MVs released from both cell types was 
substantially lower even though the amount of total protein subjected to tryptic digest 
and LC-MS/MS measurement was equivalent to the other EVs.  
In order to determine the difference in protein distribution related to parental 
cell origin, the number of potentially common proteins between HaCaT-derived EVs 
and primary keratinocyte-derived EVs were calculated and identified (Figure 4.1 C). 
The 223 proteins common to all HaCaT derived EVs (Figure 4.1 A, red text) and the 
242 proteins common to all primary-keratinocyte derived EVs (Figure 4.1 B, red 
text) were compared. The data showed that there were 106 shared proteins between 
the common HaCaT-derived EV proteins and the common primary keratinocyte-
derived EV proteins (Figure 4.1 C). Interestingly, there were 117 unique proteins in 
the common HaCaT-derived EV proteins and 136 unique proteins in the common 
primary keratinocyte-derived EV proteins. Such results suggest that the differences 
in protein composition between the EVs originating from the immortalized cell line 
and primary cells may reflect a difference in EV physiology and function.  
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Figure 4.1: Global distribution of identified proteins between parental cells and three 
EV populations released from the HaCaT cell line and primary keratinocytes.  
 
MS/MS spectra acquired using DDA mode were analysed with ProteinPilot and 
searched against the UniProt-Human-Reviewed database to obtain the EV protein 
list. The identified proteins between the different EV populations were compared to 
reveal the difference in the number of identified proteins within each EV population 
and their parental cells. The protein distribution across: A) HaCaT-derived EVs and 
HaCaT cells; and B) primary keratinocyte-derived EVs and primary keratinocytes. 
C) The number of common and unique EV proteins between HaCaT cell and primary 
keratinocytes. The data are the aggregate of three biological replicates. PKC: primary 
keratinocytes, AP: Apoptotic bodies, MV: Microvesicles, and EX: Exosomes. 
Graphs were generated using the online web-based program 
(http://bioinformatics.psb.ugent.be/webtools/Venn/). 
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4.3.2 Identification of novel exosomal proteins  
The question of whether or not the identified EX proteins in the current study 
had been reported in previous studies led to a comparison of the identified proteins 
reported herein with human proteins from the ExoCarta database 
(http://www.exocarta.org, released 29/07/2015). The ExoCarta database, a manually 
curated database of exosomal proteins and their detection and isolation methods, 
provides an opportunity to examine the most frequent expression of exosomal 
markers, compare identified proteins and reveal novel exosomal proteins in new 
studies (Simpson et al., 2012a). The initial database comprised of 34944 human 
proteins was refined to obtain a final database containing 6514 exosomal proteins. In 
addition, the current list of 948 identified proteins from HaCaT-derived EXs were 
converted successfully from UniProt-accession numbers to 751 gene names, and the 
list of 790 protein identifiers from primary keratinocytes-derived EXs were 
converted successfully to 563 gene names, by using the Retrieve/ID mapping tool 
from the UniProt website (http://www.uniprot.org). The lower number of gene names 
compared to UniProt-accession numbers is likely due to the fact there is more than 
one UniProt ID per gene depending on the sequential ordering of genes on the 
chromosome or on different naming project or system 
(http://www.uniprot.org/help/gene_name). The lists of gene names were then used 
for comparison with the refined ExoCarta entries to reveal novel EX proteins. 
The results revealed that 623 proteins from HaCaT-derived EXs had been 
described as being associated with EXs in previous studies. This meant that there 
were 128 proteins associated with HaCaT-derived EXs that had not been previously 
associated with EXs (Figure 4.2 A). In the examination of the 563 proteins from 
primary keratinocyte-derived EXs, 456 proteins had been previously identified and 
listed in the ExoCarta database, and 107 proteins had not been reported as being 
previously associated with EXs (Figure 4.2 B). Interestingly, the ExoCarta database 
contained a list of 202 proteins which had been previously associated with EXs 
released from keratinocytes. Of these only 101 and 78 exosomal proteins derived 
from HaCaT and primary keratinocytes, respectively, had been described previously 
(Figure 4.2 C and D). These results indicate that more than 100 exosomal proteins, 
which were detected in this current study, have not been previously identified in any 
study as being associated with EXs released from any cells / tissues. Additionally, 
650 of the 751 proteins associated with HaCaT-derived EXs and 485 of 563 proteins 
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associated with primary keratinocyte-derived EXs, had not been previously reported 
as being associated with EXs which originated from keratinocytes (Figure 4.2 C and 
D). Unfortunately, there are no protein databases for APs or MVs; therefore, it was 
not possible at this stage to examine the identified proteins from APs and MVs in a 
similar way to that performed for EXs. 
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Figure 4.2: Common and novel keratinocyte derived exosomal proteins 
  
The identified EX proteins were converted from UniProt-accession IDs to gene 
names and replicate proteins in the EXoCarta database were removed prior to com-
parative analysis using Venn diagram tool) to reveal previously un-reported EX 
proteins (http://bioinformatics.psb.ugent.be/webtools/Venn/). Comparison of Exo-
Carta database entries to the proteins identified from: A) HaCaT-derived EXs; and 
B) primary keratinocyte-derived EXs. Comparison of keratinocyte-derived EX 
proteins reported in ExoCarta with the proteins identified from: C) HaCaT-derived 
EXs; and D) primary keratinocyte-derived EXs.  
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4.3.3 Differential abundance and expression of identified proteins across the 
three EV populations 
In order to develop a deeper understanding of the difference in expression of 
the identified EV proteins between three EV populations, the Skyline program was 
used to measure the peak area of peptides in the mass spectra.  
 
4.3.3.1 Differential abundance levels of six identified proteins as EV markers  
Due to the inconsistent expression of protein markers examined by Western 
Blotting as mentioned in Chapter 3, the peak areas, which indicate the protein 
expression level, of the 6 protein markers (HSP70, TSG101, AGO2, CD9, CD63 and 
CD81) were examined. The MS data confirm the presence of five of the target 
protein EV biomarkers with AGO2 being not detected (Table 4.1 and 4.2). Only 
CD63 and CD9 had significantly different abundances across the three EV 
populations in primary keratinocyte-derived EVs (p<0.05). The difference in 
abundance level of protein markers was not completed for HaCaT-derived EV 
proteins since only one biological replicate was measured for their peak areas (due to 
a personal issue, the two other biological replicates will be performed in the future). 
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Table 4.1: Protein markers present in primary keratinocyte-derived EVs detected by 
mass spectrometry  
ID Gene name p-value 
Peak area 
AP MV EX 
P08962 CD63 0.002 16.152±0.08 16.653±0.31 18.816±0.76 
P21926 CD9 0.018 20.547±0.59 21.059±0.22 23.061±0.11 
P0DMV8/9 HS71A/B 0.462 22.108±0.58 21.684±0.44 22.089±0.21 
Q99816 TSG101 0.180 19.230±0.62 19.115±0.72 19.776±0.34 
P60033 CD81 0.990 22.499±2.08 22.344±1.04 22.406±0.36 
Note: ± SD, n = 3 independent biological replicates. 
 
Table 4.2: Protein markers present in HaCaT-derived EVs detected by mass 
spectrometry  
ID Gene name Peak area   
  AP MV EX 
P08962 CD63 18.510 17.574 18.433 
P21926 CD9 21.075 20.413 22.984 
P0DMV8/9 HS71A/B 22.928 22.884 22.681 
Q99816 TSG101 19.040 18.450 20.035 
P60033 CD81 22.562 22.752 21.323 
Note: n = 1 independent biological replicate (from HaCaT cells passage 50). 
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4.3.3.2 Abundance level of identified proteins classified EXs from APs and MVs  
In total, the relative abundance of 1662 peptides were measured and the data 
showed that 143 proteins were significantly differentially expressed in the three 
populations of EVs (p<0.05) (Appendix table 4.3). In order to determine the major 
differences in protein abundance levels between the three EV populations, the top 50 
proteins (ranked by p-value) were examined by hierarchical clustering (Figure 4.3 A 
and B). This analysis showed that proteins were expressed more similarly in APs and 
MVs compared to EXs for both EVs released from HaCaT and primary 
keratinocytes. Closer examination of the primary keratinocyte-derived EV proteins 
(Figure 4.3 B), resulted in the identification of eight protein groups which were 
classified according to their expression trend in the three EV populations based on 
Row Z-Score. The Row Z-Score indicates the relative abundance levels of proteins 
by colour intensity based on peak area input data, in which green reflects relatively 
low abundance and red is relatively high abundance. Some protein groups had 
similar expression trends since the proteins were more abundant in EXs and lower in 
APs and MVs such as group 2, 4, and 7 (Figure 4.3 B). Alternatively, some proteins 
were less abundant in EXs compared to APs and MVs, such as group 1, 3, 5, 6 and 8 
(Figure 4.3 B). Importantly, since the abundance levels of individual or groups of 
proteins may influence the function of specific EVs, understanding EV protein 
abundance levels is important in order to draw hypotheses about the possible specific 
roles for each EV population. Due to the limited time to finish the thesis, one single 
biological repeat was measured for the protein abundant level from HaCaT sample in 
this section only. As such, the approach to grouping of proteins was not conducted 
for those associated with HaCaT-derived EVs. These HaCaT data reported here 
(Figure 4.3 A) is only initial evidence for this section analysis and have not drawn 
too much in term of interpretation in this thesis. In all other sections, data have been 
report for three biological repeats. 
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Figure 4.3: Relative expression levels of the top 50 EV proteins ranked by p-value 
 
The hierarchical clustering was performed, using the ‘R’ statistical package, based on 
the peak areas of proteins, reflecting relative abundances, measured by the Skyline 
program. The top 50 proteins were clustered according to significance level (p-value, 
one-way ANOVA test). The colour indicates the relative expression levels, where 
green is relative low expression and red is relative high expression. A) HaCaT-
derived EVs, one biological replicate (the protein was clustered hierarchically and 
dendrogram sorted by name matched with the protein names from primary 
keratinocyte-derived EVs). B) Primary keratinocyte-derived EVs, analysis based on 
data from three independent biological replicates. 
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4.3.3.3 Four novel differentially expressed proteins and the highest abundant 
proteins were previously un-reported in the 100 most frequently reported exosomal 
proteins  
The 143 proteins, mentioned above, were compared with the previously 
detected and reported proteins in the refined ExoCarta protein database. 
Interestingly, four of the 143 proteins had not been previously described in the 
ExoCarta database (Figure 4.4). These 4 proteins included Heat shock protein 90 
alpha family class B member 4, pseudogene (HSP90AB4P), lactate dehydrogenase A 
like 6A (LDHAL6A), lactate dehydrogenase C (LDHC) and Septin 9 (SEPT9). The 
ExoCarta database only contains protein information of exosomal cargo, not cargo 
from other vesicles. This suggests that these four proteins have not been identified in 
previous EX investigations.  
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Figure 4.4: Identification of proteins with differential expression in the three EV 
populations which have not been previously described in the ExoCarta protein 
database 
 
The 143 differentially expressed proteins were compared to the EX proteins in the 
ExoCarta database to reveal previously un-reported EV proteins. The results showed 
4 EV proteins have not reported previously while 139 EV proteins had been 
previously reported. The Venn diagram was generated using web-based Venn draw 
tool (http://bioinformatics.psb.ugent.be/webtools/Venn/). 
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To more closely examine the dominant EV biology, the 20 proteins with the 
greatest peak area (greatest abundance) were selected from the 143 proteins with the 
most statistically significant difference in abundance levels between the three EV 
populations (Appendix table 4.3, red). In this regard, the proteins with highest 
abundance in each EV population may suggest an important biological roll or 
function for those EVs. Therefore, with regard to EXs, all 20 proteins were searched 
against the 100 most frequently identified exosomal proteins in the ExoCarta 
database. Unexpectedly and of interest, only four proteins (CD9 antigen; Elongation 
factor 1-alpha 1; 78 kDa glucose-regulated protein; and Integrin alpha-6) from 
HaCaT-derived EXs and five proteins (CD9 antigen; Elongation factor 1-alpha 1; 78 
kDa glucose-regulated protein; Integrin alpha-6; and Syntenin-1) from primary 
keratinocyte-derived EXs were matched to the 100 most frequently identified 
exosomal proteins (Figure 4.5 A and B, Table 4.3). As the majority of high abundant 
proteins in EXs were not matched with the 100 most frequently identified exosomal 
proteins, further analysis was performed to reveal whether these 20 proteins had been 
detected previously. This was achieved by searching the entire ExoCarta database for 
the 20 proteins. The results indicated that all 20 proteins had been identified in 
previous investigations (Figure 4.6). 
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Figure 4.5: Comparison of the 100 most frequently identified exosomal proteins with 
the 20 most abundant exosomal proteins 
  
The 100 most frequently identified proteins were downloaded from the ExoCarta 
database (http://www.exocarta.org), and the 20 most abundant EX proteins were 
sorted from the 143 differently expressed proteins based on measured peak areas 
prior to a comparative analysis. The comparison of the 20 most abundant proteins 
from A) HaCaT-derived EX and B) primary keratinocyte-derived EXs with the 100 
most frequently identified proteins from the ExoCarta database was performed using 
an online Venn diagram tool (http://bioinformatics.psb.ugent.be/webtools/Venn/).  
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Table 4.3: The 20 most abundant EX proteins  
 
HaCaT-­‐derived	  EXs	   Primary	  keratinocyte-­‐derived	  EXs	  
CD9*	  (CD9	  Antigen)	   CD9*	  
EEF1A1*	  (Eukaryotic	  Translation	  Elongation	  
Factor	  1	  Alpha	  1)	  
EEF1A1*	  
HSPA5*	  (Heat	  Shock	  Protein	  Family	  A	  Member	  
5)	  
HSPA5*	  
ITGA6*	  (Integrin	  Subunit	  Alpha	  6)	   ITGA6*	  
DES	  (Desmin)	   SDCBP*	  (Syndecan	  Binding	  Protein)	  
EEF1A2	  (Eukaryotic	  Translation	  Elongation	  
Factor	  1	  Alpha	  2)	  
CD82	  (CD82	  antigen)	  
EIF4A1	  (Eukaryotic	  Translation	  Initiation	  
Factor	  4a1)	  
DES	  
EIF4A2	  (Eukaryotic	  Translation	  Initiation	  
Factor	  4a2)	  
EEF1A2	  (Eukaryotic	  Translation	  
Elongation	  Factor	  1	  Alpha	  2)	  
GLA	  (Gla)	   GLA	  
GPRC5A	  (G	  Protein-­‐Coupled	  Receptor	  Class	  C	  
Group	  5	  Member	  A)	  
GPRC5A	  
LAMB3	  (Laminin	  Subunit	  Beta	  3)	   LAMB3	  
LIN7C	  (Lin-­‐7	  Homolog	  C)	   LIN7C	  
NT5E	  (5'-­‐Nucleotidase	  Ecto)	   NT5E	  
PDIA3	  (Protein	  Disulfide	  Isomerase	  Family	  A	  
Member	  3)	  
PDIA6	  (Protein	  Disulfide	  Isomerase	  
Family	  A	  Member	  6)	  
PDIA6	  (Protein	  Disulfide	  Isomerase	  Associated	  
6)	  
RPL24	  (Ribosomal	  Protein	  L2)	  
RPS27A	  (Ribosomal	  Protein	  S27a)	   RPS27A	  (Ribosomal	  Protein	  S27a)	  
TUBB1	  (Tubulin	  Beta	  1)	   SFN	  (Stratifin)	  
UBA52	  (Ubiquitin	  A-­‐52	  Residue	  Ribosomal	  
Protein	  Fusion	  Product	  1)	  
UBA52	  
UBB	  (Ubiquitin	  B)	   UBB	  
UBC	  (Ubiquitin	  C)	   UBC	  
 
* denotes proteins detected within the 100 most frequently identified proteins in the 
ExoCarta database. 
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Figure 4.6: Comparison of the proteins reported in ExoCarta and the 20 most 
abundant keratinocyte-derived exosomal proteins 
  
Proteins from the ExoCarta database were downloaded from the ExoCarta database 
(http://www.exocarta.org) and duplicates were removed to obtain 6514 known 
exosomal proteins. The 20 most abundant of the differentially expressed EX proteins 
were sorted from the 143 differently expressed proteins based on measured peak 
areas prior to a comparative analysis. The comparison of the reported exosomal 
proteins from the ExoCarta database with the 20 most abundant proteins from A) 
HaCaT-derived EX and B) primary keratinocyte-derived EXs was performed using 
an online Venn diagram tool (http://bioinformatics.psb.ugent.be/webtools/Venn/). 
 
 
 
 
 
 
 
 
 
6514 20 
ExoCarta database HaCaT-derived EXs 
6494 20 0 
A 
6514 20 
ExoCarta database Primary keratinocyte 
-derived EXs 
6494 20 0 
B 
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4.3.4 Functional classification and gene ontology analysis of total identified EV 
proteins 
As demonstrated in section 4.3.1, a large number of proteins were identified 
from EVs using mass spectrometry and FDR-controlled database searching. For the 
purpose of annotating the gene lists into biological terms and classes, the DAVID 
Informatics Resource 6.7 (NIH) was used (Huang et al., 2009a). The UniProt protein 
identifiers from this study were used as input and converted into DAVID identifiers, 
which were used for further analysis. A Gene Functional Classification component of 
the DAVID program was used to identify groups of proteins sharing similar 
biological functions. In addition, Gene Ontology (GO) analysis was used to classify 
the proteins into categories associated with biological processes, cellular components 
and molecular functions. Similarly, the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) tool was used to identify significant biochemical pathways to which the 
proteins belonged. 
 
4.3.4.1 Gene functional classification of identified proteins 
The DAVID Gene Functional Classification analysis revealed that most EVs 
contained ribosomal, Ras/Rab, proteasome, heat shock, tubulin, calcium binding, 
Na+/K+ transporting and keratin proteins. Closer examination of these select groups 
of proteins are described in the following sections (4.3.4.1.1 – 4.3.4.1.4). In addition, 
some common functional groups were present with high enrichment scores in 
addition to being significant (Appendix tables 4.4 – 4.9). Full details of results 
generated by Gene Functional Classification can be found in appendix tables 4.4 – 
4.9. 
 
4.3.4.1.1 Keratin proteins were prominent in both HaCaT- and primary keratinocyte-
derived EVs 
Under normal conditions, keratinocytes produce keratin proteins, which 
combine with other transmembrane and intracellular proteins to enable robust cell 
sheet formation in order to maintain the physical barrier of the skin (Haake et al., 
2001; Wikramanayake et al., 2014). In this current study, both HaCaT cell lines and 
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primary keratinocytes produced various keratin proteins, which were enriched in 
EVs. Generally, 18 keratin proteins were detected in all three populations of HaCaT-
derived EVs, while nine keratin proteins were detected in all three primary 
keratinocyte-derived EVs. The enrichment scores of keratin proteins in primary 
keratinocyte-derived EVs (Enrichment scores 6.9, 6.3 and 5.2, respectively, for APs 
in appendix table 4.5 group 7, MVs in appendix table 4.7 group 2, and EXs appendix 
table 4.9 group 8) were lower than those of HaCaT-derived EVs (Enrichment scores 
7.6, 15.2 and 7.5, respectively, for APs in appendix table 4.4 group 15, MVs in 
appendix table 4.6 group 3, and EX in appendix table 4.8 group 14). Enrichment 
scores rank the relative biological significance of gene groups, where a higher group 
score indicates the group members are more associated with the enriched roles 
(Huang et al., 2007).   
In terms of the keratin isoforms represented, seven keratin proteins (K), 
including K2, K5, K9, K10, K14, K15 and K17, were common to all EVs released 
from either HaCaT or primary keratinocyte cells. On the other hand, K78 was only 
associated with primary cell-derived EVs, whereas keratins K1, K4, K6, K7, K8, 
K13 and K19 were only associated with HaCaT-derived EVs. The high enrichment 
of keratin proteins in keratinocyte-derived EVs reflects the nature of keratinocytes 
and is therefore not particularly surprising.  
 
4.3.4.1.2 There were distinct differences in annexin and tetraspanin enrichment in 
HaCaT and primary keratinocyte-derived EVs  
In addition to keratin proteins, other members of the annexin (ANX) and 
tetraspanin (TSPAN) protein families were classified as being significantly enriched 
in EVs. Annexins are binding proteins, which are involved in regulation of many 
biological activities, such as cellular location, membrane organisation, and vesicle 
transport; some of these proteins are associated with diseases (reviewed in (Gerke et 
al., 2002)). Interestingly, EV annexins were recently found to have functions in some 
diseases (reviewed in (György et al., 2011)). In this present study, the Gene 
Functional Classification identified annexins as being highly enriched in all three EV 
populations which originated from HaCaT cells. With regard to the identified 
annexin isoforms, nine appeared as a functional group with high enrichment. These 
include ANXA1, ANXA2, ANXA3, ANXA4, ANXA5, ANXA7, ANXA8, ANXA8-
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like 2 and ANXA11. However, the relative distribution of these annexins was not 
identical in all EV populations. For example, seven out of nine ANX were enriched 
in HaCaT-derived APs and EXs, and eight out of nine ANX were enriched in 
HaCaT-derived MVs. Furthermore, ANXA8 and ANXA8-like 2 appeared in HaCaT-
derived MVs but not in HaCaT-derived APs and EXs; and the ANX7 appeared in 
HaCaT-derived APs and EXs, but not in HaCaT-derived MVs (Appendix table 4.4 
group 10, Appendix table 4.6 group 7, and Appendix table 4.8 group 11). However, 
with regard to primary keratinocyte-derived EVs, only 5 ANX proteins were 
classified in EXs, including ANXA3, ANXA4, ANXA7, ANXA11 and ANXA8-like 
1 (Appendix table 4.9, group 6), however, no ANXs were enriched in primary 
keratinocyte-derived APs and MVs. The differences in functional enrichment of the 
annexin proteins in EVs, which have different cellular origins, may suggest different 
roles for EVs derived from different cells of origin. In addition, given that some 
annexins were only enriched in specific EV populations, this might suggest that there 
are different roles for EVs associated with different annexin complements. 
The tetraspanins (TSPAN) are a family of membrane proteins which contribute 
to many important functional activities such as cell adhesion, proliferation, migration 
and activation, and are also believed to be associated with pathological conditions 
(reviewed in (Berditchevski et al., 2007)). In this current study, tetraspanins were 
only significantly enriched in the EXs released from both cell types. A total of five 
tetraspanins, including TSPAN1, TSPAN6, TSPAN14, TSPAN82 and TSPAN151, 
were classified in EXs with high enrichment scores (Appendix table 4.8 group 17, 
and appendix table 4.9 group 12). However, other tetraspanins, such as TSPAN28 
(CD81), TSPAN29 (CD9) and TSPAN30 (CD63), which are well known proteins as 
exosomal markers, were detected (see Appendix table 4.1 and 4.2) but were not part 
of a significantly enriched protein group according to the Gene Functional 
Classification tool. As such, tetraspanins were found across multiple EVs but only 
enriched in EXs, which indicates that the abundance of tetraspanins may be a distinct 
trait of this EX population and might be associated with the particular functions of 
EX. 
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4.3.4.1.3 RAS oncogene proteins are highly enriched in all HaCaT and primary 
keratinocyte-derived EVs  
The DAVID functional classification analysis revealed that RAB proteins were 
highly enriched in both HaCaT- and primary keratinocyte-derived EVs. Analysis was 
performed using the total list of identified proteins from the three HaCaT- and 
primary keratinocyte-derived EV populations. More specifically, the results from 
HaCaT-derived EV analysis showed that RAB groups were enriched in APs, MVs 
and EX released from HaCaT cells with high and significant enrichment scores 
(Enrichment scores 8.240, 7.978 and 5.185, respectively) (Appendix table 4.4 group 
14, appendix table 4.6 group 9, and appendix table 4.8 group 15). Upon closer 
examination of the number and types of RAB proteins, there were 23 RAB and 
RAB-related proteins enriched in HaCaT-derived APs, 10 RAB and RAB-related 
proteins enriched in HaCaT-derived MVs and 11 RAB and RAB-related proteins 
enriched in HaCaT-derived EXs. There were five RAB and RAB-related proteins 
enriched in all three EV populations, including RAB 10; RAB 7A; RAB 1B; ras 
homolog gene family – member C; and, v-ral simian leukemia viral oncogene 
homolog A (RALA).  Interestingly, all 11 RAB proteins enriched in HaCaT-derived 
EXs and nine out of 10 RAB proteins enriched in HaCaT-derived MVs were also 
enriched in HaCaT-derived APs.   
With regard to primary keratinocyte-derived EVs, many RAB and RAB-related 
proteins were also enriched in the three EV populations. There were 11 RAB and 
RAB-related proteins associated with primary keratinocyte-derived APs (Enrichment 
score 7.717, Appendix table 4.5 group 6); 10 RAB and RAB-related proteins 
associated with primary keratinocyte-derived MVs (Enrichment score 5.779, 
Appendix table 4.7 group 5); and 21 RAB and RAB-related proteins associated with 
primary keratinocyte-derived EXs (Enrichment score 12.572; Appendix table 4.9 
group 2). Specifically, there were seven RABs enriched in all three EVs, including 
RAB 35, RALA; RAB 1A; RAB 10; RAB 7A RAB 1B; and, ras homolog gene 
family – member C. The majority of RABs and RAB-related proteins enriched in 
APs (10 out of 11 proteins) and MVs (nine out of 10 proteins) were also enriched in 
EXs. Only the related RAS viral (r-ras) oncogene homolog 2 was unique to primary 
keratinocyte-derived APs, while RAB 6B was unique to primary keratinocyte-
derived MVs. 
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The above description regarding expression of the RAB/RAS - oncogenic 
family in EVs revealed that more RAB and RAB-related proteins enriched in 
HaCaT-derived APs than those in primary keratinocyte-derived EXs. This finding 
could be due to differences in cell culture conditions for cell line and primary 
keratinocytes, such as differences in nutrient complement required for primary cells 
(as described in cell culture section, chapter 2).  
 
4.3.4.1.4 Other important proteins enriched in HaCaT and primary keratinocyte-
derived EVs 
In addition to the above proteins, the gene functional classification analysis 
also revealed that other notable proteins such as tubulin, myosin, histones, and 
proteasome proteins, among others, were also highly enriched in the EVs. Tubulin is 
a globular protein, found in various eukaryotic cells in many forms and plays 
important roles in cell structures and functions, especially in microtubule formation 
(reviewed in (Downing, 2000; Kavallaris, 2010)). There were three types of tubulin, 
including alpha, beta and gamma, enriched within the MVs and EXs released from 
HaCaT cells and APs and EXs released from primary keratinocytes (Appendix table 
4.6 group 6, appendix table 4.8 group 8, appendix table 4.5 group 5, and appendix 
table 4.9 group 3). The alpha and beta tubulins, specifically, α1a, α1c, α4a, β2a, β2c, 
β5 and β6 were the most enriched tubulin isoforms in this current study. 
Interestingly, the γ isoform appeared only in HaCaT-derived EXs while the delta and 
epsilon isoforms, which might play roles in cell mitosis, were not enriched in any 
EVs in this current study.  
Histone proteins were also enriched in all three HaCaT-derived EV populations 
(Appendix table 4.4 group 8, Appendix table 4.6 group 8, and Appendix table 4.8 
group 6), but were not enriched in primary keratinocyte-derived EVs. Specifically, 
five histone families, including H1, H2A, H2B, H3 and H4, were represented in 
HaCaT-derived EVs. Taken together, these findings suggest that the presence of EV 
histones may reflect the physiological conditions of the parental cells. 
To summarise, the functional protein classification enrichment data revealed 
many protein groups that are important to the different EV populations. Some of 
these, including keratin, ribosomal, RAB and annexin-related terms, were detected in 
EVs that were released from both HaCaT cells and primary keratinocytes; however, 
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some functional terms, for example histones and tetraspanins, were specifically 
enriched in EVs associated with cellular origin or EV population (e.g. tetraspanins in 
EXs or histones in HaCaT-derived EVs). In addition, this analysis identified some 
functional terms that were common to multiple EV populations; however, these 
terms had variable enrichment scores across the different EV populations suggesting 
that these functions may have variable importance depending on the EV population.  
 
4.3.4.2 Gene Ontology analysis of identified HaCaT and primary keratinocyte-
derived EV proteins  
A Gene Ontology (GO) enrichment analysis was performed on the total list of 
proteins identified by MS, using the DAVID informatics web server. These analyses 
were performed in order to summarise deeper information associated with specific 
biological processes (BP), cellular components (CC) or molecular functions (MF). 
Lists of identified UniProt protein accession numbers were uploaded and analysed 
using DAVID as per the description above. Of note, not all proteins identifiers were 
successfully converted from UniProt identifiers to DAVID IDs. This could be due to 
some input accessions not being associated with any gene IDs in the DAVID 
knowledgebase. Accordingly, the analyses were performed using only the converted 
identifiers; with the level of identifier conversion reported with each biological 
interpretation.  
 
4.3.4.2.1 Involvement of identified EV proteins in biological processes 
In general, the top ten BP GO terms (ranked by p-value) associated with 
HaCaT- and primary keratinocyte-derived EV proteins were different between the 
two cell types. More specifically, with the exception of HaCaT-derived APs, the BPs 
related to translation and translational elongation, were represented in each EV 
population from both HaCaT and primary keratinocytes (Figure 4.7). Interestingly, 
there were no common BP terms shared between the two AP populations (Figure 4.7 
A and D). 
In terms of HaCaT-derived EVs, the GO terms of regulation of apoptosis; 
regulation of programmed cell death; positive regulation of programed cell death; 
regulation of cell death; positive regulation of cell death; and response to wounding 
were associated with APs but no other EVs (Figure 4.12 A, B and C). Interestingly, 
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carbohydrate catabolic processes and terms associated with actin; and cytoskeleton 
arrangement constituted the majority of terms related to HaCaT-derived MVs (Figure 
4.7 B). Furthermore, the top ten GO terms for HaCaT-derived EXs were associated 
with the ubiquitination process, including: anaphase-promoting complex-dependent 
proteasomal ubiquitin-dependent protein catabolic process; negative regulation of 
ubiquitin-protein ligase activity during mitotic cell cycle; negative regulation of 
ubiquitin-protein ligase activity; and, regulation of ubiquitin-protein ligase activity 
during the mitotic cell cycle (Figure 4.7 C). Taken together this suggests that each 
HaCaT-derived APs were enriched with proteins associated with regulation of cell 
death; while MVs were enriched with proteins associated with cell mobility and 
cytoskeletal organisation; and EXs with proteasomal degradation and ubiquitin 
dependent processes. 
On the other hand, the top ten BP GO terms arising from the primary 
keratinocyte-derived APs also included ubiquitination associated terms. These terms 
included: anaphase-promoting complex-dependent proteasomal ubiquitin-dependent 
protein catabolic process; negative regulation of ubiquitin-protein ligase activity 
during the mitotic cell cycle; negative regulation of ubiquitin-protein ligase activity; 
positive regulation of ubiquitin-protein ligase activity during the mitotic cell cycle; 
positive regulation of ubiquitin-protein ligase activity; and, regulation of ubiquitin-
protein ligase activity during the mitotic cell cycle (Figure 4.7 D). Interestingly, the 
top ten GO terms for primary keratinocyte-derived MVs included terms associated 
with epidermal activities, such as: epidermis development; epithelial cell 
differentiation; keratinocyte differentiation; epidermal cell differentiation; and, 
epithelium development (Figure 4.7 E). While, the top ten BP GO terms in primary 
keratinocyte-derived EXs included the terms: vesicle-mediated transport; cell 
adhesion; and biological adhesion (Figure 4.7 F). These data indicate that primary 
keratinocyte-derived APs were enriched with proteins associated with ubiquitin-
dependent process; while MVs were enriched with proteins associated regulation of 
the epithelium, and EXs were enriched with proteins associated with cell interaction 
and attachment. 
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Figure 4.7: Top 10 biological process GO terms associated with EV-derived proteins.  
 
GO term enrichment analysis was performed on all identified proteins for each EV 
population using DAVID Bioinformatics Resources prior to ranking and identifying 
the 10 most significant GO BP terms for HaCaT-derived A) APs; B) MVs; C) EXs; 
and Primary keratinocyte derived D) APs; E) MVs; and F) EXs. Data are presented 
as Fold enrichment for each biological process term. GO terms were ranked by p-
value most significant to least significant from left to right. Numbers on bars 
indicates numbers of genes/proteins associated with that term. AP - Apoptotic 
bodies; MV - microvesicles; EX – exosomes; PKC - primary keratinocytes; PCD - 
programmed cell death; APCDPUDPCP - anaphase-promoting complex-dependent 
proteasomal ubiquitin-dependent protein catabolic process; UPLADMCC - ubiquitin-
protein ligase activity during mitotic cell cycle; UPLA - ubiquitin-protein ligase 
activity; LA - ligase activity; NROUPLA - negative regulation of ubiquitin-protein 
ligase activity; NROPMP - negative regulation of protein modification process; 
ROUPLADMCC - regulation of ubiquitin-protein ligase activity during mitotic cell 
cycle; (-) - negative, (+)  - positive. 
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4.3.4.2.2 Distribution of identified EV proteins according to subcellular location 
The CC ontology provides information about the sub-cellular location of 
particular proteins, which include parts of cells or their extracellular environments. 
Analysis of EV proteins within the CC ontology generally revealed that all EV 
populations examined shared proteins associated with the cytosol (Figure 4.8 A - F). 
In addition, the term pigment granule was represented in all EV populations except 
HaCaT-derived MVs, while the term cytosolic part was represented in all EV 
populations except HaCaT APs. Moreover, proteins, which were associated with 
organelles, were also prevalent within most of the EV populations released from both 
HaCaT and primary keratinocytes (Figure 4.8 B, C, D, and E). 
While some of the top ten GO terms were represented in all EV populations, a 
subset of these were unique to individual EV populations that originated from the 
different cell types. In this regard, ribosomal proteins were enriched in HaCaT 
derived-MVs and EXs and primary keratinocyte-derived APs. Interestingly, vesicle-
related proteins were only represented in the top ten GO terms for HaCaT derived-
APs and primary keratinocyte-derived EXs (membrane-bound vesicle; vesicle; 
cytoplasmic vesicle; and, cytoplasmic membrane-bounded vesicle). In addition, some 
of CC terms related to the plasma membrane appear in primary keratinocyte-derived 
MVs and primary keratinocyte-derived EXs (plasma membrane; and, plasma 
membrane part) and HaCaT-derived APs (plasma membrane part; and, external side 
of plasma membrane), but do not appear in the top ten GO terms associated with 
HaCaT-derived MVs, HaCaT-derived EXs and primary keratinocyte-derived APs. 
Finally, only primary keratinocyte-derived MVs exhibited proteins associated with 
melanosome and actin cytoskeleton terms. Taken together, many of the top ten over 
represented CC GO terms were associated with proteins from most of the EV 
populations examined with a few distinct differences among the EVs (Figure 4.8). 
Generally, proteins associated with the cytosol and organelles were common to all 
EVs. In addition, proteins associated with the plasma membrane and ribosomes 
seemed to be associated with particular EV populations and EV origin. 
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Figure 4.8: Top 10 cellular component GO terms associated with EV-derived 
proteins.  
 
GO term enrichment analysis was performed on all identified proteins for each EV 
population using DAVID Bioinformatics Resources prior to ranking and identifying 
the 10 most significant GO CC terms for HaCaT-derived A) APs; B) MVs; C) EXs; 
and Primary keratinocyte derived D) APs; E) MVs; and F) EXs. Data are presented 
as Fold enrichment for each CC term. GO terms were ranked by p-value most 
significant to least significant from left to right. Numbers on bars indicates numbers 
of genes/proteins associated with that term. AP - Apoptotic bodies; MV - 
microvesicles; EX - exosomes; PKC - primary keratinocytes; CMBV - cytoplasmic 
membrane-bounded vesicle; NMBO - non-membrane-bounded organelle; INMBO - 
intracellular non-membrane-bounded organelle; CLRS - cytosolic large ribosomal 
subunit; CSRS - cytosolic small ribosomal subunit.  
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4.3.4.2.3 Different activities of identified proteins at molecular level 
The MF ontology describes activities that a gene product is associated with at 
the molecular level. The ten most significant MF GO terms, as ranked by p-value, 
indicated that the proteins in most EV populations, except for HaCaT-derived APs, 
were associated with the MF GO terms: structural molecule activity; structural 
constituents of cytoskeletons; and GTPase activity (Figure 4.9 A - F). Indeed, APs 
which originated from the two cell types did not share any of their respective top-ten 
GO terms. The two MV populations shared four GO terms (structural molecule 
activity; structural constituent of cytoskeleton; GTPase activity; and, actin binding); 
likewise, the two EX populations also shared four GO terms (structural molecule 
activity; structural constituent of cytoskeleton; GTPase activity; and, nucleotide 
binding). With respect to EV populations within each cell type, there were few 
differences in the ten most significant MF GO terms. For instance, six GO terms 
were represented in both HaCaT-derived MVs and EXs, while five GO terms were 
present in all three EVs released from primary keratinocytes. Collectively, these 
indicate that keratinocyte-derived EV proteins involved with activities associated 
with cellular structure and cellular movement through cytoskeletal filaments. 
Interestingly, the GO terms associated with cytokine activity, chemokine 
activity, chemokine receptor binding and growth factor activity appeared in the top 
ten most significant GO terms for HaCaT-derived APs but were not represented in 
the ten most significant GO terms for the other EV populations. This suggests that 
HaCaT-derived APs contain a distinct set of proteins associated with cellular 
signalling compared to primary keratinocyte-derived EVs and other HaCaT-derived 
EVs.  
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Figure 4.9: Top ten molecular function GO terms associated with EV-derived 
proteins 
 
GO term enrichment analysis was performed on all identified proteins for each EV 
population using DAVID Bioinformatics Resources prior to ranking and identifying 
the 10 most significant GO MF terms for HaCaT-derived A) APs; B) MVs; C) EXs; 
and Primary keratinocyte derived D) APs; E) MVs; and F) EXs. Data are presented 
as Fold enrichment for each MF term. GO terms were ranked by p-value most 
significant to least significant from left to right. Numbers on bars indicates numbers 
of genes/proteins associated with that term. AP - Apoptotic bodies; MV - 
microvesicles; EX - exosomes; PKC - primary keratinocytes; LAFAtRNA - ligase 
activity, forming aminoacyl-tRNA and related compounds, TFA - transcription factor 
activity.  
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In summary, GO term analysis revealed that keratinocyte-derived EV proteins 
were commonly associated with terms such as translation (BP), cytosol and the 
plasma membrane (CC), and structural molecular activity (MF). In addition, the GO 
analysis classified proteins into distinct functional groups which showed some 
relationship with EV cellular origins and EV populations.  
 
4.3.4.3 SNARE proteins were over represented in primary keratinocyte-derived 
EXs 
Soluble N-ethylmaleimide-sensitive fusion (NSF) Attachment Protein (SNAP) 
Receptor (SNARE) proteins are involved in various trafficking events of cellular 
secretory pathways, especially the fusion of lysosomes with plasma membranes 
(Jahn et al., 1999; Nehme et al., 2011; Rao et al., 2004; Scheller et al., 2001). GO 
term analysis of the EV proteome data revealed that SNARE family proteins were 
only detected in primary keratinocyte-derived EXs and they were over-represented in 
the SNARE complex CC and SNARE binding MF GO terms (Table 4.4). Furthermore, 
analysis of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway also 
revealed proteins related to SNARE interactions in vesicular transport (Table 4.4). In 
a thorough examination of these terms, five proteins, including syntaxin 3, syntaxin 
4, syntaxin 7, vesicle-associated membrane protein 8 (VAMP 8) and syntaxin 
binding protein 2 were associated with the SNARE complex GO term (p<0.05). 
Moreover, caveolin 1, syntaxin 4, syntaxin binding protein 2 and syntaxin binding 
protein 3 were represented in the molecular function category SNARE binding; 
however, this GO term was not statistically significant (p>0.05). Further KEGG 
analysis revealed the same group of proteins, namely, syntaxin 3, syntaxin 4, 
syntaxin 7 and VAMP 8 to be over-represented in hsa04130:SNARE interaction in 
vesicular transport category (p<0.05). These data suggest that primary keratinocyte-
derived EX proteins may be associated specifically with endosome / lysosome 
fusion, whereas AP and MV proteins were not (compared to whole genome). 
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Table 4.4: Proteins over-represented in GO terms enriched in primary keratinocyte-
derived EXs. 
 
Category	   GO	  term	   Uniprot-­‐
accession	  
Gene	  ID	   Gene	  name	  
CC	   GO:0031201~SNAR
E	  complex	  
(p-­‐value:	  0.0001)	  
801103	   Q7Z338	   syntaxin	  3	  
797724	   Q9BV40	   vesicle-­‐associated	  
membrane	  protein	  8	  
(VAMP	  8)	  (endobrevin)	  
799691	   Q12846	   syntaxin	  4	  
796393	   O15400	   syntaxin	  7	  
784690	   Q53GF4	   syntaxin	  binding	  protein	  
2	  
MF	   GO:0000149~SNAR
E	  binding	  	  
(p-­‐value:	  0.07)	  
798707	   Q59E85	   caveolin	  1,	  caveolae	  
protein,	  22kDa	  
799691	   Q12846	   syntaxin	  4	  
784690	   Q53GF4	   syntaxin	  binding	  protein	  
2	  
790717	   O00186	   syntaxin	  binding	  protein	  
3	  
KEGG	   hsa04130:SNARE	  
interactions	  in	  
vesicular	  transport	  
(p-­‐value:	  0.017)	  
801103	   Q7Z338	   syntaxin	  3	  
797724	   Q9BV40	   vesicle-­‐associated	  
membrane	  protein	  8	  
(VAMP	  8)	  (endobrevin)	  
799691	   Q12846	   syntaxin	  4	  
796393	   O15400	   syntaxin	  7	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4.3.4.4 Endocytosis pathway proteins were uniquely detected in primary 
keratinocyte-derived EXs 
Endocytosis is a mechanism for cells to bring extracellular materials, ligands, 
plasma membrane proteins and lipids into the cell interior (reviewed in (Doherty et 
al., 2009)). Importantly, the process of endocytosis can be divided into either 
clathrin-dependent or clathrin-independent mechanisms (reviewed in (Doherty et al., 
2009)). The proteinaceous cargo, which is located in the lumen or on the membranes 
of endocytic vesicles, are usually delivered to early endosomes, which are then 
developed into late endosomes and then lysosomes for degradation (reviewed in 
(Grant et al., 2009)), or multivesicular bodies for the release of their contents into the 
extracellular environment (reviewed in (Raposo et al., 2013)). KEGG pathway 
analysis revealed 17 significantly over-represented proteins from primary 
keratinocyte-derived EXs, but not in HaCaT-derived EXs, that are involved in 
endocytosis pathways (Table 4.5). Interestingly, the proteins detected in this study 
contribute to both clathrin-dependent and clathrin-independent endocytosis (Figure 
4.10). These data suggest that exosome proteins are associated with both mechanisms 
of clathrin-dependent and clathrin-independent endocytosis.  
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Table 4.5: List of proteins involved in endocytosis pathway 
 
Term	  
	  
Uniprot_	  
accession	  
Gene	  ID	   Gene	  name	  
hsa04144:	  
Endocytosis	  
825257	   Q6FH17	   ADP-­‐ribosylation	  factor	  6	  (ARF6)	  
816782	   P50570	   dynamin	  2	  (DNM2)	  
783723	   P09496	   clathrin,	  light	  chain	  (Lca)	  (CLTA)	  
793120	   Q32Q67	   dynamin	  1-­‐like	  (DNM1L)	  
810446	   Q15907	   RAB11B,	  member	  RAS	  oncogene	  family	  
822885	   Q8WUM4	   programmed	   cell	   death	   6	   interacting	  
protein	  (PDCD6IP)	  
777903	   Q95IG6	   major	   histocompatibility	   complex,	   class	   I,	  
A	  (HLA-­‐A)	  
777280	   Q68DI0	   adaptor-­‐related	  protein	  complex	  2,	  beta	  1	  
subunit	  (DKFZp781K0743)	  
800006	   Q9NZN3	   EH-­‐domain	  containing	  3	  (EHD3)	  
816368	   Q2TTR7	   epidermal	   growth	   factor	   receptor	  
(erythroblastic	   leukemia	   viral	   (v-­‐erb-­‐b)	  
oncogene	  homolog,	  avian)	  
774518	   Q9UH51	   low	  density	  lipoprotein	  receptor	  (LDLR)	  
789566	   Q99816	   tumor	  susceptibility	  gene	  101	  (TSG101)	  
775531	   Q59EJ3	   heat	   shock	   70kDa	  protein	   1A;	   heat	   shock	  
70kDa	  protein	  1B	  (HSP70)	  
816167	   P12931	   v-­‐src	   sarcoma	   (Schmidt-­‐Ruppin	   A-­‐2)	   viral	  
oncogene	  homolog	  (avian)	  (SRC)	  
804309	   Q9UL26	   RAB22A,	  member	  RAS	  oncogene	  family	  
818808	   Q9MYI6	   major	   histocompatibility	   complex,	   class	   I,	  
C;	  major	  histocompatibility	  complex,	  class	  
I,	  B	  (HLA-­‐B57)	  
775489	   Q548N1	   vacuolar	   protein	   sorting	   28	   homolog	   (S.	  
cerevisiae)	  (VPS28)	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Figure 4.10: Involvement of identified proteins from primary keratinocyte-derived EXs in different nodes of the endocytosis network.  
 
Primary keratinocyte-derived exosomal proteins that were over-represented in endocytosis pathways, according to KEGG analysis from DAVID 
Bioinformatics Resources, were highlighted (red) within an endocytosis network diagram using the online KEGG website 
(http://www.genome.jp/kegg/pathway.html). The process showed the EX proteins associated with both clathrin-dependent and clathrin-
independent endocytosis mechanisms. 
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4.3.4.5 ECM-receptor interaction pathways were more specifically associated with 
proteins from HaCaT-derived EXs and primary keratinocyte-derived EVs 
The extracellular matrix (ECM) is a complex mixture of extracellular 
molecules secreted by cells that play important roles in cell and tissue maintenance in 
addition to tissue and organ morphogenesis. Furthermore, the formation of the ECM 
is essential for many biological processes, such as cell growth, adhesion, 
differentiation and migration all of which are important functions of keratinocytes 
(Olczyk et al., 2014). Among the various proteins necessary for formation of the 
ECM and ECM-receptor interaction, some major protein families include: collagens; 
laminins; integrins; tenascins; and proteoglycans (Bosman et al., 2003). Interestingly, 
KEGG pathway analysis revealed that EV proteins were associated with ECM-
receptor interaction pathways (Table 4.6). These include collagens; laminins; 
integrins; tenascins; and thrombospondin, which were detected in all three primary 
keratinocyte-derived EVs and only HaCaT-derived EXs (Appendix table 4.1 and 
4.2). There were no identified EV proteins from HaCaT-derived APs and MVs that 
were over-represented in the ECM-receptor interaction pathways. Interestingly, more 
EX proteins were associated with ECM-receptor interaction (11 proteins from 
HaCaT-derived EXs and 15 proteins from primary keratinocyte-derived EXs) 
compared to those of other EVs (eight proteins from primary keratinocyte-derived 
APs, and seven proteins from primary keratinocyte-derived MVs) (Table 4.6). 
Proteins associated with ECM-receptor interactions which were detected in all three 
primary keratinocyte-derived EVs included laminin γ2, laminin β3, integrin β1, 
integrin β3 and integrin α2. Proteins associated with ECM and ECM-receptor 
interaction, which were over-represented in both HaCaT-derived EXs and primary 
keratinocyte-derived EXs, included agrin, integrin and laminin. Other ECM proteins, 
such as tenascin, syndecan, collagen and thrombospodin, were detected in primary 
keratinocyte-derived EXs only; while the ECM proteins, CD44 and CD47 were only 
detected in HaCaT-derived EXs (Table 4.6). The 15 proteins from primary 
keratinocyte-derived EXs associated with ECM-receptor interactions, including 
members of the tenascin, laminin, integrin, collagen, syndecan, argin and 
thrombospondin families, are highlighted in red in Figure 4.11. The presence of more 
ECM proteins within primary keratinocyte-derived EVs suggest that EVs that 
originate from primary keratinocytes may have greater ability to interact with ECM 
and other cells. In addition, more ECM proteins were detected in EXs compared to 
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APs and MVs released from both cell types and this may indicate that selective ECM 
proteins are secreted via an EX pathway. 
 
Table 4.6: Keratinocyte-derived EX proteins involved in the ECM / ECM-receptor 
interactions 
 
Terms Gene ID Gene symbol Gene Name 
 HaCaT-derived EXs 
 
hsa04512:ECM-
receptor interaction 
(p-value: 0.02) 
812867 CD44 CD44 molecule  
796133 CD47 CD47 molecule 
784347 AGRN agrin 
 826111 ITGA2 integrin, alpha 2  
787106 ITGA3 integrin, alpha 3  
780476 ITGA6 integrin, alpha 6 
784977 ITGB1 integrin, beta 1  
777632 ITGB4 integrin, beta 4 
798108 LAMA5 laminin, alpha 5 
822774 LAMB3 laminin, beta 3 
801278 LAMC2 laminin, gamma 2 
Primary keratinocyte-derived APs 
 
hsa04512:ECM-
receptor interaction 
(p-value: 0.031) 
812867 CD44 CD44 molecule  
800291 FN1 fFibronectin 1 
826111 ITGA2 Integrin, alpha 2  
780476 ITGA6 Integrin, alpha 6 
784977 ITGB1 Integrin, beta 1 
822774 LAMB3 Laminin, beta 3 
801278 LAMG2 Laminin, gamma 2 
817654 THBS1 Thrombospondin 1 
Primary keratinocyte-derived MVs 
 
hsa04512:ECM-
receptor interaction 
(p-value: 0.005) 
808600 COL1A1 Collagen, type I, alpha 1 
800291 FN1 Fibronectin 1 
826111 ITGA2 Integrin, alpha 2  
780476 ITGA6 Integrin, alpha 6 
784977 ITGB1 Integrin, beta 1  
822774 LAMB3 Laminin, beta 3 
801278 LAMG2 Laminin, gamma 2 
Primary keratinocyte-derived EXs 
 
hsa04512:ECM-
784347 AGRN agrin 
779750 COL6A1 collagen, type VI, alpha 
1 
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receptor interaction 
(p-value: 5.62E-06) 
797879 COL6A3 collagen, type VI, alpha 
3 826111 ITGA2 integrin, alpha 2  
816421 ITGA4 integrin, alpha 4  
780476 ITGA6 integrin, alpha 6 
784977 ITGB1 integrin, beta 1  
798108 LAMA5 laminin, alpha 5 
822774 LAMB3 laminin, beta 3 
823371 LAMC1 laminin, gamma 1 
801278 LAMC2 laminin, gamma 2 
776586 SDC1 syndecan 1 
805802, 805802 TNC tenascin C 
817654 THBS2 thrombospondin 1 
809884 THBS1 thrombospondin 2 
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Figure 4.11: Involvement of exosomal proteins originating from primary 
keratinocytes in ECM-receptor interaction pathway 
  
Primary keratinocyte-derived exosomal proteins that were over-represented in ECM-
receptor interaction pathways, according to KEGG analysis from DAVID 
Bioinformatics Resources, were highlighted (red) within an ECM-receptor 
interaction network diagram using the online KEGG website 
(http://www.genome.jp/kegg/pathway.html). Very late antigen (VLA) proteins are 
integrins. 
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4.4 DISCUSSION 
Overall the data presented in this chapter show that a large number of proteins 
were identified in the three different EV populations released from the HaCaT cell 
line and primary keratinocytes. These identified EV proteins were differentially 
distributed APs, MVs and EXs and were classified into various functional groups. In 
addition, the abundance and distribution of specific classes and groups of proteins 
potentially reveal underlying functional roles for each particular EV population.  
 
EV protein distribution 
Over the past decade, EVs have been recognised as potential candidates for 
intercellular communication due to their capacity for transfer of their contents, 
including proteins, lipids and genetic material, to target cells. As a consequence, 
there have been an increasing number of studies that have examined EVs released by 
various cell types and isolated from cell culture media and biological fluids 
(reviewed in (Ya´n˜ez-Mo´ et al., 2015)). Among those EV studies, many have 
involved proteomics-based evaluation (Ya´n˜ez-Mo´ et al., 2015). The complement 
of proteins incorporated into different EV populations during the formation and 
release process, is crucial for elucidating EV biogenesis, origins and functions. Such 
EV protein profiles depend not only on the parental cell of origin and biological 
conditions prior to and during secretion, but also on technical conditions such as 
during EV isolation and protein identification methods (Ya´n˜ez-Mo´ et al., 2015). In 
an effort to better understand the details of each EV population’s protein 
complement, a differential centrifugation approach was utilised to separate three 
populations of EVs, including APs, MVs and EXs, which were released from either 
HaCaT or primary keratinocyte cell cultures. As may be expected, this current study 
identified a large number of proteins in all three EV populations derived from both 
human HaCaT cell line and primary epidermal keratinocytes that also revealed 
protein sets common to all EV populations or unique to particular EV populations 
(Figure 4.1). This is consistent with previous comparisons which have also shown 
that EVs from cells of common origins share a common set of proteins, but also 
carry their own unique suite of proteins (Keerthikumar et al., 2015). Moreover, the 
number of identified proteins derived from MVs, investigated in this study, was 
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substantially lower than those derived from APs and EXs, even though the amount of 
total protein subjected to tryptic digestion and LC-MS/MS analysis was equivalent 
(Figure 4.1). This could be explained by the complexity and dynamic range of 
samples and different mechanism of formation and release (Kreimer et al., 2015).  
The number of proteins identified and reported herein was determined from the 
combined analysis of three independent biological replicates. Thus, it is possible that 
some proteins may have only been identified in a single replicate but were still 
included in the total protein inventory. Each biological replicate contained a distinct 
subset of identified proteins (Appendix table 4.1) the specific composition of which, 
may have resulted from cells which generated EVs at slightly different states of 
differentiation or from differences related to the physiological condition of each skin 
donor (for primary keratinocytes), or slight differences in the confluence of cells 
producing the EVs (for both primary keratinocytes and HaCaT cells). Therefore, it is 
possible that some of the differences reported herein are influenced by either 
biological or technical variation.  
In the study described herein, 143 out of 1662 quantified proteins were found 
to have significantly different abundance between the three populations of EV 
populations. The trend in protein abundance levels was similar between APs and 
MVs, but differed to EXs potentially indicating that MVs and APs, may be more 
closely related while exosomes may be a more distinct class of EVs. These 
differences in protein complement abundance levels between EV populations were 
observed previously and could be due to the different formation and release 
mechanisms, which are known to sort specific protein sets into specific EV 
populations. For instance, APs are products of apoptosis, MVs are shed directly from 
the cell plasma membrane, and EXs are known to have an endocytotic origin (Choi et 
al., 2012; Jeppesen et al., 2014a; Keerthikumar et al., 2015; Turiák et al., 2011). 
In order to determine the actual differences between separate EV populations, 
comparisons should be made between EV populations that originate from a single 
cell source. However, there are few such comparative investigations of EV 
populations reported in the literature, therefore individual investigations on different 
EV populations released from a single cell type could show general distinctions 
instead. Reviews from György et al. (2011) and the Ya´n˜ez-Mo et al. (2015) 
summarised data from research groups worldwide, indicating that all EVs are 
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generally enriched with cytoskeletal proteins, cytosolic proteins, nuclear and plasma 
membrane proteins which is supported by the data presented in this current study 
(Figure 4.9 and 4.13) (György et al., 2011; Ya´n˜ez-Mo´ et al., 2015). However, 
MVs were also highly enriched with mitochondrial proteins and lower levels of 
Golgi, endoplasmic reticulum and lysosomal proteins (György et al., 2011). In 
addition to the intracellular origin of EV proteins, the functional classification of EV 
proteins provided potential biological roles for the EV populations.  
The inconsistent expression of protein markers analysed by Western Blot and 
reported in chapter 3 was re-examined within the mass spectrometry data reported in 
this chapter. Only five out of six EV markers were identified, excluding AGO2. It 
could be that the AGO2 protein was destroyed by the sample processing steps in 
preparation for LC-MS/MS. Furthermore, the tetraspanins CD9 and CD63, were 
determined to be more abundant in EX fractions compared to APs and MVs (Table 
4.1 and 4.2). This indicates that CD9 and CD63 may be present in all three EV types, 
but they were expressed in higher levels in EXs than in MVs and APs, which may 
have led to the positive immunoreactivity observed exclusively in the EX fraction 
but not in MVs and APs as reported in Chapter 3.  
 
Protein components associated EV biogenesis 
Identified proteins associated with EX biogenesis 
EXs are thought to have an endocytic origin and are released to the 
extracellular environment via exocytosis, which suggests that EXs could carry 
proteins specifically related to the endocytic pathways and trafficking mechanisms 
(reviewed in (Urbanelli et al., 2013)). For the study described herein, RAB and 
SNARE proteins, which are involved in membrane trafficking and secretory 
pathways (Frühbeis et al., 2013; Hsu et al., 2010; Ostrowski et al., 2010; Savina et 
al., 2002; Teng et al., 2001) and proteins associated with endocytosis pathway were 
associated with EXs (Appendix table 4.1 and 4.2, Appendix table 4.5, Figure 4.15).  
RAB proteins are a part of the RAS oncogene family and in humans, consist of 
more than 60 proteins, most of which play a role in regulation of various steps in 
membrane trafficking pathways (reviewed in (Stenmark, 2009)). Of particular 
interest to this author, RAB 11, RAB 35 and RAB 27, which were identified in this 
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study (Appendix table 4.1 and 4.2), are involved in endosome recycling, early 
endosome sorting and late endosome secretion, respectively (Kouranti et al., 2006; 
Ostrowski et al., 2010; Ullrich et al., 1996). Previously, RAB 35 was also confirmed 
to be involved in EX release through facilitation of multivesicular body (MVB) 
docking to the plasma membrane and subsequent release of proteolipid protein-
carrying EXs (Frühbeis et al., 2013; Hsu et al., 2010). In addition, inhibition studies 
of RAB 27A, RAB 27B, RAB 2B, RAB 5A, RAB 9A and RAB 11 led to a decrease 
in EX release in both the human HeLa and erythroleukemia cell lines (Ostrowski et 
al., 2010; Savina et al., 2002). However, in retinal epithelial cells, both RAB 11 and 
RAB 35 enhanced the release of EXs containing flotillin and anthrax toxin, but RAB 
27A and RAB 27B did not (Abrami et al., 2013). These studies reveal the varied 
involvement of RABs with EX formation and release, which may depend on the 
specific composition of RABs in each specific EV population. Taken together, the 
RAB distribution in different EV populations and how these RABs may be involved 
in EX biogenesis are complex. In order to more clearly understand the roles of this 
important family of proteins in relation to their influence over EV biology requires 
more investigation.  
SNARE proteins are involved in various intracellular trafficking events and 
secretory pathways with more than one hundred SNARE proteins discovered in 
diverse organisms (Fader et al., 2009; Jahn et al., 1999; Rao et al., 2004; Scheller et 
al., 2001). SNARE proteins were originally classified as: v-SNARE and t-SNARE 
(v: vesicle; t: target), based on either a vesicle or target membrane location of the 
particular SNARE protein of interest (Söllner et al., 1993); or R-SNAREs (arginine-
containing SNAREs) and Q-SNAREs (glutamine-containing SNAREs), based on 
their highly conserved residues (Fasshauer et al., 1998). The role of SNARE proteins 
in membrane fusion has been investigated and they are thought to be involved in 
specific intracellular trafficking steps, endocytosis and exocytosis (reviewed in 
(Scheller et al., 2001; Teng et al., 2001)). In this study, GO term enrichment analysis 
indicated that SNARE proteins were significantly over represented exclusively in 
primary keratinocyte-derived EXs, despite the identification of SNARE proteins in 
other EVs (Table 4.6, Appendix table 4.1 and 4.2). Some SNARE proteins are 
involved in the fusion of lysosomes with plasma membranes (Nehme et al., 2011; 
Rao et al., 2004), but practical evidence of SNARE involvement in EX secretion and 
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MV shedding remains to be investigated. Preliminary evidence has shown the 
requirement of R-SNARE Ykt6 protein (in HECK293 cells and Drosophila cells) in 
the secretion of Wnt (Wingless-related integration site) via EX pathways (Gross et 
al., 2012), and syntaxin 1a (in Drosophila S2 cells) for Evi (Evenness interrupted)-
carrying EX release (Koles et al., 2012). In contrast, a down-regulation of Ykt6 and 
syntaxin 1 increased exosome secretion in Hela cells (Colombo et al., 2014). These 
data indicate that distinct SNAREs may be involved in the fusion of specific 
organelles and EV populations in individual cell types.  
 
Identified proteins associated with MV biogenesis 
The mechanisms involved in MV formation and release are incompletely 
understood. This complex process requires a change of plasma membrane 
components at the vesicle formation site and requires coordinated action of 
cytoskeletal proteins (actin and microtubules), molecular motor proteins (myosin and 
kinesins), molecular switches (small GTPases) and membrane fusion machinery 
(SNARE and tethering factors) (reviewed in (Muralidharan-Chari et al., 2010)). 
More specifically, studies in a melanoma cell line found that ADP-ribosylation factor 
6 (ARF6), a small GTPase, was involved in MV biogenesis via stimulation of 
phospholipase D activity. This in turn resulted in extracellular signal-regulated 
kinase (ERK) mediated phosphorylation of myosin light chain and an increase in the 
contraction of actin-based cytoskeletal structures at vesicle necks and the subsequent 
release of MVs (Muralidharan-Chari et al., 2009). In this study, ARF6 was only 
detected in HaCaT-derived MVs (Appendix table 4.1), which is consistent with the 
presence of this protein in tumor-derived MVs (D'Souza-Schorey Crislyn et al., 
2012; Muralidharan-Chari et al., 2009). However, the ARF6 was not detected in 
primary keratinocyte-derived MVs raising the question as to whether or not ARF6 
was sorted to MVs during formation in this cell type. In addition to ARF6, myosin, 
which is a motor element associated with vesicle transport (Ã‘eco et al., 2004; Rosé 
et al., 2003), was also detected in this current study. The involvement of myosin in 
MV release has been reported previously, but interestingly, the specific myosin 
isoforms associated with MV release seem to depend on the parental cells 
(McConnell et al., 2009; Muralidharan-Chari et al., 2009). Specifically, myosin 1A 
is necessary for MV release from enterocytes (McConnell et al., 2009), but myosin II 
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is necessary for MV release from melanoma cells (Muralidharan-Chari et al., 2009). 
Therefore, it remains unclear which precise myosin isoforms are required for MV 
formation or how this is related to the release of selective cargo in MVs. 
Unexpectedly, neither myosin 1 A nor myosin II were detected in the EVs derived 
from either HaCaT cells or primary keratinocyte cells in this current study. However, 
myosin 1B and myosin 1D were identified in MVs that originated from both cell 
types (Appendix table 4.1 and 4.2). Thus, it is possible that myosin 1B and 1D, could 
be involved MV biogenesis in keratinocytes, however, this hypothesis obviously 
requires further investigation.  
 
Identified histone proteins associated with APs  
APs are distinct EV populations that are produced when cells undergo 
programed cell death, known as apoptosis, while EXs and MVs are formed and 
released during normal cellular processes. Histones, are a family of proteins which 
play a major role in DNA packaging and regulation of DNA transcription 
(Annunziato, 2008). In this regard, histones were more highly enriched in the 
HaCaT-derived EVs investigated in this study (Appendix tables 4.4, 4.6 and 4.8). 
Interestingly, most of the detected histones were present in HaCaT derived APs and 
EXs but not in MVs. More specifically, while a subset of histone 1 isoforms was 
detected in both APs and EXs, a majority of histone 2 and 3 isoforms were only 
detected in APs. The detection of histones in APs is not surprising as APs carry DNA 
fragments, and histones normally have intracellular function and are not actively 
released into the extracellular environment (Annunziato, 2008). However, the present 
evidence of extracellular histones in EXs may suggest a role of extracellular histones 
in EX population differ from roles of histones in AP population (Annunziato, 2008; 
Westman et al., 2015). The proteomics literature concerning APs is limited, as most 
investigations about apoptosis have focused predominantly on the apoptotic process 
and changes in apoptotic cells but not on the products or constituents of APs. As a 
consequence, there is a lack of information about the specific AP protein 
complement. Thus, the data described in this chapter provides an initial glimpse into 
the content of this extracellular vesicle. 
 
 140 Chapter 4: Identification of proteins present in extracellular membrane vesicles 
Many exosomal proteins have not been reported previously 
One of the most interesting findings described in this chapter, is that many 
proteins identified by mass spectrometry have not been previously reported in the 
exosomal protein database. When exosomal proteins in this current study were 
compared to exosomal proteins in the ExoCarta database, the results showed that 128 
and 107 proteins, released from HaCaT-derived and primary keratinocyte-derived 
EXs respectively, are novel exosomal proteins. The ExoCarta database is a collection 
of identified exosomal components, including proteins, RNAs and lipids, from 
various published and unpublished investigations from multiple organisms. The web-
based database of EXs, which were isolated using various methods, provides 
information for researchers in identifying and comparing molecular signatures that 
are specific to cells / tissues and species (Simpson et al., 2012a). With specific regard 
to exosomal proteins which originated from keratinocytes, only 202 proteins are 
reported in the ExoCarta database. However, in the study described herein, a total of 
751 and 563 proteins were detected in EXs released from HaCaT cells and primary 
keratinocytes, respectively (Figure 4.2 A and B). In addition, approximately 100 
identified exosomal proteins in this study had been previously associated with 
keratinocytes (reported in ExoCarta database) (Figure 4.2 C and D). This difference 
between the number of exosomal proteins identified in this study and the number 
previously identified in the database may be due to differences in the differentiation 
state, culture confluence, or culture conditions for keratinocytes (Chavez-Muñoz et 
al., 2009; Ghahary et al., 2005). Furthermore, differences in the detection and protein 
identification methods may also play a significant role (Stamer et al., 2011). The fact 
that hundreds of exosomal proteins identified in this current study were not reported 
in the ExoCarta database may also be indicative of the limited number of studies of 
keratinocyte derived exosomal protein content. Thus, the results of this study may 
facilitate new investigations into the biology of keratinocyte-derived EXs. 
The top 100 proteins in the ExoCarta database are those most frequently 
detected in EX studies and are summarised from a wide variety of investigations. As 
such these proteins could be used as a reference to choose EX markers (Mathivanan 
et al., 2012). While it was expected that all or most of the 20 most highly expressed 
proteins from the HaCaT and primary keratinocyte-derived EX preparations would 
match to the top 100 most frequently identified exosomal proteins from the ExoCarta 
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database, only four and five, respectively, were matched with the database in both 
lists (Figure 4.5). Among the matched proteins, two proteins (CD9 and ITGA6) were 
membrane proteins, while three others (HSPA5, EEF1A1 and SDCBP) were 
cytoplasmic proteins. Tetraspanin 29 protein (or CD9) is a well-known exosomal 
marker, and was also detected using immunoblotting in the study described in the 
previous chapter of this thesis (Figure 3.7). Importantly, these proteins play a role in 
skin development and repair (ITGA6) (Takada et al., 2007), cell adhesion (CD9) 
(Lagaudrière-Gesbert et al., 1997; Masellis-Smith et al., 1994), or cell migration and 
cell extension (SDCBP, CD9) (Klein-Soyer et al., 2000; Tae et al., 2002). The 
remaining 16 EX proteins from HaCaT and 15 EX proteins from primary 
keratinocytes in the 20 most highly abundant exosomal proteins were not matched 
with the top 100 most frequently identified proteins; however, these proteins were 
found within the remaining entries within the ExoCarta protein database (Figure 4.6). 
It is therefore possible that these exosomal proteins may be specifically highly 
enriched in EXs released from keratinocytes, whereas they are less frequently 
identified in EXs released from other cell types. This could reflect the specific 
physiological role of keratinocyte-derived EXs. 
 
EV proteins associated with ECM 
The identification and bioinformatics analysis of EV proteins provides 
information to assist with the understanding of EV biogenesis and markers as well as 
insight into EV function. In this study, it was discovered that some groups of proteins 
were associated with biological process GO terms involved in cell proliferation, 
migration, differentiation and angiogenesis (Data not shown). The presence and 
abundance of ECM related proteins which have an influence on these biological 
processes (reviewed in (Olczyk et al., 2014)), including laminins; intergrins; 
collagens; tenascin; thrombospondin; and syndecan, were observed (Table 4.6 and 
Figure 4.11). This may suggest that EVs are associated with ECM formation and 
degradation. Such a hypothesis is consistent with previous proteomic investigations 
that detected many ECM related proteins in EV populations (reviewed in (Xiao et al., 
2009)). For example, in EXs isolated from an osteoblast cell line, proteins involved 
in ECM formation included collagen, perlecan, and proteoglycan (Xiao et al., 2007). 
In addition, some proteins, which are related to ECM degradation, were also detected 
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in EXs released from a human melanoma cell line and human umbilical endothelial 
cells, including matrix metalloproteinase (MMP) 2, MMP9 and membrane type 1-
matrix metalloproteinase (MT1MMP/MP14) (Muralidharan-Chari et al., 2009; 
Taraboletti et al., 2002). Notably, in this current study, the important ECM-related 
proteins were only detected in primary keratinocyte culture-derived APs and MVs 
but not in HaCaT-derived APs and MVs. This may be indicative of the physiological 
context of these cells, for instance, HaCaTs are an immortalised human keratinocyte 
cell line which have a protein profile different from that of primary keratinocytes 
(Seo et al., 2012). Additionally, the presence of IGTA4 and COL6, which are not 
normally expressed in keratinocytes, in EXs derived from primary keratinocytes may 
have been due to contamination from the mouse fibroblast feeder cells. However, a 
further comparison of the COL6 and ITGA4 sequence data obtained in this study and 
sequence information for the human and mouse proteins from the UniProt website 
(www.uniprot.org) showed that the COL6 and ITGA4 detected in this study were 
from human but not from mouse (Appendix table 4.10). This indicates that these 
proteins were likely selectively sorted into EXs for particular roles, for example in 
ECM interaction. Furthermore, the abundance level of the aforementioned ECM-
related proteins in EXs released from both HaCaT and primary keratinocytes also 
suggest that EXs may play an important role in ECM biology. However, there is 
limited evidence regarding the direct assembly of these EV proteins during ECM 
formation and therefore, warrants further investigation.  
 
Potential EV-derived protein mediators of epidermal keratinocyte and dermal 
fibroblast interaction  
During processes such as wound healing, communication must occur between 
various cell types including dermal fibroblasts and epidermal keratinocytes. For 
example, it has been shown that keratinocytes stimulate fibroblasts to synthesize 
growth factors (Spiekstra et al., 2007), which in turn feedback and stimulate 
keratinocyte proliferation (Werner et al., 2007). In acute wounds, the ECM provides 
a scaffold to direct cells migrating to wounded areas and activates them by secreting 
growth factors to form new ECM and to stimulate wound closure. In addition to the 
presence of ECM-associated proteins in EVs as discussed above, some growth 
factors, cytokines, integrins, metalloproteinases, stratifins and cadherins were 
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identified in keratinocyte-derived EVs in the current study (Appendix table 4.1 and 
4.2). Those proteins were also previously identified in EXs released from other cells, 
such as dendritic cells, keratinocytes and platelets (Chavez-Muñoz et al., 2009; 
Heijnen et al., 1999; Thery et al., 2001). In addition, within the dermal - epidermal 
interaction, keratinocytes released many stratifin isoforms (Aitken, 1995; Ghahary et 
al., 2005; Leffers et al., 1993; Medina et al., 2007), which have been shown to, 
among other biological effects, increase the expression levels of MMP1 and collagen 
in fibroblasts (Ghahary et al., 2004; Ghahary et al., 2005). The stratifin family of 
proteins are associated with many biological events, such as cell cycle control; 
cellular signalling; cell tracking; cell apoptosis; exocytosis; cell differentiation and so 
on, and interestingly, has been shown to play roles in keratinocyte-fibroblast 
interaction (reviewed in (Medina et al., 2007)). Importantly, stratifin proteins were 
shown to be secreted from keratinocytes via the EX pathway and led to up-regulation 
of MMP1 expression levels in fibroblasts (Chavez-Muñoz et al., 2009). This 
evidence implicates stratifin as being part of a communication pathway between 
keratinocytes and fibroblasts in skin. Interestingly, MMP 10 or stromelysin-2 was 
detected in EXs and laminin was detected in APs and EXs in the present study (Table 
4.6, Appendix table 4.1). Recently, MMP 10 and laminin-5 were reported to be 
involved in skin wound healing and the control of keratinocyte migration (Goldfinger 
et al., 1998; Krampert et al., 2004; Rechardt et al., 2000). Laminin-5 is a major 
substrate of MMP10 in wounded skin, where MMP10 mediated degradation of 
laminin-5 permits normal migration of keratinocytes (Krampert et al., 2004; 
Rechardt et al., 2000). In non-wounded sites, the activity of MMP10 may be blocked 
by MMP inhibitor or MMP10 mediated degradation of laminin-5 may be impaired 
through binding competition with α6-integrin which in turn may lead to reduced 
keratinocyte migration (Krampert et al., 2004). However, to the best of this author, 
there was no literary evidence for MMP10 and laminin-5 control of fibroblast 
migration. As such, it suggests a potential model for future investigations that 
examine the potential for keratinocytes to mediate fibroblast migration via the release 
of stratifin, MMP10 and laminin-5-carrying EVs.  
Additionally, fibroblast growth factor binding protein 1 (FGFBP1), which was 
detected in EVs described herein, is known to bind to FGF2 through its C-terminal 
fragment to enhance the activity of FGF2 (Xie et al., 2005), including the induction 
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of ERK2 phosphorylation and subsequent enhancement of NIH-3T3 fibroblast cell 
proliferation (Tassi et al., 2001). Interestingly, FGFBP1 was detected in all three EV 
populations released from primary keratinocytes and HaCaT-derived EXs in the 
current study. This potentially suggests that FGFBP1 may be associated with the 
dermal fibroblast response to primary keratinocytes and to a lesser degree, the 
immortalized HaCaT cell line. In addition, these current and previous findings 
potentially indicate that EVs could also mediate keratinocyte and fibroblast biology 
via interaction of the EV proteins and FGF2 (Grella et al., 2016; Tassi et al., 2011). 
A part of this hypothesis with regard to the effect of keratinocyte-derived EVs on 
fibroblast migration will be examined further in chapter 6. 
In the data presented in this chapter, keratin was a prominent protein detected 
in all samples. This may reflect the nature of keratinocytes, but keratin is also a 
common contamination of MS/MS analysis. Unfortunately, there were no controls, 
such as a cell free control sample or non-keratin producing cells, included in this 
current MS/MS experiment to determine the level of potential keratin contamination. 
That no keratin control is a potential limitation of this study should be addressed in 
future experiments. 
 
4.5 CONCLUSION 
In conclusion, a suite of un-reported and previously documented proteins was 
identified in EVs released from both the HaCaT cell line and primary keratinocytes. 
There were over one hundred proteins identified which are reported in EXs for the 
first time in this investigation. Moreover, the bioinformatics data revealed that the 
identified proteins could be classified into different functional groups and this may 
indicate how they may contribute to various specific biological processes. This 
inference is further supported by the presence of specific wound healing proteins 
within the EVs. Overall, the proteome data herein contributes to the scientific 
knowledge of the different EV populations, their cargo and potential roles. 
Importantly, EVs are known to contain other molecules with potential functional 
roles such as microRNAs, which is the subject of the following chapter. 
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Chapter 5: Identification of microRNAs 
present in extracellular 
membrane vesicles 
5.1 INTRODUCTION 
MicroRNAs are small non-coding RNAs, generally 19-24 nucleotides long, that 
have recently been shown to target mRNAs for cleavage or translational repression 
(Bartel, 2004). Since the first miRNAs were discovered in the 1990s in the nematode 
C. elegans (Lee et al., 1993), they have been identified in various species and their 
functions further determined throughout the 2000s (Lagos-Quintana et al., 2001; Lau 
et al., 2001; Müller et al., 2000; Pasquinelli et al., 2000). miRNA formation primarily 
begins within the intergenic regions and is transcribed to generate primary miRNAs 
(pri-RNAs) by RNA polymerase II in parallel with their host transcripts (Kim, 2005; 
Rodriguez et al., 2004). These pri-miRNAs undergo a nuclear cleavage via Drosha 
RNase III endonuclease to become precursor miRNAs (pre-miRNAs). These pre-
miRNAs are then actively transported from the nucleus to the cytoplasm as part of a 
RAN-GTP and Exportin 5 complex of. In the cytoplasm, pre-miRNAs continue to be 
cleaved by the Dicer enzyme to become duplex miRNAs, which include a mature 
miRNA strand (miRNA) and a similar-size fragment (miRNA*) opposite to the 
mature miRNA strand. The miRNA:miRNA* duplex is then incorporated with RNA-
induced silencing complex (RISC) and the miRNA* is peeled away and degraded 
(Bartel, 2004). The RISC complex comprises Argonaute proteins, Vasa intronic gene 
(VIG), Fragile X-related proteins and nuclease Tudo-SN (Caudy et al., 2002; Denli et 
al., 2003; Hammond et al., 2001). These miRNAs, when combined with RISC, can 
down-regulate gene expression by either post-transcriptional or translational 
repression (Bartel, 2009). Moreover, it is now estimated that miRNAs regulate more 
than 60% of protein translation via multiple pathways (Esteller, 2011; Krol et al., 
2010). The specific mechanisms that miRNAs use to regulate their target transcripts 
have been controversial. However, it is widely accepted that miRNAs, when 
incorporated into RISC (Bartel, 2004; Meister et al., 2004), form partial duplexes 
with their target mRNAs through 3’UTR interactions (Bartel, 2009). Normally, this 
involves pairing between nucleotides two and seven at the 5’ end of the miRNA and 
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the target site (Pasquinelli, 2012; Rigoutsos, 2009). Through this interaction, 
miRNAs can silence their target mRNAs through RNA degradation leading to 
repression of translation (Huntzinger, 2011).  
Previously, miRNAs have been found in EVs released from various sources, 
such as cell culture media; plasma; saliva; and urine, and these EV-derived miRNAs 
are able to be transferred to cells distal to the source cells and facilitate a number of 
EV-mediated biological functions (Hanke et al., 2010; Hunter et al., 2008; Michael et 
al., 2010; Montecalvo et al., 2012; Wang et al., 2010). To facilitate their functions, 
EV miRNAs may control protein levels in target cells by directly down-regulating or 
indirectly up-regulating target genes (Mittelbrunn et al., 2011; Morel et al., 2013) 
leading to regulation of biological activities such as haematopoiesis, exocytosis, 
angiogenesis and tumorigenesis (Valadi et al., 2007). In addition, it has been 
suggested that EV-derived miRNAs may serve as diagnostic biomarkers of cancers 
such as ovarian, lung and prostate cancer (Nilsson et al., 2009; Rabinowits et al., 
2009; Taylor et al., 2008). Interestingly, recent evidence has demonstrated that 
miRNAs were associated with various events in the cutaneous wound healing process 
(reviewed in (Banerjee et al., 2011)). During the inflammation and proliferation 
phases, miRNAs have been shown to be involved in affecting inflammatory cytokine 
released from immune cells, including PDGF regulation, endothelial cell migration, 
capillary sprouting and tubulogenesis (Eberhart et al., 2008; Kuehbacher et al., 2007; 
Shilo et al., 2008; Suárez et al., 2007). Of particular relevance to the studies 
described herein, miRNAs also influence keratinocyte proliferation, migration, 
epithelialisation and ECM biology during the proliferation and remodelling phases 
(Viticchiè et al., 2012; Yang et al., 2011). Despite the above evidence indicating the 
presence of miRNAs in EVs and the influence of EV miRNAs on dermal and 
epidermal cells, there has been scant observations as to the diversity and abundance 
of miRNAs in different EV populations and if there are differences between 
immortalized cell lines and primary cells. Indeed, to the best of this author’s 
knowledge, no such studies have been reported for keratinocytes.  
Hence, the aims of the research described in this chapter were to first profile 
and compare the miRNA species present in the three EV populations released from 
HaCaT and primary keratinocytes using a Next-generation sequencing approach.  The 
subsequent aim was to use the miRNA profile and abundance information to 
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determine which potential genes were likely targets of the most abundant EV miRNA 
for each EV population.  
 
5.2 METHODS 
5.2.1 Materials 
Cells, including HaCaT (passage 50 and 52) and primary keratinocytes isolated 
from four donors (passage 2, donor 325; passage 2, donor 363; passage 1, donor 366; 
and passage 1, donor 377) were cultured to produce EVs which were analysed to 
produce the data described in this chapter. Cell cultures and EV production and 
isolation are described in chapter 2. EV pellets were resuspended in 100 µL PBS and 
were then stored at -20 ºC for 2 weeks or -80 ºC for longer periods prior to total RNA 
extraction. Details of reagents used for experiments described in this chapter are 
detailed in section 2.1 Chapter 2. 
 
5.2.2 Methods 
In this chapter, quantitative reverse-transcription polymerase chain 
reaction (qRT-PCR) and miRNA sequencing (Illumina® Next Seq500 platform) were 
used to identify and quantify miRNAs in the three EV populations released and 
isolated from HaCaT cells and primary keratinocytes. An initial qRT-PCR analysis 
was performed to examine the quantitative differences of select miRNAs across the 
three EV populations as part of a pilot investigation. Success of this pilot study 
sanctioned the principal work for this chapter, namely the use of next generation 
sequencing of the same EV populations in order to profile and compare the miRNA 
profile of each population and parent cells. 
 
5.2.2.1 Total RNA extraction and quantification 
Frozen isolated EVs (section 2.3.1) were thawed on ice prior to extraction of 
total RNA using the Trizol™ method as described in detail in section 2.12.1. Briefly, 
whole cells or EV suspension were mixed with Trizol™ reagent in a 2 mL Eppendorf 
tube prior to addition of MgCl2 solution to the Trizol™ - vesicle mixture, followed by 
addition of Glycogen azure; and chloroform. The mixture was then vortexed prior to 
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incubation at room temperature for 10 minutes, centrifugation at 12,000 x g for 5 
minutes and subsequent transfer of the aqueous phase to a fresh 2 mL Eppendorf 
tube. The total RNA was precipitated from the aqueous phase by addition of 
isopropanol and subsequent centrifugation. The RNA pellets were then were washed 
twice using RNAse-free 75 % ethanol and allowed to air dry prior to resuspension in 
10 – 20 µL RNase-free water (depending on the size of the RNA pellets).  
The total RNAs were then quantified using a Nanodrop® ND-1000 
spectrometer as described in section 2.12.2. 
 
5.2.2.2 cDNA synthesis and quantitative reverse transcription polymerase chain 
reaction (RT-PCR) 
The extracted total RNAs were used as template RNAs to prepare 
complementary deoxyribonucleic acid (cDNA) using a miScript II RT kit following 
the manufacturer’s instructions and is described fully in section 2.12.3. Briefly, 2 µL 
5x miScript Hispec Buffer, 1 µL 10x miScript Nucleics Mix, 1 µL miScript Reverse 
Transcriptase Mix and 6 µL template RNA were added in a 0.5 mL eppendorf tube to 
a total volume of 10 µL and incubated in a Bio-Rad T100TM Thermal Cycler at 37 ºC 
for 1 hour, 95 ºC for 5 minutes and then 6 ºC to protect cDNA from degradation. 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was 
employed to quantify target miRNAs of interest including: hsa-miR 146a; hsa-miR 
29a; hsa-miR let7b; hsa-miR 21; hsa-miR 141; and hsa-miR 203. Briefly, each well 
in a MicroAmp® Fast optical 96 well plate received 5 µL SYBR Green, 1 µL 10X 
miScript Universal Primer, 1 µL 10x miScript Primer Assay, 1.5 µL RNAse-free 
water and 1.5 µL cDNA template (1 ng of cDNA). The plate was sealed tightly and 
subsequently performed qRT-PCR for 40 cycles. More details of reagents, miRNA 
primers, qRT-PCR preparation, and qRT-PCR conditions can be found in section 
2.12.4. The qRT-PCR data were exported to a Microsoft Excel file and analysed for 
Ct-value.  
 
5.2.2.3 Sequence analysis of microRNAs using Illumina® Next Seq500 and 
microRNA identification 
An RNA library was prepared using the Illumina®TruSeq®Small RNA Library 
Prep Kit as per the manufacturer’s instructions. Briefly, RNA 3’ and RNA 5’ adapters 
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were ligated to cDNA structures. Reverse transcription was then performed to create 
cDNA constructs based on the small RNA ligated with 3' and 5' adapters, prior to 
amplification by PCR using primers designed to anneal to the ends of the adapters 
(More details can be found in section 2.12.5). The amplified products from PCR 
(cDNA library) were purified using gel electrophoresis and the cDNA library was 
eluted in 200 µL pure water. The cDNA library was diluted to 2 nM using a solution 
of Tris – HCl 10 nM, pH 8.5 and 0.1 % Tween-20 before being loaded onto an 
Illumina chip and sequencing using Illumina® Next Seq500. Full stepwise details can 
be found in section 2.12.5. 
The raw data generated from the Illumina® Next Seq500 were exported in a 
FASTQ file format. The file was then processed for the removal of index and adaptor 
sequences using the TagCleaner program and trimmed to 28 nucleotides using the 
FASTX-Toolkit program prior to submitting the file to the miRDeep2 software 
version 2.0.0.7 for subsequent analysis (for full details of software program web 
addresses see section 2.12.6). The human genome (hg19) and miRNA database, 
including human mature and hairpin miRNA sequence information, were 
downloaded and extracted prior to alignment of the identified sequences to the human 
genome using the mapper module in miRDeep2. The quantifier module in miRDeep2 
was used to quantify miRNAs and generate a file which contained a summary of 
identified miRNAs and their raw counts determined for each sample. The identified 
miRNA raw count data were then filtered, normalised and tested for differential 
expression using a negative binomial generalised linear model using DESeq2 
software (version 1.10.1) (Love et al., 2014). A Wald test was used to calculate 
statistical significance and was adjusted for multiple testing using the Benjamini and 
Hochberg procedure. Differences between results were considered statistically 
different where there was an adjusted p-value < 0.01 between groups. Graphs and 
heat maps were produced using the online R statistical environment (R version 3.2.2, 
last update 14/8/2015) and gplots package (version 2.17.0) were used (R 
Development Core Team, 2011). More details regarding the miRNA identification 
and analysis can be found in section 2.12.6. 
Read counts generated from miRDeep2 were reported for the abundance of 
identified miRNAs after normalisation using the Reads Per Million (RPM) method 
(Mortazavi et al., 2008). The formula used to normalise the data is detailed as 
follows: 
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A t-test was used to determine statistical difference in normalised read counts (RPM) 
data between HaCaT- and primary keratinocyte-derived APs, HaCaT- and primary 
keratinocyte-derived MVs, and HaCaT- and primary keratinocyte-derived EXs. 
 
5.2.2.4 Analysis of global EV miRNA distribution, miRNA target genes and 
functional biology of EV miRNAs 
Novel EX miRNAs were identified by comparison of the identified EX miRNA 
profiles with previously identified EX miRNAs recorded in the ExoCarta database.  
Briefly, the distribution of identified miRNAs between the three different EV 
populations and parent cells was determined using an online Venn draw program 
(http://bioinformatics.psb.ugent.be/webtools/Venn/). This enabled identification of 
miRNAs represented in each EV population. The list of identified EX miRNA and 
the previously identified miRNAs listed in the ExoCarta database were amended by 
removing the 3’ and 5’ arm information in the miRNA name for compatibly prior to 
analysis to determine the number of novel and previously reported EX miRNAs. 
Details of the adjustment process and comparison can be found in section 2.12.8. 
In order to analyse the miRNA-target gene interactions, the miRbase IDs of the 
five most abundant EX miRNAs was obtained from the miRBase website and the 
target miRTarBase database (version 6.0) was downloaded from the miRTarBase 
website (accessed 5/1/2016). The EV miRNA target genes were identified by 
submission of the miRbase IDs for the EV miRNAs to Cytoscape (version 3.2.1) and 
searching against the miRTarBase database using the CyTargetLinker tool in 
Cytoscape. An interaction network of the miRNAs and their target genes was created 
and exported for further interpretation. Full details of these processes are described in 
section 2.12.7. 
The miRNA-target gene interaction data were exported and subsequently used 
for analysis of their functional roles using DAVID Bioinformatics Resources v6.7 for 
Sum of total read counts (all miRNAs)  
1,000,000 
A = 
RPM  =    
A  
Raw counts of the miRNA of interest  
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Gene Ontology (GO) categories, including Biological Process (BP_FAT), Cellular 
Component (CC_FAT) and Molecular Function (MF_FAT), and Kyoto Encyclopedia 
of Genes and Genomes (KEGG). Parameters with a threshold count set to 2, EASE 
set to 0.1 and Benjamini-Hochberg for comparison correction were used for GO 
analysis within DAVID Bioinformatics Resources. GO terms with a p-value < 0.05 
were considered significant. 
 
5.3 RESULTS 
5.3.1 Differential expression of specific miRNAs in three EV populations 
released from HaCaT and primary keratinocytes 
It is currently unknown whether all EV populations contain miRNAs. 
Therefore, an initial qRT-PCR pilot study was performed in order to determine if 
miRNAs were present in each EV population. In this regard, the expression levels of 
six previously-detected EX miRNAs, including: hsa-miR-21; hsa-miR-203; hsa-miR-
29a; hsa-miR-141; hsa-let-7c and hsa-miR-146a (Than et al., 2015), were determined 
in the EV populations and their parental cells. The results showed that all miRNAs 
were detected in all assayed EV populations released from HaCaT and primary 
keratinocytes and in the respective parental cells (Figure 5.1). The miRNA expression 
levels are represented by raw Ct values which indicates their relative abundance 
levels in 1 ng of input cDNA. Upon closer examination of the Ct data, the abundance 
levels of hsa-miR-21, hsa-miR-203, hsa-miR-141 and hsa-miR-29a, were 
significantly different in HaCaT cells compared to primary keratinocytes (Figure 5.1 
A, B, C and D). However, there was little difference in the expression level of hsa-
miR-21, hsa-miR-141 or hsa-miR-29a between HaCaT and primary keratinocytes for 
any of the EV fractions. Only AP- and EX-derived hsa-miR-203 was expressed 
differently (p<0.05 and 0.01 respectively) in EV fractions from HaCaT and primary 
keratinocytes (Figure 5.1 B). There were two miRNAs, hsa-let-7c and hsa-miR-146a, 
which exhibited equivalent expression levels between both parental cells and between 
EV populations (Figure 5.1 E and F). Taken together, these data indicate that while 
there was little variation in the expression levels of the target miRNAs between 
HaCaT and primary keratinocyte-derived EVs, the miRNAs from the isolated EVs 
were abundant and the data indicated that the total RNA collected was of good 
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quality. Thus, further investigation of the miRNA complement of each EV population 
using a Next-Generation sequencing approach was warranted. 
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Figure 5.1: Select miRNA expression between parental cells and three EV 
populations.  
 
The raw Ct values generated from qRT-PCR were analysed using GraphPad Prism 6 
to reveal the differences in miRNA abundance levels. Data are expressed as the mean 
(± SD). Ct-values are derived from n=3 biological replicates. A) hsa-miR-21; B) hsa-
miR-203; C) hsa-miR-141; D) hsa-miR-29a; E) hsa-let-7c; F) hsa-miR-146a. HaCaT: 
HaCaT cells, PKC: primary keratinocytes, AP: Apoptotic bodies, MV: Microvesicles, 
EX: Exosomes. Statistical significance was determined by T-test using GraphPad 
Prism 6 and is indicated by * (p<0.05) or ** (p<0.01). 
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5.3.2 Large numbers of miRNAs were detected in the three EV populations 
released from HaCaT and primary keratinocytes 
Since the qRT-PCR experiments confirmed that keratinocyte-derived EVs 
contain miRNAs, this justified further investigation of the identity and distribution of 
other potential miRNAs that might form part of the EV miRNA inventory. Thus, 
Next-generation sequencing technology was used to acquire EV and parental cell 
miRNA sequence data after which the miRDeep2 program was used to detect and 
profile miRNA expression levels in each EV population and parental cell type. 
 
5.3.2.1 Distribution of miRNAs across EV populations 
The raw EV and parental cell sequencing data were imported into the 
miRDeep2 program to map and identify miRNAs and their expression. The results 
indicated that there were a number of common and unique miRNAs associated with 
the three EV populations and the respective parental cells. There were 1246 miRNAs 
detected in HaCaT parental cells and HaCaT derived EVs in total with 941, 1048, 
906 and 704 miRNAs identified in HaCaT cells and HaCaT-derived APs, MVs and 
EXs respectively (Figure 5.2 A). Furthermore, all but 92 of the 941 miRNAs 
identified in the HaCaT parental cells were also identified in one or more of the 
HaCaT derived EV populations, while 623 miRNAs were common to the three 
populations of HaCaT-derived EVs (Figure 5.2 A). More specifically with regard to 
EV derived miRNAs, APs and MVs shared 215 miRNAs in common, while APs and 
EXs shared 31 miRNAs in common and MVs and EXs had 12 miRNAs in common 
(Figure 5.2 A). Notably, each EV population also contained unique miRNAs 
including: 179 unique miRNAs in APs, 56 unique miRNAs in MVs and 38 unique 
miRNAs from EXs (Figure 5.2 A).  
There were 1273 miRNAs detected in the parental primary keratinocytes and 
primary keratinocyte-derived EVs in total with 1226, 608, 506 and 622 miRNAs 
identified in primary keratinocytes and primary keratinocyte-derived APs, MVs and 
EXs respectively (Figure 5.2 B). Interestingly, 533 of the 1226 miRNAs identified in 
the primary keratinocyte-derived parental cells were unique to the parental cells 
(Figure 5.2 B). The remaining 693 miRNAs were also identified in one or more of 
the primary keratinocyte-derived EV populations (Figure 5.2 B). Furthermore, there 
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were 437 miRNAs common to the three populations of primary keratinocyte-derived 
EVs (Figure 5.2 B). More specifically with regard to EV derived miRNAs, APs and 
MVs shared 33 miRNAs in common, while APs and EXs shared 75 miRNAs in 
common and MVs and EXs had 14 miRNAs in common (Figure 5.2 B). Notably, 
each EV population also contained unique miRNAs including: 63 unique miRNAs in 
APs, 22 unique miRNAs in MVs and 96 unique miRNAs from EXs (Figure 5.2 B). 
In order to determine if there were any differences in the EV miRNA 
composition associated with cellular origin, the 623 common HaCaT-derived EV 
miRNAs (5.2 A) and the 437 common primary keratinocyte-derived EV miRNAs 
(5.2 B) were compared. The results showed that there were 381 miRNAs common to 
both HaCaT and primary keratinocytes (Figure 5.2 C). Moreover, 242 miRNAs were 
unique to HaCaT-derived EVs, whereas 56 miRNAs were unique to primary 
keratinocyte-derived EVs. Among the common HaCaT- and primary keratinocyte-
derived EV miRNAs, 18 were members of the hsa-let-7 miRNA family (Table 5.1). 
Indeed, analysis of the normalised mean read count data for hsa-let-7 miRNAs 
revealed that six and eleven members respectively from HaCaT-derived APs and EXs 
had significantly higher abundance for individual miRNAs compared to those in APs 
and EXs from the primary keratinocytes (p<0.05) (Table 5.1). Similarly, there were 
three and two let -7 members in HaCaT-derived APs and EXs having significant 
lower abundance compared to those from primary keratinocyte-derived APs and EXs. 
However, only two members of hsa-let-7 miRNA family in MVs were significantly 
different from either the HaCaT cells or the primary keratinocytes (one is higher in 
the HaCaT and one is higher in the primary keratinocyte). In addition, several hsa-let-
7 miRNAs exhibited significantly different abundance levels between the three EV 
populations (Appendix table 5.1). In addition to the let 7 family, the common HaCaT- 
and primary keratinocyte-derived EV miRNAs also included: hsa-mir-181; hsa-mir-
100; hsa-mir-30; hsa-mir-125; and, hsa-mir-27 among others (Appendix table 5.2). 
Taken together, these results suggest that cell origin or physiological conditions of 
HaCaT cells or primary keratinocytes may impact on the sorting of select miRNAs 
into EVs. 
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Figure 5.2: miRNA distribution between parental HaCaT and primary keratinocytes 
and respective EV populations 
 
The distributions of the identified miRNAs, with at least two counts, from A) 
HaCaT-derived EVs and HaCaT cells (n=2 independent biological replicates); and  
B) primary keratinocyte-derived EVs and primary keratinocytes (n=4 independent 
biological replicates). C) The distribution of common miRNAs from HaCaT-derived 
EVs (red number from A, 623 miRNAs) and primary keratinocyte-derived EVs (red 
number from B, 437 miRNAs). PKC: primary keratinocytes. Venn diagrams were 
generated using web-base Venn draw tool 
(http://bioinformatics.psb.ugent.be/webtools/Venn/).
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Table 5.1: Let-7 miRNAs common to both HaCaT- and primary keratinocyte-derived EVs 
 
 
Note: Statistical analysis was performed using a t-test (Statistical Analysis System program v9.3) for the abundance of miRNAs between HaCaT and primary keratinocytes for 
each EV population. SD: Standard Deviation.  * denotes p<0.05, ** denotes p<0.01. 
 
miRNA&name!
Mean&normalised&read&counts&(RPM)&±&SD!
AP! MV! EX!
HaCaT!! Primary!
keratinocytes!
HaCaT!! Primary!
keratinocytes!
HaCaT!! Primary!
keratinocytes!
hsa:let:7a:1:3p! 148.0!±23.8*! 77.3!±28.2! 129.1!±32.7! 93.3!±73! 253.8!±23.4**! 92.5!±42.2!
hsa:let:7a:1:5p! 16237.2!±2551.9*! 9749.1!±2630.1! 13012.4!±4160! 12851.6!±5257.5! 29576.1!±1171.1**! 15927.9!±2496.8!
hsa:let:7a:2:5p! 16232.7!±2554.4*! 9748.5!±2632.2! 13018.9!±4176.8! 12854.1!±5262.4! 29576.1!±1163.7**! 15950.5!±2483.5!
hsa:let:7a:3:3p! 147.8!±24.1*! 77.3!±28.2! 129.1!±32.7! 93.3!±73! 252.9!±24.6**! 92.5!±42.2!
hsa:let:7a:3:5p! 16243.1!±2557.4*! 9747.0!±2635.3! 13015.5!±4168.6! 12857.3!±5251.6! 29613.48!±1183**! 15964.9!±2508.5!
hsa:let:7b:3p! 83.8!±15.2! 56.5!±48.6! 79.9!±17.1! 72.4!±49.6! 131.8!±47.3! 112.1!±81.4!
hsa:let:7b:5p! 5845.6!±1085.4! 5590.8!±1016.2! 4539.3!±934.2! 3266.6!±638.2! 4122.6!±327.6! 3420.0!±668.8!
hsa:let:7c:5p! 167.3!±85.1! 1040.1!±548.2! 313.8!±66.3! 1099.6!±355.9*! 372.1!±49.1! 767.5!±291.4!
hsa:let:7d:3p! 180.3!±7.7! 157.5!±96.5! 240.7!±115.1! 276.3!±197.2! 649.0!±147.4*! 387.5!±77.4!
hsa:let:7d:5p! 1226.5!±197.2*! 569.4!±161.5! 1266.3!±379.5*! 714.3!±142! 1203.8!±4.9**! 675.7!±142.8!
hsa:let:7e:3p! 11.3!±0.3! 17.5!±19! 9.3!±1.3! 8.1!±5.5! 21.0!±7.5! 6.0!±7.9!
hsa:let:7e:5p! 932.5!±30.5! 1643.1!±270.7*! 1130.0!±49.2! 2589.8!±949.4! 1190.6!±225! 2106.9!±288.2*!
hsa:let:7f:1:3p! 33.6!±0.6! 18.0!±25.7! 29.5!±4.4! 16.6!±15.3! 39.8!±6.7**! 4.3!±5.1!
hsa:let:7f:1:5p! 24983.0!±5306.8! 15256.8!±6114.6! 30334.9!±19507.5! 22351.6!±5770.8! 35612.9!±629.3**! 24868.0!±2259.9!
hsa:let:7f:2:5p! 26313.0!±5347.9! 15842.8!±6265.8! 31921.8!±20195.9! 23269.1!±5794.5! 37045.2!±646.8**! 25633.1!±2166.9!
hsa:let:7g:5p! 3100.6!±354.7! 2462.3!±382.5! 2807.3!±438.1! 1861.9!±541.9! 2697.9!±549*! 1747.1!±180.7!
hsa:let:7i:3p! 24.2!±5.8! 60.7!±16*! 16.7!±4.7! 94.7!±102.7! 8.3!±6.8! 21.1!±17.7!
hsa:let:7i:5p! 5141.7!±101.1! 11677.9!±2127.8*! 4884.5!±53.3! 7497.3!±1936.9! 3783.2!±743.9! 6135.7!±948.636*!
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5.3.2.2 Correlation analysis of EV miRNAs revealed relationships between the 
three EV populations  
APs, MVs and EXs are formed and released from cells through different 
pathways and carry distinct information inherent within their cargo (Raposo et al., 
2013). The degree of correlation between the miRNA contents of the three EV 
populations was revealed using Euclidean distance analysis and visualized as a heat 
map based on normalised counts. These data indicate that APs and MVs are more 
closely related in terms of miRNA abundance whereas clearly EXs separate into their 
own clade (Figure 5.3 A). Upon closer examination, APs and MVs originating from 
passage 50 HaCaT cells (Hp50) were clustered together while APs and MVs from 
passage 52 HaCaT cells (Hp52) were also clustered together (Figure 5.3 A). This 
indicates that the status of the cells of origin had a quantifiable influence over the 
content of APs and MVs in addition to the apparent difference in EV type. Similarly, 
with reference to primary keratinocytes, EXs released from donors # 325 and # 363 
were classified together with MVs released from donor # 363, whereas EXs released 
from donors # 377 and # 366 were classified together (Figure 5.3 B). Thus the 
clustering of primary cell EV-derived miRNAs reflected both the EV population but 
also in some cases the donor as well. Therefore, these results suggest that studies of 
EV miRNAs will likely be more consistent when using continuous cell lines than 
using EVs derived from primary cells.  
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Figure 5.3: Euclidean distance analysis indicating the clustering of APs and MVs and 
distinguishing EXs 
 
The identified EV miRNAs were examined for correlations between the three EV 
populations using Euclidean distance analysis, based on the miRNA raw counts. EVs 
derived from A) HaCaT cells (n=2 - HaCaT p50 and p52); B) primary keratinocytes 
(n=4 independent biological replicates). The colour scale indicates the degree of 
correlation between EVs, in which a dark blue colour indicates closer correlation and 
lighter colour scale indicates less correlation. Numbers 377, 366, 363 and 325 refer 
to donor number. AP - Apoptotic bodies; MV - Microvesicles; EX - Exosomes. The 
Euclidian distance graphs were generated in the R program. 
A 
B 
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5.3.3 HaCaT and primary keratinocyte-derived EXs contained novel exosomal 
miRNAs  
To determine if any of the detected exosomal miRNAs had been previously 
reported in exosomes, the lists of EX miRNAs were compared with the ExoCarta 
miRNA database. The miRNA database was downloaded from the ExoCarta website 
(exocarta.org, version 5, released on 29 July 2015) which contained a total of 2766 
miRNAs (Homo sapiens). Since not all miRNA names in the database contain the 
stem loop component of the full miRNA name, these were added manually following 
retrieval from the miRTarbase website, by matching the Entrez Gene ID with the 
miRNA name information. Next, the annotated miRNA list was sorted to remove 
duplicates (miRNAs detected by different methods) and to produce a final list of 926 
miRNAs for the comparison. The empirical miRNA lists (with at least two counts) 
were also adjusted by removal of the 5’ and 3’ lettered suffix from the precursor 
miRNAs to ensure miRNA names were compatible with those in the ExoCarta 
database. Accordingly, 581 miRNAs from HaCaT-derived EXs and 508 miRNAs 
from primary keratinocyte-derived EXs were searched against the ExoCarta miRNA 
database. The comparison revealed that 369 miRNAs out of 581 miRNAs from 
HaCaT-derived EXs (64%) had been previously described in the ExoCarta database 
(Figure 5.4 A) whereas, 358 miRNAs out of 838 miRNAs (43%) from the primary 
keratinocyte-derived EXs had been previously reported (Figure 5.4 B). Thus, 212 
and 150 miRNAs from HaCaT-derived EXs and primary keratinocyte-derived EXs 
respectively have not been previously described in ExoCarta (Figure 5.4 A and B, 
Appendix tables 5.3 and 5.4). Taken together, these data indicate that a large number 
of the EX miRNAs released from HaCaT and primary keratinocytes have not been 
previously identified as EX cargo. These, as yet, un-reported EX miRNAs identified 
in this current study will contribute to some extent to the EX miRNA list in the 
ExoCarta database. 
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Figure 5.4: EXs from HaCaT and primary keratinocytes contain miRNAs previously 
un-reported as EX cargo.  
 
The EX miRNAs from the ExoCarta database and the identified EV miRNAs were 
modified by removal of the lettered suffix indicating 5’ and 3’ of the precursor 
miRNAs to ensure that the miRNA name was in a compatible format prior to 
analysis to determine the number of previously un-reported miRNAs. The analysis 
and Venn diagram were generated using the R program. The 926 miRNAs in the 
ExoCarta database were compared to: A) HaCaT-derived EXs; and B) primary 
keratinocyte-derived EXs.  
 
 
 
 
 
 
 
 
 
 
!
EX miRNAs (primary 
keratinocytes) (508) 
358 150 568 
ExoCarta (926) 
B 
EX miRNAs (HaCaT) (581) 
369 212 557 
ExoCarta (926) 
A 
(43%)! (57%)!
(64%)! (36%)!
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5.3.4 Differential expression of EV miRNAs discriminated EXs from APs and 
MVs  
The utilisation of deep sequencing technology resulted in the identification of 
hundreds of EV derived miRNAs in the current study. While the determination of 
whether or not they are all bioactive is an important question, it is out of the scope of 
this study to examine the bioactivity of all individual miRNAs. However, a previous 
study suggested that only high abundant miRNAs have sufficient competitiveness for 
the miRNA-mRNA interaction to significantly suppress their targets (Mullokandov 
et al., 2012). Thus, in an attempt to best understand which populations of EV 
miRNAs might have substantial bioactivity, an analysis of the miRNA abundance 
levels (represented by total raw count number) within each EV population was 
conducted. There were 181, 186 and 189 miRNAs with greater than 100 Reads Per 
Million (RPM) and 78, 78 and 69 miRNAs having greater than 1000 RPM from 
HaCaT-derived APs, MVs and EXs, respectively (Table 5.2). For primary 
keratinocyte-derived EVs, there were 210, 214 and 210 miRNAs exhibiting greater 
than 100 RPM and 82, 81 and 79 miRNAs having greater than 1000 raw counts, in 
APs, MVs and EXs respectively. Thus these highest abundant miRNAs may be 
hypothesised to have bioactivity and elicit functional effects on other cells and 
tissues. 
 
Table 5.2: Number of high abundant EV miRNAs with RPM greater than 100 and 
greater than 1000. 
Parental	  cell	  types	   	   AP	   MV	   EX	  
HaCaT	   >	  100	  RPM	   181	   186	   189	  
>	  1000	  RPM	   78	   78	   69	  
	   	   	   	   	  Primary	  keratinocytes	   >	  100	  RPM	   210	   214	   210	  
>	  1000	  RPM	   82	   81	   79	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The number of counts measured represent the abundance levels of each 
specific miRNA in each EV population. While some miRNAs were found to have 
large count numbers across all EV populations, others had varied read count numbers 
across each EV population. Statistical analysis of the miRNA expression level 
revealed that there were 73 and 16 miRNAs that exhibited significantly different 
abundance between the three EVs populations released from HaCaT and primary 
keratinocytes, respectively (p<0.01; Wald test). Hierarchical clustering of the 12 
most significant differentially expressed miRNAs showed that HaCaT APs, MVs and 
EXs clearly clustered into their respective groupings (Figure 5.5A). While clustering 
of the 12 most significant differentially expressed miRNAs from primary 
keratinocyte derived APs and EXs clustered into their respective groupings the MVs 
did not (Figure 5.5B). 
Within the 12 most significant differentially expressed HaCaT-derived EV 
miRNA, two main groups of miRNAs had discordant expression in APs, MVs and 
EXs. These included six miRNAs: hsa-miR-222-5p; hsa-miR-1273g-3p; hsa-miR-
7977; hsa-miR-7704; hsa-miR-27a-5p; and, hsa -miR-3614-5p, that were more 
abundant in EXs compared to either MVs or APs (Figure 5.5 A; Table 5.3). Another 
group of six miRNAs, including: hsa-miR-19b-1-3p; hsa-miR-19b-2-3p; hsa-miR-
19a-3p; hsa-miR-197-3p; hsa-miR-29b-2-3p; and, hsa-miR-29b-1-3p, were most 
abundant in APs and MVs compared to EXs (Figure 5.5 A; Table 5.3). With regard 
to the 12 most significant differentially expressed primary keratinocyte-derive EV 
miRNAs, three distinct groups of miRNAs with differential expression trends were 
observed. The first miRNA group, including: hsa-miR-146a-5p; hsa-miR-4485-3p; 
hsa-miR-7641-1; hsa-miR-7641-2; and, hsa-miR-107, were more abundant in APs, 
generally lower in abundance in MVs, and had the lowest abundance in EXs (Figure 
5 B; Table 5.4). The exception to this trend was hsa-miR-379-5p, which was more 
abundant in MVs, compared to APs and EXs. The remaining group of miRNAs, 
including: hsa-miR-7704; hsa-miR-200b-3p; hsa-miR-4492; hsa-miR-30c-1-5p; hsa-
miR-30c-2-5p; and, hsa-miR-1273g-3p, were most abundant in EXs, lower in MVs 
and lowest in APs (Figure 5.5 B; Table 5.4). However, the expression of these 
miRNAs in primary keratinocyte-derived EVs appears to be more variable between 
donors (Figure 5.5 B) as compared to the miRNA expressed in HaCaT-derived EVs 
(Figure 5.5 A). This is likely due to the HaCaT biological replicate being derived 
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from the same cell source where as the primary keratinocyte-derived EV data likely 
reflects inter-individual biological variation. 
The miRNA data was clearly able to discriminate EXs from APs and MVs, and 
indicated a difference in EV miRNAs associated with parental cells (Figure 5.3 and 
5.5). The stable trend in expression level of HaCaT-derived EVs may be due to the 
physiological condition of the cell line at different passages being highly similar, 
compared to the inter-individual biological variation of the primary cells.  
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Figure 5.5: The 12 most significant differentially expressed miRNAs in three EV 
populations discriminate EXs from APs and MVs 
  
The keratinocyte-derived EV miRNAs were analysed for their differential expression 
using DESeq2. There were 73 and 16 miRNAs that were significantly differentially 
expressed between the three EVs populations released from HaCaT and primary 
keratinocytes, respectively. Hierarchical clustering analysis of the twelve most 
significant differentially expressed miRNAs expressed in: A) HaCaT derived-EVs; 
or B) primary keratinocyte-derived EVs. The colour scale indicates the abundance 
level of miRNAs. miRNAs were ranked based on p-values in which the most 
significant differentially expressed miRNAs are listed first in the list. Hp50 and 
Hp52 indicate HaCaT cells were at passage 50 and 52; 377, 366, 325 and 353 
indicate skin donor numbers. AP - Apoptotic bodies; MV - Microvesicles; EX - 
Exosomes. Heat maps were generated using R program (v 3.2.2). 
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Table 5.3:  The 12 most significant differentially expressed miRNAs in EVs released 
from HaCaT cells 
miRNA	  name	   p-­‐adj	  
Mean	  normalised	  read	  counts	  (RPM)	  ±SD	  
AP	   MV	   EX	  
hsa-­‐miR-­‐222-­‐5p	   3.31E-­‐29	   29.5	  ±4.4	   100.2	  ±13.2	   455.1	  ±34.9	  
hsa-­‐miR-­‐1273g-­‐3p	   3.10E-­‐17	   9.8	  ±3.8	   11.8	  ±0.9	   196.5	  ±77.5	  
hsa-­‐miR-­‐7977	   1.17E-­‐16	   11.8	  ±5	   49.9	  ±35.1	   1154.1	  ±477.9	  
hsa-­‐miR-­‐7704	   1.76E-­‐16	   21.6	  ±13.7	   32.9	  ±7.9	   1618.0	  ±1096.8	  
hsa-­‐miR-­‐27a-­‐5p	   4.90E-­‐11	   29.5	  ±11.4	   87.6	  ±24.6	   260.3	  ±32.7	  
hsa-­‐miR-­‐19b-­‐1-­‐3p	   5.10E-­‐10	   8344.8	  ±3046.4	   7176.7	  ±2976.6	   798.0	  ±181.7	  
hsa-­‐miR-­‐19b-­‐2-­‐3p	   5.10E-­‐10	   8350.8	  ±3050.6	   7185.2	  ±2972.1	   800.2	  ±182.3	  
hsa-­‐miR-­‐19a-­‐3p	   1.83E-­‐09	   3577.0	  ±1635.5	   3441.3	  ±1426.6	   311.1	  ±57.3	  
hsa-­‐miR-­‐3614-­‐5p	   4.89E-­‐09	   1.9	  ±0.8	   3.6	  ±0.4	   59.2	  ±35.5	  
hsa-­‐miR-­‐197-­‐3p	   9.68E-­‐09	   409.7	  ±84.9	   266.7	  ±54.1	   84.1	  ±14.6	  
hsa-­‐miR-­‐29b-­‐2-­‐3p	   1.32E-­‐07	   317.5	  ±40.1	   197.9	  ±37.3	   53.0	  ±17.8	  
hsa-­‐miR-­‐29b-­‐1-­‐3p	   1.60E-­‐07	   315.1	  ±40.4	   197.6	  ±37.6	   53.0	  ±17.8	  
Note: p-ajd (p-ajusted) indicates the confidence of the miRNA expression analysed using Wald test 
(the standard DESeq2); RPM (Reads Per Million) indicates the normalisation method used for 
reported counts, n = 2 independent biological replicates, Mean ±SD (Standard Deviation). 
 
Table 5.4: The 12 most significant differentially expressed miRNAs in EVs released 
from primary keratinocytes  
miRNA	  name	   p-­‐adj	  
Mean	  normalised	  read	  counts	  (RPM)	  ±SD	  
AP	   MV	   EX	  
hsa-­‐miR-­‐146a-­‐5p	   3.83E-­‐10	   2749.2	  ±1043.4	   1577.2	  ±681	   351.4	  ±101.1	  
hsa-­‐miR-­‐7704	   4.18E-­‐08	   327.4	  ±211.2	   244.7	  ±82.4	   6610.9	  ±6975.4	  
hsa-­‐miR-­‐4485-­‐3p	   2.29E-­‐05	   227.5	  ±120	   16.8	  ±19.5	   13.4	  ±14.5	  
hsa-­‐miR-­‐7641-­‐1	   2.29E-­‐05	   1528.8	  ±1179	   238.5	  ±70.7	   139.2	  ±179.5	  
hsa-­‐miR-­‐7641-­‐2	   2.29E-­‐05	   1528.8	  ±1179	   238.5	  ±70.7	   139.2	  ±179.5	  
hsa-­‐miR-­‐200b-­‐3p	   2.57E-­‐05	   2123.2	  ±704.9	   4041.2	  ±515.3	   6456.8	  ±1779.5	  
hsa-­‐miR-­‐107	   3.84E-­‐05	   1797.5	  ±368.9	   1133.1	  ±569.1	   472.1	  ±194.3	  
hsa-­‐miR-­‐4492	   0.000136	   21.9	  ±17.3	   102.4	  ±98.1	   507.8	  ±504.9	  
hsa-­‐miR-­‐30c-­‐1-­‐5p	   0.000290	   1025.2	  ±289.7	   1766.8	  ±266.1	   2911.3	  ±1015.1	  
hsa-­‐miR-­‐30c-­‐2-­‐5p	   0.000290	   1025.2	  ±289.7	   1766.8	  ±266.1	   2912.3	  ±1015.6	  
hsa-­‐miR-­‐379-­‐5p	   0.001166	   26.2	  ±39.4	   179.0	  ±222.1	   0	  	  
hsa-­‐miR-­‐1273g-­‐3p	   0.002867	   41.9	  ±58	   13.7	  ±10.9	   244.7	  ±194.5	  
Note: p-ajd (p-ajusted) indicates the confidence of the miRNA expression analysed using Wald test 
(the standard DESeq2); RPM (Reads Per Million) indicates the normalisation method used for 
reported counts, n = 4 independent biological replicates, Mean normalised read counts ±SD (Standard 
Deviation). 
  
Chapter 5: Identification of microRNAs present in extracellular membrane vesicles 167 
5.3.5 Numerous genes are targets of EV miRNAs 
miRNAs typically function in RNA silencing and post-transcriptional 
regulation of gene expression. It is therefore important to investigate which genes 
may be targeted by specific miRNAs identified in this study. For the study herein, 
the CyTargetLinker Cytoscape plug-in was employed to build a miRNA-target 
interaction network for specific EV miRNAs of interest. 
 
5.3.5.1 Let 7 family of miRNAs targets a large number of genes 
As described above (Section 5.3.2.1), over half of the members of the hsa-let 7 
family of miRNAs were detected in high abundance in EVs released from both 
HaCaT and primary keratinocytes (RPM > 1000). In addition, the hsa-let 7 miRNAs 
target various protein encoding genes and thus have functions involved in the 
regulation of many biological processes in living organisms (Roush et al., 2008). 
Therefore the target genes of hsa-let 7 miRNA family members were examined in an 
attempt to elucidate the potential hsa-let 7-related keratinocyte-derived EV functions. 
In this study, five of the 18 common hsa-let 7 miRNAs (Table 5.1) including hsa-let 
7f-2-5p, hsa-let 7c-5p, hsa-let 7a-3-5p, hsa-let 7a-3-3p and hsa-let 7a-2-5p, have no 
known specific target genes based on a search of the miRTarbase (v6.0) using the 
CyTargetLinker Cytoscape plug-in for miRNA-target analysis. However, the 
remaining 13 hsa-let 7 miRNAs target a total of 4002 protein encoding genes 
(miRTarbase v6.0) (Data not shown). Among these 13 hsa-let-7 miRNAs, eight 
regulate the expression of genes important in wound healing, including: various 
collagen (COL) genes; fibronectin (FN1); platelet-derived growth factor subunit A 
and B (PDGFA and PDGFB respectively); platelet-derived growth factor receptor 
alpha (PDGFRA); tumor necrosis factors (TNF) such as TNF super family (TNFSF) 
1A, 9, 12 and TNF alpha induced protein 1 (TNFAIP1); transforming growth factor β 
receptor 3 (TGFBR3); fibroblast growth factor receptor like 1 (FGFRL1); and 
epidermal growth factor receptor (EGFR) (Table 5.5). Upon closer examination of 
these miRNAs, some targets genes, such as TGFBR3 gene, COL8A1, and TNFSF9, 
were listed as each being regulated by several members of the hsa-let 7 family. 
However, some miRNA target genes were regulated by only one hsa-let 7 miRNA 
such as COL3A1, COL6A1, COL1A2, PDGFA, PDGFB and PDGFRA (Table 5.5). 
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This data may indicate that the hsa-let 7 family of EV miRNAs are associated with 
ECM proteins and fibroblast function.  
 
Table 5.5: Genes associated with wound healing processes that are regulated by hsa-
let 7 family miRNAs 
 
miR	  name	   Target	  gene	  symbol	  
hsa-­‐let-­‐7a-­‐1-­‐5p	   EGFR,	  TGFBR3,	  TNFSF9	  
hsa-­‐let-­‐7b-­‐5p	   COL3A1,	  COL8A1,	  PDGFRA,	  TGFBR3,	  TNFSF12,	  TNFSF9,	  FGFRL1	  
hsa-­‐let-­‐7d-­‐5p	   PDGFA,	  COL8A1,	  TGFBR3,	  TNFSF9	  
hsa-­‐let-­‐7e-­‐5p	   COL6A1,	  COL8A1,	  TGFBR3,	  TNFSF9,	  TNFAIP1,	  TNFSF1A	  
hsa-­‐let-­‐7f-­‐1-­‐5p	   PDGFB,	  COL8A1,	  TGFBR3,	  TNFSF9	  
hsa-­‐let-­‐7g-­‐5p	   COL1A2,	  COL8A1,	  TGFBR3,	  TNFSF9,	  FN1	  
hsa-­‐let-­‐7i-­‐5p	   COL8A1,	  TGFBR3,	  TNFSF9	  
EGFR: Epidermal growth factor receptor; TGFBR3: Transforming growth factor beta receptor 3; 
TNFSF9: Tumor necrosis factor super family 9; TNFSF1A: Tumor necrosis factor super family 1 A; 
TNFSF12: Tumor necrosis factor super family 12; TNFAIP1: Tumor necrosis factor alpha induced 
protein; COL3A1: Collagen type III alpha 1 chain; COL6A1: Collagen type VI alpha 1 chain; 
COL8A1: Collagen type VIII alpha 1 chain; COL1A2: Collagen type I alpha 2 chain; PDGFRA: 
Platelet-derived growth factor receptor alpha; PDGFA: Platelet-derived growth factor subunit A; 
PDGFB: Platelet-derived growth factor subunit B; TGFBR3: Transforming growth factor beta 
receptor 3; FGFRL1: Fibroblast growth factor receptor like 1; FN1: Fibronectin 1. 
 
 
5.3.5.2 A large number of target genes are regulated by the five most abundant 
miRNAs 
Bartel and Mullokandov suggested that only miRNAs with high abundance can 
regulate their target genes (Bartel, 2009; Mullokandov et al., 2012). Therefore, it is 
possible that the most highly expressed EV miRNAs, detected in this study, are able 
to elicit functional responses in target cells. Furthermore, the identity of these 
miRNA might also suggest an overall functional effect for the specific EVs 
transporting them. Therefore, an examination of the miRNA-target gene interactions 
for the five most abundant miRNAs from each EV population was conducted (Table 
5.6). The initial aspect of this analysis, in HaCaT-derived EVs, revealed that the five 
most abundant AP- and MV-derived miRNAs were identical, whereas the five most 
abundant EX miRNAs differed by one (Table 5.6). Specifically, hsa-miR-181a-1-5p 
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was included in the top 5 most abundant miRNAs in APs and MVs was replaced by 
hsa-miR-92a-1-3p in EXs (Table 5.6). Similarly, hsa-miR-143-3p in primary 
keratinocyte-derived APs and MVs was replaced by hsa-miR-205-5p in primary 
keratinocyte-derived EXs, whereas the remaining four miRNAs were common to all 
primary keratinocyte-derived EVs (Table 5.6). In terms of commonality of the most 
abundant miRNAs, hsa-miR-22-3p, hsa-miR-27b-3p and hsa-miR-21-5p were common 
across both cell types (Table 5.5 and 5.6). Furthermore, as alluded to above, hsa-miR-
181a-1-5p and hsa-miR-92a-1-3p were unique to HaCaT-derived EVs, whereas hsa-
miR-143-3p and hsa-miR-205-5p were unique to primary keratinocytes-derived EVs. 
In total, there are eight different miRNAs represented in the most abundant EV-
derived miRNAs originating from both HaCaT and primary keratinocytes. The 
similarity in the complement of the most abundant miRNAs among EVs from both cell 
types may indicate that there are relatively few differences in target genes for 
keratinocyte derived EV miRNAs, especially with regard to AP and MV miRNAs. 
However, a deeper analysis of individual miRNA and their target genes may offer 
further insight into the different functions of the EVs. 
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Table 5.6: The relative abundance levels of the five most abundant miRNAs from HaCaT and primary keratinocyte-derived EVs 
HaCaT	  
AP	   MV	   EX	  
miRNA	  name	   MN	  counts	  	  ±SD	   miRNA	  name	   MN	  counts	  ±SD	   miRNA	  name	   MN	  counts	  ±SD	  
hsa-­‐miR-­‐205-­‐5p	   106506.6	  ±8267.9	   hsa-­‐miR-­‐205-­‐5p	   123329.2	  ±44355.9	   hsa-­‐miR-­‐205-­‐5p	   100832.8	  ±16630.3	  
hsa-­‐miR-­‐22-­‐3p	   92576.7	  ±16680	   hsa-­‐miR-­‐27b-­‐3p	   60380.3	  ±11723.7	   hsa-­‐miR-­‐22-­‐3p	   77505.6	  ±14611.1	  
hsa-­‐miR-­‐27b-­‐3p	   57661.6	  ±7889.6	   hsa-­‐miR-­‐22-­‐3p	   59791.6	  ±4818.9	   hsa-­‐miR-­‐27b-­‐3p	   51490.9	  ±237.7	  
hsa-­‐miR-­‐21-­‐5p	   49946.5	  ±6634.3	   hsa-­‐miR-­‐21-­‐5p	   45496.7	  ±3357	   hsa-­‐miR-­‐21-­‐5p	   49943.9	  ±4831.5	  
hsa-­‐miR-­‐181a-­‐1-­‐5p	   48805.9	  ±1721.1	   hsa-­‐miR-­‐181a-­‐1-­‐5p	   45541.5	  ±3393.9	   hsa-­‐miR-­‐92a-­‐1-­‐3p	   37858.4	  ±523.1	  
	   Primary	  keratinocytes	  
AP	   MV	   EX	  
miRNA	  name	   MN	  counts	  ±SD	   miRNA	  name	   MN	  counts	  ±SD	   miRNA	  name	   MN	  counts	  ±SD	  
hsa-­‐miR-­‐22-­‐3p	   139339.8	  ±43597.7	   hsa-­‐miR-­‐22-­‐3p	   93878.6	  ±29984.7	   hsa-­‐miR-­‐21-­‐5p	   110112.7	  ±15649.5	  
hsa-­‐miR-­‐21-­‐5p	   81954.5	  ±31594.6	   hsa-­‐miR-­‐21-­‐5p	   86901.3	  ±21422.5	   hsa-­‐miR-­‐22-­‐3p	   111055.9	  ±9430.8	  
hsa-­‐miR-­‐143-­‐3p	   42915.2	  ±24838.4	   hsa-­‐miR-­‐143-­‐3p	   38016.7	  ±17012.7	   hsa-­‐miR-­‐27b-­‐3p	   52399.1	  ±8430.5	  
hsa-­‐miR-­‐203a-­‐3p	   40830.8	  ±7053.9	   hsa-­‐miR-­‐27b-­‐3p	   45115.2	  ±3168.5	   hsa-­‐miR-­‐203a-­‐3p	   49640.4	  ±10579.5	  
hsa-­‐miR-­‐27b-­‐3p	   40707.7	  ±12724.9	   hsa-­‐miR-­‐203a-­‐3p	   34067.1	  ±13381.3	   hsa-­‐miR-­‐205-­‐5p	   44981.6	  ±10617.4	  
MN counts: Mean of normalised read counts using RPM method. RPM: Read Per Million. SD: Standard Deviation.  
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The miRNA-target gene interaction results revealed that each of the common 5 
most abundant miRNA potentially regulates many protein-coding target genes 
(Figure 5.6). Individually, hsa-mir-181a-1-5p regulates 523 mRNAs (Figure 5.6; 
Appendix table 5.5), hsa-miR-21-5p regulates 578 mRNAs (Figure 5.6; Appendix table 
5.6), hsa-miR-22-3p regulates 134 mRNAs (Figure 5.6; Appendix table 5.7), hsa-miR-
27b-3p regulates 386 mRNAs (Figure 5.6; Appendix table 5.8), hsa-miR-205-5p 
regulates 168 mRNAs (Figure 5.6; Appendix table 5.9), hsa-mir-92a-1-3p regulates 65 
mRNAs (Figure 5.6; Appendix table 5.10), hsa-miR-143-3p regulates 157 mRNAs 
(Figure 5.6; Appendix table 5.11), and hsa-miR-203a-3p regulates 282 mRNAs (Figure 
5.6; Appendix table 5.12). Pairwise analysis of these miRNA targets revealed common 
regulation of a great number of target genes (Figure 5.6; Appendix table 5.13), thereby 
hinting at redundancy in the gene suppression network. 
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Figure 5.6: The number of target genes regulated by the five most abundant EV 
miRNAs 
  
The number in each white square represents the number of target genes shared by the 
relevant miRNA pairs. The blue squares illustrate the total number of target genes for 
the eight individual miRNAs.  
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Among the target genes of the five most abundant miRNAs, there are genes 
encoding for proteins important to wound healing processes, such as collagen; 
Platelet- derived growth factor (PDGF); vascular endothelial growth factor (VEGF) 
A and C; Transforming growth factor beta receptor 3 (TGFBR3), Tumor necrosis 
factor super family 11B (TNFSF11B); Endothelial growth factor (EGF); stromal 
cell-derived factor; and intercellular adhesion molecule 1. Most of these wound 
healing-associated genes are targets of hsa-miR-21-5p; while some of them are 
targets of hsa-miR-203a-3p, hsa-miR-181a-1-5p, hsa-miR-92a-1-3p, hsa-miR-27b-3p 
and hsa-miR-143-3p. However, none of them are targets of hsa-miR-22-3p.  
 
5.3.6 EV bioactivity might be predicted from the target genes by EV miRNAs 
The relative success of miRNA mediated regulation of specific target mRNAs 
depends on two main factors: 1) the abundance level of individual miRNAs capable 
of regulating the specific mRNA; and 2) the number of miRNAs capable of 
regulating the specific target mRNA (Mullokandov et al., 2012). As such, an analysis 
of the co-regulation of the target genes of the five most abundant miRNAs was 
performed, with a focus on target genes regulated by at least three of the five most 
abundant EV miRNAs. The target gene symbols analysed in this section are 
described in Table 5.7. 
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Table 5.7: The target genes regulated by at least three of the five most abundant EV 
miRNA 
 
Gene Symbol Description 
AFF4 AF4/FMR2 family member 4 
BCL2 B-cell lymphoma 2 
BMPR2 Bone morphogenetic protein receptor type 2 
CDK6 Cyclin dependent kinase 6 
CREB1 Camp responsive element binding protein 1 
E2F1 E2f transcription factor 1 
H3F3B H3 histone family member 3B 
IGF1R Insulin like growth factor 1 receptor 
JMY Junction mediating and regulatory protein 
KIAA155 Chromosome 12 open reading frame 35 
LCOR Ligand dependent nuclear receptor corepressor 
LIFR Leukemia inhibitory factor receptor alpha 
LPCAT1 Lysophosphatidylcholine acyltransferase 1 
LYSMD3 Lysm domain containing 3 
NAA50 N(alpha)-acetyltransferase 50 
NCAPG Non-smc condensin i complex subunit g 
NOTCH2 Notch 2 
NUFIP2 Nuclear fragile x mental retardation protein interacting protein 2 
PTEN Phosphatase and tensin homolog 
RAP2B Ras-related protein Rap-2b 
RMND5A Required for meiotic nuclear division 5 homolog a 
SETD1B Set domain containing 1b 
SFXN1 Sideroflexin 1 
SLC25A25 Solute carrier family 25 member 25 
SMAD4 Smad family member 4 
SP1 Sp1 transcription factor 
TGFR3 Transforming growth factor beta receptor type 3 
TNPO1 Transportin 1 
VEGFA Vascular endothelial growth factor a 
ZADH2 Zinc binding alcohol dehydrogenase domain containing 2 
ZNF460 Zinc finger protein 460 
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5.3.6.1 The co-regulated miRNA-target genes of the five most abundant miRNAs 
in HaCaT-derived APs and MVs 
The five most abundant miRNAs from HaCaT-derived APs and MVs regulate 
a total of 1791 genes. Importantly, 223 of these genes are known to be regulated by 
at least two miRNAs. Furthermore, 21 of the 1791 genes are known to be regulated 
by at least three miRNAs (Figure 5.7). These target genes, especially the 21 genes 
regulated by at least three of the most abundant miRNAs, may help to infer a 
biological role for HaCaT-derived APs and MVs. In this regard, GO and KEGG 
analysis were performed on these 21 target gene sets. 
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Figure 5.7: miRNA-target gene interaction network of the five most abundant 
miRNAs from HaCaT-derived APs and MVs showing target genes regulated by at 
least three miRNAs 
 
A) A summary network illustrating the shared target genes. A1 – A7) Individual 
clusters separated from the summary network where each cluster represents the genes 
with redundant regulation from at least three miRNAs. Networks were generated 
using Cytoscape (v3.2.1) connected to CyTargetlinker linked with target database 
(version 6.0) (http://mirtarbase.mbc.nctu.edu.tw). 
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GO analysis of the 21 target genes with redundant regulation, using the 
DAVID Bioinformatics Resource 6.7, revealed that these genes were enriched within 
nineteen BP GO terms, two CC GO terms and one KEGG term (Table 5.8). 
Examination of these BP GO terms indicated that hemopoiesis, hemopoietic or 
lymphoid organ development and immune system development exhibited the most 
significant enrichment (enriched with NOTCH2, SP1, BCL2, CDK6 and SFXN1). In 
addition, terms related to regulation appeared often, including regulation of cell-
matrix adhesion; regulation of cell-substrate adhesion; regulation of ossification; 
regulation of cell adhesion; regulation of cell proliferation; negative regulation of 
cell proliferation; regulation of protein stability; and regulation of osteoblast 
differentiation (mostly enriched with BCL2, PTEN, CDK6 and BMPR2). Moreover, 
important BP GO terms related to cell cycle, development and morphogenesis were 
enriched with this gene group (Table 5.8). In addition to the nineteen BP GO terms, 
two CC GO terms (envelope and organelle envelope) and one KEGG term (small cell 
lung cancer) were enriched with BCL2, CDK6 and PTEN genes. These data may 
suggest that HaCaT-derived APs and MVs could be associated with regulation of cell 
fate. 
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Table 5.8: GO term enrichment analysis of 21 target genes regulated by at least three 
of the five most abundant miRNAs in HaCaT-derived APs and MVs 
Category Terms P-value 
Fold 
Enrichment 
BP GO:0030097~hemopoiesis 1.39E-04 16.8594 
GO:0048534~hemopoietic or lymphoid organ 
development 2.02E-04 15.3031 
GO:0002520~immune system development 2.54E-04 14.4160 
GO:0001952~regulation of cell-matrix adhesion 4.52E-04 88.4183 
GO:0010810~regulation of cell-substrate 
adhesion 0.00131 51.8976 
GO:0030278~regulation of ossification 0.00373 30.6063 
GO:0048872~homeostasis of number of cells 0.00606 23.8729 
GO:0008285~negative regulation of cell 
proliferation 0.00815 8.8173 
GO:0030155~regulation of cell adhesion 0.01113 17.4255 
GO:0042127~regulation of cell proliferation 0.01179 5.0556 
GO:0048729~tissue morphogenesis 0.01869 13.2627 
GO:0031667~response to nutrient levels 0.02214 12.1182 
GO:0022402~cell cycle process 0.02703 5.6337 
GO:0009991~response to extracellular stimulus 0.02719 10.8513 
GO:0035295~tube development 0.02719 10.8513 
GO:0031647~regulation of protein stability 0.04856 37.8935 
GO:0045667~regulation of osteoblast 
differentiation 0.04968 37.0123 
GO:0030218~erythrocyte differentiation 0.04968 37.0123 
GO:0048598~embryonic morphogenesis 0.04996 7.7762 
   CC GO:0031967~organelle envelope 0.02770 5.4976 
GO:0031975~envelope 0.02793 5.4799 
   KEGG hsa05222:Small cell lung cancer 0.00387 25.943 
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5.3.5.2 The co-regulated miRNA-target genes of the five most abundant miRNAs 
in HaCaT-derived EXs 
The five most abundant miRNAs from HaCaT-derived EXs together regulated 
a total of 1331 genes. Among these 1331 genes, 112 genes were regulated by at least 
two miRNAs, and eight genes were regulated by at least three miRNAs (Figure 5.8). 
Since a single gene can be regulated by multiple miRNAs (Bartel, 2009) and it is 
thought that only abundant miRNAs are able to elicit functional effects, the target 
genes of those miRNAs may be considered to be functionally important. For the 
HaCaT-derived EX miRNA this may especially apply to the eight genes regulated by 
at least three miRNA which include: PTEN; CDK6; NUFIP2; SP1; RMND5A; 
SFXN1; ZNF460; and SETD1B (Figure 5.8). As for the target genes for the APs and 
MVs these eight target genes are regulated by at least three of the most abundant 
miRNAs, which may help to infer a biological role for HaCaT-derived EXs.  
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Figure 5.8: miRNA-target gene interaction network for the five most abundant 
miRNAs from HaCaT-derived EXs showing target genes regulated by at least three 
miRNAs  
 
A) A summary network illustrating the shared target genes. A1 – A5) Individual 
clusters separated from the summary network where each cluster represents the genes 
with redundant regulation from at least three miRNAs. Networks were generated 
using Cytoscape (v3.2.1) connected to CyTargetlinker linked with target database 
(version 6.0) (http://mirtarbase.mbc.nctu.edu.tw). 
A1 
A2 
A4 A5 
A3 
A1 
A2 
A3 
A4 
A5 
A 
  
Chapter 5: Identification of microRNAs present in extracellular membrane vesicles 181 
To reveal the potential functions of these eight target genes regulated by at 
least three of the most abundant miRNAs, GO analysis was performed using the 
DAVID Bioinformatics Resources 6.7. This analysis showed that ten BP GO terms, 
and four KEGG terms were enriched with these eight genes (Table 5.9). Strikingly, 
there are five BP GO terms related to the blood and immune system, and other 
important GO terms associated with regulation of cell adhesion, which were enriched 
with four genes including CDK6, PTEN, SP1 and SFXN1. These indicate that 
HaCaT-derived EXs may related to phosphorylation and cell cycle regulation 
resulting to the EXs associated with the above described BP GO terms and pathways. 
A full description of gene ontology can be found in Table 5.9. 
 
Table 5.9: GO term enrichment analysis of 8 target genes regulated by at least three 
of the most abundant miRNAs in HaCaT-derived EXs 
Category Terms P-value 
Fold 
Enrichment 
BP GO:0030097~hemopoiesis 0.0029 28.661 
GO:0048534~hemopoietic or lymphoid organ 
development 0.0035 26.015 
GO:0002520~immune system development 0.0039 24.507 
GO:0001952~regulation of cell-matrix 
adhesion 0.0099 167.01 
GO:0030218~erythrocyte differentiation 0.0157 104.86 
GO:0010810~regulation of cell-substrate 
adhesion 0.0168 98.028 
GO:0034101~erythrocyte homeostasis 0.0179 92.027 
GO:0030099~myeloid cell differentiation 0.0339 48.487 
GO:0048872~homeostasis of number of cells 0.0364 45.093 
GO:0030155~regulation of cell adhesion 0.0496 32.914 
KEGG hsa05214:Glioma 0.0367 40.357 
hsa04115:p53 signaling pathway 0.0395 37.389 
hsa05218:Melanoma 0.0413 35.809 
hsa05222:Small cell lung cancer 0.0487 30.267 
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5.3.6.3 The co-regulated miRNA-target genes of the five most abundant miRNAs 
in primary keratinocyte-derived APs and MVs 
Of the primary keratinocyte-derived EVs, the five most abundant miRNAs in 
APs and MVs regulate a total of 1538 genes in which 120 genes were regulated by at 
least two miRNAs. Importantly, nine out of 1538 genes were regulated by at least 
three miRNAs, including CDK6, NUFIP2, SP1, RMND5A, SFXN1, ZNF460, LIFR, 
JMY and IGF1R (Figure 5.9). Interestingly, the IGF1R is a gene encoding for 
Insulin-like growth factor 1 receptor protein, which is activated by IGF-1 and IGF-2 
and well-known to be involved in cancer as well as normal tissue development 
(Dupont et al., 2003; Pollak et al., 2004). The functional impact of regulating the 
miRNA targets can be more generally examined through GO analysis. 
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Figure 5.9: miRNA-target gene interaction network of the five most abundant 
miRNAs from primary keratinocyte-derived APs and MVs showing target genes 
regulated by at least three miRNAs.  
 
A) A summary network illustrating the shared target genes. A1 – A5) Individual 
clusters separated from the summary network where each cluster represents the genes 
with redundant regulation from at least three miRNAs. Networks were generated 
using Cytoscape (v3.2.1) connected to CyTargetlinker linked with target database 
(version 6.0) (http://mirtarbase.mbc.nctu.edu.tw). 
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The analysis of these nine target genes of three of the most abundant miRNAs 
presented in primary keratinocyte-derived APs and MVs showed that of the nine BP 
GO terms and two KEGG terms four, related to: hemopoiesis; hemopoietic or 
lymphoid organ development; erythrocyte differentiation; and erythrocyte 
homeostasis, were significantly enriched with SP1, CDK6 and SFXN1 (Table 5.10). 
Moreover, IGF1R, LIFR and CDK6 were associated with positive regulation of cell 
proliferation and regulation of cell proliferation. SFXN1 and SP1 were significantly 
over represented in the terms immune system development, myeloid cell 
differentiation and homeostasis of number of cells. These data may suggest that these 
primary keratinocyte-derived APs and MVs may be able to regulate cellular growth 
and development. 
 
Table 5.10: GO term enrichment analysis of nine target genes regulated by at least 
three of the most abundant miRNAs in primary keratinocyte-derived APs and MVs 
Category Terms P-value 
Fold 
Enrichment 
BP GO:0030097~hemopoiesis 0.00434 24.5665 
GO:0048534~hemopoietic or lymphoid organ 
development 0.00524 22.2989 
GO:0002520~immune system development 0.00589 21.0062 
GO:0008284~positive regulation of cell 
proliferation 0.01291 14.0041 
GO:0030218~erythrocyte differentiation 0.01892 89.8870 
GO:0034101~erythrocyte homeostasis 0.02154 78.8804 
GO:0030099~myeloid cell differentiation 0.04055 41.5606 
GO:0042127~regulation of cell proliferation 0.04335 7.36685 
GO:0048872~homeostasis of number of cells 0.04354 38.6514 
   KEGG hsa05214:Glioma 0.03671 40.3571 
hsa05218:Melanoma 0.04131 35.8098 
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5.3.6.4 The co-regulated miRNA-target genes of the five most abundant miRNAs 
in primary keratinocytes-derived EXs 
The most abundant miRNAs from primary keratinocyte-derived EXs together 
regulate a total of 1548 genes. There were 179 genes regulated by at least two 
miRNAs and fifteen genes regulated by at least three miRNAs (Figure 5.10). These 
genes with redundant miRNA regulation may be important to the functional role of 
the keratinocyte EXs. In particular, VEGFA, one of the fifteen genes which were 
found to be regulated by three separate miRNAs (hsa-21-5p, hsa-203a-3p and hsa-
205-5p), is essential for angiogenesis and the stimulation of cell migration.  
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Figure 5.10: miRNA-target gene interaction network of the five most abundant 
miRNAs from primary keratinocyte-derived EXs showing target genes regulated by 
at least three miRNAs.  
 
A) A summary network illustrating the shared target genes. A1 – A9) Individual 
clusters separated from the summary network where each cluster represents the genes 
with redundant regulation from at least three miRNAs. Networks were generated 
using Cytoscapte (v3.2.1) connected to CyTargetlinker linked with target database 
(version 6.0) (http://mirtarbase.mbc.nctu.edu.tw). 
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Analysis of the fifteen target genes showed that they were enriched with 43 BP 
GO terms, four CC GO terms, nine MF GO terms and eight KEGG terms. Among 
the 43 BP GO terms, eight were associated with transcription, several terms relate to 
cell cycle and cell death, and six BP GO terms were related to the circulatory system. 
Furthermore, some terms involved in various metabolic processes, regulation and 
development were also enriched in BP analysis. With regard to CC and MF GO 
terms, three out of four CC terms were related to organelles, and the majority of the 
MF terms were associated with transcription activities. Interestingly, seven out of 
eight KEGG terms were associated with different types of cancer and cell cycle. 
More descriptions of the GO terms and KEGG pathway can be found in Table 5.11. 
The most frequently enriched genes in GO terms and KEGG pathways include SP1, 
SMAD4, E2F1, PTEN, CREB1, CDK6, SFXN1 and LCOR. This may indicate the 
functional roles of primary keratinocyte-derived EXs on biological processes through 
the regulation of transcription. 
 
 
Table 5.11: GO term enrichment analysis of fifteen target genes regulated by at least 
three of the most abundant miRNAs in primary keratinocyte-derived EXs 
 
Category Terms P-value 
Fold 
Enrichment 
BP GO:0006357~regulation of transcription from 
RNA polymerase II promoter 1.65E-05 10.0196 
GO:0007167~enzyme linked receptor protein 
signaling pathway 1.69E-04 15.2136 
GO:0045944~positive regulation of 
transcription from RNA polymerase II 
promoter 2.31E-04 14.0244 
GO:0006355~regulation of transcription, 
DNA-dependent 2.85E-04 4.69538 
GO:0051252~regulation of RNA metabolic 
process 3.28E-04 4.59179 
GO:0030182~neuron differentiation 4.36E-04 11.8791 
GO:0045893~positive regulation of 
transcription, DNA-dependent 6.03E-04 10.9079 
GO:0051254~positive regulation of RNA 
metabolic process 6.22E-04 10.8172 
GO:0030218~erythrocyte differentiation 6.38E-04 72.6010 
GO:0034101~erythrocyte homeostasis 8.29E-04 63.7111 
GO:0030097~hemopoiesis 0.00102 17.6375 
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GO:0045941~positive regulation of 
transcription 0.00113 9.22531 
GO:0010628~positive regulation of gene 
expression 0.00126 8.95538 
GO:0048534~hemopoietic or lymphoid organ 
development 0.00135 16.0094 
GO:0002520~immune system development 0.00161 15.0813 
GO:0045935~positive regulation of 
nucleobase, nucleoside, nucleotide and nucleic 
acid metabolic process 0.00164 8.33826 
GO:0051173~positive regulation of nitrogen 
compound metabolic process 0.00185 8.07931 
GO:0010557~positive regulation of 
macromolecule biosynthetic process 0.00196 7.95577 
GO:0031328~positive regulation of cellular 
biosynthetic process 0.00232 7.59573 
GO:0009891~positive regulation of 
biosynthetic process 0.00245 7.48644 
GO:0048666~neuron development 0.00290 12.2786 
GO:0030099~myeloid cell differentiation 0.00295 33.5682 
GO:0045449~regulation of transcription 0.00306 3.20066 
GO:0048872~homeostasis of number of cells 0.00340 31.2184 
GO:0042127~regulation of cell proliferation 0.00386 6.61127 
GO:0010604~positive regulation of 
macromolecule metabolic process 0.00525 6.07126 
GO:0035295~tube development 0.01560 14.1902 
GO:0000080~G1 phase of mitotic cell cycle 0.01585 115.623 
GO:0048008~platelet-derived growth factor 
receptor signaling pathway 0.01673 109.538 
GO:0051318~G1 phase 0.01847 99.1062 
GO:0031175~neuron projection development 0.02077 12.1947 
GO:0001952~regulation of cell-matrix 
adhesion 0.02369 77.0826 
GO:0006350~transcription 0.02744 2.97177 
GO:0042981~regulation of apoptosis 0.03073 5.17719 
GO:0043067~regulation of programmed cell 
death 0.03153 5.12618 
GO:0010941~regulation of cell death 0.03183 5.10731 
GO:0051726~regulation of cell cycle 0.03350 9.43155 
GO:0045892~negative regulation of 
transcription, DNA-dependent 0.03829 8.76923 
GO:0048593~camera-type eye morphogenesis 0.03835 47.3006 
GO:0008285~negative regulation of cell 
proliferation 0.03927 8.64777 
GO:0051253~negative regulation of RNA 
metabolic process 0.03947 8.62388 
GO:0010810~regulation of cell-substrate 
adhesion 0.04006 45.2441 
GO:0030030~cell projection organization 0.04067 8.48327 
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CC GO:0005667~transcription factor complex 0.01108 16.6 
GO:0043233~organelle lumen 0.04216 3.19230 
GO:0031974~membrane-enclosed lumen 0.04493 3.13038 
GO:0005739~mitochondrion 0.04677 4.27598 
   MF GO:0016563~transcription activator activity 0.00706 9.04738 
GO:0005161~platelet-derived growth factor 
receptor binding 0.01096 168.610 
GO:0030528~transcription regulator activity 0.01225 3.67998 
GO:0008134~transcription factor binding 0.01304 7.23085 
GO:0003700~transcription factor activity 0.01305 4.75567 
GO:0046983~protein dimerization activity 0.01513 6.84396 
GO:0003702~RNA polymerase II transcription 
factor activity 0.02393 11.4019 
GO:0042803~protein homodimerization 
activity 0.04268 8.32955 
GO:0003712~transcription cofactor activity 0.04961 7.66410 
   KEGG hsa05212:Pancreatic cancer 0.00009 35.3125 
hsa05200:Pathways in cancer 0.00050 9.68940 
hsa05214:Glioma 0.00304 30.2678 
hsa05218:Melanoma 0.00385 26.8573 
hsa05220:Chronic myeloid leukemia 0.00429 25.425 
hsa05222:Small cell lung cancer 0.00536 22.7008 
hsa05215:Prostate cancer 0.00600 21.4255 
hsa04110:Cell cycle 0.01161 15.255 
 
 
Taken together, there were a total of 31 target genes which are known to be 
regulated by at least three of the most abundant miRNAs carried by any of the three 
EV populations released from both HaCaT and primary keratinocytes (Figure 5.11). 
The most frequent target genes regulated by EV miRNAs from both cell types were 
CDK6, NUFIP2, PTEN, RMND5A, SFXN1, SP1, and ZNF460 (Figure 5.11). Of 
particular interest, fifteen of these genes were unique to HaCaT-derived EVs, and nine 
were unique to primary keratinocyte-derived EVs (Figure 5.11). In addition, genes 
regulated by at least three of the five most abundant miRNAs in APs and MVs were 
associated with fewer BP, CC, MF and KEGG terms compared to those in EXs. 
Furthermore, regulation- and circulatory system-related terms were the most common 
across all the EV populations, in addition to various cancer pathways. Moreover, other 
GO terms which were different between EVs included: (BPs) transcription, cell cycle, 
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cell death, regulation and development; (MFs) transcription activities; and (CC) 
organelle. These data indicate that EVs could share common bioactivities beside their 
specific and unique functions. This was especially apparent with the target genes from 
primary keratinocyte-derived EXs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: The common and unique target genes regulated by at least three of the 
most abundant miRNAs in all EVs released from HaCaT cells and primary 
keratinocytes. 
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5.4 DISCUSSION 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR), 
miRNA microarray and RNA sequencing are techniques used to study miRNAs from 
various samples including cells, tissues and body fluids (reviewed in (Pritchard et al., 
2012)). While, qRT-PCR and miRNA microarray have been the most widely used 
approaches for investigation of EV miRNAs (Alvarez et al., 2012; Hessvik et al., 
2012; Ji et al., 2014; Michael et al., 2010; Rana et al., 2013; Valadi et al., 2007), 
some studies have also used RNA deep sequencing to profile EV miRNAs (Huang et 
al., 2013; Ji et al., 2014; Lunavat et al., 2015; van Balkom et al., 2015). Each 
approach has benefits and limitations. For instance qRT-PCR and microRNA 
microarray are more targeted approaches but cannot be used to detect novel miRNAs 
and are medium-throughput with respect to sample numbers processed per day. In 
contrast, deep sequencing is a high-throughput and highly sensitive technique that 
can identify novel miRNAs, but this approach is costly (Pritchard et al., 2012). In 
this current study, qRT-PCR was used to conduct some preliminary investigations of 
some miRNAs of interest in EVs. The six targeted EV miRNAs included: hsa-miR 
146a; hsa-miR 29a; hsa-miR let7b; hsa-miR 21; hsa-miR 141; and hsa-miR 203, and 
their abundance levels were not different between the different EVs and their 
respective parental cells (Figure 5.1). The examination of these miRNAs in EVs is 
consistent with previous investigations, especially with regard to EXs and using 
similar technique and approaches (exocarta.org, (Lunavat et al., 2015)). Importantly 
the qRT-PCR data indicated that the total RNA samples were extracted successfully 
using the TrizolTM method and this sanctioned the use of the extracted RNAs for 
miRNA deep sequencing. Through utilisation of the deep sequencing technology, in 
this present study, large numbers of miRNAs were identified in EVs and their 
respective parental cells. At the time of drafting this thesis, only five investigations 
have utilised a deep sequencing approach to profile EV miRNAs (Huang et al., 2013; 
Ji et al., 2014; Lunavat et al., 2015; van Balkom et al., 2015; Zhou et al., 2012). The 
first two instances detected miRNAs in EXs isolated from human breast milk and 
plasma (Huang et al., 2013; Zhou et al., 2012), and more recently Ji et al., (2014) 
and van Balkom et al., (2015) identified miRNAs in EXs and MVs released from the 
human colon carcinoma cell line LIM 1863 and miRNAs in EXs released from an 
endothelial cell line (Ji et al., 2014; van Balkom et al., 2015). More specifically 
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aligned with the study described herein, Lunavat et al. (2015) detected 1041 
miRNAs in melanoma cell-derived EVs, including APs, MVs and EXs (Lunavat et 
al., 2015). In this study, deep sequencing technology was utilised to successfully 
profile miRNAs in populations of APs, MVs and EXs that were released from both 
HaCaT and primary keratinocyte cultures. These data provide valuable information 
for the study of EVs in skin, particularly given the detection of miRNAs that have 
not been previously reported as EV cargo. In this regard, 1048 and 608 miRNAs 
were detected in APs, 906 and 506 miRNAs in MVs, and 704 and 622 miRNAs in 
EXs, released from HaCaT and primary keratinocytes, respectively. The large 
number of identified miRNA detected in this study is similar to the number of 
miRNAs identified in the study by Lunavat et al. (2015) (1041 miRNAs) and greater 
than observed in the other aforementioned related studies (Huang et al., 2013; Ji et 
al., 2014; Lunavat et al., 2015; van Balkom et al., 2015). In addition, there were 
differences in the specific complement of miRNAs detected in parental cells 
compared to their respective EV derived miRNAs (Figure 5.2 A & B). These 
molecular signals in EVs differ from their parental cells may reflect particular 
functions of EV populations (Nazarenko et al., 2010; Skog et al., 2008; Valadi et al., 
2007). The detection of numerous specific miRNAs in individual EV populations but 
not in their respective parental cells (Figure 5.2) provides some evidence that these 
miRNAs are selectively sorted into the different EV populations during formation 
and release processes. The selective sorting of miRNAs into EVs could depend on: 
1) polyuridylation (a non-templated nucleotide) enhancing miRNA incorporation 
into EVs; 2) miRNA maturation pathway that depends on AGO2; 3) the sequence of 
mature miRNA; 4) the abundance levels of complementary 3’ UTR mRNA 
fragments in EV; or 5) the binding of miRNAs to heterogeneous nuclear 
ribonucleoprotein A2B1 (hnRNPA2B1) and subsequently sorted to EVs (Anna et al., 
2015; Villarroya-Beltri et al., 2013). It is important to note that the mechanism 
involved in selective miRNA sorting to EVs may be altered given potential 
physiological or pathological differences of EV producers (Villarroya-Beltri et al., 
2013; Zernecke et al., 2009). 
In an attempt to discriminate the three EV populations under investigation, the 
miRNA contents of each were examined for common and unique miRNA (Figure 5.2 
A and B). Euclidean distance clustering indicated APs and MVs to be more closely 
  
Chapter 5: Identification of microRNAs present in extracellular membrane vesicles 193 
related than either is to EXs (Figure 5.3). Furthermore, analysis of the miRNAs with 
the most significant differential expression via hierarchical clustering also indicated 
that EXs had a different miRNA abundance profile to APs and MVs which were 
more similar (Figure 5.5). These data are similar to the results from the analysis of 
APs, MVs and EXs released from melanoma cells, whereby APs and MVs had a 
greater correlation when compared to EXs (Lunavat et al., 2015). Closer examination 
of the Euclidean distance maps and hierarchical clustering analysis in the study 
reported herein, demonstrated a more complicated miRNA based EV distribution for 
primary keratinocytes compared to HaCaT cells (Figure 5.3 B and figure 5.5 B). It 
seems that the correlation of miRNA content between EVs depends on both the 
specific EV population (biogenesis) and also the specific parental cell source (HaCaT 
cells and individual donors for the primary keratinocytes). Indeed, as mentioned 
above, the selective deposition of miRNAs to EVs may depend on the specific 
miRNA sorting mechanism associated with EV formation and release (Anna et al., 
2015). The variation observed in the miRNA profiles of the primary keratinocyte-
derived EVs isolated from individual donors may reflect the inter-individual 
physiological variation due to demographic differences such as age or subclinical 
disease such as diabetes etc. Alternatively, it is also possible that minor 
inconsistencies in sample preparation may have resulted in incompletely pure EV 
populations leading to cross contamination of EVs and therefore variation in the 
miRNA profiles. In summary, these data indicate that the three EV populations 
examined in this study may be discriminated by miRNA profile and that these 
differences may depend on both the mechanism of EV biogenesis and the 
physiological conditions under which the parental cells (HaCaT and primary 
keratinocytes) are cultured or arise from. 
Although this current investigation revealed that EVs contain a large number of 
miRNAs, it is important to determine if those miRNAs have been detected in 
previous EV studies or if some of them are novel. Therefore, a comparison of the 
miRNA complement identified in this study with the ExoCarta miRNA database was 
performed and in turn revealed that 212 novel miRNAs from HaCaT-derived EXs 
and 150 miRNAs from primary keratinocyte-derived EXs had not been reported 
previously in any EX study. The large number of novel exosomal miRNAs 
discovered in this study may be due to the research area being relatively new and 
 194 Chapter 5: Identification of microRNAs present in extracellular membrane vesicles 
there having been only a few studies that have investigated the EV miRNAs but no 
study that have investigated the keratinocyte-derived EV miRNAs (Huang et al., 
2013; Ji et al., 2014; Lunavat et al., 2015; van Balkom et al., 2015). Importantly, the 
ExoCarta database, only gathers information for exosomes, leaving a deficit in the 
curated knowledge of AP and MV miRNA cargo. Therefore, it is currently very 
challenging to interpret the novelty of AP and MV miRNA findings. In this regard 
there is a need for continued curation of exosomal miRNAs as well as an initiative to 
curate AP and MV miRNA findings. 
Through the comparison of EV miRNAs released from HaCaT cells and 
primary keratinocytes, this study found that the 18 members of the let 7 family of 
miRNAs were common to each of the EV populations released from the two parental 
cells of origin. Let 7 was the first human miRNA detected and is expressed 
differently in various human tissues (Müller et al., 2000). Let 7 and its family 
members have a highly conserved sequence across species and function to regulate 
many biological processes, such as cell proliferation, cell differentiation, limb 
development and cancer (Johnson et al., 2005; Müller et al., 2000; Roush et al., 
2008; Wulczyn et al., 2007; Yu et al., 2007a; Yu et al., 2007b). Recently, let 7 
miRNA family members were detected in EVs, including APs, MVs and EXs, 
released from cultured cells (Bellingham et al., 2012; Hessvik et al., 2012; Ji et al., 
2014; Lunavat et al., 2015; Valadi et al., 2007), isolated from plasma (Huang et al., 
2013) and saliva (Michael et al., 2010). In the study reported herein, 15 of the 18 
common hsa-miR-let 7 family members exhibited different abundance levels, 
according to normalised mean read counts detected, between EVs released from two 
cell types (Table 5.1). Similarly, eight of the 18 hsa-miR-let 7 family members 
exhibited different abundance levels between APs, MVs or EXs in one or other of the 
2 cell types (Appendix table 5.1). This may be due to the ubiquitous presence of the 
let 7 family of miRNAs in every tissue and their important and various functions, as 
reported previously (reviewed in (Roush et al., 2008)). Despite the fact that many let 
7 members were detected, not all of them are known to target protein encoding 
genes. Several hsa-let-7 members, including hsa-let-7a-2-5p; hsa-let-7a-3-3p; hsa-let-
7a-3-5p; hsa-let-7c-5p; and hsa-let-7f-2-5p, are not known to target any gene 
(miRTarBase v6.0). Given that hsa-let-7a-2-5p, hsa-let-7a-3-5p, and hsa-let-7f-2-5p 
exhibited relatively high abundance in both HaCaT cell and primary keratinocyte-
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derived EVs, these cell systems might offer an ideal model in which to more closely 
investigate their potential functional roles and molecular targets. However, other hsa-
let-7 members are known to target protein encoding genes. Of particular interest are 
those genes with roles associated with wound healing processes, such as collagen; 
platelet-derived growth factor subunit B; platelet-derived growth factor receptor 
alpha; fibroblast growth factor receptor like 1; and epidermal growth factor etc. 
(Table 5.5). Although there have not been any experiments to examine the roles of 
let-7 miRNAs in this study, the high normalised mean read count data indicate 
abundant levels of miRNAs. Together, the results of this study have confirmed 
previous reports that the common hsa-let-7 family are consistently expressed in 
keratinocyte-derived EVs and parental cells (Bellingham et al., 2012; Hessvik et al., 
2012; Ji et al., 2014; Lunavat et al., 2015).  As such the hsa-let-7 could be 
investigated further as potential endogenous reference genes for extracellular vesicles 
in the future. 
Despite the large number of miRNAs identified in this current study, how 
many or which of these are active and able to regulate their target mRNAs remains 
an important question. Evidently, only highly expressed miRNAs are able to 
significantly regulate their targets (Brown et al., 2007; Hafner et al., 2010; 
Mullokandov et al., 2012). As Brown et al. (2007) demonstrated, miRNAs which are 
expressed at high levels (greater than 100 copies / pg of the short RNA fraction) 
significantly supressed their targets, while miRNAs which were expressed at lower 
levels (less than or equal to 50 copies / pg small RNAs) did not show significant 
suppressive activity (Brown et al., 2007). Similarly, Mullokandov et al. (2012) 
showed that 80% of miRNAs, which have greater than 100 reads per million (reads) 
have suppressive activity (Mullokandov et al., 2012). However, these authors also 
found that the suppression level is not directly correlated to the expression level of an 
individual miRNA species, but rather it corresponds with the cumulative 
concentration of entire members of the miRNA family (Mullokandov et al., 2012). In 
addition, to further complicate matters, not all highly-expressed miRNAs suppress 
their targets, for example as miRNA-223 was similarly highly expressed in U937 
monocyte cells, 293T kidney cells and HuH7 liver cells, but only suppressed its 
target mRNA in monocyte cells but not in the other cell types (Brown et al., 2007). 
In the study presented here, only 181 and 210 miRNAs in APs, 186 and 214 miRNAs 
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in MVs and 189 and 210 miRNAs in EXs released from HaCaT and primary 
keratinocytes, respectively, were highly abundant (greater than 100 reads per 
million) (Table 5.2). Therefore, of the complete compliment of EV-derived miRNAs, 
it is possible that these relatively high abundant miRNAs are the most likely to be 
active and affect cellular functions. Additionally, another important question 
regarding how many miRNA copies can be transferred by EVs to the target cells so 
that they reach the functional threshold has not yet been addressed. To the best of 
this author’s knowledge, only two studies by Chevillet et al. (2014) and Stevanato et 
al. (2016) have performed a stoichiometric analysis of the absolute copy number of a 
given miRNA and the number of EXs. These studies found that there was less than 
one miRNA copy per EX isolated from the plasma of prostate cancer patients 
(Chevillet et al., 2014) and at least 10 miRNA copies per EX released by a human 
neural stem cell line (Stevanato et al., 2016). This indicates that an individual EX 
does not carry a biologically significant number of miRNAs which supports the 
hypotheses discussed above that only abundant miRNAs elicit significant bioactivity 
(Brown et al., 2007; Mullokandov et al., 2012). However, exosomal miRNAs with 
low copy numbers have been functionally transferred into recipient cells (Stevanato 
et al., 2016). Thus potentially, a high level of up-take of EXs or nonconventional 
miRNA activation would be required to elicit exosomal miRNA-mediated effects 
(Chevillet et al., 2014). Given the apparent relationship between miRNA copy 
numbers and their function, more research is required to ascertain the association of 
EV miRNA copies with their functional effects, including in keratinocyte models. 
Importantly, the suppressive activity, or otherwise, of the miRNAs described in the 
lists generated in this study will need to be further examined experimentally in the 
future. More details of the future direction will be discussed in chapter 7. 
Although very little practical evidence regarding the association of EV 
miRNAs and biological events is available, bioinformatics analysis of the genes 
regulated by EV miRNAs can potentially provide insight as to the relative 
contribution of EVs and EV miRNAs to various biological activities. For instance, 
preliminary bioinformatic analysis of genes targeted by miRNAs detected in LIM 
1863 colon cancer cell line-derived EVs resulted in various enrichment of BP, CC 
and MF GO terms such as extracellular matrix, membrane and cancer progression (Ji 
et al., 2014). Furthermore, important pathways, such as the p53 signalling pathway; 
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TGF-beta signalling pathway; MAPK signalling pathway; cell cycle; among others, 
have been associated previously with miRNA regulation (De Caestecker et al., 2000; 
Harris et al., 2005; Ji et al., 2014). Consistent with these studies, the above pathways 
were also associated with keratinocyte-derived EV miRNA target genes reported as 
part of this study (Tables 5.7 – 5.10). Importantly, some of the GO terms associated 
with the EV miRNA target genes, described herein, are distinctly associated with 
either specific EV populations and / or parental cell origin (Table 5.8 – 5.11). These 
disparities may arise from the specific differences in the physiological conditions 
between the HaCaT cell line, which resemble normal keratinocytes, and primary 
keratinocyte cells, which while are more biologically relevant are subject to variation 
between donors (Seo et al., 2012; Sprenger et al., 2013). Although bioinformatics 
information may serve to indicate the potential connections between EV miRNAs 
and functional consequences, it is important that further experiments be performed to 
more deeply understand the mechanisms of EV miRNA regulation of their target 
genes and subsequent biological functions. 
Within recent years, consideration of the roles of miRNAs in the regulation of 
the physiological states of living organisms has increased. Evidence has 
demonstrated the link between miRNAs and cancer (Gorenchtein et al., 2012; 
Gumireddy et al., 2008), and the connections between miRNAs with various stages 
of wound healing biology, such as inflammation, proliferation and remodelling 
(reviewed in (Banerjee et al., 2011; Roy et al., 2012; Sen et al., 2008)). With regard 
to wound healing, miRNAs play roles in cell differentiation, proliferation, migration, 
epithelialisation, regulation of ECM biology, immune response and angiogenesis 
(Banerjee et al., 2011; Bertero et al., 2011; Kuo et al., 2013; Li et al., 2009; Zhou et 
al., 2011; Zhuang et al., 2012). Closer examination of the relationship between 
particular miRNAs, including miRNA-21, miRNA-203 and miRNA-205, which were 
identified in this current study, infer an association with the wound healing processes 
through regulation of various cellular functions such as cell migration, cell 
proliferation, and epithelialisation (Viticchiè et al., 2012; Wang et al., 2012a; Yang 
et al., 2011; Yu et al., 2010). In this regard, miRNA-21 was shown to be up-
regulated in activated epithelial cells of the epidermis and mesenchymal cells of the 
dermis, after wounding, while the antagonism of this miRNA led to a healing delay 
through the impairment of wound contraction and collagen deposition (Wang et al., 
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2012a). In addition, miRNA-21 is also known to promote keratinocyte migration by 
targeting Tissue inhibitor of metalloproteinase-3 (TIMP3) and T-lymphoma invasion 
and metastasis inducing protein (TIAM1) via TGF-β1, which is a key event required 
for the closure of the epidermis (Yang et al., 2011). The expression of miRNA-21 
was increased in TGF-β1-treated cells leading to a reduction of TIAM1 and TIMP3 
expression then promoted the keratinocyte migration (Yang et al., 2011). Moreover, 
the migration and proliferation of keratinocytes are also regulated by miRNA-203, 
which directly targets p63, Ras-related nuclear protein (RAN), Ras Association 
(RalGDS/AF-6) And Pleckstrin Homology Domains 1 (RAPH1) and LIM and SH3 
domain protein 1 (LASP1) (Viticchiè et al., 2012). Specifically, the expression of 
p63, RAN, RAPH1 and LASP1 were reduced if miRNA-203 was overexpressed, 
leading to a reduction of primary human keratinocyte migration and proliferation 
(Viticchiè et al., 2012). Furthermore, using an in vivo mouse skin model, normal 
wound healing was shown to proceed with low expression of miRNA-203 at the 
wounded area (Viticchiè et al., 2012). In contrast, an increase in miRNA-205 
expression led to a decrease in the expression level of SH2-domain containing 
inositol 5-phospatase 2 (SHIP2) gene that resulted in the promotion of keratinocyte 
migration and rapid wound closure (Yu et al., 2010). Importantly for this study, 
miRNA-21, miRNA-203 and miRNA-205 were among the most abundant miRNAs 
from EVs released from either HaCaT or primary keratinocytes (Table 5.6). This 
finding indicates that the EV miRNAs and EVs described herein may also have 
functions in wound healing. With regard to cancers and other biological events, 
activities such as angiogenesis, haematopoiesis, exocytosis, and tumorogenesis, have 
been found to be regulated by exosomal miRNAs (including miRNA-1, miRNA-17, 
miRNA-181 and miRNA-375) (Valadi et al., 2007) and MV miRNAs (miRNA-9) 
(Zhuang et al., 2012). Furthermore, cell migration, cell proliferation and 
angiogenesis were enhanced by “large oncosome” (1 – 10 µm in diameter) miRNA-
1227, however the mechanism was not investigated (Morello et al., 2013) and MV 
miRNA-9 via target gene SOCS5 (Suppressor of cytokine signalling 5) and activated 
JAK-STAT signalling pathway (Zhuang et al., 2012). Those miRNAs were detected 
in this current study but they were not in the top most abundant EV miRNAs 
analysed. In brief, previous evidence and the data presented here in supports the 
involvement of EV miRNAs in various biological events including cutaneous wound 
healing. 
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Together, the EV miRNA data presented herein are valuable for helping to 
understand EV miRNA composition and to provide an insight into the potential role 
of EV miRNAs in specific biological processes. At the time of drafting, this was the 
first investigation to profile miRNAs from all three EV populations released from 
keratinocytes using a deep sequencing approach. Data arising from the study 
described herein revealed different miRNA populations and enabled discrimination 
between the three different EV populations based on miRNA abundance levels. This 
was especially relevant for EXs, which were separated from APs and MVs based on 
their miRNA profiles and abundance levels (Figure 5.3 and 5.5). Importantly, the 
target genes of the most abundant EV miRNAs encode for some important proteins 
associated with many biological activities including dermal-epidermal wound 
healing. Furthermore, while the keratinocyte-derived EVs utilised in this study were 
not produced from a defined wound healing model the data may still suggest that 
some EV miRNAs could become potential candidates as cutaneous wound healing 
therapeutics or diagnostics in the future. Consequently, in order to begin to explore 
this more, a preliminary examination of the capacity of keratinocyte-derived EVs to 
influence primary dermal fibroblast migration in a scratch wound model is reported 
in the next chapter. 
 
5.5 CONCLUSION 
This is the first study to identify miRNAs in all three EV populations released 
from keratinocytes using a deep sequencing platform. A collection of novel and 
previously identified miRNAs was identified in EVs released from the HaCaT cell 
line and primary keratinocytes. The miRNA presence and abundance varied among 
different EV populations and EV parental cells (HaCaT or primary keratinocytes). Of 
interest, there were over one hundred identified exosomal miRNAs which are 
reported for the first time as EV cargo in this investigation. In addition, the 
identification of the highest abundant miRNAs in each EV population allowed 
bioinformatics based determination of their respective target genes and elucidation of 
the potential contribution of each EV to various bioactivities. Importantly, a suite of 
these target genes have known connections to wound healing. Overall, the data 
herein contribute to the understanding of keratinocyte-derived EV molecular cargo, 
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and perhaps enable the prediction of the potential roles of keratinocyte-derived EVs 
in living organisms. 
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Chapter 6: Capacity of keratinocyte-derived 
extracellular membrane vesicles 
to stimulate cell migration 
6.1 INTRODUCTION 
Cutaneous wound healing is a complex process due to continuous and 
overlapping events, such as cell migration, proliferation, angiogenesis, extracellular 
matrix deposition and tissue remodelling which are controlled by interactions of 
various epidermal and dermal cells (Sonnemann et al., 2011). In the reparative 
dermis, fibroblast and keratinocyte interactions become prominent and these support 
capillary growth, collagen synthesis and granulation tissue formation at the wound 
site (Guo et al., 2010). For instance, changes in fibroblast gene expression and 
cellular biology were induced by keratinocytes in an in vitro cell co-culture system, 
illustrating the influence of intercellular communication on cell function between 
these cell types (Shephard et al., 2004). The functions of fibroblasts within the 
wound bed are pivotal as they facilitate activities such as, fibrin clot break down, 
formation of new ECM, and wound contraction (Bainbridge, 2013; Guo et al., 2010; 
Li et al., 2011; Rozario et al., 2010). Wherever fibroblasts originate, they migrate 
into the wound bed by a mechanism known as ‘contact guidance’ which involves 
migration along ECM fibres such as collagen and / or fibronectin (Guido et al., 1993; 
Trebaul et al., 2007). The process is mediated by integral ECM-binding membrane 
proteins known as integrins (Wòjciak-Stothard et al., 1997; Xu et al., 1996).  
The potential of EVs to affect biological processes is now well known but still 
poorly understood. Recently, some pioneering studies have been conducted with the 
aim to investigate the role of EVs on wound healing, including cell migration, cell 
proliferation, angiogenesis or collagen production (Cheng et al., 2008a; Huang et al., 
2015; Keerthikumar et al., 2015; Moulin et al., 2010; Shabbir et al., 2015). In 
addition, preliminary analysis of identified EV proteins and miRNAs from chapter 4 
and 5 respectively suggested that keratinocyte-derived EVs are probably involved in 
many biological processes. However, little is known about whether or not the 
keratinocyte-derived EV populations, APs, MVs and EXs, can facilitate interactions 
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between epidermal and dermal cells which are important for wound healing. 
Previous studies have indicated that keratinocyte-derived EXs which carry HSP90 
and keratinocyte-derived MVs which activated Mitogen-activated protein kinase 
(MAPK) and Smad pathways stimulated fibroblast migration (Cheng et al., 2008a; 
Huang et al., 2015). As such, the influence of these three keratinocyte-derived EV 
populations on fibroblast migration was investigated.  
 
6.2 METHODS 
6.2.1 Materials 
HaCaT (passage 50, 52 and 53) and primary epidermal keratinocytes at passage 
1 (isolated from donor # 378, 386 and 389) were cultured for EV production.  
Primary dermal fibroblasts isolated from donors # 363, # 367 and 378 were used for 
the culture media optimisation as described in section 6.3.1. Primary dermal 
fibroblasts isolated from donor # 300 (chosen randomly from 4 patients # 300, 363, 
367 and 378) were used for the conduction of migration assays. 
Details of other reagents used for the experiments described in this chapter can 
be found in section 2.1 from chapter 2. 
 
6.2.2 Methods 
A brief overview of the methods utilised for the examination of the functional 
effect of each EV population on primary fibroblast cell migration is described below. 
Full details can be found in chapter 2 of this thesis.  
 
6.2.2.1 EV production and EV collection 
HaCaT and primary keratinocytes were cultured as detailed in section 2.2.1 and 
2.2.2. Once 80 % confluent, the HaCaT cultures were washed with fresh DMEM and 
irradiated 3T3 feeder cells were removed from primary keratinocyte cultures then 
washed with fresh DMEM prior to subjecting both cell types to serum-free media for 
48 h to produce EVs as described in section 2.2.5.  
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The resulting EVs were then isolated and classified as APs, MVs and EXs as 
described in section 2.3.1. The protein concentration was determined using a BCA 
protein assay kit assay as described in section 2.4, in order to determine EV doses 
corresponding to 1 µg, 10 µg, and 20 µg of total protein. EV pellets were then 
resuspended in 100 µL DMEM which were then stored at 4 ºC for maximum 4 days 
prior to cell treatment. EVs at these doses were used to treat fibroblasts in a scratch 
wound assay system.  
 
6.2.2.2 Cell culture media preparation 
The media compositions to be tested in the migration assay included: normal 
fibroblast media (NM) (88 % DMEM, 10% FCS, 1% Pen/Strep and 1% L-
glutamine); vesicle-depleted media (DM) (as per NM but with vesicle depleted FCS 
as per section 2.13.1); and conditioned media (CM) (media collected following EV 
isolation, as detailed in section 2.3.1.3). Full details of media preparation can be 
found in section 2.13.1. Each media composition was tested in a fibroblast scratch 
wound assay as described below. 
In addition, DM was utilised as the base media for examination of the effect of 
isolated EV populations on fibroblast migration. EV specific media were prepared by 
the addition of isolated EVs to a final concertation of 1 µg, 10 µg and 20 µg per 100 
µL DM, based on the EV total protein concentration (as described in section 6.2.2.1). 
A ratio calculation of exosome numbers to protein amounts has been reported in 
appendix table 6.1. 
 
6.2.2.3 Primary dermal fibroblast culture for scratch wound assay 
Primary dermal fibroblasts were isolated from donor skin (donor # 300) as 
described in section 2.2.3 and cultured until passage 3, harvested using trypsin and 
seeded into a 96 well ImageLock plate at 2.4 x 104 cells / well and incubated at 5% 
CO2 and 37 ºC for 4 hours to generate a 100 % confluent passage 4 culture. Cell 
proliferation was then inhibited using 10 µg of Mitomycin C in 50 µL normal culture 
media per well and incubated for 2 hours at 5% CO2 and 37 ºC. Following removal 
of Mitomycin C, the cells were incubated in normal media, at 5% CO2 and 37 ºC 
during EV preparation (6 – 8 hours) and prior to creation of a scratch wound using a 
 204 Chapter 6: Capacity of keratinocyte-derived extracellular membrane vesicles to stimulate cell migration 
Woundmaker™ device. Fibroblast cell migration was measured using the IncuCyte® 
ROOM system equipped with a microscope to capture images. Complete details of 
primary fibroblast culture and scratch wound creation can be found in section 2.13.2. 
6.2.2.4 Migration assay 
In order to determine an appropriate control conditions for subsequent assays 
to examine the effect of each EV population on fibroblast cell migration, scratch 
wound migration assays were first performed using the NM, DM and CM 
compositions. The cell migration assay was performed over a 44 hour period using 
the IncuCyte® ROOM system, with 10 hourly image capture (with the exception of 
the final time point which was a 4 hour interval. At the completion of the assay the 
extent of cell migration was determined by calculation of the total area of wound 
closure using ImageJ as described below and more fully in section 2.13.4. 
In order to determine the capacity of each EV population to influence primary 
dermal fibroblast migration, scratch wounded fibroblast cultures were treated with 
APs, MVs or EXs, each at concentrations of 1 µg, 10 µg and 20 µg per 100 µL DM / 
well (prepared as described in section 6.2.2.2). Cell migration was measured over 24 
hours using the IncuCyte® ROOM system as described above (Full details can be 
found in section 2.13.3). At the completion of the assay the extent of cell migration 
was determined by calculation of the total area of wound closure using ImageJ as 
described below and more fully in section 2.13.4. Experiments were performed using 
keratinocyte-derived EVs collected from three independent biological replicates 
(donors). The primary dermal fibroblasts utilised for all migration assays were 
isolated from a single donor (donor # 300). 
Image analysis was performed on images captured at 10 hourly intervals for the 
control media evaluations and at 0 hour, 6 hours, 12 hours and 24 hours for the EV-
treated cultures in order to calculate the percentage of total wound area closed (Full 
details are as described in section 2.13.4). Graphs and statistical analysis (one-way or 
two-way ANOVA and Tukey’s multiple comparison tests, as indicated in each 
figure) were performed with Prism 6 (GraphPad) or Statistic Analysis System 
program (SAS v9.3). 
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6.2.2.6 Investigate change in miRNA expression using qRT-PCR 
miRNA-21 is known to influence fibroblast migration (Madhyastha et al., 
2012; Yang et al., 2011). In addition, the expression of some miRNA-21 target genes 
in fibroblasts were altered following treatment with EVs (Huang et al., 2015; Shabbir 
et al., 2015). These findings led to the hypothesis that EVs are able to either alter the 
expression of miRNA-21 in fibroblasts or deliver miRNA-21 to fibroblasts which 
may then alter target gene expression leading to cell function change. Therefore, 
qRT-PCR was used to examine the capacity of EVs to alter the abundance of 
miRNA-21 in treated fibroblasts. Briefly, total RNA was extracted from wounded 
dermal fibroblast cultures following 24 hours of culture in the presence or absence of 
keratinocyte derived EVs. The extracted total RNA was quantified (as described in 
section 2.12.1 and 2.12.2) and converted to cDNAs (as described in section 2.12.3) 
prior to qRT-PCR (as described in section 2.12.4). Information on the primer design 
to target has-miR-21 was described in section 2.12.4 (table 2.1). Graphs and 
statistical analysis (T-test) of the resulting Ct values was performed with Prism 6 
(GraphPad). Wounded fibroblast cultures that received DM media alone without 
addition of EVs served as controls.   
 
6.3 RESULTS 
6.3.1 EV-depleted media (DM) and normal cell culture media (NM) have a 
similar influence on fibroblast migration 
The EV-depleted media (DM) which consisted of EV-depleted FCS, served as 
the control cell migration media and to form the base media for the EV-treated media 
composition for the cell migration assays. However, prior to the analysis of the effect 
of each EV population on fibroblast migration, three different media compositions 
were compared in order to ascertain if the DM substantially affected fibroblast 
migration rate.  
The results showed that the cells treated with CM exhibited the lowest rate of 
cell migration in terms of closure of the wounded area, probably due to the depleted 
nutrient content (Figure 6.1) (see details of conditioned media in section 2.2.3). 
While there was no difference in the wound closure rate between fibroblasts treated 
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with either NM or DM, both exhibited higher rates of wound closure compared to 
CM (Figure 6.1). It is likely that factors in FCS, have an overwhelming influence on 
cell migration compared to any EVs present in FCS. Despite there being no 
difference in the influence of NM and DM on cell migration, DM was used for 
fibroblast migration assay. This was done in order to ensure that any FCS-derived 
EVs could not interfere with the effect of the different keratinocyte-derived EV 
populations added to DM for the subsequent migration assays. 
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Figure 6.1: Depletion of FCS-derived EVs does not affect primary human dermal 
fibroblast migration in a scratch wound assay 
 
The rate of wound closure was measured at 10 hour intervals up to a 44 hour 
endpoint. NM: normal fibroblast culture media; DM: vesicle-depleted fibroblast 
culture media; and CM: conditioned media. Data are presented as the mean 
percentage of wound closure ± SD from three independent biological replicates 
(fibroblasts isolated from donors # 363, 367 and 378). Two-way ANOVA and 
Tukey’s multiple comparison tests were used to evaluate statistical significance 
which is denoted as * p<0.05, *** p<0.001 and **** p< 0.0001. The graph was 
generated using a SAS program (v9.3). 
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6.3.2 Primary dermal fibroblast migration is modulated by specific 
keratinocyte-derived EVs depending on their cellular origin 
In order to study the influence of keratinocyte-derived EVs on fibroblast 
migration, a fibroblast scratch wound assay was created and subsequently treated 
with keratinocyte-derived EVs. In general, human dermal fibroblasts exhibited a 
more significant migration response, relative to controls, in the presence of primary 
keratinocyte-derived EV treatments compared to those incubated with HaCaT-
derived EV treatments (Figure 6.2). Specifically, human dermal fibroblasts did not 
respond to the treatment of HaCaT-derived EVs over and above the control DM only 
treatment (Figure 6.2 A, C and E). Fibroblasts treated with 10 µg of HaCaT-derived 
MVs migrated further, by the 24-hour time point, compared to those treated with 10 
µg of HaCaT-derived EX (Figure 6.2 C). In addition, enhanced migration effects 
were observed for cells treated with 20 µg of HaCaT-derived MVs compared to cells 
treated with 20 µg of HaCaT-derived APs at the 18 hour and 24 hour time points 
(Figure 6.2 E). However, none of the treatments with HaCaT-derived EVs resulted in 
migration that was statistically different to the control (Figure 6.2 A, C and E).  
In contrast, observation of primary fibroblasts treated with primary 
keratinocyte-derived EVs revealed that the fibroblasts responded to all EV 
populations (Figure 6.2 B, D, and F). Specifically, the fibroblasts treated with 1 µg of 
primary keratinocyte-derived MVs and those treated with 1 µg of primary 
keratinocyte-derived EXs exhibited greater migration at each time point after 12 
hours and after 18 hours respectively, compared to the fibroblasts treated with 1 µg 
of primary keratinocyte-derived APs and the control fibroblast cultures (Figure 6.2 
B). In addition, fibroblasts treated with 10 µg of primary keratinocyte-derived MVs 
and EXs migrated faster compared to the control fibroblasts after the 12 hour time 
point (Figure 6.2 D). At the 24 hour time point, primary keratinocyte-derived MVs or 
EXs had generally enhanced the migration of dermal fibroblasts over the control 
condition, irrespective of dose. Interestingly, primary keratinocyte-derived APs did 
not enhance fibroblast migration at doses of 1 µg (Figure 6.2 B, 24h) and 10 µg 
(Figure 6.2 D, 24h), but did elevate cell migration rate with a dose of 20 µg (Figure 
6.2 F) compared to the control group. Taken together this indicates that dermal 
fibroblasts responded differently to various primary keratinocyte-derived EV 
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populations. More generally, the response of fibroblasts to EVs is dependent on the 
EV’s parental cells of origin, time point after treatment and concentration of EVs.   
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Figure 6.2: Primary keratinocyte-derived EVs promote greater primary dermal 
fibroblast migration compared to those derived from HaCaT cells.  
 
Isolated EVs were added to scratch wounded primary fibroblast cultures to a final 
total EV protein concentration of: A) 1 µg HaCaT-derived EVs / 0.1 mL DM; B) 1 
µg primary keratinocyte-derived EVs / 0.1 mL DM; C) 10 µg HaCaT-derived EVs / 
0.1 mL DM; D) 10 µg primary keratinocyte-derived EVs / 0.1 mL DM; E) 20 µg 
HaCaT-derived EVs / 0.1 mL DM; F) 20 µg primary keratinocyte-derived EVs / 0.1 
mL DM. The fibroblasts incubated at 5% CO2 and 37 ºC and allowed to migrate for 
24 hours with images captured at 6 hourly intervals. Image analysis was performed 
using Image J and data are presented as mean percent area of wound coverage in µm2 
± SD, from at least 3 independent biological replicates. Two-way ANOVA and 
Tukey’s multiple comparison tests were used to evaluate statistical significance 
which is denoted as * where p< 0.05; ** p< 0.01; *** p< 0.001; and **** p< 0.0001. 
AP: Apoptotic bodies; MV: Microvesicles; EX: Exosomes; CT: Control.  
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6.3.3 Primary dermal fibroblast migration is modulated by primary 
keratinocyte-derived EVs with unclear response to EV doses 
In addition to the analysis of the influence of EV type on cell migration, the 
same data (from 6.3.2) could be rearranged to more clearly evaluate the influence of 
EV concentration or dose on the migration of primary human fibroblasts (Figure 6.3 
A - F). As described above, the results revealed that HaCaT-derived EVs did not 
noticeably affect or enhance primary dermal fibroblast migration compared to the 
control at any EV concentration (1 µg, 10 µg or 20 µg) (Figure 6.3 A, C and E). 
Moreover, while primary keratinocyte-derived EVs did significantly influence 
dermal fibroblast cell migration by 24 hours at specific concentrations, there was no 
consistent dose response noted (Figure 6.3 B, D and F). Specifically, with regard to 
primary keratinocyte-derived APs, only treatment at 20 µg / 0.1 mL / well was 
shown to promote significantly greater fibroblast migration over the control 
conditions (p<0.05) (Figure 6.3 B). Conversely, all MV doses significantly enhanced 
fibroblast migration over the control condition (p<0.01), although there was no 
difference in the response between the different MV concentrations (Figure 6.3d). 
Interestingly, primary keratinocyte-derived EXs at 10 µg / 0.1 mL promoted 
significantly elevated fibroblast migration over both the control condition (p<0.0001) 
and the other two EX concentrations, 1 µg / 0.1 mL and 20 µg / 0.1 mL (p<0.01) 
(Figure 6.3 F). However, there was no difference between the migration response to 
EXs at 1 µg / 0.1 mL or EXs at 20 µg / 0.1 mL although both still induced a 
significantly greater migration response by 24 hours compared to control conditions 
(p<0.05 and p<0.01 respectively) (Figure 6.3 F). Taken together, these data indicate 
that while primary keratinocyte-derived EVs generally enhanced the migration 
response of fibroblast cells, the response to dose was relatively inconsistent and 
therefore did not appear to be dose dependant.  
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Figure 6.3: Primary dermal fibroblast migration is modulated by primary 
keratinocyte-derived EVs but is not dose dependant. 
 
Isolated A) HaCaT-derived APs; B) primary keratinocyte-derived APs; C) HaCaT-
derived MVs; D) primary keratinocyte-derived MVs; E) HaCaT-derived EXs; or F) 
primary keratinocyte-derived EXs were added to scratch wounded primary fibroblast 
cultures to final total EV protein concentration of 1 µg, 10 µg or 20 µg / 0.1mL DM 
as indicated. The fibroblasts were incubated at 5% CO2 and 37 ºC and allowed to 
migrate for 24 hours with images captured at 6 hourly intervals. Image analysis was 
performed using Image J and data are presented as mean percent area of wound 
coverage in µm2 ± SD, from at least 3 independent biological replicates. Two-way 
ANOVA and Tukey’s multiple comparison tests were used to evaluate statistical 
significance which is denoted as * where p< 0.05; ** p< 0.01; *** p< 0.001; and 
**** p< 0.0001. AP: Apoptotic bodies; MV: Microvesicles; EX: Exosomes; CT: 
Control.   
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In order to obtain a better sense of the migration process, representative images 
of primary dermal fibroblast scratch wound assays treated with primary keratinocyte-
derived EXs at 1 µg, 10 µg or 20 µg / 0.1mL DM, were extracted from the individual 
image files and visually examined for morphological changes over time. At time 0 
the scratch wound was clearly defined (Figure 6.4 A1, B1, C1 and D1). By the 12 
hour-time point, fibroblasts at the two wound edges had migrated into the wound 
(Figure 6.4 A2, B2, C2 and D2) and nearly filled the scratch wound at the 24 hour-
time point (Figure 6.4 A3, B3, C3 and D3). 
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Figure 6.4: Primary keratinocyte-derived EXs facilitate migration of dermal fibroblasts in 2D culture. 
 
Isolated primary keratinocyte-derived EXs were added to scratch wounded primary fibroblast cultures to final total EV protein concentration of 1 
µg (A), 10 µg (B) or 20 µg (C) / 0.1mL DM as indicated. D: controls that fibroblasts were cultured with DM only. Fibroblasts cultured within 
DM only served as controls. The wounded fibroblast cultures were incubated at 5% CO2 and 37 ºC and allowed to migrate for 24 hours in the 
presence or absence of primary keratinocyte derived EXs with images captured at 6 hourly intervals. Representative images were extracted from 
the captured IncuCyteTM images at: A1, B1, C1 and D1) T = 0 hours; A2, B2, C2 and D2) T = 12 hours; and A3, B3, C3 and D3) T = 24 hours. 
A) 1 Images were captured using a 4X objective. The scale bar = 300 µm and the dotted lines represent the wound edge / migrating cell front. 
Images presented are representative of images captured from at least 3 independent biological replicates.  
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6.3.4 Keratinocyte-derived EVs did not alter the abundance of hsa-miRNA-21 
in treated fibroblasts 
Despite previous investigations, the mechanisms underlying EV mediated 
modulation of fibroblast migration remains unclear. miRNA-21 has been previously 
reported to control multiple aspects of cutaneous wound healing, including fibroblast 
and keratinocyte migration (Madhyastha et al., 2012; Yang et al., 2011). 
Furthermore, others have shown that EV treatment could alter gene expression, such 
as down regulation of Tissue inhibitor of metalloproteinases 3 (TIMP3), and up 
regulation of Transforming growth factor beta receptor II (TGFBRII) and c-myc, 
which are all targeted by miRNA-21, in treated fibroblasts (Huang et al., 2015; 
Shabbir et al., 2015). The change in expression of TIMP3 and TGFBRII, which are 
directly targets of miRNA-21, and c-myc, an indirect target of miRNA-21, may be 
resulted from a change in miRNA-21 expression after cells were treated with EVs. 
Thus, it was hypothesised that the abundance of miRNA-21 would be altered in the 
human primary dermal fibroblasts which were treated with EVs compared to those 
fibroblasts which were not treated with EVs. Therefore, following the capture of 
images for analysis of EV mediated modulation of fibroblast migration, the 
fibroblasts were subjected to RNA extraction and subsequent qRT-PCR targeting 
miRNA-21 abundance. The Ct (cycle threshold) data indicated that there was no 
statistical difference in miRNA-21 abundance between fibroblasts exposed to EV 
treatment and cells that were exposed to DM alone (controls) (Figure 6.5). These 
data suggest that keratinocyte-derived EVs have no effect on miRNA-21 abundance 
in primary dermal fibroblasts.  
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Figure 6.5: miRNA-21 abundance in migrating primary dermal fibroblasts is not 
altered following exposure to primary keratinocyte-derived EVs.  
 
Isolated A) HaCaT-derived APs; B) primary keratinocyte-derived APs; C) HaCaT-
derived MVs; D) primary keratinocyte-derived MVs; E) HaCaT-derived EXs; or F) 
primary keratinocyte-derived EXs were added to scratch wounded primary fibroblast 
cultures to final total EV protein concentration of 1 µg, 10 µg or 20 µg / 0.1 mL DM 
as indicated. The fibroblasts were incubated at 5% CO2 and 37 ºC and allowed to 
migrate for 24 hours prior to extraction of total RNA, generation of cDNA and 
subsequent qRT-PCR targeting miRNA-21. Data are presented as the mean raw Ct 
values ± SD from three independent biological replicates. Control data is derived 
from two independent biological replicates. Statistically significant differences 
between each treatment group and the control were determined by two tailed T-test; 
p values are as indicated. AP: Apoptotic bodies; MV: Microvesicles; EX: Exosomes; 
CT: Control. 
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6.4 DISCUSSION 
Much remains unknown regarding how EVs influence cell migration. Cell-to-
cell communication is an essential mechanism that cells use to transfer components 
from one cell to another (Hervé et al., 2013). The mechanism, which includes the 
recruitment of cell junctions, adhesion contacts and soluble factors, are very complex 
and associated with intercellular and intracellular signals (Majka et al., 2001; Rustom 
et al., 2004; Sherer et al., 2008). Recently, EVs have been reported to be an 
additional means of cell-to-cell communication as these vesicles carry functional 
components and can transfer them to neighbouring cells (Cocucci et al., 2009). Once 
released, EVs may bind to neighbouring cells, the ECM or be distributed to distant 
sites via the circulation or other bodily fluids (Camussi et al., 2010). Although still 
incompletely understood, EV communication has been characterised as occurring by: 
ligand-receptor interactions with recipient cells via a ligand receptor on the cell 
surface; internalisation into the cytoplasm of recipient cells where the EVs release 
their contents; and direct membrane fusion with the cellular membrane of recipient 
cells (Smith et al., 2015). Thus, by one of the above means, EVs carrying functional 
molecules can alter the function of target cells (Del Conde et al., 2005; Hoen et al., 
2009; Janowska-Wieczorek et al., 2001; Morelli et al., 2004).  
During the human cutaneous wound healing process, the movement of 
fibroblasts to the wound site and subsequent differentiation to myofibroblasts is 
vitally important for producing essential components of the ECM, such as collagens, 
glycosaminoglycans, proteoglycans, laminins, and thrombospondins (reviewed in (Li 
et al., 2011; Tracy et al., 2016)). Interestingly, investigations have recently shown 
that EVs are associated with wound healing processes, whereby these EVs have the 
capacity to control cell proliferation, migration (including fibroblast migration) and 
angiogenesis (Cheng et al., 2008a; Huang et al., 2015; Leoni et al., 2015; Shabbir et 
al., 2015; Zhang et al., 2015). In the study described herein, APs, MVs and EXs, that 
were released from primary human keratinocytes, promoted primary human dermal 
fibroblast migration leading to accelerated closure of scratch wounds by 24-hours 
post-wounding (Figure 6.2, 6.3 and 6.4), which are consistent with results from 
Cheng et al. (2008) and Huang et al. (2015) that keratinocyte-derived EXs and MVs 
enhance dermal fibroblast migration (Cheng et al., 2008a; Huang et al., 2015). 
However, at earlier time points, EVs did not clearly enhance fibroblast wound 
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closure herein. In this regard, the cells may have been under stress immediately post-
wounding, or it is possible that the EVs did not immediately trigger cell migration, 
possibly requiring some time to interact with or be internalised into recipient cells in 
order to release their cargo to elicit a functional response (Shabbir et al., 2015; Xie et 
al., 2010b). Importantly, since EVs contain a large range of molecules, more work is 
required in order to determine which molecules are associated with support of 
fibroblast migration. If EV-derived miRNAs influence migration processes, it could 
be expected that there may be a delay between the introduction of miRNAs and the 
functional response of the target cells (Ruan et al., 2016). This point was observed 
and supported by the study described herein, as cell migration was sustained / 
enhanced in response to EV treatment after the 12 - 18 hour time point compared to 
the control cultures. This may be due to the suppressive action of EV-derived 
miRNAs on their target genes and their direct (miRNA - target gene) or indirect 
(target gene mediation of other genes) influence on the cell migration. 
While few previous investigations have demonstrated that keratinocyte-derived 
EVs can influence fibroblast migration, EXs and MVs released from human 
keratinocytes have been shown to enhance fibroblast migration via a HSP90-α and 
LRP-1/CD91 cell surface receptor mediated mechanism and alteration of gene 
expression (Cheng et al., 2008a; Huang et al., 2015). However, these investigations 
only studied EXs and MVs separately but did not compare all three EV populations.  
Interestingly, data from the study described herein showed that human primary 
fibroblasts seem more sensitive to EXs and MVs, responding to the smallest doses 
tested (1 µg / 0.1 mL) (Figure 6.3 D and F). This is in contrast to the findings that 
fibroblasts did not respond to APs at the same low concentration, and only 
significantly responded to a dose of 20 µg / 0.1 mL. These findings support previous 
findings by Shabbir et al. (2015) who showed a clear migration response relationship 
between fibroblasts and exosomes released from human mesenchymal stem cells 
(Shabbir et al., 2015). Specifically, the greater the concentration of EXs used to treat 
the primary fibroblasts (50 µg / mL or 100 µg / mL), the greater the migration rate of 
the cells to infiltrate the scratch wound (Shabbir et al., 2015). While it is unclear 
which EV derived molecules influenced the migration response of dermal fibroblasts 
in the current study, the responses of fibroblasts to different EVs at the various 
concentrations are possibly a consequence of the differences in EV cargo. As 
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described in previous chapters, the three EV populations share common proteins and 
miRNAs, but they also contain unique components, or common components which 
differ in abundance. Therefore, the components, responsible for fibroblast migration 
in this context, may have been enriched in MVs and EXs compared to APs. On the 
other hand, the physiological status of recipient cells may also influence their 
migration. For example, fibroblasts derived from diabetic patients have been found to 
be more sensitive to low concentrations of mesenchymal stem cell-derived exosomes 
compared to normal adult fibroblasts (Shabbir et al., 2015). The diabetic fibroblasts 
exhibited a significant migration response to a dose of 1 µg EX / mL, whereas 
normal fibroblasts only exhibited a significant migration response to a dose of 10 µg 
EX / mL (Shabbir et al., 2015). The physiological status of the skin donors (donors # 
378, 386 and 389 for EV production; and donor # 300 for fibroblast migration assay) 
for this current study was not available due to ethical restrictions and as such their 
disease-related sensitivity to EXs and MVs remains unknown. However, the data 
support a model where fibroblast migration was supported by both EV populations.  
In contrast to primary keratinocyte-derived EVs, HaCaT-derived EVs did not 
promote the migration of primary human dermal fibroblasts over levels sustained by 
the control treatment (Figure 6.2 a, c and e). The difference in the capacity of EVs to 
stimulate fibroblast migration could be due to the specific EV cargo, the specific 
composition of which is dependent on the cellular origin (Leoni et al., 2015; Vlassov 
et al., 2012). For instance, specific EV components are known to be selectively 
sorted into EVs depending on the physiological conditions and disease states of the 
parental cells (Vlassov et al., 2012). The data reported in Chapter 4 and Chapter 5 
herein have revealed the different composition of proteins and miRNAs in each of 
the three EV populations from each of the two cell types. Therefore, it might be 
expected that the fibroblasts could behave differently if the cells were treated with 
HaCaT-derived EVs compared to primary keratinocyte-derived EVs. Furthermore, 
even though EVs may originate from a common cell type, they are known to have 
distinct influence on target cells (Leoni et al., 2015). For instance, ANXA1-carring 
EVs released from intestinal epithelial cells promoted the migration of intestinal 
epithelial cells while EVs which did not contain ANXA1 did not promote cell 
migration (Leoni et al., 2015).  
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It is noted that, in this current study, the EV mediated fibroblast migration 
experiments were established by the addition of isolated EVs to media containing 
serum that had been depleted of bovine derived EVs and compared to fibroblasts 
which were cultured in serum EV-free media (control media). While comparison of 
the control media and normal media indicated that there was no difference in the 
effect on cell migration, previous evidence has shown that serum EVs can have a 
substantial functional effect on cultured cell behaviour (Shelke et al., 2014). Thus, 
while the use of serum-free media for the migration assays may remove the potential 
impact of serum EVs on cell migration, it could also prevent the potentially 
overwhelming impact of the soluble serum components on cell functional response. 
As such, the serum EV-free media was utilised as the control group, and any change 
in fibroblast migration was then the result of the addition of the EVs.  
While a detailed investigation of the mechanistic processes of EV mediated 
intercellular communication was beyond the scope of the study described herein, this 
is a key area for future investigation. This is especially relevant given the importance 
of keratinocyte / fibroblast communication in wound healing processes such as 
migration, proliferation and differentiation. As a basis for such future investigation, 
the bioinformatics data presented in chapter 4 and 5 suggest that the keratinocyte-
derived EV molecular constituents are associated with the regulation of many genes, 
proteins and biological events associated with cell migration (Full bioinformatics 
data not shown in chapter 4 and 5). Furthermore, many of the detected proteins 
reported in chapter 4 are related to ECM components, including collagens, laminins, 
integrins, matrix metalloproteinases (Appendix table 4.1 and 4.2), which are also 
important for facilitating cell migration. Similarly, some of the miRNAs reported in 
chapter 5, such as miRNA-21, miRNA-203 and miRNA 9 have been previously 
associated with regulation of cell migration in vitro (Madhyastha et al., 2012; Yang 
et al., 2011; Yu et al., 2010; Zhuang et al., 2012). Since miRNA-21 expression has 
been found to be up-regulated in epidermal and dermal mesenchymal cells after 
wounding in vitro (Wang et al., 2012a) and the expression of genes targeted by 
miRNA-21 were altered after dermal fibroblasts were treated with MVs and EXs 
(Huang et al., 2015; Shabbir et al., 2015), the potential for keratinocyte-derived EVs 
to induce a change in miRNA-21 abundance in recipient fibroblasts was investigated 
(Figure 6.5). The results suggested that EVs did not substantially affect miRNA-21 
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abundance in the dermal fibroblasts either by induction of miRNA in the fibroblasts 
themselves or by delivery of substantial amounts of miRNA-21 from the keratinocyte 
derived EVs. Interestingly, in mouse experiments, miRNA-21 was found to be up-
regulated in tissues of wounded-normal skin, but down-regulated in tissues of 
wounded-diabetic skin (Madhyastha et al., 2012). This perhaps suggests that 
miRNA-21 may be expressed differently in normal wounds versus disease-related 
wounds, which is to suggest that miRNA-21 influence may vary depending on the 
physiological condition of the specific donor cells and tissues. 
In summary, the data presented in this chapter, generally supports previous 
findings reported in the literature wherein EVs derived from primary human 
keratinocytes, in particular MVs and EXs can stimulate human primary dermal 
fibroblast cell migration. However, while the fibroblasts responded to EVs in a 
parental cell of origin dependant manner, there was no clear evidence of an EV 
mediated dose response effect on cell migration. The abundance of miRNA-21 in 
fibroblasts was not altered following treatment of the fibroblasts with the three 
keratinocyte-derived EV populations. Of course, further investigations are required 
to uncover the mechanisms associated with migration and other processes such as 
cell proliferation and ECM production of keratinocyte-derived EV-treated fibroblasts 
and the means of communication used by EVs to deliver their contents.  
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Historically, membrane-enclosed vesicles, known as shedding vesicles or 
micro-particles, were first described as existing outside cells in the 1960s (Anderson, 
1969). In the 1980s, more complex pathways of vesicle secretion were described 
(Harding et al., 1983; Pan et al., 1983), and the term exosomes (EX) was used to 
indicate the endosomal origin of these vesicles. Similarly, the terms microvesicles 
(MVs) or shedding vesicles were used for vesicles released as a result of cell 
membrane budding (Cocucci et al., 2009; Colombo et al., 2014; Johnstone et al., 
1987). Furthermore, although programmed cell death had been discovered and 
described previously, the term apoptosis was first used in the 1970s (reviewed in 
(Elmore, 2007)) and the currently accepted name for the vesicular products of 
apoptosis, apoptotic bodies (APs) was coined. Over the past decade, there has been a 
rapid increase in the number of EV related investigations, which have revealed that 
EVs are released from various cell types and are present in bodily fluids. In 
particular, many studies have shown that EVs carry functional molecules which can 
be transferred to other recipient cells and elicit various biological respopnses. 
However, challenges remain since there are no gold standard methods or traits with 
which to isolate and characterise EVs, although there is substantial research effort to 
develop these (Witwer et al., 2013). Significantly, the study described herein is the 
first to examine APs, MVs and EXs, released from individual keratinocyte sources in 
vitro, using both differential centrifugation and filtration approaches of isolation. 
Obviously, this study provides evidence with which to compare the expression of EV 
markers between the different EV populations and between EVs released from a 
keratinocyte cell line, HaCaTs, and primary epidermal keratinocytes. However, even 
though there are differences between the content and function of the various EVs 
released from the HaCaT cell line and primary keratinocytes, these may reflect 
differences in the culture conditions between the 2 cell types such as the use of a 
feeder cell layer for the primary cells or the specific medium used for each cell type. 
Why is the study of EVs important? In the past, EVs were considered to be 
membrane debris without real biological importance. However, this opinion has 
changed since 1996, since Raposo et al. (1996) demonstrated EVs could stimulate an 
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immune response (Raposo et al., 1996). After this seminal work, EVs were thought 
to facilitate intercellular communication, whereby they shuttle their cargo to, and 
alter the functions of recipient cells (Del Conde et al., 2005; Hoen et al., 2009; 
Janowska-Wieczorek et al., 2001; Morelli et al., 2004; Shabbir et al., 2015). 
Mechanisms of delivery and the exchange of information between cells via EVs 
include ligand interactions, membrane fusion and internalization of EV cargo 
(reviewed in (Smith et al., 2015)). In addition, EVs also serve as biomarkers via their 
selective enrichment components (Duijvesz et al., 2011; Escola et al., 1998). In the 
study described herein, a large number of protein and miRNA components in each 
EV sub-population were profiled and compared. The results showed that all EVs 
shared common components, but they also contained unique proteins and miRNAs. 
As these proteins and miRNAs constitute the various functional components of EVs, 
their particular combinations may elicit various biological processes in recipient 
cells. Indeed, many of the EV proteins and miRNAs identified in this current study 
have not been reported previously in the ExoCarta database and this therefore 
constitutes a significant contribution of knowledge to the field of EV biology.  
As demonstrated herein, a modified workflow for isolation and characterisation 
of keratinocyte-derived EV sub-populations, EV contents (proteins and miRNAs), 
and EV functions was established. The methods used for each chapter are high 
throughput, sensitive and precise with regard to the identification of EV cargo. The 
contribution of the project data to the knowledge of EV content is clearly important 
given the large number of EV proteins and miRNAs identified. This is especially true 
for the hundreds of novel EX proteins and miRNAs and the potential involvement of 
keratinocyte-derived EVs in the modulation of fibroblast migration. Indeed, to the 
best of this author’s knowledge, this is the first investigation of all three EV sub-
populations released from keratinocytes in 2D cultures and these data will be 
substantially meaningful for future reference of EV content and comparison between 
the three EV populations.  
A number of limitations of the project remain: Firstly, although EV isolation 
and purification methods within the EV field have continued to be optimised over the 
course of this project, differential ultracentrifugation was utilised here as it is 
accepted within the literature as a key method with which to isolate EV populations. 
A modification to this approach was also employed whereby a series of filtration 
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steps were combined with the differential centrifugation. However, while the 
rationale for the application of the filtration steps was to try to limit EV cross 
contamination based on EV size it is likely that this approach does not completely 
remove all cross contaminating EVs. As a result, it is not possible to categorically 
state that the EV populations studied in this present study were completely pure, 
however, the results of the characterisation of individual EV traits were similar to 
previous studies in terms of biomarkers, size and morphology (Hristov et al., 2004; 
Keerthikumar et al., 2015; Rossella et al., 2013; Théry et al., 2006) and size 
distribution for EXs (Lo¨tvall, 2014). In addition, EV characterisation in this current 
study included proteomics (transmembrane proteins, cytosolic proteins and 
intracellular proteins associated with vesicle related cellular compartments). 
Secondly, the size of the MVs and APs were out of the detection range of the 
nanoparticle tracking analysis (NTA) system, therefore it was difficult to 
systematically analyse the size distribution of APs and MVs, in contrast to EXs, as 
part of the characterisation. Thirdly, despite the capacity of EVs to promote 
fibroblast migration, the mechanisms underlying this have not been unravelled. A 
key future direction for this research would be to investigate what mechanism and 
molecules are associated with EV mediated fibroblast migration. In addition, many 
of the identified molecules present in EVs have functions related to different 
biological processes, including migration, therefore the data from this study will 
serve as a solid starting point from which to draw new testable hypotheses.  
One of the aims of this study was to examine the role of keratinocyte derived 
EVs on cell migration in the context of cutaneous wound healing. Thus with regard 
to keratinocyte migration, previous studies have suggested that EVs containing 
HSP90-α stimulated keratinocyte migration via ERK1/2 (Cheng et al., 2008a). In 
addition, EVs containing C4.4A (A glycosyl-phosphatidyl-inositol-anchored 
molecule belongs to Lys family), α6β4 integrin and MMP14 promoted cell migration 
via laminin degradation (Ngora et al., 2012). Interestingly, miRNA-205, which was 
highly abundant in EVs in the study described herein, was previously shown to target 
phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 (SHIP2 or INPPL1) leading 
to a promotion of keratinocyte migration (Yu et al., 2010). Conversely, miRNA-21 
another highly abundant miRNA reported herein, was shown to induce keratinocyte 
migration via regulation of T-lymphoma invasion and metastasis-inducing protein 1 
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(TIAM1), metalloproteinase inhibitor 3 (TIMP3), vinculin (VCL) and early growth 
response 3 factor (EGR3) both in vitro and in vivo (Pastar et al., 2012; Yang et al., 
2011). Importantly, as described herein, those genes (SHIP2/INNPL1, TIAM1 and 
TIMP3) were direct target genes of the EV miRNAs (miRNA-205 and miRNA-21) 
(Appendix table 5.6 and 5.9). In addition, EVs contained substantial ECM related 
proteins such as laminin, integrins, tenascin, thrombospondin and collagen. This may 
indicate the potential for the keratinocyte-derived EVs to influence keratinocyte 
migration through autocrine or paracrine type mechanisms. Taken together, a 
predictive model of the interaction of the above mentioned EV proteins and EV 
miRNAs to regulate keratinocyte migration is described in Figure 7.1. This model 
could contribute to the understanding of keratinocyte-keratinocyte interaction via 
EVs to regulate keratinocyte migration and thereby affect re-epithelialisation and 
cutaneous wound healing rates. Improved understanding of the role of EVs in 
modulation of the mechanisms and molecules that control epidermal keratinocyte 
migration will enable the future development of potential therapeutic approaches 
whereby EVs may serve as a targeted drug delivery system to enhance wound 
closure.  
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Figure 7.1: Schematic diagram that describes the interaction of keratinocyte-derived 
EV molecules with other molecular components in the context of keratinocyte 
migration 
 
Firstly, EV-derived ECM related proteins, including integrins (ITG), laminins, 
tenascins, thrombospondin (THBS), collagen and syndecan, enhance cell attachment. 
Coincidently, other EV proteins, such as MMP14 promoting LNM degration and 
HSP90α activating ERK1/2 pathway lead to promote cell migration. Secondly, EV 
miRNA, such as miRNA-21 and miRNA-205, suppress directly their target genes 
such as TIAM1, TIMP3 and SHIP2 (Appendix table 5.6 and 5.9) or 
directly/indirectly (unknown) the target genes EGR3 and VCL leading to the 
enhancement / inhibition of cell migration. LMN: laminin; TIAM1: T-lymphoma 
invasion and metastasis-inducing protein 1; TIMP3: Metalloproteinase inhibitor 3; 
EGR3: Early growth response 3 factor; VCL: Vinculin, SHIP2: Phosphatidylinositol 
3,4,5-trisphosphate 5-phosphatase 2. 
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The wound healing process requires fibroblast migration and differentiation at 
the wound site to produce specific components such as ECM constituents and 
facilitate wound closure (Li et al., 2011). Some genes, such as TGFβ, PDGF and 
FGF that stimulate fibroblast migration (Schreier et al., 1993), are targets of EV 
miRNAs found in the study described herein (Table 5.11). Collagen, also plays a role 
in cell adhesion (Herbst et al., 1988), and is a target gene of miRNA-143, which was 
identified in high abundance in EVs described herein. Therefore, EV miRNAs may 
participate in controlling fibroblast migration through regulation of their target genes. 
However, EV miRNAs are not the only molecules associated with regulation of 
fibroblast activities. EV proteins such as stratifin, which has been shown to be 
released from differentiated keratinocytes and keratinocyte- derived EVs, may also 
be involved. Indeed, stratifin has been shown to increase the expression of MMP1 in 
fibroblasts, leading to an increase in collagenase expression in the fibroblasts as well 
(Chavez-Muñoz et al., 2008; Ghahary et al., 2005). Moreover, as described above 
EVs that deliver HSP90α to the fibroblast cytoplasm, are associated with ERK1/2 
mediated promotion of cell migration (Cheng et al., 2008a). Furthermore, 
extracellular HSP90α present in conditioned media interacts with fibroblasts via 
LRP-/CD91 receptors and was shown to enhance cell migration via unknown 
mechanisms (Cheng et al., 2008a).  Since stratifin, HSP90α, ECM proteins and other 
miRNA-regulated genes were identified in the EVs in this present study (Table 4.6, 
Table 5.11, Figure 4.11, Appendix table 4.1 and 4.2), a predicted schematic of the 
role of EVs in mediating various fibroblast functions is described in Figure 7.2 
below. However, the hypothesis that EVs could carry and deliver integrins to 
fibroblasts might be undermined by the low probability that EVs could deliver a 
large enough number of these integrins to recipient cells to be functional. On the 
other hand, a previous study has demonstrated that nanovesicles within ECM 
bioscaffolds could only be separated from the ECM by enzymatic digestion (Huleihel 
et al., 2016). This suggests that EVs might use these integrins to adhere to the matrix 
and so their presence in EVs might not relate to cellular adhesion as much as EV 
bioavailability. Either way these possibilities require further careful examination.  
In the context of cutaneous wound healing, dermal fibroblasts play important 
roles in the formation of granulation tissue in addition to the release of important 
molecules for attracting other cells to the wound bed. If the mechanism that 
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keratinocyte-derived EVs promote fibroblast migration is revealed, it will be 
important in the design of the future clinical protocol for the treatment of chronic 
wound with EVs or EV-like medicine particles. To test the schematics, EV miRNA 
function will be blocked prior to the use for treating on fibroblasts. The fibroblast 
treated with functional miRNA-blocked EVs will be assessed for changes in 
gene/protein expression (targeted by functional blocked EV miRNA) and migration 
capacity. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2: Schematic diagram that describes the interaction of EV molecules with 
other components in fibroblasts 
  
EV derived ECM related proteins, including integrin (ITG), laminin, tenascin, 
thrombospondin (THBS), collagen and syndecan, enhance cell attachment. 
Coincidently, other EV proteins such as HSP90α promote cell migration and 
proliferation via activation of ERK1/2 in the cytoplasm; and EV HSP90, from the 
extracellular environment interacts with the cell via LRP-1/CD91 receptor and 
promotes cell migration via an unknown mechanism. EV miRNA, such as miRNA-
21, miRNA-203, miRNA-143 and miRNA-27, suppress their target genes (TGF, 
PDGF, FGF and COL) leading to stimulation or inhibition of cell migration, 
proliferation, adhesion and ECM degradation. HSP90α: Heat shock protein 90-alpha; 
TGF: Transforming growth factor; PDGF: Platelet-derived growth factor; FGF: 
Fibroblast growth factor; COL: Collagen; MMP1: Matrix metalloproteinase-1. 
 
HSP90α 
ERK1/2 
Cell migration Cell proliferation Cell adhesion 
LRP-1/ 
CD91 
HSP90α 
EVs EVs 
Stratifin 
MMP1 
ECM degradation 
??? 
TGFβ PDGF FGF 
EV-
miRNAs 
COL 
EV-
miRNAs 
ITGα2 ITGβ4 ITGβ1 ITGα6 ITGβ1 Syndecan 
ITGα6 
Nucleus 
Cytoplasm 
Integrin Laminin Tenascin THBS 
Activation 
Inhibition 
Collagen fibrils 
EVs 
??? 
 230 Chapter 7: General Discussion 
One of the main causes of abnormal scar formation is the over-accumulation of 
collagen (COL) during the remodelling phase at wound sites. In pulmonary 
fibroblasts, TGFβ1 has been shown to enhance the expression of miRNA-21 via 
TGFβ1RII, which then promoted the expression of SMAD2, FN and α-SMA via 
unknown mechanism; and, inhibited directly the expression of SMAD7, leading to an 
increase in collagen deposition (Liu et al., 2010). In addition, Wang et al. (2012) also 
showed evidence of regulation of collagen production (COL1 and COL3) by 
miRNA-21, however, the mechanism was not clarified (Wang et al., 2012a). 
Importantly, PTEN (phosphatase and tensin homologue), which is suppressed by 
TGFβ1 (Kato et al., 2009; Trojanowska, 2009; Yang et al., 2009), is a common 
target of some of the most abundant EV miRNAs identified in the study described 
herein (Figures 5.7 A7, 5.8 A1, and 5.10 A8). PTEN is known to inhibit the 
expression of COL1 and CCN2 (connective tissue growth factor – CTGF), thereby 
reducing collagen deposition (Parapuram et al., 2011). In addition, SMAD2 is a 
target of some of the miRNAs described herein, such as miRNA-27; miRNA-203; 
and, miRNA-181, which may indicate the regulation of collagen formation and 
deposition via SMAD2 by those EV miRNAs. A limited prediction of EV miRNAs 
and proteins associated with collagen production is described in Figure 7.3. The use 
of molecular approaches, such as the ‘antagomir’ technique to block specific EV 
miRNA function (miRNA-21, miRNA-92, miRNA-205, miRNA-22, miRNA-203, 
miRNA-27 and miRNA-181) will supress the relevant miRNA target genes (as 
outlined in the figures below) leading to direct or indirect influence on collagen 
production. This approach might then be adapted for therapeutic use to influence 
normal or abnormal scar formation. The control of expression of specific miRNAs or 
miRNA target genes by treatment of wound sites could control aberrant collagen 
production and perhaps elicit more normal scar formation during the re-modelling 
phase of cutaneous wound healing. 
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Figure 7.3: Schematic diagram of the interaction between EV miRNAs and TGFβ1 
in fibroblasts leading to the formation of abnormal scars 
 
TGFβ1 mediated signalling promotes the expression of miRNA-21 and other 
miRNAs via TGFβ1RII. The miRNAs regulate directly PTEN (miRNA-92, miRNA-
205 and miRNA-22) and SMAD7 (miRNA-21) and directly/or indirectly (via as yet 
unknown intermediates) SMAD2, FN and α-SMA (miRNA-21) in addition to direct 
regulation of SMAD2 (miRNA-181, miRNA-27 and miRNA-203) to control 
collagen production. When these miRNAs are highly expressed in fibroblasts and 
wound sites, it leads to over-deposition of collagen and results in formation of 
abnormal scars. TGFβ1: Transforming growth factor beta 1; TGF-β1RII: 
Transforming growth factor - β1 receptor II; PTEN: Phosphatase and tensin 
homologue; FN: Fibronectin; α-SMA: α-smooth muscle actin; COL1: Collagen I; 
CCN: connective tissue growth factor. 
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One of the vital events that occurs during the cutaneous healing process is the 
formation of new blood vessels within the wound bed, which requires the expression 
of growth factors and recruitment of endothelial cells (Sabine et al., 2003). Growth 
factors include VEGFA, which is a strong angiogenic factor and is associated with 
endothelial cell growth and vessel formation (Coultas et al., 2005). In addition, 
TGFβ, TNF, PDGF and FGF are also essential for vascular development, cell 
proliferation, migration and adhesion (reviewed in (Liekens et al., 2001)). 
Importantly, genes encoding for these growth factors are regulated by one or more 
miRNAs detected in high abundance in this study including miRNA-21, miRNA-27 
and miRNA-203 (Appendix table 5.6, 5.8 and 5.12). To regulate cell proliferation, 
the complex of SMAD2/3-E2F4/5 is required for the repression activity of c-MYC 
(Chen et al., 2002). Additionally, SMAD, is a target of miRNA-205 described 
herein, in association with RUNX2 (Drissi et al., 2003) mediates the migration, 
proliferation and differentiation of endothelial cells (Pierce et al., 2012; Sun et al., 
2001).  Some of the EV proteins and miRNAs described herein combined with 
previously reported data suggest a potentially interesting hypothesis. That is, that 
EVs mediate endothelial cell angiogenesis through EV ECM related proteins (Table 
4.6, Figure 4.7) and miRNAs, such as miRNA-21; miRNA-27; miRNA-203; 
miRNA-143; and, miRNA-205. The proposed hypothesis is illustrated in the 
schematic of EV regulation of endothelial cell biology is described in Figure 7.4. 
Future research to examine the relevance of this model will contribute to the 
understanding of the potential role of EVs in the formation of new vasculature within 
wound sites. Experiments to assess the influence whole EVs on angiogenesis will be 
performed by a treatment of keratinocyte-derived EVs on endothelial cells in vitro. 
Following these experiments would be blocking individual miRNA function (as 
listed in the below schematic) to investigate changes in miRNA target gene 
expressions and reveal key EV miRNA/target genes in addition to mechanism of EV 
miRNAs mediating the angiogenesis. Finally, in vivo models will be established to 
test in vitro data. 
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Figure 7.4: Schematic of relationship between EV miRNAs/proteins and endothelial 
cell biology 
 
After EVs are internalised and release their contents into recipient cells, EV miRNAs 
including miRNA-21, miRNA-27, miRNA-203, miRNA205 and miRNA-143 
inhibited TSP1 resulting in promotion of angiogenesis or supressed SMAD family 
genes which in association with RUNX2 and MYC resulting inhibition of cell 
migration, proliferation, adhesion and angiogenesis. Alternatively, these EV 
miRNAs directly target growth factor gene translation, such as EVGFA, TGF, FGF, 
TNA and PDGF leading an inhibition of biological processes in endothelial cells. 
Indeed, extracellular EVs and internalised EVs provide a source of ECM proteins for 
cell attachment to ECM. EVGFA: Vascular endothelial growth factor A; TSP1: 
Thrombospondin-1; RUNX2: Runt-related transcription factor 2; TGF: Transforming 
growth factor; PDGF: Platelet-derived growth factor; FGF: Fibroblast growth factor; 
TNF: Tumour necrosis factor. 
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Following on from this PhD project, further research is required to more 
completely investigate the potential specific roles of the three different EVs and their 
molecular cargo on the biological processes associated with keratinocytes, fibroblasts 
and endothelial cells as suggested above (Figure 7.1 - 7.4). Further functional 
assessment of cell migration, cell proliferation, angiogenesis and collagen production 
should be completed to examine the roles of the keratinocyte-derived EV miRNAs 
(miRNAs with the most abundance in table 5.6) and their target genes on these 
processes. A miRNA of particular interest to this author was miRNA-30, which was 
found to have high abundance in all three EV populations released from primary 
keratinocytes in addition to the presence of two members of the miRNA-30 family 
on the top most significant expression (Figure 5.5, Tables 5.4). In addition, miRNA 
loss-of-function experiments utilising so called “antagomir” technology should be 
employed to study the above specific functions of particular miRNAs and their effect 
on their respective target genes. The antagomir mechanisms of action are 
summarised in (Figure 7.5). After blocking miRNAs of interest, the expression of the 
miRNA target genes could be evaluated using RT-PCR prior to investigation of their 
protein level using immunoblotting or a quantitative LC-MS/MS approach such as 
selected reaction monitoring (SRM). Changes in the expression of mRNA targets and 
their proteins leading to altered cell function will inform regarding the role of 
miRNAs in addition to evaluation of EV bioactivity which will enable development 
of new treatment approaches to improve wound healing outcomes. 
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Figure 7.5: Mechanism of action of anti-miRNA sequester the EV miRNAs 
 
An anti-miRNA, which is a sequence of chemically modified antisense 
oligonucleotides, sequesters the targeted mature miRNA sequence in competition 
with cellular target mRNAs leading to functional inhibition of the miRNA and de-
repression of the direct targets (protein encoding genes) (Rajeev et al., 2005). Target 
genes of miRNAs encode proteins which could have enhancement or inhibition 
influence on biological processes. 7mG: 7-methylguanosine cap; AAAAA: poly-A 
tail. 
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In conclusion, this PhD project has successfully isolated and characterised 
three EV populations, which were released from keratinocyte cultures. Specifically, 
APs, MVs and EXs were separated in terms of biomarkers, size and morphology. 
Indeed, the project has identified a cargo of proteins and miRNAs for each EV 
population. Importantly, a suite of exosomal proteins and miRNAs are reported for 
the first time and these constitute a significant and novel contribution to the 
knowledge of EV content and biology. Moreover, from those molecular signatures, 
the three EV populations could be distinguished from one another along with their 
varied capacity for the regulation of fibroblast migration. Importantly, the identified 
EV cargo and preliminary investigation of EV bioactivity may help to provide new 
insight into the capacity of EVs to modulate a number of key biological processes, 
particularly cell migration. Finally, these EV studies are important for the guidance 
of future research directions as they provide information on the biology of human 
epidermal primary keratinocyte cells compared to the human keratinocyte cell line 
(HaCaT) which could inform the study of skin-related diseases and potentially 
therapeutic development. 
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Appendices 
Appendix figure 3.1: Staining PI and Annexin V revealed MVs negative with 
nuclear fragments but positive with Annexin V. 
 
 
 
MVs were stained with PI (red) and AnnexinV (green) to reveal the presence of 
nucleic acid fragments and expression of PS - Annexin V respectively. MVs were 
only positive for PS (green) but negative for nucleic acid fragments (red) which are 
different from APs. Images are representative for MVs released from primary 
keratinocytes (isolated from donor # 288.) The stained MVs were examined and 
photographed using Leica TSC SP5 Confocal microscopy, objective 60X. 
  
Red Green Merge 
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Appendix figure 3.2: Quantification of exosomes released from HaCaT and 
primary keratinocytes (PKCs) calculated to proteins and parental cells. 
 
 
HaCaT and PKC-derived exsosomes were quantified by using NTA, protein 
concentration as measured by BCA. A) The number of cells were counted at the time 
of harvest of conditioned media for EV isolation, B) Protein concentration in 
exosome preparation, C) Total number of exosomes released by cell numbers in A, D) 
Number of exosomes released by one cell, E) Number of exosomes per 1 µg protein. 
Error bars indicate ± SD from two biological replicates (three technical repeats for 
each biological replicate) for each cell types. * denotes p < 0.05. 
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Appendix table 3.1: The top 100 frequently identified exosomal proteins 
(downloaded from ExoCarta) 
 
 
Gene 
Symbol 
Number of 
times 
identified 
(%) 
Gene 
Symbol 
Number of 
times 
identified 
(%) 
Gene 
Symbol 
Number of 
times 
identified 
(%) 
CD9  98 HSPA5  58 KPNB1  48 
PDCD6IP  96 SLC3A2  57 EZR  48 
HSPA8  96 HIST1H4A  57 ANXA4  48 
GAPDH  95 GNB2  57 ACLY  48 
ACTB  93 ATP1A1  57 TUBA1C  47 
ANXA2  83 YWHAQ  56 TFRC  47 
CD63  82 FLOT1  56 RAB14  47 
SDCBP  78 FLNA  56 HIST2H4A  47 
ENO1  78 CLIC1  56 GNB1  47 
HSP90AA1  77 CCT2  56 THBS1  46 
TSG101  75 CDC42  55 RAN  46 
PKM  72 YWHAG  54 RAB5A  46 
LDHA  72 A2M  54 PTGFRN  46 
EEF1A1  71 TUBA1B  53 CCT5  46 
YWHAZ  69 RAC1  53 CCT3  46 
PGK1  69 LGALS3BP  53 AHCY  46 
EEF2  69 HSPA1A  53 UBA1  45 
ALDOA  69 GNAI2  53 RAB5B  45 
HSP90AB1  67 ANXA1  53 RAB1A  45 
ANXA5  67 RHOA  52 LAMP2  45 
FASN  66 MFGE8  52 ITGA6  45 
YWHAE  65 PRDX2  51 HIST1H4B  45 
CLTC  64 GDI2  51 BSG  45 
CD81  64 EHD4  51 YWHAH  44 
ALB  63 ACTN4  51 TUBA1A  44 
VCP  62 YWHAB  50 TKT  44 
TPI1  62 RAB7A  50 TCP1  44 
PPIA  62 LDHB  50 STOM  44 
MSN  62 GNAS  50 SLC16A1  44 
CFL1  62 RAB5C  49 RAB8A  44 
PRDX1  61 ARF1  49 MYH9  44 
PFN1  61 ANXA6  49 MVP  44 
RAP1B  60 ANXA11  49 
	   	  ITGB1  60 ACTG1  49 
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Appendix figure 4.1: Global distribution of identified proteins across three EV 
populations from two cell origins  
 
 
 
 
 
 
 
 
 
 
 
 
The Venn analysis reveals differences in the identified protein composition of 
different EV types and EVs released from different cell types. A) The protein 
distribution across HaCaT-derived EVs. B) The protein distribution across primary 
keratinocyte-derived EVs. The data were pooled from three biological replicates. 
PKC: primary keratinocytes, AP: Apoptotic bodies, MV: Microvesicles, and EX: 
Exosomes. Data were re-arranged from Figure 4.1 A and B. 
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Appendix table 4.1: The total proteins were identified in three biological 
replicates (EVs released from HaCaT)  
 
Data are in the USB comes with the thesis (excel file). The red text indicates 
proteins detected in all three independent biological replicates. 
 
 
 
 
Appendix table 4.2: The total proteins were identified in three biological 
replicates (EVs released from primary keratinocytes) 
 
Data are in the USB comes with the thesis (excel file). The red text indicates 
proteins detected in all three independent biological replicates. 
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Appendix table 4.3A: The 143 proteins with significant difference in abundant 
levels in EVs released from primary keratinocytes 
(Red colour indicates the top 20 greatest peak areas) 
 
Accession	  
ID	  
Gene	  
name	  
P-­‐value	   Peak	  areas	  ±SD	  
AP	   MV	   EX	  
Q14651	   PLSI	   7.28296E-­‐05	   19.603	  ±0.08	   19.915	  ±0.111	   18.949	  ±0.115	  
P31949	   S10AB	   0.000110077	   22.677	  ±0.508	   22.887	  ±0.103	   20.431	  ±0.105	  
P0CG48	   UBC	   0.000131616	   24.115	  ±0.168	   24.089	  ±0.159	   26.232	  ±0.436	  
P0CG47	   UBB	   0.00015047	   22.457	  ±0.199	   22.876	  ±0.374	   24.875	  ±0.32	  
P62081	   RS7	   0.000214363	   18.971	  ±0.539	   17.002	  ±0.238	   16.341	  ±0.101	  
Q9UBI6	   GBG12	   0.000250774	   17.613	  ±0.281	   18.787	  ±0.194	   19.269	  ±0.174	  
Q9UMS4	   PRP19	   0.000308753	   18.481	  ±0.263	   18.823	  ±0.114	   19.805	  ±0.144	  
P60660	   MYL6	   0.000310926	   21.495	  ±0.288	   20.806	  ±0.109	   20.059	  ±0.132	  
P07237	   PDIA1	   0.000689685	   20.546	  ±0.262	   19.343	  ±0.172	   19.776	  ±0.098	  
Q14247	   SRC8	   0.000743773	   16.024	  ±0.323	   16.356	  ±0.261	   17.496	  ±0.077	  
P48509	   CD151	   0.000755743	   16.768	  ±0.349	   18.607	  ±0.536	   19.623	  ±0.47	  
P62987	   RL40	   0.000815231	   20.858	  ±0.122	   21.412	  ±0.416	   23.277	  ±0.556	  
Q02487	   DSC2	   0.001052067	   15.12	  ±0.228	   16.429	  ±0.428	   16.671	  ±0.034	  
Q9HDC9	   APMAP	   0.001112378	   17.857	  ±0.332	   16.454	  ±0.055	   17.903	  ±0.349	  
Q03169	   TNAP2	   0.001127095	   15.977	  ±0.66	   18.872	  ±0.615	   18.36	  ±0.135	  
P62979	   RS27A	   0.001669547	   21.067	  ±0.245	   21.54	  ±0.417	   23.317	  ±0.579	  
P06703	   S10A6	   0.001739236	   20.344	  ±0.373	   20.239	  ±0.439	   18.274	  ±0.475	  
P08962	   CD63	   0.001788998	   16.152	  ±0.493	   16.653	  ±0.277	   18.817	  ±0.715	  
Q92597	   NDRG1	   0.002166367	   18.377	  ±0.231	   19.206	  ±0.169	   19.065	  ±0.079	  
Q9Y277	   VDAC3	   0.002230278	   19.373	  ±0.207	   19.534	  ±0.207	   18.489	  ±0.238	  
Q9UJZ1	   STML2	   0.003192006	   15.494	  ±0.591	   12.648	  ±0.887	   12.765	  ±0.455	  
O75955	   FLOT1	   0.003194635	   19.819	  ±0.316	   18.888	  ±0.16	   18.73	  ±0.232	  
Q9Y376	   CAB39	   0.003532236	   16.153	  ±0.342	   17.556	  ±0.214	   16.924	  ±0.322	  
O00560	   SDCB1	   0.003643557	   19.537	  ±0.361	   20.359	  ±0.337	   21.82	  ±0.697	  
P63167	   DYL1	   0.00366601	   17.205	  ±0.102	   16.251	  ±0.411	   16.084	  ±0.146	  
P83731	   RL24	   0.004084693	   20.384	  ±0.42	   20.203	  ±0.232	   21.737	  ±0.413	  
P07195	   LDHB	   0.004129102	   21.584	  ±0.348	   21.165	  ±0.194	   20.367	  ±0.245	  
P28074	   PSB5	   0.00543258	   18.49	  ±0.307	   18.021	  ±0.213	   17.289	  ±0.308	  
Q05639	   EF1A2	   0.005784352	   22.696	  ±0.06	   21.692	  ±0.324	   21.896	  ±0.276	  
P11021	   GRP78	   0.005807691	   22.466	  ±0.139	   21.641	  ±0.235	   21.579	  ±0.294	  
Q8NFJ5	   RAI3	   0.005887671	   19.63	  ±0.393	   19.701	  ±0.739	   21.88	  ±0.617	  
Q01082	   SPTB2	   0.005951419	   19.728	  ±0.477	   21.124	  ±0.537	   19.389	  ±0.213	  
Q9BTW9	   TBCD	   0.006422701	   21.885	  ±0.256	   22.702	  ±0.081	   20.622	  ±0.825	  
O14773	   TPP1	   0.006574958	   15.375	  ±0.151	   17.382	  ±0.528	   16.605	  ±0.638	  
P53675	   CLH2	   0.006871546	   20.929	  ±0.328	   20.4	  ±0.137	   21.38	  ±0.207	  
Q9C0B5	   ZDHC5	   0.007263994	   15.391	  ±0.739	   15.369	  ±0.254	   17.112	  ±0.333	  
Q14254	   FLOT2	   0.007266685	   19.607	  ±0.094	   20.259	  ±0.567	   18.772	  ±0.264	  
P84098	   RL19	   0.007317771	   17.971	  ±0.471	   16.678	  ±0.426	   15.804	  ±0.675	  
P30101	   PDIA3	   0.0073399	   21.441	  ±0.223	   20.571	  ±0.311	   20.404	  ±0.28	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P53985	   MOT1	   0.007794406	   21.362	  ±0.255	   21.572	  ±0.236	   19.51	  ±0.913	  
P24928	   RPB1	   0.008476422	   16.688	  ±0.308	   17.637	  ±0.504	   15.917	  ±0.47	  
P07864	   LDHC	   0.008487585	   20.425	  ±0.585	   20.109	  ±0.248	   18.541	  ±0.616	  
Q6ZMR3	   LDH6A	   0.008487585	   20.425	  ±0.585	   20.109	  ±0.248	   18.541	  ±0.616	  
Q14240	   IF4A2	   0.008507962	   19.525	  ±0.212	   18.84	  ±0.336	   20.396	  ±0.557	  
P35232	   PHB	   0.00855337	   19.363	  ±0.175	   19.27	  ±0.253	   18.542	  ±0.247	  
Q9H4B7	   TBB1	   0.009149528	   21.413	  ±0.469	   19.897	  ±0.441	   21.431	  ±0.447	  
Q8IWA5	   CTL2	   0.009349399	   20.135	  ±0.249	   19.823	  ±0.178	   20.834	  ±0.347	  
P49419	   AL7A1	   0.009624446	   17.235	  ±0.245	   16.762	  ±0.123	   17.554	  ±0.231	  
P38606	   VATA	   0.010283538	   19.647	  ±0.263	   20.013	  ±0.253	   18.875	  ±0.385	  
Q14847	   LASP1	   0.01053076	   17.038	  ±0.656	   16.628	  ±0.314	   18.362	  ±0.404	  
P11234	   RALB	   0.010642508	   18.249	  ±0.152	   18.898	  ±0.166	   19.227	  ±0.399	  
Q9Y2J2	   E41L3	   0.010849153	   18.809	  ±0.479	   19.018	  ±0.175	   17.695	  ±0.414	  
Q9UHD8	   SEPT9	   0.010972748	   19.02	  ±0.216	   18.075	  ±0.371	   18.391	  ±0.118	  
Q15366	   PCBP2	   0.011620586	   18.604	  ±0.21	   17.92	  ±0.296	   18.666	  ±0.137	  
Q16658	   FSCN1	   0.0124147	   19.88	  ±0.309	   20.508	  ±0.145	   19.849	  ±0.091	  
P50914	   RL14	   0.012602796	   18.96	  ±0.516	   18.453	  ±0.166	   17.515	  ±0.442	  
Q8WUX1	   S38A5	   0.012784278	   18.244	  ±0.586	   17.943	  ±0.267	   19.261	  ±0.148	  
P62277	   RS13	   0.013551174	   19.603	  ±0.422	   18.527	  ±0.245	   18.883	  ±0.21	  
Q15717	   ELAV1	   0.014732249	   17.464	  ±0.197	   18.477	  ±0.596	   18.84	  ±0.317	  
P04844	   RPN2	   0.014750022	   18.888	  ±0.078	   17.859	  ±0.551	   17.971	  ±0.036	  
Q9BRX8	   F213A	   0.014807409	   17.784	  ±0.295	   17.745	  ±0.093	   18.619	  ±0.378	  
Q9Y287	   ITM2B	   0.01539763	   18.219	  ±0.088	   17.621	  ±0.412	   17.334	  ±0.159	  
P67812	   SC11A	   0.015508163	   17.026	  ±0.055	   17.461	  ±0.528	   16.335	  ±0.197	  
P21589	   5NTD	   0.016199744	   20.783	  ±0.454	   20.779	  ±0.032	   21.658	  ±0.232	  
Q58FF6	   H90B4	   0.016202927	   19.633	  ±0.422	   19.287	  ±0.161	   18.618	  ±0.257	  
P24844	   MYL9	   0.016711011	   20.057	  ±0.227	   19.535	  ±0.534	   18.542	  ±0.523	  
P49755	   TMEDA	   0.017080118	   18.037	  ±0.311	   16.705	  ±0.533	   16.591	  ±0.541	  
Q7L2H7	   EIF3M	   0.01721016	   18.034	  ±0.115	   18.052	  ±0.234	   19.083	  ±0.555	  
Q14574	   DSC3	   0.017283324	   18.241	  ±0.633	   18.893	  ±0.378	   19.818	  ±0.336	  
P21926	   CD9	   0.0180663	   20.547	  ±1.104	   21.06	  ±0.633	   23.061	  ±0.513	  
P12273	   PIP	   0.018414576	   18.744	  ±0.76	   19.317	  ±0.147	   17.329	  ±0.726	  
Q12959	   DLG1	   0.018552637	   17.041	  ±0.114	   18.003	  ±0.283	   18.426	  ±0.672	  
P18621	   RL17	   0.019532187	   18.84	  ±0.311	   17.719	  ±0.704	   17.22	  ±0.411	  
Q86UP2	   KTN1	   0.019770461	   18.43	  ±0.475	   17.833	  ±0.523	   19.351	  ±0.389	  
P05121	   PAI1	   0.01981729	   20.823	  ±0.386	   20.522	  ±0.423	   19.627	  ±0.321	  
P22090	   RS4Y1	   0.019946894	   18.032	  ±0.401	   16.864	  ±0.405	   17.48	  ±0.238	  
O43143	   DHX15	   0.020668528	   20.357	  ±0.759	   19.534	  ±0.286	   18.491	  ±0.579	  
P62241	   RS8	   0.021014979	   20.252	  ±0.081	   19.879	  ±0.5	   21.025	  ±0.367	  
Q99714	   HCD2	   0.022592953	   15.297	  ±0.764	   16.767	  ±1.037	   14.407	  ±0.139	  
Q9P2J5	   SYLC	   0.022613763	   19.41	  ±0.125	   19.066	  ±0.384	   20.26	  ±0.533	  
P15104	   GLNA	   0.022753804	   16.09	  ±0.311	   17.87	  ±0.862	   16.612	  ±0.392	  
P00492	   HPRT	   0.022836086	   15.776	  ±0.305	   16.549	  ±0.528	   14.567	  ±0.902	  
P46783	   RS10	   0.023411973	   17.438	  ±0.643	   15.247	  ±1.021	   16	  ±0.183	  
P08708	   RS17	   0.023628939	   19.415	  ±0.602	   18.355	  ±0.243	   18.308	  ±0.226	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P60842	   IF4A1	   0.023810541	   20.299	  ±0.379	   19.67	  ±0.29	   21.046	  ±0.589	  
O00625	   PIR	   0.024084568	   17.241	  ±0.596	   17.273	  ±0.581	   18.88	  ±0.614	  
P78539	   SRPX	   0.024523276	   16.978	  ±0.496	   17.77	  ±0.365	   18.263	  ±0.37	  
Q13751	   LAMB3	   0.026546713	   21.636	  ±0.064	   21.179	  ±0.289	   22.146	  ±0.459	  
P55036	   PSMD4	   0.026966072	   17.518	  ±0.526	   18.898	  ±0.044	   20.378	  ±1.533	  
P17174	   AATC	   0.027426433	   18.997	  ±0.198	   19.077	  ±0.272	   18.282	  ±0.367	  
P63092	   GNAS2	   0.027524267	   19.558	  ±0.261	   20.448	  ±0.121	   20.3	  ±0.461	  
Q5JWF2	   GNAS1	   0.027524267	   19.558	  ±0.261	   20.448	  ±0.121	   20.3	  ±0.461	  
P48444	   COPD	   0.02900071	   17.19	  ±0.133	   15.82	  ±0.689	   16.75	  ±0.399	  
P22735	   TGM1	   0.029193095	   19.636	  ±0.173	   20.277	  ±0.109	   20.159	  ±0.337	  
P14649	   MYL6B	   0.029828057	   20.409	  ±0.366	   18.992	  ±1.033	   18.349	  ±0.545	  
P51805	   PLXA3	   0.03049612	   16.481	  ±0.903	   17.95	  ±0.144	   17.778	  ±0.205	  
Q9NRW1	   RAB6B	   0.030606531	   18.809	  ±0.03	   18.623	  ±0.12	   18.841	  ±0.06	  
Q14344	   GNA13	   0.031040125	   18.281	  ±0.572	   19.693	  ±0.457	   19.502	  ±0.519	  
Q6ZVX7	   FBX50	   0.031068639	   17.031	  ±0.51	   17.377	  ±0.436	   16.008	  ±0.496	  
Q96QD8	   S38A2	   0.031359459	   17.567	  ±0.348	   19.49	  ±1.09	   19.155	  ±0.386	  
P09874	   PARP1	   0.032783452	   16.587	  ±0.323	   16.195	  ±0.416	   17.109	  ±0.14	  
P49006	   MRP	   0.032970374	   16.126	  ±0.614	   17.749	  ±0.458	   17.165	  ±0.608	  
O95274	   LYPD3	   0.033357135	   14.68	  ±0.852	   15.871	  ±0.29	   16.409	  ±0.552	  
P59998	   ARPC4	   0.03350666	   18.75	  ±0.459	   19.767	  ±0.076	   18.593	  ±0.603	  
P47929	   LEG7	   0.033545679	   20.444	  ±0.753	   20.94	  ±0.4	   19.29	  ±0.544	  
Q9P1U1	   ARP3B	   0.033729201	   17.117	  ±0.668	   16.093	  ±0.704	   14.832	  ±0.967	  
Q8NG11	   TSN14	   0.034093388	   18.794	  ±0.691	   18.24	  ±0.533	   19.737	  ±0.252	  
Q9NQC3	   RTN4	   0.034104347	   19.472	  ±0.71	   18.491	  ±0.235	   20.004	  ±0.537	  
Q16531	   DDB1	   0.034317137	   17.627	  ±0.883	   17.915	  ±0.362	   19.335	  ±0.544	  
P06280	   AGAL	   0.034453679	   17.336	  ±0.219	   17.403	  ±0.739	   16.136	  ±0.378	  
Q08380	   LG3BP	   0.034660471	   20.692	  ±0.438	   21.09	  ±0.965	   22.474	  ±0.385	  
Q9P035	   HACD3	   0.034888175	   16.529	  ±0.603	   15.428	  ±0.343	   16.73	  ±0.485	  
Q9BTT6	   LRRC1	   0.034962302	   16.209	  ±0.04	   17.895	  ±1.122	   16.255	  ±0.291	  
Q9BS26	   ERP44	   0.035298701	   17.246	  ±0.715	   17.82	  ±0.868	   19.077	  ±0.138	  
P07954	   FUMH	   0.035329342	   18.865	  ±0.186	   17.762	  ±0.536	   18.382	  ±0.354	  
P38405	   GNAL	   0.035519514	   18.014	  ±0.846	   19.681	  ±0.319	   19.415	  ±0.6	  
O95336	   6PGL	   0.0355583	   18.402	  ±0.903	   16.48	  ±1.211	   15.924	  ±0.45	  
P05388	   RLA0	   0.036655112	   21.057	  ±0.437	   19.812	  ±0.203	   20.625	  ±0.604	  
Q9HB71	   CYBP	   0.036682701	   17.219	  ±0.418	   18.535	  ±0.627	   18.917	  ±0.785	  
Q9UBM7	   DHCR7	   0.03671597	   16.41	  ±0.605	   16.877	  ±0.175	   14.179	  ±1.646	  
P60953	   CDC42	   0.036828766	   19.624	  ±0.351	   20.402	  ±0.046	   20.224	  ±0.351	  
P62263	   RS14	   0.037073985	   18.3	  ±0.175	   16.905	  ±0.179	   17.203	  ±0.865	  
P12830	   CADH1	   0.037987562	   19.235	  ±0.264	   19.864	  ±0.182	   19.665	  ±0.232	  
Q15758	   AAAT	   0.038187176	   19.158	  ±0.772	   19.491	  ±0.29	   20.615	  ±0.456	  
P10768	   ESTD	   0.038195909	   18.604	  ±0.806	   17.278	  ±0.145	   17.348	  ±0.42	  
P30408	   T4S1	   0.038229573	   11.888	  ±1.007	   16.95	  ±1.612	   15.052	  ±2.521	  
Q15084	   PDIA6	   0.038695742	   19.168	  ±0.111	   20.407	  ±0.502	   20.347	  ±0.696	  
Q3ZCM7	   TBB8	   0.038763407	   21.706	  ±0.408	   20.812	  ±0.242	   21.766	  ±0.461	  
P12111	   CO6A3	   0.039877192	   18.807	  ±0.055	   18.308	  ±0.311	   18.306	  ±0.172	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P57735	   RAB25	   0.040117141	   18.166	  ±0.212	   18.53	  ±0.415	   19.002	  ±0.241	  
P17661	   DESM	   0.040311615	   19.691	  ±0.943	   17.898	  ±0.511	   17.975	  ±0.677	  
P68104	   EF1A1	   0.04087393	   23.52	  ±0.609	   22.461	  ±0.346	   22.487	  ±0.291	  
Q9NUP9	   LIN7C	   0.041319999	   17.398	  ±0.594	   18.379	  ±0.424	   18.704	  ±0.447	  
A6NNZ2	   TBB8L	   0.041731554	   21.548	  ±0.459	   20.616	  ±0.349	   21.704	  ±0.468	  
P16615	   AT2A2	   0.041886227	   19.306	  ±0.153	   18.583	  ±0.408	   18.33	  ±0.47	  
Q9UGV2	   NDRG3	   0.042101984	   17.426	  ±0.285	   18.448	  ±0.546	   18.469	  ±0.436	  
O60488	   ACSL4	   0.042755973	   17.567	  ±0.241	   17.827	  ±0.096	   19.169	  ±1.061	  
P23229	   ITA6	   0.044462529	   21.997	  ±0.168	   22.377	  ±0.186	   23.021	  ±0.615	  
P27701	   CD82	   0.04525787	   19.7	  ±0.519	   20	  ±0.13	   21.587	  ±1.192	  
O15533	   TPSN	   0.046289425	   14.714	  ±0.445	   15.073	  ±1.065	   17.464	  ±1.557	  
P09493	   TPM1	   0.047058666	   20.364	  ±0.582	   19.925	  ±0.202	   19.416	  ±0.039	  
O95573	   ACSL3	   0.049289861	   17.515	  ±0.514	   16.42	  ±0.369	   18.343	  ±1.102	  
P31947	   1433S	   0.04945117	   22.969	  ±0.752	   22.895	  ±0.239	   21.821	  ±0.309	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Appendix table 4.3B: The 143 proteins in EVs released from HaCaT (sorted by 
name matched with the protein name from primary keratinocyte, Appendix 
table 4.3A) 
(Red colour indicates the top 20 greatest peak areas; n = 1 biological replicate) 
 
Accession	  ID	   Gene	  name	   Peak	  areas	  
AP	   MV	   EX	  
P68104	   EF1A1	   24.22448007	   24.0739885	   22.89477497	  
Q5VTE0	   EF1A3	   24.22448007	   24.0739885	   22.89477497	  
Q05639	   EF1A2	   23.43639241	   23.21616432	   22.36454745	  
P53985	   MOT1	   23.32945681	   22.20472912	   19.65950933	  
P0CG48	   UBC	   23.19463629	   24.24335851	   26.1067445	  
Q9BTW9	   TBCD	   23.11240766	   21.96285983	   16.09835379	  
P31947	   1433S	   23.01385328	   22.56200742	   21.0048613	  
P11021	   GRP78	   22.27344348	   22.3051207	   21.46760403	  
P23229	   ITA6	   22.14955613	   21.87865424	   22.01678162	  
P31949	   S10AB	   22.0613059	   21.54718217	   20.47392651	  
P0CG47	   UBB	   21.67186691	   22.61545633	   23.43639241	  
Q3ZCM7	   TBB8	   21.6443592	   22.79255924	   22.04817982	  
P05388	   RLA0	   21.63913186	   21.26365663	   20.38757361	  
P07195	   LDHB	   21.49149247	   20.94640937	   19.89998233	  
P60660	   MYL6	   21.44713154	   21.68804932	   19.9654775	  
A6NNZ2	   TBB8L	   21.357231	   22.62622406	   21.85508438	  
P30101	   PDIA3	   21.24073692	   21.6023229	   21.53308156	  
P21926	   CD9	   21.07518999	   20.41374656	   22.98465949	  
Q9H4B7	   TBB1	   21.05219271	   22.4218705	   21.69810943	  
P53675	   CLH2	   21.01143925	   21.19199829	   21.23343653	  
Q08380	   LG3BP	   20.92813651	   21.610365	   21.67938712	  
P60842	   IF4A1	   20.85313877	   21.13615047	   21.71799348	  
P21589	   5NTD	   20.82998106	   20.02025194	   22.10867694	  
Q15758	   AAAT	   20.75741939	   19.60642437	   20.54668442	  
P14649	   MYL6B	   20.72389198	   20.50156404	   17.9323849	  
O00625	   PIR	   20.63140095	   20.24341851	   16.65708905	  
Q16658	   FSCN1	   20.55715562	   20.31200092	   20.82488681	  
P63092	   GNAS2	   20.53881021	   19.66348015	   19.70824626	  
Q5JWF2	   GNAS1	   20.53881021	   19.66348015	   19.70824626	  
Q14240	   IF4A2	   20.46233356	   20.33093498	   21.27627316	  
P62241	   RS8	   20.17505033	   20.90944584	   19.92834204	  
P09493	   TPM1	   20.15759841	   20.21294584	   18.98496853	  
Q13751	   LAMB3	   20.14350237	   21.18021349	   21.63282227	  
P62979	   RS27A	   20.09366952	   21.45009814	   22.55414706	  
P62987	   RL40	   20.05545716	   21.32320657	   22.53617352	  
O60488	   ACSL4	   20.02417537	   19.2618498	   17.72008631	  
P07864	   LDHC	   20.00352704	   19.59127167	   18.37164258	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Q6ZMR3	   LDH6A	   20.00352704	   19.59127167	   18.37164258	  
P60953	   CDC42	   19.98352878	   19.80065408	   19.85157814	  
Q8NFJ5	   RAI3	   19.97893151	   19.30757746	   21.97555444	  
P06703	   S10A6	   19.96051773	   18.13115801	   18.32626419	  
Q9NRW1	   RAB6B	   19.91002304	   19.68944102	   17.78805092	  
Q9HB71	   CYBP	   19.86901254	   19.46134641	   18.79766455	  
Q9BRX8	   F213A	   19.83758898	   20.11047099	   18.31346439	  
P47929	   LEG7	   19.76171112	   19.18594337	   18.86629397	  
P07237	   PDIA1	   19.70929045	   20.29592229	   19.60024086	  
Q14651	   PLSI	   19.64173979	   18.75455073	   18.68974908	  
P62277	   RS13	   19.63180432	   19.42135362	   18.81827953	  
Q16531	   DDB1	   19.59547506	   19.1014462	   17.90164126	  
Q8WUX1	   S38A5	   19.48651344	   19.51426191	   19.8667331	  
P83731	   RL24	   19.45254296	   20.12456622	   21.20161518	  
P18621	   RL17	   19.41406526	   19.63180432	   17.20579053	  
Q9UMS4	   PRP19	   19.41097667	   19.46541141	   19.88137344	  
Q14344	   GNA13	   19.40594356	   18.42126732	   18.13387807	  
Q8IWA5	   CTL2	   19.39129339	   19.46827329	   20.53526069	  
P38405	   GNAL	   19.33924526	   18.63312509	   18.04465477	  
O00560	   SDCB1	   19.26789215	   19.24006646	   21.22449768	  
P08708	   RS17	   19.21704899	   18.92875854	   19.83125294	  
P27701	   CD82	   19.20059195	   18.86629397	   20.26741311	  
P24844	   MYL9	   19.15484885	   19.27048014	   18.90065978	  
P22090	   RS4Y1	   19.08380454	   19.76917091	   18.48225904	  
Q14574	   DSC3	   19.01360612	   19.39873441	   19.48918089	  
P59998	   ARPC4	   18.97183644	   19.41406526	   19.01028542	  
Q15366	   PCBP2	   18.9634356	   19.80373543	   18.37952905	  
Q9Y277	   VDAC3	   18.95201215	   18.64505809	   19.2436686	  
P35232	   PHB	   18.93230263	   19.06479741	   19.04093219	  
Q14254	   FLOT2	   18.9215608	   19.56145282	   19.41406526	  
P38606	   VATA	   18.89823693	   18.85593293	   19.6228286	  
P22735	   TGM1	   18.85838013	   19.35072477	   19.47533233	  
Q9UHD8	   SEPT9	   18.84668391	   18.37952905	   19.22310179	  
Q58FF6	   H90B4	   18.74334466	   19.19747507	   19.05094916	  
Q9P2J5	   SYLC	   18.73570049	   19.92834204	   19.49722791	  
P57735	   RAB25	   18.66986925	   19.73170305	   18.301128	  
P50914	   RL14	   18.66813713	   19.35922436	   17.62185102	  
Q9UBI6	   GBG12	   18.64890538	   17.95333811	   17.78352565	  
O75955	   FLOT1	   18.57209505	   18.31514765	   18.89021092	  
Q03169	   TNAP2	   18.55064853	   17.46893783	   15.83602597	  
P16615	   AT2A2	   18.53618053	   18.64165839	   18.42983225	  
Q01082	   SPTB2	   18.51477451	   19.10568316	   19.40124229	  
P08962	   CD63	   18.51062809	   17.57461117	   18.4331302	  
O43143	   DHX15	   18.45041725	   18.91698175	   18.97480196	  
P12830	   CADH1	   18.44768621	   18.91259261	   19.84498547	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P04844	   RPN2	   18.41803565	   18.54345076	   18.88399823	  
Q9NQC3	   RTN4	   18.3958303	   17.98737504	   18.97003197	  
P11234	   RALB	   18.39295723	   17.7774742	   18.26736286	  
P17661	   DESM	   18.34029721	   17.92338834	   17.92672828	  
P15104	   GLNA	   18.32133801	   16.62790695	   16.99525934	  
P78539	   SRPX	   18.30305177	   17.34704723	   18.23167517	  
P51805	   PLXA3	   18.29572479	   18.06076447	   18.81175587	  
Q9NUP9	   LIN7C	   18.2906698	   18.68974908	   17.00001378	  
P67812	   SC11A	   18.28904237	   17.19000579	   16.12111069	  
P17174	   AATC	   18.27238799	   19.49371422	   18.55235504	  
Q9UGV2	   NDRG3	   18.24487539	   18.60997233	   17.01439273	  
Q14247	   SRC8	   18.10597133	   16.66276298	   15.76259664	  
Q8NG11	   TSN14	   18.10109958	   18.24487539	   19.42135362	  
O95573	   ACSL3	   18.08770747	   17.37236629	   17.81366929	  
Q9HDC9	   APMAP	   18.07814355	   17.67581599	   18.65376248	  
Q14847	   LASP1	   18.05784807	   17.2331302	   17.90836497	  
P48509	   CD151	   18.03765959	   17.65816831	   18.12791917	  
P62263	   RS14	   18.0269848	   18.04940724	   17.56347409	  
P12273	   PIP	   18.00277106	   17.39555709	   16.60777941	  
Q9BS26	   ERP44	   17.98415176	   18.5304823	   18.80566961	  
Q86UP2	   KTN1	   17.96701785	   19.20059195	   17.70471798	  
P05121	   PAI1	   17.89657009	   18.2906698	   18.97183644	  
Q7L2H7	   EIF3M	   17.85939449	   19.08918147	   18.86839319	  
P55036	   PSMD4	   17.80432988	   17.58375133	   20.97012591	  
P46783	   RS10	   17.76445423	   15.47541116	   18.50243222	  
P28074	   PSB5	   17.74974317	   17.8622225	   18.04940724	  
P48444	   COPD	   17.74100194	   16.29884421	   17.15301246	  
Q15084	   PDIA6	   17.73337292	   18.12300607	   19.98352878	  
P10768	   ESTD	   17.70057474	   17.29495957	   18.64505809	  
P49755	   TMEDA	   17.64232708	   17.60240479	   16.45109277	  
P07954	   FUMH	   17.58700326	   17.47502891	   18.42126732	  
Q9P035	   HACD3	   17.55939377	   17.06868353	   17.21964564	  
Q92597	   NDRG1	   17.47010128	   19.30005156	   17.82498661	  
P09874	   PARP1	   17.41200052	   16.99001303	   17.28522653	  
Q15717	   ELAV1	   17.40362886	   18.76698676	   17.53913989	  
P12111	   CO6A3	   17.30428229	   18.53618053	   18.88071553	  
P62081	   RS7	   17.29048104	   17.97876411	   19.00136918	  
O95336	   6PGL	   17.26402034	   16.13087209	   16.33022377	  
Q12959	   DLG1	   17.24028239	   17.01935681	   18.09143207	  
Q9Y287	   ITM2B	   17.04602931	   16.49499028	   17.51529993	  
Q6ZVX7	   FBX50	   17.01439273	   17.15940361	   16.3907185	  
P49419	   AL7A1	   17.00001378	   16.58876429	   17.18194222	  
Q96QD8	   S38A2	   16.93976434	   17.981839	   18.15737823	  
Q9BTT6	   LRRC1	   16.91232727	   16.19746207	   15.4167015	  
Q9Y2J2	   E41L3	   16.8171583	   17.60571607	   18.35352742	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O14773	   TPP1	   16.69228425	   15.95145112	   17.02679387	  
P84098	   RL19	   16.67914986	   18.24906866	   15.75581314	  
P06280	   AGAL	   16.53727591	   17.62916924	   15.96996166	  
O95274	   LYPD3	   16.50807039	   16.09835379	   17.08381007	  
P24928	   RPB1	   16.48070206	   17.96701785	   17.13520584	  
Q9Y376	   CAB39	   16.3769442	   21.39743393	   16.24677716	  
Q02487	   DSC2	   16.01484448	   15.82281718	   16.18981034	  
P49006	   MRP	   15.99536766	   16.40220708	   16.43864202	  
Q99714	   HCD2	   15.92101678	   14.71945056	   16.66276298	  
P00492	   HPRT	   15.88816375	   15.2178487	   15.74826383	  
P30408	   T4S1	   15.66849592	   14.19709737	   13.46483171	  
Q9C0B5	   ZDHC5	   15.64385291	   16.14797451	   15.57331121	  
Q9UBM7	   DHCR7	   15.18825098	   16.9099923	   14.99857318	  
O15533	   TPSN	   14.69996993	   14.3186941	   13.27216218	  
Q9UJZ1	   STML2	   14.68704839	   12.92393148	   13.02589773	  
Q9P1U1	   ARP3B	   14.24762253	   15.43496674	   15.77430242	  
P63167	   DYL1	   12.98234526	   16.88823571	   17.89657009	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Appendix table 4.4: Gene functional classification of total proteins present in 
HaCaT-derived APs 
 
Gene Group 1 Enrichment Score: 44.18102546363843 
UNIPROT_ACC. Gene Name 
788853 eukaryotic translation initiation factor 3, subunit D 
788335 eukaryotic translation initiation factor 3, subunit H 
818804 eukaryotic translation initiation factor 3, subunit L 
798064 eukaryotic translation initiation factor 3, subunit M 
800360 eukaryotic translation initiation factor 3, subunit I 
792561 eukaryotic translation initiation factor 3, subunit G 
  Gene Group 2 Enrichment Score: 40.81159075096537 
UNIPROT_ACC. Gene Name 
823648 ribosomal protein L23a 
822027 ribosomal protein L13 pseudogene 12; ribosomal protein L13 
801125 ribosomal protein L8; ribosomal protein L8 pseudogene 2 
781935 ribosomal protein S25 pseudogene 8; ribosomal protein S25 
783263, 783263 ribosomal protein L12  
793235 ribosomal protein L21  
821732 
ribosomal protein S8; ribosomal protein S8 pseudogene 8; 
ribosomal protein S8 pseudogene 10 
776035 ribosomal protein L18 
780689 ribosomal protein L23 pseudogene 6; ribosomal protein L23 
801872 ribosomal protein S23 
782492 ribosomal protein L22 pseudogene 11; ribosomal protein L22 
795791 ribosomal protein L6 pseudogene 27/19/10  
800729 ribosomal protein S12  
797877 ribosomal protein S5 
776216, 776216 ribosomal protein S2 
823999 ribosomal protein L29  
794927 ribosomal protein S21 
810885 ribosomal protein L11 
786754 
ribosomal protein L4; ribosomal protein L4 pseudogene 5; 
ribosomal protein L4 pseudogene 4 
808508 
ribosomal protein S6 pseudogene 25; ribosomal protein S6; 
ribosomal protein S6 pseudogene 1 
803377 
ribosomal protein L35; ribosomal protein L35 pseudogene 1; 
ribosomal protein L35 pseudogene 2 
802424, 802424 ribosomal protein L3; similar to 60S ribosomal protein L3 (L4) 
803657 
ribosomal protein S13 pseudogene 8; ribosomal protein S13; 
ribosomal protein S13 pseudogene 2 
796817 
ribosomal protein L10a pseudogene 6; ribosomal protein L10a; 
ribosomal protein L10a pseudogene 9 
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786934 ribosomal protein L36; ribosomal protein L36 pseudogene 14 
791016 ribosomal protein L13a  
791681 
ribosomal protein S4X pseudogene 6; ribosomal protein S4X 
pseudogene 13; ribosomal protein S4, X-linked 
778568 ribosomal protein L9; ribosomal protein L9 pseudogene 25 
789968 
ribosomal protein S3A; hypothetical LOC100131699; hypothetical 
LOC100130107 
823404 ribosomal protein L7a  
799749 ribosomal protein S19 pseudogene 3; ribosomal protein S19 
817032 ribosomal protein S14 
785872 
ribosomal protein L26 pseudogene 33; ribosomal protein L26; 
ribosomal protein L26 pseudogene 16; ribosomal protein L26 
pseudogene 19; ribosomal protein L26 pseudogene 6 
781689 ribosomal protein S20 
773042 ribosomal protein S7 
786531 ribosomal protein L19; ribosomal protein L19 pseudogene 12 
788428 ribosomal protein S15a 
790706 
ribosomal protein S16 pseudogene 1; ribosomal protein S16 
pseudogene 10; ribosomal protein S16 
804383 
ribosomal protein L5 pseudogene 34; ribosomal protein L5 
pseudogene 1; ribosomal protein L5 
777970 ribosomal protein L35a 
789083 ribosomal protein S27  
786137 ribosomal protein S11 pseudogene 5; ribosomal protein S11 
819005, 819005 ribosomal protein L27a 
814248 
ribosomal protein S18 pseudogene 12; ribosomal protein S18 
pseudogene 5; ribosomal protein S18 
  Gene Group 3 Enrichment Score: 25.295419199273347 
UNIPROT_ACC. Gene Name 
782385 eukaryotic translation initiation factor 5 
821677, 821677 
eukaryotic translation elongation factor 1 alpha-like 7; eukaryotic 
translation elongation factor 1 alpha-like 3; similar to eukaryotic 
translation elongation factor 1 alpha 1; eukaryotic translation 
elongation factor 1 alpha 1 
776090 eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa 
789266 elongation factor Tu GTP binding domain containing 2 
794612 eukaryotic translation elongation factor 1 alpha 2 
793126 eukaryotic translation elongation factor 2 
799635 Tu translation elongation factor, mitochondrial 
  Gene Group 4 Enrichment Score: 19.83330915084889 
UNIPROT_ACC. Gene Name 
816797 phenylalanyl-tRNA synthetase, beta subunit 
821074, 821074 
similar to chaperonin containing TCP1, subunit 8 (theta); 
chaperonin containing TCP1, subunit 8 (theta) 
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779168 chaperonin containing TCP1, subunit 6A (zeta 1) 
783837, 783837 ARP2 actin-related protein 2 homolog (yeast) 
812033 hypothetical gene supported by BC000665; t-complex 1 
775531, 775531 heat shock 70kDa protein 1A; heat shock 70kDa protein 1B 
796391 chaperonin containing TCP1, subunit 3 (gamma) 
816561 chaperonin containing TCP1, subunit 7 (eta) 
801999 chaperonin containing TCP1, subunit 4 (delta) 
785154 phenylalanyl-tRNA synthetase, alpha subunit 
823976 heat shock 70kDa protein 8 
  Gene Group 5 Enrichment Score: 19.6103417247131 
UNIPROT_ACC. Gene Name 
816797 phenylalanyl-tRNA synthetase, beta subunit 
795407 tyrosyl-tRNA synthetase 
819048 arginyl-tRNA synthetase 
813801 asparaginyl-tRNA synthetase 
788040 glutamyl-prolyl-tRNA synthetase 
778056 aspartyl-tRNA synthetase 
785252 lysyl-tRNA synthetase 
781476 cysteinyl-tRNA synthetase 
800451, 800451 isoleucyl-tRNA synthetase 
795667 glutaminyl-tRNA synthetase 
785154 phenylalanyl-tRNA synthetase, alpha subunit 
795388 glycyl-tRNA synthetase 
792673, 792673 threonyl-tRNA synthetase 
  Gene Group 6 Enrichment Score: 16.13051504616907 
UNIPROT_ACC. Gene Name 
817329 
small nuclear ribonucleoprotein D2 polypeptide 16.5kDa; similar 
to hCG2040270 
824519 heterogeneous nuclear ribonucleoprotein A1-like 3 
819770 splicing factor 3b, subunit 1, 155kDa 
789266 elongation factor Tu GTP binding domain containing 2 
812576 splicing factor, arginine/serine-rich 2 
792174 nucleolin 
796448 
RNA binding protein, autoantigenic (hnRNP-associated with lethal 
yellow homolog (mouse)) 
811579 synaptotagmin binding, cytoplasmic RNA interacting protein 
816370 fusion (involved in t(12;16) in malignant liposarcoma) 
785911 poly(A) binding protein, nuclear 1 
826656 
splicing factor proline/glutamine-rich (polypyrimidine tract 
binding protein associated) 
811567 splicing factor, arginine/serine-rich 3 
803294 heterogeneous nuclear ribonucleoprotein K  
825901 polypyrimidine tract binding protein 1 
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792435 splicing factor 3b, subunit 3, 130kDa 
812172, 812172 heterogeneous nuclear ribonucleoprotein L 
791398 heterogeneous nuclear ribonucleoprotein M 
776169 
small nuclear ribonucleoprotein D1 polypeptide 16kDa; 
hypothetical protein LOC100129492 
822931 small nuclear ribonucleoprotein D3 polypeptide 18kDa 
802909 heterogeneous nuclear ribonucleoprotein H3 (2H9) 
822132 heterogeneous nuclear ribonucleoprotein R 
802485 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu 
antigen R) 
799658 
heterogeneous nuclear ribonucleoprotein D (AU-rich element 
RNA binding protein 1, 37kDa) 
  Gene Group 7 Enrichment Score: 15.866610211487343 
UNIPROT_ACC. Gene Name 
808209 proteasome (prosome, macropain) 26S subunit, ATPase, 5 
800265, 800265 proteasome (prosome, macropain) subunit, alpha type, 7 
784614 proteasome (prosome, macropain) subunit, alpha type, 4 
822964 proteasome (prosome, macropain) subunit, alpha type, 2 
789403 proteasome (prosome, macropain) subunit, beta type, 3 
793113 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 
772714 proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 
790104, 790104 proteasome (prosome, macropain) subunit, alpha type, 3 
801384 proteasome (prosome, macropain) subunit, beta type, 4 
809326 ribosomal protein S27a  
788315 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 
792073 
proteasome (prosome, macropain) 26S subunit, ATPase, 1; similar 
to protease (prosome, macropain) 26S subunit, ATPase 1 
823937 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 
784081 proteasome (prosome, macropain) subunit, beta type, 5 
791833 proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 
808423 proteasome (prosome, macropain) subunit, beta type, 2 
787507, 787507 proteasome (prosome, macropain) subunit, alpha type, 5 
821110 proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 
823269 
similar to 26S protease regulatory subunit 6B (MIP224) (MB67-
interacting protein) (TAT-binding protein 7) (TBP-7); proteasome 
(prosome, macropain) 26S subunit, ATPase, 4 
824584 proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 
823033 proteasome (prosome, macropain) activator subunit 2 (PA28 beta) 
782800, 782800 proteasome (prosome, macropain) subunit, beta type, 1 
783409 proteasome (prosome, macropain) subunit, beta type, 7 
785147 proteasome (prosome, macropain) subunit, beta type, 6 
802342 
proteasome (prosome, macropain) activator subunit 1 (PA28 
alpha) 
792471 proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 
805348 proteasome (prosome, macropain) subunit, alpha type, 1 
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799755, 799755 proteasome (prosome, macropain) 26S subunit, ATPase, 2 
  Gene Group 8 Enrichment Score: 13.971243779646386 
UNIPROT_ACC. Gene Name 
775719 histone cluster 1, H2ae; histone cluster 1, H2ab 
809572 H3 histone 
813779 histone cluster 1, H2aa 
776633 histone cluster 2, H2aa3; histone cluster 2, H2aa4 
784865 histone cluster 1, H1c 
798572 H1 histone family, member X 
820028 H2A histone family, member J 
821106 H2A histone family, member V 
799393 histone cluster 1, H1b 
781820 histone cluster 1, H1d 
817975 H2B histone family, member S 
783474 H2A histone family, member Y 
781795 histone cluster 1, H1e 
784692 histone cluster 1, H4l  
812936, 812936 histone cluster 1 
821975 H1 histone family, member 0 
  Gene Group 9 Enrichment Score: 12.844011447238529 
UNIPROT_ACC. Gene Name 
823629 
solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 6 
802856 sideroflexin 1 
811526 up-regulated during skeletal muscle growth 5 homolog (mouse) 
813015, 813015 cytochrome c oxidase subunit IV isoform 1 
779088, 779088 mitochondrial carrier homolog 2 (C. elegans) 
775407 
solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 5;  
802706 
solute carrier family 25 (mitochondrial carrier; oxoglutarate 
carrier), member 11 
797071 
solute carrier family 25 (mitochondrial carrier; citrate transporter), 
member 1 
785522 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 
783313 stomatin (EPB72)-like 2 
785774 sulfide quinone reductase-like (yeast) 
791524 
solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 3 
  Gene Group 10 Enrichment Score: 12.434259349630642 
UNIPROT_ACC. Gene Name 
772506 annexin A11 
817614, 817614 annexin A1 
786439, 786439 annexin A4 
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812167 annexin A3 
787053 annexin A2 pseudogene 3; annexin A2; annexin A2 pseudogene 1 
798403 annexin A7 
818455 annexin A5 
  Gene Group 11 Enrichment Score: 12.03581361055844 
UNIPROT_ACC. Gene Name 
790279 cytochrome c oxidase subunit Vb 
814383 cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 
811526 up-regulated during skeletal muscle growth 5 homolog (mouse) 
803359 
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide-
like 1 
793950 
NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa 
(NADH-coenzyme Q reductase) 
813015, 813015 cytochrome c oxidase subunit IV isoform 1 
779088, 779088 mitochondrial carrier homolog 2 (C. elegans) 
775108 succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 
806108 cytochrome c oxidase subunit Va 
785522 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 
785774 sulfide quinone reductase-like (yeast) 
788119 ubiquinol-cytochrome c reductase core protein II 
  Gene Group 12 Enrichment Score: 11.04623633783345 
UNIPROT_ACC. Gene Name 
799578 phosphofructokinase, platelet 
797595 phosphoglycerate kinase 1 
786438 phosphofructokinase, liver 
777438 hexokinase 1 
774963 
similar to Pyruvate kinase, isozymes M1/M2 (Pyruvate kinase 
muscle isozyme) (Cytosolic thyroid hormone-binding protein) 
(CTHBP) (THBP1); pyruvate kinase, muscle 
  Gene Group 13 Enrichment Score: 9.583331345056456 
UNIPROT_ACC. Gene Name 
816672 
similar to eukaryotic translation initiation factor 4A2; eukaryotic 
translation initiation factor 4A, isoform 2 
808870 DEAH (Asp-Glu-Ala-His) box polypeptide 15 
811155 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
822287 DEAH (Asp-Glu-Ala-His) box polypeptide 9 
797679, 797679 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 
803332 GTPase activating protein (SH3 domain) binding protein 1 
775919 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
  Gene Group 14 Enrichment Score: 8.240003195546322 
UNIPROT_ACC. Gene Name 
798903 related RAS viral (r-ras) oncogene homolog 2; similar to related 
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RAS viral (r-ras) oncogene homolog 2 
825692 SAR1 homolog A (S. cerevisiae) 
813143 ras homolog gene family, member G (rho G) 
777282 similar to hCG1778032; RAB35, member RAS oncogene family 
824702 RAB13, member RAS oncogene family; similar to hCG24991 
807076 ras homolog gene family, member C 
811823 RAB34, member RAS oncogene family 
823808 RAB10, member RAS oncogene family 
823289 ADP-ribosylation factor 5 
798896 RAP2B, member of RAS oncogene family 
804583 v-ral simian leukemia viral oncogene homolog A (ras related) 
825257 ADP-ribosylation factor 6 
805986 RAB25, member RAS oncogene family 
810446 RAB11B, member RAS oncogene family 
780924 
RAB6C, member RAS oncogene family; RAB6A, member RAS 
oncogene family; hypothetical LOC100130819; RAB6C-like 
819932 RAB27B, member RAS oncogene family 
819977, 819977 RAB1B, member RAS oncogene family 
814242 RAB1A, member RAS oncogene family 
778710 ADP-ribosylation factor-like 1 
803992 RAP1A, member of RAS oncogene family 
798256 RAB5B, member RAS oncogene family 
794683 ADP-ribosylation factor 4 
796982 RAB7A, member RAS oncogene family 
  Gene Group 15 Enrichment Score: 7.625352128597404 
UNIPROT_ACC. Gene Name 
796258 keratin 8 pseudogene 9; similar to keratin 8; keratin 8 
808606, 808606 keratin 15 
772288, 772288 keratin 13 
808880 keratin 7 
783234 keratin 4 
813039 keratin 17; keratin 17 pseudogene 3 
799307 keratin 2 
825203 lamin B1 
822924 keratin 10 
813056 keratin 19 
808801 keratin 5 
787776 keratin 14 
811716 keratin 9 
  Gene Group 16 Enrichment Score: 6.8803225374779 
UNIPROT_ACC. Gene Name 
805919 coatomer protein complex, subunit beta 1 
797086 adaptor-related protein complex 2, alpha 1 subunit 
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808517 coatomer protein complex, subunit gamma 
783723 clathrin, light chain (Lca) 
813250 coatomer protein complex, subunit epsilon 
772954 archain 1 
786977 coatomer protein complex, subunit beta 2 (beta prime) 
783500 clathrin, heavy chain (Hc) 
787777 adaptor-related protein complex 1, beta 1 subunit 
787361 coatomer protein complex, subunit alpha 
826483 adaptor-related protein complex 1, gamma 1 subunit 
794259 transmembrane emp24-like trafficking protein 10 (yeast) 
  Gene Group 17 Enrichment Score: 6.44224171184403 
UNIPROT_ACC. Gene Name 
783032 ATPase, Na+/K+ transporting, alpha 1 polypeptide 
799291 ATPase, Na+/K+ transporting, beta 3 polypeptide 
775279 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit d 
785466 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit G 
780472 ATPase, H+ transporting, lysosomal V0 subunit a1 
795255 ATPase, Na+/K+ transporting, beta 1 polypeptide 
799992 
ATP synthase, H+ transporting, mitochondrial F1 complex, 
gamma polypeptide 1 
782027 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
818987 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit B1 
777586 ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 
787383 
ATP synthase, H+ transporting, mitochondrial F1 complex, O 
subunit 
811371 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit F2 
  Gene Group 18 Enrichment Score: 5.83899872387564 
UNIPROT_ACC. Gene Name 
790855 S100 calcium binding protein A2 
798322 calpain, small subunit 2 
776432 visinin-like 1 
791568 S100 calcium binding protein A16 
783393 S100 calcium binding protein A11 
780609 S100 calcium binding protein P 
778585 S100 calcium binding protein A14 
783621 S100 calcium binding protein A8 
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Appendix table 4.5: Gene functional classification of total proteins present in 
primary keratinocyte-derived APs 
 
Gene Group 1 Enrichment Score: 35.96225940193078 
UNIPROT_ACC. Gene Name 
823648 ribosomal protein L23a  
822027 ribosomal protein L13 pseudogene 12; ribosomal protein L13 
801125 ribosomal protein L8; ribosomal protein L8 pseudogene 2 
781935 ribosomal protein S25 pseudogene 8; ribosomal protein S25 
783263, 783263 ribosomal protein L12  
821732 ribosomal protein S8  
780689 ribosomal protein L23 pseudogene 6; ribosomal protein L23 
782492 ribosomal protein L22 pseudogene 11; ribosomal protein L22 
795791 
ribosomal protein L6 pseudogene 27; ribosomal protein L6 
pseudogene 19; ribosomal protein L6; ribosomal protein L6 
pseudogene 10 
800729 ribosomal protein S12  
778688 ribosomal protein L18a pseudogene 6; ribosomal protein L18a 
797877 ribosomal protein S5 
776216 ribosomal protein S2  
810885 ribosomal protein L11 
786754 ribosomal protein L4  
808508 ribosomal protein S6  
802424 ribosomal protein L3  
803657 ribosomal protein S13  
786934 ribosomal protein L36; ribosomal protein L36 pseudogene 14 
791016 ribosomal protein L13a  
791681 
ribosomal protein S4X pseudogene 6; ribosomal protein S4X 
pseudogene 13; ribosomal protein S4, X-linked 
778568 ribosomal protein L9; ribosomal protein L9 pseudogene 25 
789968, 789968 
ribosomal protein S3A; hypothetical LOC100131699; hypothetical 
LOC100130107 
799749 ribosomal protein S19 pseudogene 3; ribosomal protein S19 
823404 ribosomal protein L7a  
796227, 796227 ribosomal protein, large, P0 pseudogene 2  
817032 ribosomal protein S14 
785872 ribosomal protein L26 pseudogene 6 
781689 ribosomal protein S20 
777984 ribosomal protein L14 
773042 ribosomal protein S7  
786531 ribosomal protein L19; ribosomal protein L19 pseudogene 12 
794792 ribosomal protein, large, P1 
790706 ribosomal protein S16 
804383 ribosomal protein L5 
777970 ribosomal protein L35a 
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789083 ribosomal protein S27  
786137 ribosomal protein S11 pseudogene 5; ribosomal protein S11 
819005 ribosomal protein L27a 
814248 
ribosomal protein S18 pseudogene 12; ribosomal protein S18 
pseudogene 5; ribosomal protein S18 
820040 ribosomal protein L28 
  Gene Group 2 Enrichment Score: 11.794506625379913 
UNIPROT_ACC. Gene Name 
821074 
similar to chaperonin containing TCP1, subunit 8 (theta); 
chaperonin containing TCP1, subunit 8 (theta) 
783837 ARP2 actin-related protein 2 homolog (yeast) 
812033 hypothetical gene supported by BC000665; t-complex 1 
783535 heat shock 70kDa protein 9 (mortalin) 
775531 heat shock 70kDa protein 1A; heat shock 70kDa protein 1B 
796391 chaperonin containing TCP1, subunit 3 (gamma) 
816561, 816561 chaperonin containing TCP1, subunit 7 (eta) 
801999 chaperonin containing TCP1, subunit 4 (delta) 
785154 phenylalanyl-tRNA synthetase, alpha subunit 
823976 heat shock 70kDa protein 8 
  Gene Group 3 Enrichment Score: 11.070539090979564 
UNIPROT_ACC. Gene Name 
808209 proteasome (prosome, macropain) 26S subunit, ATPase, 5 
800265 proteasome (prosome, macropain) subunit, alpha type, 7 
822964 proteasome (prosome, macropain) subunit, alpha type, 2 
789403 proteasome (prosome, macropain) subunit, beta type, 3 
793113 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 
790104 proteasome (prosome, macropain) subunit, alpha type, 3 
801384 proteasome (prosome, macropain) subunit, beta type, 4 
792073 
proteasome (prosome, macropain) 26S subunit, ATPase, 1; similar 
to protease (prosome, macropain) 26S subunit, ATPase 1 
823937 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 
784081 proteasome (prosome, macropain) subunit, beta type, 5 
791833 proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 
808423 proteasome (prosome, macropain) subunit, beta type, 2 
787507 proteasome (prosome, macropain) subunit, alpha type, 5 
821110 proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 
823033 proteasome (prosome, macropain) activator subunit 2 (PA28 beta) 
824584 proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 
782800 proteasome (prosome, macropain) subunit, beta type, 1 
785147 proteasome (prosome, macropain) subunit, beta type, 6 
799755 proteasome (prosome, macropain) 26S subunit, ATPase, 2 
  Gene Group 4 Enrichment Score: 10.878031534544409 
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UNIPROT_ACC. Gene Name 
816561, 816561 chaperonin containing TCP1, subunit 7 (eta) 
795407 tyrosyl-tRNA synthetase 
785154 phenylalanyl-tRNA synthetase, alpha subunit 
792673 threonyl-tRNA synthetase 
806048 histidyl-tRNA synthetase 
788040 glutamyl-prolyl-tRNA synthetase 
795388 glycyl-tRNA synthetase 
  Gene Group 5 Enrichment Score: 9.792886213758853 
UNIPROT_ACC. Gene Name 
792713 tubulin, beta 6 
800083 
tubulin, beta; similar to tubulin, beta 5; tubulin, beta pseudogene 2; 
tubulin, beta pseudogene 1 
826978 tubulin, alpha 4a 
823156 tubulin, alpha 1c 
776899 tubulin, beta 2C 
  Gene Group 6 Enrichment Score: 7.716695203706186 
UNIPROT_ACC. Gene Name 
798903 
related RAS viral (r-ras) oncogene homolog 2; similar to related 
RAS viral (r-ras) oncogene homolog 2 
777282 similar to hCG1778032; RAB35, member RAS oncogene family 
804583 v-ral simian leukemia viral oncogene homolog A (ras related) 
814242 RAB1A, member RAS oncogene family 
798256 RAB5B, member RAS oncogene family 
823808 RAB10, member RAS oncogene family 
794683 ADP-ribosylation factor 4 
796982 RAB7A, member RAS oncogene family 
807076 ras homolog gene family, member C 
780924 
RAB6C, member RAS oncogene family; RAB6A, member RAS 
oncogene family; hypothetical LOC100130819; RAB6C-like 
819977 RAB1B, member RAS oncogene family 
  Gene Group 7 Enrichment Score: 6.9758968504842045 
UNIPROT_ACC. Gene Name 
813039 keratin 17; keratin 17 pseudogene 3 
799223 keratin 16; keratin type 16-like 
811716 keratin 9 
808801 keratin 5 
822924 keratin 10 
799307 keratin 2 
787776 keratin 14 
  Gene Group 8 Enrichment Score: 4.701094299953847 
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UNIPROT_ACC. Gene Name 
790855 S100 calcium binding protein A2 
791568 S100 calcium binding protein A16 
780609 S100 calcium binding protein P 
778585 S100 calcium binding protein A14 
783621 S100 calcium binding protein A8 
826596 S100 calcium binding protein A4 
  Gene Group 9 Enrichment Score: 2.2961752178510157 
UNIPROT_ACC. Gene Name 
783032 ATPase, Na+/K+ transporting, alpha 1 polypeptide 
799291 ATPase, Na+/K+ transporting, beta 3 polypeptide 
823049 ATPase, H+/K+ exchanging, alpha polypeptide 
786659 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 
799166 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 
795255 ATPase, Na+/K+ transporting, beta 1 polypeptide 
782027 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
777586 ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 
787383 
ATP synthase, H+ transporting, mitochondrial F1 complex, O 
subunit 
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Appendix table 4.6: Gene functional classification of total proteins present in 
HaCaT-derived MVs 
 
Gene Group 1 Enrichment Score: 44.759038203654335 
UNIPROT_ACC. Gene Name 
779090 ribosomal protein L15  
822027, 822027 ribosomal protein L13 pseudogene 12; ribosomal protein L13 
781935 ribosomal protein S25 pseudogene 8; ribosomal protein S25 
801125 ribosomal protein L8; ribosomal protein L8 pseudogene 2 
783263, 783263 ribosomal protein L12  
772335 ribosomal protein S26  
821732, 821732 
ribosomal protein S8; ribosomal protein S8 pseudogene 8; 
ribosomal protein S8 pseudogene 10 
776035 ribosomal protein L18 
780689, 780689 ribosomal protein L23 pseudogene 6; ribosomal protein L23 
782492 ribosomal protein L22 pseudogene 11; ribosomal protein L22 
795791 ribosomal protein L6  
800729 ribosomal protein S12  
778688 ribosomal protein L18a pseudogene 6; ribosomal protein L18a 
797877, 797877 ribosomal protein S5 
776216, 776216 ribosomal protein S2 
798725 ribosomal protein L30 
810885, 810885 ribosomal protein L11 
786754, 786754 
ribosomal protein L4; ribosomal protein L4 pseudogene 5; 
ribosomal protein L4 pseudogene 4 
808508 
ribosomal protein S6 pseudogene 25; ribosomal protein S6; 
ribosomal protein S6 pseudogene 1 
803377 
ribosomal protein L35; ribosomal protein L35 pseudogene 1; 
ribosomal protein L35 pseudogene 2 
783997 ribosomal protein L17  
825605 ribosomal protein L7  
802424 ribosomal protein L3; similar to 60S ribosomal protein L3 (L4) 
803657 
ribosomal protein S13 pseudogene 8; ribosomal protein S13; 
ribosomal protein S13 pseudogene 2 
796817 ribosomal protein L10a  
811161 
ribosomal protein, large, P2 pseudogene 3; ribosomal protein, 
large, P2 
775912 ribosomal protein SA  
791016, 791016 ribosomal protein L13a  
791681, 791681 
ribosomal protein S4X pseudogene 6; ribosomal protein S4X 
pseudogene 13; ribosomal protein S4, X-linked 
778568 ribosomal protein L9; ribosomal protein L9 pseudogene 25 
789968 
ribosomal protein S3A; hypothetical LOC100131699; hypothetical 
LOC100130107 
776761 small nucleolar RNA, H/ACA box 7A;  
823404 ribosomal protein L7a  
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800698 ribosomal protein L24; ribosomal protein L24 pseudogene 6 
798227 ribosomal protein S9; ribosomal protein S9 pseudogene 4 
796227 ribosomal protein, large, P0  
817032 ribosomal protein S14 
777984 ribosomal protein L14 
786531 ribosomal protein L19; ribosomal protein L19 pseudogene 12 
788428 ribosomal protein S15a  
790706 ribosomal protein S16  
819005, 819005 ribosomal protein L27a 
799716 ribosomal protein L10  
814248 ribosomal protein S18  
820040 ribosomal protein L28 
  Gene Group 2 Enrichment Score: 16.430972917506814 
UNIPROT_ACC. Gene Name 
821074, 821074 
similar to chaperonin containing TCP1, subunit 8 (theta); 
chaperonin containing TCP1, subunit 8 (theta) 
779168 chaperonin containing TCP1, subunit 6A (zeta 1) 
812033 hypothetical gene supported by BC000665; t-complex 1 
775531, 775531 heat shock 70kDa protein 1A; heat shock 70kDa protein 1B 
796391, 796391 chaperonin containing TCP1, subunit 3 (gamma) 
816561 chaperonin containing TCP1, subunit 7 (eta) 
801999 chaperonin containing TCP1, subunit 4 (delta) 
819354 chaperonin containing TCP1, subunit 2 (beta) 
823976 heat shock 70kDa protein 8 
  Gene Group 3 Enrichment Score: 15.29996213389579 
UNIPROT_ACC. Gene Name 
783908, 783908 lamin A/C 
813039 keratin 17; keratin 17 pseudogene 3 
772288, 772288 keratin 13 
796258 keratin 8 pseudogene 9; similar to keratin 8; keratin 8 
811716 keratin 9 
783234 keratin 4 
819470 keratin 18; keratin 18 pseudogene 26; keratin 18 pseudogene 19 
808801 keratin 5 
799307 keratin 2 
815379 keratin 6C 
789384 keratin 6B 
808606 keratin 15 
776457 keratin 6A 
777061 keratin 1 
808880 keratin 7 
787776 keratin 14 
813056 keratin 19 
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822924 keratin 10 
  Gene Group 4 Enrichment Score: 13.507044298764358 
UNIPROT_ACC. Gene Name 
803294, 803294 
heterogeneous nuclear ribonucleoprotein K; similar to 
heterogeneous nuclear ribonucleoprotein K 
799658, 799658 
heterogeneous nuclear ribonucleoprotein D (AU-rich element 
RNA binding protein 1, 37kDa) 
825901 polypyrimidine tract binding protein 1 
782567 poly(rC) binding protein 2 
817941 
heterogeneous nuclear ribonucleoprotein U (scaffold attachment 
factor A) 
813133 heterogeneous nuclear ribonucleoprotein A1-like 2 
791398 heterogeneous nuclear ribonucleoprotein M 
810069 heterogeneous nuclear ribonucleoprotein A3 
784420 heterogeneous nuclear ribonucleoprotein C (C1/C2) 
814227 heterogeneous nuclear ribonucleoprotein A2/B1 
798469, 798469 poly(rC) binding protein 1 
826437 heterogeneous nuclear ribonucleoprotein H1 (H) 
811579 synaptotagmin binding, cytoplasmic RNA interacting protein 
  Gene Group 5 Enrichment Score: 13.245714614447332 
UNIPROT_ACC. Gene Name 
813801 asparaginyl-tRNA synthetase 
779168 chaperonin containing TCP1, subunit 6A (zeta 1) 
778056 aspartyl-tRNA synthetase 
792673 threonyl-tRNA synthetase 
814244 tryptophanyl-tRNA synthetase 
821074, 821074 
similar to chaperonin containing TCP1, subunit 8 (theta); 
chaperonin containing TCP1, subunit 8 (theta) 
788040 glutamyl-prolyl-tRNA synthetase 
  Gene Group 6 Enrichment Score: 12.659253550500635 
UNIPROT_ACC. Gene Name 
826978 tubulin, alpha 4a 
800083, 800083 
tubulin, beta; similar to tubulin, beta 5; tubulin, beta pseudogene 2; 
tubulin, beta pseudogene 1 
823156 tubulin, alpha 1c 
776899, 776899 tubulin, beta 2C 
811901 tubulin, alpha 1a 
  Gene Group 7 Enrichment Score: 10.59957877853169 
UNIPROT_ACC. Gene Name 
772506, 772506 annexin A11 
825613 annexin A8-like 2 
817614, 817614 annexin A1 
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786439 annexin A4 
812167 annexin A3 
787053 annexin A2 pseudogene 3; annexin A2; annexin A2 pseudogene 1 
825839 annexin A8 
818455 annexin A5 
  Gene Group 8 Enrichment Score: 9.676725072766516 
UNIPROT_ACC. Gene Name 
775719 histone cluster 1, H2ae; histone cluster 1, H2ab 
784692, 784692 
histone cluster 1, H4l; histone cluster 1, H4k; histone cluster 4, 
H4; histone cluster 1, H4h; histone cluster 1, H4j; histone cluster 
1, H4i; histone cluster 1,  
803490 histone cluster 1, H2bl 
781795 histone cluster 1, H1e 
785159 histone cluster 3, H2bb 
820028 H2A histone family, member J 
  Gene Group 9 Enrichment Score: 7.978061671428546 
UNIPROT_ACC. Gene Name 
804583 v-ral simian leukemia viral oncogene homolog A (ras related) 
814242 RAB1A, member RAS oncogene family 
810446 RAB11B, member RAS oncogene family 
823808 RAB10, member RAS oncogene family 
803034 ADP-ribosylation factor 1 
794683 ADP-ribosylation factor 4 
796982 RAB7A, member RAS oncogene family 
775592 RAB5C, member RAS oncogene family 
807076 ras homolog gene family, member C 
819977 RAB1B, member RAS oncogene family 
  Gene Group 10 Enrichment Score: 6.857555529440164 
UNIPROT_ACC. Gene Name 
789403 proteasome (prosome, macropain) subunit, beta type, 3 
790104, 790104 proteasome (prosome, macropain) subunit, alpha type, 3 
787507 proteasome (prosome, macropain) subunit, alpha type, 5 
775955 proteasome (prosome, macropain) subunit, alpha type, 6 
800265 proteasome (prosome, macropain) subunit, alpha type, 7 
802342 
proteasome (prosome, macropain) activator subunit 1 (PA28 
alpha) 
785147 proteasome (prosome, macropain) subunit, beta type, 6 
808423 proteasome (prosome, macropain) subunit, beta type, 2 
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Appendix table 4.7: Gene functional classification of total proteins present in 
primary keratinocyte -derived MVs 
 
Gene Group 1 Enrichment Score: 8.833994230319584 
UNIPROT_ACC. Gene Name 
783263 ribosomal protein L12  
786754 ribosomal protein L4  
796227 ribosomal protein, large, P0  
801125 ribosomal protein L8; ribosomal protein L8 pseudogene 2 
776216 ribosomal protein S2  
821732 ribosomal protein S8 
782492 ribosomal protein L22 pseudogene 11; ribosomal protein L22 
800729 ribosomal protein S12  
823404 ribosomal protein L7a  
814248 ribosomal protein S18  
  Gene Group 2 Enrichment Score: 6.332017872936069 
UNIPROT_ACC. Gene Name 
813039 keratin 17; keratin 17 pseudogene 3 
799223 keratin 16; keratin type 16-like 
808801 keratin 5 
811716 keratin 9 
822924 keratin 10 
799307 keratin 2 
784148 keratin 78 
787776 keratin 14 
  Gene Group 3 Enrichment Score: 6.125567480688464 
UNIPROT_ACC. Gene Name 
783837 ARP2 actin-related protein 2 homolog (yeast) 
816561 chaperonin containing TCP1, subunit 7 (eta) 
779168 chaperonin containing TCP1, subunit 6A (zeta 1) 
796391 chaperonin containing TCP1, subunit 3 (gamma) 
812033 hypothetical gene supported by BC000665; t-complex 1 
821074 
similar to chaperonin containing TCP1, subunit 8 (theta); 
chaperonin containing TCP1, subunit 8 (theta) 
  Gene Group 4 Enrichment Score: 5.879780362628678 
UNIPROT_ACC. Gene Name 
790855 S100 calcium binding protein A2 
774078 filaggrin family member 2 
791568 S100 calcium binding protein A16 
772988 S100 calcium binding protein A10 
778585 S100 calcium binding protein A14 
783621 S100 calcium binding protein A8 
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  Gene Group 5 Enrichment Score: 5.778787869150742 
UNIPROT_ACC. Gene Name 
804583 v-ral simian leukemia viral oncogene homolog A (ras related) 
777282 similar to hCG1778032; RAB35, member RAS oncogene family 
814242 RAB1A, member RAS oncogene family 
823808 RAB10, member RAS oncogene family 
798896 RAP2B, member of RAS oncogene family 
796982 RAB7A, member RAS oncogene family 
792103 RAB6B, member RAS oncogene family 
807076 ras homolog gene family, member C 
803992, 803992 RAP1A, member of RAS oncogene family 
819977 RAB1B, member RAS oncogene family 
  Gene Group 6 Enrichment Score: 1.7463485983557223 
UNIPROT_ACC. Gene Name 
787321 
hypothetical protein LOC100133690; activated leukocyte cell 
adhesion molecule 
805733 myelin protein zero-like 1 
774965, 774965 prostaglandin F2 receptor negative regulator 
823595 F11 receptor 
781354 neuroplastin 
  Gene Group 7 Enrichment Score: 1.6522253097435986 
UNIPROT_ACC. Gene Name 
795255 ATPase, Na+/K+ transporting, beta 1 polypeptide 
802404 ATPase, Ca++ transporting, plasma membrane 1 
799291 ATPase, Na+/K+ transporting, beta 3 polypeptide 
783032 ATPase, Na+/K+ transporting, alpha 1 polypeptide 
777586 ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 
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Appendix table 4.8: Gene functional classification of total proteins present in 
HaCaT-derived EXs 
 
Gene Group 1 Enrichment Score: 27.42624403220511 
UNIPROT_ACC. Gene Name 
822027 ribosomal protein L13 pseudogene 12; ribosomal protein L13 
799749 ribosomal protein S19 pseudogene 3; ribosomal protein S19 
810885 ribosomal protein L11 
789968 ribosomal protein S3A  
800729 ribosomal protein S12 
782492 ribosomal protein L22 pseudogene 11; ribosomal protein L22 
786531 ribosomal protein L19; ribosomal protein L19 pseudogene 12 
773042 ribosomal protein S7  
781689 ribosomal protein S20 
817032 ribosomal protein S14 
821732 ribosomal protein S8  
796817 ribosomal protein L10a  
790706 ribosomal protein S16  
804383 ribosomal protein L5  
794792 ribosomal protein, large, P1 
786754 ribosomal protein  
814248 ribosomal protein S18  
780689 ribosomal protein L23 pseudogene 6; ribosomal protein L23 
785199 ribosomal protein L36a  
786137 ribosomal protein S11 pseudogene 5; ribosomal protein S11 
808508 
ribosomal protein S6 pseudogene 25; ribosomal protein S6; 
ribosomal protein S6 pseudogene 1 
778568 ribosomal protein L9; ribosomal protein L9 pseudogene 25 
791681 ribosomal protein S4, X-linked 
776216, 776216 ribosomal protein S2 
783263 ribosomal protein L12  
791016 ribosomal protein L13a  
801872 ribosomal protein S23 
797877 ribosomal protein S5 
803657 
ribosomal protein S13 pseudogene 8; ribosomal protein S13; 
ribosomal protein S13 pseudogene 2 
788428 ribosomal protein S15a  
  Gene Group 2 Enrichment Score: 18.987322977392367 
UNIPROT_ACC. Gene Name 
782385 eukaryotic translation initiation factor 5 
821677, 821677 eukaryotic translation elongation factor 1 alpha-like 7;  
789266 elongation factor Tu GTP binding domain containing 2 
794612 eukaryotic translation elongation factor 1 alpha 2 
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793126 eukaryotic translation elongation factor 2 
  Gene Group 3 Enrichment Score: 17.053321962828687 
UNIPROT_ACC. Gene Name 
816797 phenylalanyl-tRNA synthetase, beta subunit 
795407 tyrosyl-tRNA synthetase 
819048 arginyl-tRNA synthetase 
820495 alanyl-tRNA synthetase 
813801 asparaginyl-tRNA synthetase 
788040 glutamyl-prolyl-tRNA synthetase 
778056 aspartyl-tRNA synthetase 
785252 lysyl-tRNA synthetase 
800451 isoleucyl-tRNA synthetase 
795667 glutaminyl-tRNA synthetase 
785154 phenylalanyl-tRNA synthetase, alpha subunit 
795388 glycyl-tRNA synthetase 
792673 threonyl-tRNA synthetase 
  Gene Group 4 Enrichment Score: 16.838693948149935 
UNIPROT_ACC. Gene Name 
808209 proteasome (prosome, macropain) 26S subunit, ATPase, 5 
800265, 800265 proteasome (prosome, macropain) subunit, alpha type, 7 
784614 proteasome (prosome, macropain) subunit, alpha type, 4 
822964 proteasome (prosome, macropain) subunit, alpha type, 2 
789403 proteasome (prosome, macropain) subunit, beta type, 3 
793113 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 
801384 proteasome (prosome, macropain) subunit, beta type, 4 
790104 proteasome (prosome, macropain) subunit, alpha type, 3 
772714 proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 
777224 proteasome (prosome, macropain) 26S subunit, ATPase, 6 
818676 ubiquitin A-52 residue ribosomal protein fusion product 1 
792073 
proteasome (prosome, macropain) 26S subunit, ATPase, 1; 
similar to protease (prosome, macropain) 26S subunit, ATPase 
1 
784081 proteasome (prosome, macropain) subunit, beta type, 5 
823937 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 
11 
791833 proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 
808423 proteasome (prosome, macropain) subunit, beta type, 2 
792631 budding uninhibited by benzimidazoles 3 homolog (yeast) 
787507, 787507 proteasome (prosome, macropain) subunit, alpha type, 5 
821110 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 
14 
823269 
similar to 26S protease regulatory subunit 6B (MIP224) 
(MB67-interacting protein) (TAT-binding protein 7) (TBP-7)  
823033 proteasome (prosome, macropain) activator subunit 2 (PA28 
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beta) 
824584 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 
13 
782800 proteasome (prosome, macropain) subunit, beta type, 1 
783409 proteasome (prosome, macropain) subunit, beta type, 7 
802342 
proteasome (prosome, macropain) activator subunit 1 (PA28 
alpha) 
792471 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 
12 
799755 proteasome (prosome, macropain) 26S subunit, ATPase, 2 
  Gene Group 5 Enrichment Score: 15.36116625568255 
UNIPROT_ACC. Gene Name 
823976 heat shock 70kDa protein 8 
783837 ARP2 actin-related protein 2 homolog (yeast) 
816561 chaperonin containing TCP1, subunit 7 (eta) 
809846 
ARP1 actin-related protein 1 homolog A, centractin alpha 
(yeast) 
796391 chaperonin containing TCP1, subunit 3 (gamma) 
812033 hypothetical gene supported by BC000665; t-complex 1 
821074 
similar to chaperonin containing TCP1, subunit 8 (theta); 
chaperonin containing TCP1, subunit 8 (theta) 
801999 chaperonin containing TCP1, subunit 4 (delta) 
  Gene Group 6 Enrichment Score: 12.975324144435492 
UNIPROT_ACC. Gene Name 
796971 heterochromatin protein 1, binding protein 3 
775719 histone cluster 1, H2ae; histone cluster 1, H2ab 
784865 histone cluster 1, H1c 
798572 H1 histone family, member X 
820028 H2A histone family, member J 
785159 histone cluster 3, H2bb 
797970 histone cluster 1, H2bm 
821106 H2A histone family, member V 
794356 H2A histone family, member X 
799393 histone cluster 1, H1b 
781820 histone cluster 1, H1d 
784027 histone cluster 2, H2be 
781795 histone cluster 1, H1e 
783474 H2A histone family, member Y 
821975 H1 histone family, member 0 
812936, 812936 
histone cluster 1, H3j; histone cluster 1, H3i; histone cluster 1, 
H3h; histone cluster 1, H3g; histone cluster 1, H3f; histone 
cluster 1, H3e; histone cluster 1, H3d; histone cluster 1, H3c; 
histone cluster 1, H3b; histone cluster 1, H3a; histone cluster 1, 
H2ad; histone cluster 2, H3a; histone cluster 2, H3c; histone 
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cluster 2, H3d 
784692, 784692 histone cluster 1; histone cluster 2 
  Gene Group 7 Enrichment Score: 12.439223781552958 
UNIPROT_ACC. Gene Name 
778964 small nuclear ribonucleoprotein 40kDa (U5) 
825801 PRP4 pre-mRNA processing factor 4 homolog (yeast) 
804403, 804403 
guanine nucleotide binding protein (G protein), beta 
polypeptide 2 
794786 coronin, actin binding protein, 2A 
815100 smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans) 
800360 eukaryotic translation initiation factor 3, subunit I 
  Gene Group 8 Enrichment Score: 11.851773659442781 
UNIPROT_ACC. Gene Name 
800083 
tubulin, beta; similar to tubulin, beta 5; tubulin, beta 
pseudogene 2; tubulin, beta pseudogene 1 
826978 tubulin, alpha 4a 
797163 septin 9 
823156 tubulin, alpha 1c 
776899, 776899 tubulin, beta 2C 
790725 tubulin, gamma 1; similar to Tubulin, gamma 1 
807411 septin 7 
  Gene Group 9 Enrichment Score: 11.730690502702897 
UNIPROT_ACC. Gene Name 
803294, 803294 
heterogeneous nuclear ribonucleoprotein K; similar to 
heterogeneous nuclear ribonucleoprotein K 
812172 similar to heterogeneous nuclear ribonucleoprotein L-like;  
799658 
heterogeneous nuclear ribonucleoprotein D (AU-rich element 
RNA binding protein 1, 37kDa) 
825901 polypyrimidine tract binding protein 1 
791398 heterogeneous nuclear ribonucleoprotein M 
826656 
splicing factor proline/glutamine-rich (polypyrimidine tract 
binding protein associated) 
792174, 792174 nucleolin 
796448 
RNA binding protein, autoantigenic (hnRNP-associated with 
lethal yellow homolog (mouse)) 
785199 ribosomal protein L36a  
811579 synaptotagmin binding, cytoplasmic RNA interacting protein 
  Gene Group 10 Enrichment Score: 10.631126094489659 
UNIPROT_ACC. Gene Name 
784244 PRP8 pre-mRNA processing factor 8 homolog (S. cerevisiae) 
825901 polypyrimidine tract binding protein 1 
825801 PRP4 pre-mRNA processing factor 4 homolog (yeast) 
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792435 splicing factor 3b, subunit 3, 130kDa 
819770 splicing factor 3b, subunit 1, 155kDa 
  Gene Group 11 Enrichment Score: 10.510310293472315 
UNIPROT_ACC. Gene Name 
772506, 772506, 
772506 annexin A11 
817614, 817614 annexin A1 
786439 annexin A4 
812167 annexin A3 
787053 
annexin A2 pseudogene 3; annexin A2; annexin A2 
pseudogene 1 
798403 annexin A7 
818455 annexin A5 
  Gene Group 12 Enrichment Score: 8.65430794866716 
UNIPROT_ACC. Gene Name 
816672 similar to eukaryotic translation initiation factor 4A2;  
778808 
similar to U5 snRNP-specific protein, 200 kDa; small nuclear 
ribonucleoprotein 200kDa (U5) 
808870 DEAH (Asp-Glu-Ala-His) box polypeptide 15 
822287 DEAH (Asp-Glu-Ala-His) box polypeptide 9 
797679 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 
803332 GTPase activating protein (SH3 domain) binding protein 1 
775919 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
  Gene Group 13 Enrichment Score: 7.7333105388307 
UNIPROT_ACC. Gene Name 
805919 coatomer protein complex, subunit beta 1 
797086 adaptor-related protein complex 2, alpha 1 subunit 
808517, 808517 coatomer protein complex, subunit gamma 
772954 archain 1 
817660 Sec23 homolog B (S. cerevisiae) 
786977 coatomer protein complex, subunit beta 2 (beta prime) 
783500 clathrin, heavy chain (Hc) 
787361 coatomer protein complex, subunit alpha 
826483 adaptor-related protein complex 1, gamma 1 subunit 
  Gene Group 14 Enrichment Score: 7.5102787108337665 
UNIPROT_ACC. Gene Name 
796258 keratin 8 pseudogene 9; similar to keratin 8; keratin 8 
799223 keratin 16; keratin type 16-like 
808606 keratin 15 
808880 keratin 7 
813039 keratin 17; keratin 17 pseudogene 3 
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799307 keratin 2 
822924 keratin 10 
808801 keratin 5 
813056 keratin 19 
777061 keratin 1 
787776 keratin 14 
811716 keratin 9 
  Gene Group 15 Enrichment Score: 5.184927777341389 
UNIPROT_ACC. Gene Name 
798903 
related RAS viral (r-ras) oncogene homolog 2; similar to 
related RAS viral (r-ras) oncogene homolog 2 
804583 v-ral simian leukemia viral oncogene homolog A (ras related) 
777282 
similar to hCG1778032; RAB35, member RAS oncogene 
family 
823808 RAB10, member RAS oncogene family 
798896 RAP2B, member of RAS oncogene family 
796982 RAB7A, member RAS oncogene family 
807076 ras homolog gene family, member C 
780924 
RAB6C, member RAS oncogene family; RAB6A, member 
RAS oncogene family; hypothetical LOC100130819; RAB6C-
like 
819977, 819977 RAB1B, member RAS oncogene family 
823289 ADP-ribosylation factor 5 
813143 ras homolog gene family, member G (rho G) 
  Gene Group 16 Enrichment Score: 4.003857169380483 
UNIPROT_ACC. Gene Name 
790855 S100 calcium binding protein A2 
791568 S100 calcium binding protein A16 
776432 visinin-like 1 
772988 S100 calcium binding protein A10 
783393 
S100 calcium binding protein A11; S100 calcium binding 
protein A11 pseudogene 
778585 S100 calcium binding protein A14 
  Gene Group 17 Enrichment Score: 3.346101590801618 
UNIPROT_ACC. Gene Name 
816575 immunoglobulin superfamily, member 3 
792228 immunoglobulin superfamily, member 8 
773473 tetraspanin 6 
779533 G protein-coupled receptor, family C, group 5, member C 
803407, 803407 
solute carrier family 1 (neutral amino acid transporter), 
member 5 
784606 solute carrier family 29 (nucleoside transporters), member 1 
800440 tetraspanin 14 
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Appendix table 4.9: Gene functional classification of total proteins present in 
primary keratinocyte -derived EXs 
 
Gene Group 1 Enrichment Score: 13.786879892295088 
UNIPROT_ACC. Gene Name 
810885 ribosomal protein L11 
777984 ribosomal protein L14 
778688 ribosomal protein L18a pseudogene 6; ribosomal protein L18a 
789968 ribosomal protein S3A  
821732 
ribosomal protein S8; ribosomal protein S8 pseudogene 8; 
ribosomal protein S8 pseudogene 10 
796817 
ribosomal protein L10a pseudogene 6; ribosomal protein L10a; 
ribosomal protein L10a pseudogene 9 
804383 
ribosomal protein L5 pseudogene 34; ribosomal protein L5 
pseudogene 1; ribosomal protein L5 
790706 
ribosomal protein S16 pseudogene 1; ribosomal protein S16 
pseudogene 10; ribosomal protein S16 
786754 
ribosomal protein L4; ribosomal protein L4 pseudogene 5; 
ribosomal protein L4 pseudogene 4 
814248 ribosomal protein S18 pseudogene 12; ribosomal protein S18 
774965 prostaglandin F2 receptor negative regulator 
814490 tumor-associated calcium signal transducer 2 
782895, 782895 CD82 molecule 
793704 epithelial cell adhesion molecule 
823595 F11 receptor 
805733 myelin protein zero-like 1 
814848 
solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4) 
817290 G protein-coupled receptor, family C, group 5, member A 
795618 podocalyxin-like 
818271 tetraspanin 1 
819728 CD151 molecule (Raph blood group) 
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pseudogene 5; ribosomal protein S18 
780689 ribosomal protein L23 pseudogene 6; ribosomal protein L23 
776035 ribosomal protein L18 
786137 ribosomal protein S11 pseudogene 5; ribosomal protein S11 
791681, 791681 
ribosomal protein S4X pseudogene 6; ribosomal protein S4X 
pseudogene 13; ribosomal protein S4, X-linked 
823404 ribosomal protein L7a  
776216, 776216 ribosomal protein S2  
783263 ribosomal protein L12  
791016 ribosomal protein L13a  
797877 ribosomal protein S5 
796227 ribosomal protein, large, P0  
  Gene Group 2 Enrichment Score: 12.572317162373862 
UNIPROT_ACC. Gene Name 
804309 RAB22A, member RAS oncogene family 
813143 ras homolog gene family, member G (rho G) 
802521 RAB38, member RAS oncogene family 
791053 RAP2C, member of RAS oncogene family 
777282 similar to hCG1778032; RAB35, member RAS oncogene family 
824702 RAB13, member RAS oncogene family; similar to hCG24991 
807076 ras homolog gene family, member C 
823808 RAB10, member RAS oncogene family 
804583 v-ral simian leukemia viral oncogene homolog A (ras related) 
798896 RAP2B, member of RAS oncogene family 
805986 RAB25, member RAS oncogene family 
810446 RAB11B, member RAS oncogene family 
780924 
RAB6C, member RAS oncogene family; RAB6A, member RAS 
oncogene family; hypothetical LOC100130819; RAB6C-like 
819932 RAB27B, member RAS oncogene family 
819977 RAB1B, member RAS oncogene family 
814242 RAB1A, member RAS oncogene family 
803992 RAP1A, member of RAS oncogene family 
781385 
RAB43, member RAS oncogene family; hypothetical 
LOC100131426 
798256 RAB5B, member RAS oncogene family 
794683 ADP-ribosylation factor 4 
796982 RAB7A, member RAS oncogene family 
  Gene Group 3 Enrichment Score: 10.28587946776525 
UNIPROT_ACC. Gene Name 
826978 tubulin, alpha 4a 
800083 tubulin, beta  
792713 tubulin, beta 6 
823156 tubulin, alpha 1c 
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811901 tubulin, alpha 1a 
776899 tubulin, beta 2C 
801263 tubulin, beta 2A 
  Gene Group 4 Enrichment Score: 10.209781103350453 
UNIPROT_ACC. Gene Name 
779168 chaperonin containing TCP1, subunit 6A (zeta 1) 
821074 
similar to chaperonin containing TCP1, subunit 8 (theta); 
chaperonin containing TCP1, subunit 8 (theta) 
783837, 783837 ARP2 actin-related protein 2 homolog (yeast) 
812033 hypothetical gene supported by BC000665; t-complex 1 
797358 actin, beta-like 2 
796391 chaperonin containing TCP1, subunit 3 (gamma) 
809846 ARP1 actin-related protein 1 homolog A, centractin alpha (yeast) 
796299, 796299 myosin ID 
816561, 816561 chaperonin containing TCP1, subunit 7 (eta) 
  Gene Group 5 Enrichment Score: 9.42993381082597 
UNIPROT_ACC. Gene Name 
819048 arginyl-tRNA synthetase 
813801 asparaginyl-tRNA synthetase 
820495 alanyl-tRNA synthetase 
795667 glutaminyl-tRNA synthetase 
800451 isoleucyl-tRNA synthetase 
792673 threonyl-tRNA synthetase 
795388 glycyl-tRNA synthetase 
788040 glutamyl-prolyl-tRNA synthetase 
  Gene Group 6 Enrichment Score: 5.633309410124588 
UNIPROT_ACC. Gene Name 
772506 annexin A11 
786439 annexin A4 
812167 annexin A3 
798403 annexin A7 
781694 annexin A8-like 1 
  Gene Group 7 Enrichment Score: 5.4859633365251055 
UNIPROT_ACC. Gene Name 
777280 adaptor-related protein complex 2, beta 1 subunit 
808517 coatomer protein complex, subunit gamma 
783723 clathrin, light chain (Lca) 
805919 coatomer protein complex, subunit beta 1 
786977 coatomer protein complex, subunit beta 2 (beta prime) 
783500 clathrin, heavy chain (Hc) 
787361 coatomer protein complex, subunit alpha 
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  Gene Group 8 Enrichment Score: 5.26772647379684 
UNIPROT_ACC. Gene Name 
813039 keratin 17; keratin 17 pseudogene 3 
799223 keratin 16; keratin type 16-like 
808606 keratin 15 
808801 keratin 5 
811716 keratin 9 
822924 keratin 10 
799307 keratin 2 
787776 keratin 14 
  Gene Group 9 Enrichment Score: 4.843686749790918 
UNIPROT_ACC. Gene Name 
799755 proteasome (prosome, macropain) 26S subunit, ATPase, 2 
792073 
proteasome (prosome, macropain) 26S subunit, ATPase, 1; 
similar to protease (prosome, macropain) 26S subunit, ATPase 1 
808209 proteasome (prosome, macropain) 26S subunit, ATPase, 5 
791833 proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 
824584 proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 
821110 proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 
823937 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 
823269 
similar to 26S protease regulatory subunit 6B (MIP224) (MB67-
interacting protein) (TAT-binding protein 7) (TBP-7);  
792471 proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 
793113 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 
  Gene Group 10 Enrichment Score: 4.781832033421352 
UNIPROT_ACC. Gene Name 
787313 sciellin 
820356 small proline-rich protein 2B 
780898 small proline-rich protein 2D 
815196 small proline-rich protein 1B (cornifin) 
819688 small proline-rich protein 1A 
  Gene Group 11 Enrichment Score: 4.584209456932841 
UNIPROT_ACC. Gene Name 
816672 
similar to eukaryotic translation initiation factor 4A2; eukaryotic 
translation initiation factor 4A, isoform 2 
822287 DEAH (Asp-Glu-Ala-His) box polypeptide 9 
810340 HLA-B associated transcript 1 
797679, 797679 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 
775919 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
  Gene Group 12 Enrichment Score: 4.131462722264355 
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UNIPROT_ACC. Gene Name 
797636 prominin 2 
816575 immunoglobulin superfamily, member 3 
792228 immunoglobulin superfamily, member 8 
819159 transmembrane 4 L six family member 1 
811214 
coxsackie virus and adenovirus receptor pseudogene 2; coxsackie 
virus and adenovirus receptor 
773473 tetraspanin 6 
792739 solute carrier family 38, member 1 
803407 
solute carrier family 1 (neutral amino acid transporter), member 
5 
784606 solute carrier family 29 (nucleoside transporters), member 1 
800440 tetraspanin 14 
774965 prostaglandin F2 receptor negative regulator 
784645 
solute carrier family 16, member 1 (monocarboxylic acid 
transporter 1) 
814490 tumor-associated calcium signal transducer 2 
781354 neuroplastin 
787321 
hypothetical protein LOC100133690; activated leukocyte cell 
adhesion molecule 
772273 solute carrier family 31 (copper transporters), member 1 
782895 CD82 molecule 
823595 F11 receptor 
789895 hyaluronan synthase 2 
805733 myelin protein zero-like 1 
793512 solute carrier family 6 (amino acid transporter), member 14 
814848 
solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4) 
776067 
carcinoembryonic antigen-related cell adhesion molecule 1 
(biliary glycoprotein) 
  Gene Group 13 Enrichment Score: 3.830074626339663 
UNIPROT_ACC. Gene Name 
790855 S100 calcium binding protein A2 
791568 S100 calcium binding protein A16 
778585 S100 calcium binding protein A14 
780609 S100 calcium binding protein P 
783621 S100 calcium binding protein A8 
  Gene Group 14 Enrichment Score: 1.96093420404786 
UNIPROT_ACC. Gene Name 
795255 ATPase, Na+/K+ transporting, beta 1 polypeptide 
799291 ATPase, Na+/K+ transporting, beta 3 polypeptide 
783032 ATPase, Na+/K+ transporting, alpha 1 polypeptide 
823049 ATPase, H+/K+ exchanging, alpha polypeptide 
777586 ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 
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786659 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 
799166 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 
  Gene Group 15 Enrichment Score: 1.2922447935702437 
UNIPROT_ACC. Gene Name 
773661 protease, serine, 1 (trypsin 1); trypsinogen C 
811699 protease, serine, 3 
805052, 805052 kallikrein-related peptidase 10 
783622 kallikrein-related peptidase 5 
796986 HtrA serine peptidase 1 
 
 
Appendix table 4.10: Collagen alpha 6 and integrin alpha 4 were exported from 
UniProt for Homo sapiens and Mus musculus (accessed date 16/06/2017). The 
red text indicates that proteins were detected in this current study 
Collagen alpha 6 
Human Mouse 
Entry Protein name Entry Protein name 
P12111 Collagen alpha-3(VI) chain Q04857 Collagen alpha-1(VI) chain 
P12110 Collagen alpha-2(VI) chain Q02788 Collagen alpha-2(VI) chain 
P12109 Collagen alpha-1(VI) chain A2AX52 Collagen alpha-4(VI) chain 
A6NMZ7 Collagen alpha-6(VI) chain A6H584 Collagen alpha-5(VI) chain  
D9ZGF2 Collagen, type VI, alpha 3 Q8C6K9 Collagen alpha-6(VI) chain 
E9PAL5 Collagen alpha-5(VI) chain E9PWQ3 Collagen, type VI, alpha 3 
E7ENL6 Collagen alpha-3(VI) chain J3QQ16 Collagen, type VI, alpha 3 
C9JH44 
Collagen alpha-2(VI) chain 
(Fragment) A0A087WS16 Collagen, type VI, alpha 3 
C9JNG9 
Collagen alpha-3(VI) chain 
(Fragment) O88493 
Type VI collagen alpha 3 
subunit 
A0A087X0S5 Collagen alpha-1(VI) chain D3YWD1 
Collagen, type VI, alpha 3 
(Fragment) 
I3L392 
Collagen alpha-3(VI) chain 
(Fragment) A0A087WQN9 
Collagen, type VI, alpha 3 
(Fragment) 
H0Y393 
Collagen alpha-5(VI) chain 
(Fragment) Q9Z0I9 Collagen alpha3(VI) (Fragment) 
H0Y9T2 
Collagen alpha-5(VI) chain 
(Fragment) Q05504 
Collagen alpha 3 chain type VI 
(Fragment) 
H0Y935 
Collagen alpha-5(VI) chain 
(Fragment) O88494 
Type VI collagen alpha 3 
subunit N7 domain (Fragment) 
H7C0M5 
Collagen alpha-2(VI) chain 
(Fragment) D3Z7D5 Collagen alpha-2(VI) chain 
H0YA33 
Collagen alpha-6(VI) chain 
(Fragment) E9Q6A6 Collagen alpha-6(VI) chain 
H0Y940 
Collagen alpha-6(VI) chain 
(Fragment) A0A140T8W1 Collagen alpha-5(VI) chain 
  
A0A140T8T7 Collagen alpha-5(VI) chain 
  
Q66K11 Col6a3 protein (Fragment) 
  
Q99K31 Col6a3 protein (Fragment) 
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Q80VJ0 Col6a3 protein 
  
B0LAD9 
Procollagen type VI alpha 1 
(Fragment) 
  
A0A1W2P6K8 
Collagen alpha-4(VI) chain 
(Fragment) 
 Integrein alpha 4 
Human Mouse 
Entry Protein names Entry Protein names 
P13612 
Integrin alpha-4 (CD49 
antigen-like family member 
D) (Integrin alpha-IV) (VLA-
4 subunit alpha) (CD antigen 
CD49d) Q00651 
Integrin alpha-4 (CD49 antigen-
like family member D) (Integrin 
alpha-IV) (Lymphocyte Peyer 
patch adhesion molecules 
subunit alpha) (LPAM subunit 
alpha) (VLA-4 subunit alpha) 
(CD antigen CD49d) 
E7EP60 Integrin alpha-4 (Fragment) Q792F9 
Alpha-4 integrin (Integrin alpha 
4) (Integrin alpha-4) (Integrin 
alpha-4 subunit) 
Q6PJE7 ITGA4 protein (Fragment) T2HRB1 Integrin alpha4B 
Q68EM9 ITGA4 protein Q6NV53 Integrin alpha 4 
A0A023IP86 
Integrin a4-subunit 
(Fragment) Q8BQ25 
Putative uncharacterized 
protein (Fragment) 
A0A023IPH8 Integrin a4 subunit (Fragment) Q3U0V9 
Putative uncharacterized protein 
(Fragment) 
A0A023IPI3 Integrin a4 subunit (Fragment) Q3U1F2 
Putative uncharacterized protein 
(Fragment) 
A0A023IQJ5 Integrin a4 subunit (Fragment) Q78E20 Alpha 4 integrin (Fragment) 
A0A023IPH2 Integrin a4 subunit (Fragment) Q3TAI7 Putative uncharacterized protein 
A0A023IP88 Integrin a4 subunit (Fragment) 
  A0A023IPA8 Integrin a4 subunit (Fragment) 
  A0A023IP90 Integrin a4 subunit (Fragment) 
  A0A023IQJ3 Integrin a4 subunit (Fragment) 
  Q13682 Alpha-4 integrin (Fragment) 
  A0A023IQK0 Integrin a4 subunit (Fragment) 
  A0A023IPA9 Integrin a4 subunit (Fragment) 
  A0A023IQA6 Integrin a4 subunit (Fragment) 
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Appendix table 5.1: Abundant levels of let-7 miRNAs common to both HaCaT- and primary keratinocyte-derived EVs 
 
miRNA	  name	  
	   	   Mean	  normalised	  read	  counts	  (RPM)	  ±	  SD	  
	   HaCaT	   Primary	  keratinocytes	  
AP	   MV	   EX	   p-­‐value	   AP	   MV	   EX	   p-­‐value	  
hsa-­‐let-­‐7a-­‐1-­‐3p	   148.0	  ±23.8	   129.1	  ±32.7	   253.8	  ±23.4	   0.035	   77.3	  ±28.2	   93.3	  ±73	   92.5	  ±42.2	   0.885	  
hsa-­‐let-­‐7a-­‐1-­‐5p	   16237.2	  
±2551.9	  
13012.4	  ±4160	   29576.1	  
±1171.1	  
0.020	   9749.1	  ±2630.1	   12851.6	  ±5257.5	   15927.9	  ±2496.8	   0.113	  
hsa-­‐let-­‐7a-­‐2-­‐5p	   16232.7	  
±2554.4	  
13018.9	  
±4176.8	  
29576.1	  
±1163.7	  
0.020	   9748.5	  ±2632.2	   12854.1	  ±5262.4	   15950.5	  ±2483.5	   0.111	  
hsa-­‐let-­‐7a-­‐3-­‐3p	   147.8	  ±24.1	   129.1	  ±32.7	   252.9	  ±24.6	   0.037	   77.3	  ±28.2	   93.3	  ±73	   92.5	  ±42.2	   0.885	  
hsa-­‐let-­‐7a-­‐3-­‐5p	   16243.1	  
±2557.4	  
13015.5	  
±4168.6	  
29613.48	  
±1183	  
0.021	   9747.0	  ±2635.3	   12857.3	  ±5251.6	   15964.9	  ±2508.5	   0.110	  
hsa-­‐let-­‐7b-­‐3p	   83.8	  ±15.2	   79.9	  ±17.1	   131.8	  ±47.3	   0.304	   56.5	  ±48.6	   72.4	  ±49.6	   112.1	  ±81.4	   0.455	  
hsa-­‐let-­‐7b-­‐5p	   5845.6	  
±1085.4	  
4539.3	  ±934.2	   4122.6	  ±327.6	   0.253	   5590.8	  ±1016.2	   3266.6	  ±638.2	   3420.0	  ±668.8	   0.004	  
hsa-­‐let-­‐7c-­‐5p	   167.3	  ±85.1	   313.8	  ±66.3	   372.1	  ±49.1	   0.117	   1040.1	  ±548.2	   1099.6	  ±355.9	   767.5	  ±291.4	   0.506	  
hsa-­‐let-­‐7d-­‐3p	   180.3	  ±7.7	   240.7	  ±115.1	   649.0	  ±147.4	   0.041	   157.5	  ±96.5	   276.3	  ±197.2	   387.5	  ±77.4	   0.105	  
hsa-­‐let-­‐7d-­‐5p	   1226.5	  ±197.2	   1266.3	  ±379.5	   1203.8	  ±4.9	   0.968	   569.4	  ±161.5	   714.3	  ±142	   675.7	  ±142.8	   0.4	  
hsa-­‐let-­‐7e-­‐3p	   11.3	  ±0.3	   9.3	  ±1.3	   21.0	  ±7.5	   0.140	   17.5	  ±19	   8.1	  ±5.5	   6.0	  ±7.9	   0.411	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Note: Statistical analysis was performed using one-way ANOVA (Statistical Analysis System program v9.3) for the abundance of three EVs 
released from one cell type.  
 
 
 
 
 
hsa-­‐let-­‐7e-­‐5p	   932.5	  ±30.5	   1130.0	  ±49.2	   1190.6	  ±225	   0.278	   1643.1	  ±270.7	   2589.8	  ±949.4	   2106.9	  ±288.2	   0.133	  
hsa-­‐let-­‐7f-­‐1-­‐3p	   33.6	  ±0.6	   29.5	  ±4.4	   39.8	  ±6.7	   0.227	   18.0	  ±25.7	   16.6	  ±15.3	   4.3	  ±5.1	   0.505	  
hsa-­‐let-­‐7f-­‐1-­‐5p	   24983.0	  
±5306.8	  
30334.9	  
±19507.5	  
35612.9	  
±629.3	  
0.694	   15256.8	  ±6114.6	   22351.6	  ±5770.8	   24868.0	  ±2259.9	   0.059	  
hsa-­‐let-­‐7f-­‐2-­‐5p	   26313.0	  
±5347.9	  
31921.8	  
±20195.9	  
37045.2	  
±646.8	  
0.704	   15842.8	  ±6265.8	   23269.1	  ±5794.5	   25633.1	  ±2166.9	   0.0559	  
hsa-­‐let-­‐7g-­‐5p	   3100.6	  ±354.7	   2807.3	  ±438.1	   2697.9	  ±549	   0.690	   2462.3	  ±382.5	   1861.9	  ±541.9	   1747.1	  ±180.7	   0.065	  
hsa-­‐let-­‐7i-­‐3p	   24.2	  ±5.8	   16.7	  ±4.7	   8.3	  ±6.8	   0.152	   60.7	  ±16	   94.7	  ±102.7	   21.1	  ±17.7	   0.281	  
hsa-­‐let-­‐7i-­‐5p	   5141.7	  ±101.1	   4884.5	  ±53.3	   3783.2	  ±743.9	   0.099	   11677.9	  ±2127.8	   7497.3	  ±1936.9	   6135.7	  ±948.636	   0.004	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Appendix table 5.2: List of 381 shared miRNAs between common miRNAs from 
HaCaT- and primary keratinocyte-derived EVs 
 
miRNA name 
hsa-let-7a-1-3p hsa-mir-16-2-3p hsa-mir-29b-2-3p hsa-mir-4520-1-3p 
hsa-let-7a-1-5p hsa-mir-16-2-5p hsa-mir-29c-3p hsa-mir-4520-2-3p 
hsa-let-7a-2-5p hsa-mir-17-3p hsa-mir-29c-5p hsa-mir-454-3p 
hsa-let-7a-3-3p hsa-mir-17-5p hsa-mir-301a-3p hsa-mir-454-5p 
hsa-let-7a-3-5p hsa-mir-181a-1-3p hsa-mir-301b-3p hsa-mir-455-3p 
hsa-let-7b-3p hsa-mir-181a-1-5p hsa-mir-3065-3p hsa-mir-455-5p 
hsa-let-7b-5p hsa-mir-181a-2-3p hsa-mir-3065-5p hsa-mir-4775 
hsa-let-7c-5p hsa-mir-181a-2-5p hsa-mir-30a-3p hsa-mir-4792 
hsa-let-7d-3p hsa-mir-181b-1-5p hsa-mir-30a-5p hsa-mir-484 
hsa-let-7d-5p hsa-mir-181b-2-5p hsa-mir-30b-5p hsa-mir-486-1-5p 
hsa-let-7e-3p hsa-mir-181c-3p hsa-mir-30c-1-3p hsa-mir-486-2-5p 
hsa-let-7e-5p hsa-mir-181c-5p hsa-mir-30c-1-5p hsa-mir-487b-3p 
hsa-let-7f-1-3p hsa-mir-181d-5p hsa-mir-30c-2-3p hsa-mir-493-3p 
hsa-let-7f-1-5p hsa-mir-182-5p hsa-mir-30c-2-5p hsa-mir-493-5p 
hsa-let-7f-2-5p hsa-mir-183-3p hsa-mir-30d-3p hsa-mir-497-5p 
hsa-let-7g-5p hsa-mir-183-5p hsa-mir-30d-5p hsa-mir-500a-3p 
hsa-let-7i-3p hsa-mir-184 hsa-mir-30e-3p hsa-mir-501-3p 
hsa-let-7i-5p hsa-mir-185-5p hsa-mir-30e-5p hsa-mir-502-3p 
hsa-mir-100-3p hsa-mir-186-5p hsa-mir-31-3p hsa-mir-505-3p 
hsa-mir-100-5p hsa-mir-188-5p hsa-mir-31-5p hsa-mir-509-1-3p 
hsa-mir-101-1-3p hsa-mir-18a-3p hsa-mir-3158-1-3p hsa-mir-509-2-3p 
hsa-mir-101-2-3p hsa-mir-18a-5p hsa-mir-3158-2-3p hsa-mir-509-3-3p 
hsa-mir-103a-1-3p hsa-mir-190a-5p hsa-mir-3176 hsa-mir-5096 
hsa-mir-103a-2-3p hsa-mir-191-5p hsa-mir-3178 hsa-mir-5100 
hsa-mir-106b-3p hsa-mir-1910-5p hsa-mir-3195 hsa-mir-532-3p 
hsa-mir-106b-5p hsa-mir-192-5p hsa-mir-3196 hsa-mir-532-5p 
hsa-mir-107 hsa-mir-193a-3p hsa-mir-32-5p hsa-mir-542-3p 
hsa-mir-10a-5p hsa-mir-193b-3p hsa-mir-320a hsa-mir-548e-3p 
hsa-mir-10b-5p hsa-mir-193b-5p hsa-mir-320b-1 hsa-mir-548k 
hsa-mir-1180-3p hsa-mir-194-1-5p hsa-mir-320b-2 hsa-mir-548o-2-3p 
hsa-mir-1246 hsa-mir-194-2-5p hsa-mir-320c-1 hsa-mir-548o-3p 
hsa-mir-125a-3p hsa-mir-195-5p hsa-mir-320c-2 hsa-mir-550a-1-3p 
hsa-mir-125a-5p hsa-mir-196a-1-5p hsa-mir-324-3p hsa-mir-550a-2-3p 
hsa-mir-125b-1-3p hsa-mir-196a-2-5p hsa-mir-324-5p hsa-mir-550a-3-3p 
hsa-mir-125b-1-5p hsa-mir-196b-5p hsa-mir-328-3p hsa-mir-5585-3p 
hsa-mir-125b-2-3p hsa-mir-197-3p hsa-mir-330-3p hsa-mir-561-5p 
hsa-mir-125b-2-5p hsa-mir-199a-1-3p hsa-mir-330-5p hsa-mir-574-3p 
hsa-mir-126-3p hsa-mir-199a-1-5p hsa-mir-331-3p hsa-mir-574-5p 
hsa-mir-126-5p hsa-mir-199a-2-3p hsa-mir-331-5p hsa-mir-576-5p 
hsa-mir-1260a hsa-mir-199a-2-5p hsa-mir-335-5p hsa-mir-582-3p 
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hsa-mir-1260b hsa-mir-199b-3p hsa-mir-339-3p hsa-mir-582-5p 
hsa-mir-1268a hsa-mir-199b-5p hsa-mir-339-5p hsa-mir-584-5p 
hsa-mir-1268b hsa-mir-19a-3p hsa-mir-33a-5p hsa-mir-589-3p 
hsa-mir-127-3p hsa-mir-19b-1-3p hsa-mir-33b-5p hsa-mir-589-5p 
hsa-mir-1271-5p hsa-mir-19b-2-3p hsa-mir-340-5p hsa-mir-590-3p 
hsa-mir-1273g-3p hsa-mir-200a-3p hsa-mir-342-3p hsa-mir-598-3p 
hsa-mir-1275 hsa-mir-200a-5p hsa-mir-345-5p hsa-mir-6087 
hsa-mir-1277-5p hsa-mir-200b-3p hsa-mir-34a-5p hsa-mir-615-3p 
hsa-mir-128-1-3p hsa-mir-200b-5p hsa-mir-34c-5p hsa-mir-619-5p 
hsa-mir-128-2-3p hsa-mir-200c-3p hsa-mir-361-3p hsa-mir-627-3p 
hsa-mir-1285-1-3p hsa-mir-203a-3p hsa-mir-361-5p hsa-mir-629-5p 
hsa-mir-1285-1-5p hsa-mir-203a-5p hsa-mir-3614-5p hsa-mir-641 
hsa-mir-1285-2-3p hsa-mir-203b-3p hsa-mir-3615 hsa-mir-6499-5p 
hsa-mir-1290 hsa-mir-205-3p hsa-mir-362-5p hsa-mir-651-5p 
hsa-mir-1293 hsa-mir-205-5p hsa-mir-3656 hsa-mir-6510-3p 
hsa-mir-1296-5p hsa-mir-20a-5p hsa-mir-365a-3p hsa-mir-652-3p 
hsa-mir-1301-3p hsa-mir-21-3p hsa-mir-365b-3p hsa-mir-654-3p 
hsa-mir-1304-3p hsa-mir-21-5p hsa-mir-369-3p hsa-mir-660-5p 
hsa-mir-1307-3p hsa-mir-210-3p hsa-mir-374a-3p hsa-mir-664a-3p 
hsa-mir-1307-5p hsa-mir-210-5p hsa-mir-374a-5p hsa-mir-665 
hsa-mir-130a-3p hsa-mir-2110 hsa-mir-374b-5p hsa-mir-671-3p 
hsa-mir-130b-3p hsa-mir-2116-3p hsa-mir-375 hsa-mir-7-1-3p 
hsa-mir-132-3p hsa-mir-212-3p hsa-mir-376a-1-5p hsa-mir-708-3p 
hsa-mir-132-5p hsa-mir-215-5p hsa-mir-378a-3p hsa-mir-708-5p 
hsa-mir-135b-3p hsa-mir-218-1-5p hsa-mir-378c hsa-mir-744-5p 
hsa-mir-135b-5p hsa-mir-218-2-5p hsa-mir-378d-1 hsa-mir-7641-1 
hsa-mir-136-3p hsa-mir-22-3p hsa-mir-378d-2 hsa-mir-7641-2 
hsa-mir-138-1-3p hsa-mir-22-5p hsa-mir-378e hsa-mir-769-5p 
hsa-mir-138-1-5p hsa-mir-221-3p hsa-mir-378i hsa-mir-7704 
hsa-mir-138-2-5p hsa-mir-221-5p hsa-mir-381-3p hsa-mir-7706 
hsa-mir-140-3p hsa-mir-222-3p hsa-mir-3909 hsa-mir-7977 
hsa-mir-140-5p hsa-mir-222-5p hsa-mir-3960 hsa-mir-873-5p 
hsa-mir-141-3p hsa-mir-224-3p hsa-mir-409-3p hsa-mir-874-3p 
hsa-mir-141-5p hsa-mir-224-5p hsa-mir-410-3p hsa-mir-877-5p 
hsa-mir-142-5p hsa-mir-2355-5p hsa-mir-411-5p hsa-mir-92a-1-3p 
hsa-mir-143-3p hsa-mir-23a-3p hsa-mir-421 hsa-mir-92a-2-3p 
hsa-mir-145-3p hsa-mir-23b-3p hsa-mir-423-3p hsa-mir-92b-3p 
hsa-mir-145-5p hsa-mir-24-1-3p hsa-mir-423-5p hsa-mir-93-3p 
hsa-mir-146a-5p hsa-mir-24-2-3p hsa-mir-424-3p hsa-mir-93-5p 
hsa-mir-146b-5p hsa-mir-24-2-5p hsa-mir-424-5p hsa-mir-941-1 
hsa-mir-147b hsa-mir-25-3p hsa-mir-425-3p hsa-mir-941-2 
hsa-mir-148a-3p hsa-mir-25-5p hsa-mir-425-5p hsa-mir-941-3 
hsa-mir-148a-5p hsa-mir-26a-1-5p hsa-mir-4286 hsa-mir-941-4 
hsa-mir-148b-3p hsa-mir-26a-2-5p hsa-mir-429 hsa-mir-941-5 
hsa-mir-148b-5p hsa-mir-26b-3p hsa-mir-431-5p hsa-mir-942-5p 
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hsa-mir-149-5p hsa-mir-26b-5p hsa-mir-432-5p hsa-mir-944 
hsa-mir-151a-3p hsa-mir-27a-3p hsa-mir-4448 hsa-mir-95-3p 
hsa-mir-151a-5p hsa-mir-27a-5p hsa-mir-4454 hsa-mir-96-5p 
hsa-mir-151b hsa-mir-27b-3p hsa-mir-4485-3p hsa-mir-98-3p 
hsa-mir-152-3p hsa-mir-27b-5p hsa-mir-4492 hsa-mir-98-5p 
hsa-mir-152-5p hsa-mir-28-3p hsa-mir-4508 hsa-mir-99a-5p 
hsa-mir-155-5p hsa-mir-28-5p hsa-mir-450a-1-5p hsa-mir-99b-3p 
hsa-mir-15a-5p hsa-mir-296-3p hsa-mir-450a-2-5p hsa-mir-99b-5p 
hsa-mir-15b-3p hsa-mir-29a-3p hsa-mir-450b-5p 
 hsa-mir-15b-5p hsa-mir-29a-5p hsa-mir-4516 
 hsa-mir-16-1-5p hsa-mir-29b-1-3p hsa-mir-452-5p 
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Appendix table 5.3: List of exosomal miRNAs from HaCaT-derived EXs 
reported the first time herein  
 
Novel miRNA from HaCaT-derived EXs 
hsa-mir-1226-3p hsa-mir-3942-5p hsa-mir-514a-3-3p hsa-mir-6501-5p 
hsa-mir-1244-2 hsa-mir-425-3p hsa-mir-548aa-1 hsa-mir-651-5p 
hsa-mir-1244-3 hsa-mir-425-5p hsa-mir-548aa-2 hsa-mir-6510-3p 
hsa-mir-1244-4 hsa-mir-4301 hsa-mir-548ab hsa-mir-6511a-1-3p 
hsa-mir-1253 hsa-mir-4435-1 hsa-mir-548ae-2-5p hsa-mir-6511a-2-3p 
hsa-mir-1254-1 hsa-mir-4435-2 hsa-mir-548aj-2-5p hsa-mir-6511a-3-3p 
hsa-mir-1254-2 hsa-mir-4444-1 hsa-mir-548am-3p hsa-mir-6511a-4-3p 
hsa-mir-1255a hsa-mir-4444-2 hsa-mir-548am-5p hsa-mir-6513-3p 
hsa-mir-1260a hsa-mir-4449 hsa-mir-548aq-3p hsa-mir-6516-3p 
hsa-mir-1273a hsa-mir-4459 hsa-mir-548ar-5p hsa-mir-663a 
hsa-mir-1273d hsa-mir-4477b hsa-mir-548au-5p hsa-mir-6716-3p 
hsa-mir-1273e hsa-mir-4479 hsa-mir-548av-3p hsa-mir-6719-3p 
hsa-mir-1273f hsa-mir-4485-3p hsa-mir-548ay-5p hsa-mir-6720-3p 
hsa-mir-1286 hsa-mir-449b-5p hsa-mir-548d-1-5p hsa-mir-6720-5p 
hsa-mir-129 hsa-mir-449c-5p hsa-mir-548d-2-5p hsa-mir-6723-5p 
hsa-mir-1296-3p hsa-mir-4504 hsa-mir-548e-3p hsa-mir-6724-1-5p 
hsa-mir-1303 hsa-mir-4505 hsa-mir-548e-5p hsa-mir-6724-2-5p 
hsa-mir-1343-3p hsa-mir-450a-2-5p hsa-mir-548f-1-3p hsa-mir-6724-3-5p 
hsa-mir-1469 hsa-mir-4511 hsa-mir-548f-1-5p hsa-mir-6724-4-5p 
hsa-mir-1908-3p hsa-mir-4516 hsa-mir-548f-2-3p hsa-mir-6735-5p 
hsa-mir-23c hsa-mir-4520-1-3p hsa-mir-548f-3-3p hsa-mir-6737-3p 
hsa-mir-301b-3p hsa-mir-4520-2-3p hsa-mir-548f-4-3p hsa-mir-6754-3p 
hsa-mir-3065-3p hsa-mir-4633-3p hsa-mir-548g-5p hsa-mir-6767-5p 
hsa-mir-3127-5p hsa-mir-4636 hsa-mir-548h-1-5p hsa-mir-6777-5p 
hsa-mir-3130-1-3p hsa-mir-4639-5p hsa-mir-548h-2-5p hsa-mir-6796-5p 
hsa-mir-3130-2-3p hsa-mir-4661-5p hsa-mir-548h-3-5p hsa-mir-6807-5p 
hsa-mir-3142 hsa-mir-4666a-5p hsa-mir-548h-4-3p hsa-mir-6824-3p 
hsa-mir-3142_var2 hsa-mir-4676-3p hsa-mir-548h-4-5p hsa-mir-6829-5p 
hsa-mir-3157-3p hsa-mir-4677-3p hsa-mir-548h-5-5p hsa-mir-6836-5p 
hsa-mir-3158-1-3p hsa-mir-4677-5p hsa-mir-548o-2-3p hsa-mir-6869-5p 
hsa-mir-3158-2-3p hsa-mir-4686 hsa-mir-548o-2-5p hsa-mir-6894-5p 
hsa-mir-3159 hsa-mir-4691-5p hsa-mir-548p hsa-mir-7-1-5p 
hsa-mir-3160-1-3p hsa-mir-4697-3p hsa-mir-548x-5p hsa-mir-7-2-5p 
hsa-mir-3160-2-3p hsa-mir-4709-3p hsa-mir-550 hsa-mir-7-3-5p 
hsa-mir-3166 hsa-mir-4709-5p hsa-mir-556-3p hsa-mir-7161-5p 
hsa-mir-3178 hsa-mir-4714-3p hsa-mir-556-5p hsa-mir-7641-1 
hsa-mir-3195 hsa-mir-4717-3p hsa-mir-5579-3p hsa-mir-7641-2 
hsa-mir-3196 hsa-mir-4738-3p hsa-mir-5585-3p hsa-mir-7703 
hsa-mir-320e hsa-mir-4741 hsa-mir-561-5p hsa-mir-7847-3p 
hsa-mir-3651 hsa-mir-4746-5p hsa-mir-5699-3p hsa-mir-7975 
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hsa-mir-3684 hsa-mir-4755-3p hsa-mir-5700 hsa-mir-7976 
hsa-mir-3687-1 hsa-mir-4775 hsa-mir-5701-1 hsa-mir-7977 
hsa-mir-3687-2 hsa-mir-4797-3p hsa-mir-5701-2 hsa-mir-8061 
hsa-mir-376a-1-5p hsa-mir-4800-3p hsa-mir-5701-3 hsa-mir-9 
hsa-mir-378d-2 hsa-mir-486 hsa-mir-580-3p hsa-mir-934 
hsa-mir-378h hsa-mir-4999-5p hsa-mir-598-3p hsa-mir-937-3p 
hsa-mir-378i hsa-mir-509-1-3p hsa-mir-600 hsa-mir-937-5p 
hsa-mir-3912-3p hsa-mir-509-2-3p hsa-mir-619-5p hsa-mir-941-1 
hsa-mir-3928-3p hsa-mir-509-3-3p hsa-mir-627-3p hsa-mir-941-2 
hsa-mir-3934-5p hsa-mir-5095 hsa-mir-627-5p hsa-mir-941-3 
hsa-mir-3935 hsa-mir-5096 hsa-mir-636 hsa-mir-941-4 
hsa-mir-3940-3p hsa-mir-514a-1-3p hsa-mir-643 hsa-mir-941-5 
hsa-mir-3942-3p hsa-mir-514a-2-3p hsa-mir-6499-5p hsa-mir-944 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 316 Appendices 
Appendix table 5.4: List of exosomal miRNAs from primary keratinocyte-
derived EXs reported the first time herein  
 
Primary keratinocyte-derived Exs 
hsa-mir-1199-5p hsa-mir-3648-1 hsa-mir-4743-3p hsa-mir-6511a-2-3p 
hsa-mir-1253 hsa-mir-3648-2 hsa-mir-4775 hsa-mir-6511a-3-3p 
hsa-mir-1254-1 hsa-mir-3687-1 hsa-mir-486 hsa-mir-6511a-4-3p 
hsa-mir-1254-2 hsa-mir-3687-2 hsa-mir-5001-3p hsa-mir-6511b-1-5p 
hsa-mir-1260a hsa-mir-3688-1-3p hsa-mir-509-1-3p hsa-mir-6511b-2-5p 
hsa-mir-1273d hsa-mir-3688-2-3p hsa-mir-509-2-3p hsa-mir-6513-3p 
hsa-mir-1273e hsa-mir-3692-5p hsa-mir-509-3-3p hsa-mir-6724-1-5p 
hsa-mir-1273f hsa-mir-376a-1-5p hsa-mir-5095 hsa-mir-6724-2-5p 
hsa-mir-1273h-5p hsa-mir-378d-2 hsa-mir-5096 hsa-mir-6724-3-5p 
hsa-mir-1286 hsa-mir-378i hsa-mir-548am-5p hsa-mir-6724-4-5p 
hsa-mir-129 hsa-mir-3912-3p hsa-mir-548au-5p hsa-mir-6753-3p 
hsa-mir-1303 hsa-mir-3928-3p hsa-mir-548ba hsa-mir-6787-3p 
hsa-mir-134-5p hsa-mir-3929 hsa-mir-548e-3p hsa-mir-6824-3p 
hsa-mir-1469 hsa-mir-425-3p hsa-mir-548e-5p hsa-mir-6840-5p 
hsa-mir-1972-1 hsa-mir-425-5p hsa-mir-548h-4-3p hsa-mir-6866-5p 
hsa-mir-1972-2 hsa-mir-4435-1 hsa-mir-548o-2-3p hsa-mir-6886-5p 
hsa-mir-301b-3p hsa-mir-4435-2 hsa-mir-548o-2-5p hsa-mir-6887-5p 
hsa-mir-3065-3p hsa-mir-4459 hsa-mir-548u hsa-mir-7641-1 
hsa-mir-3130-1-3p hsa-mir-4485-3p hsa-mir-550 hsa-mir-7641-2 
hsa-mir-3130-2-3p hsa-mir-4505 hsa-mir-5585-3p hsa-mir-7703 
hsa-mir-3130-2-5p hsa-mir-450a-2-5p hsa-mir-561-5p hsa-mir-7851-3p 
hsa-mir-3155b hsa-mir-4512 hsa-mir-5680 hsa-mir-7854-3p 
hsa-mir-3158-1-3p hsa-mir-4516 hsa-mir-5700 hsa-mir-7975 
hsa-mir-3158-2-3p hsa-mir-4520-1-3p hsa-mir-5701-1 hsa-mir-7976 
hsa-mir-3166 hsa-mir-4520-2-3p hsa-mir-5701-2 hsa-mir-7977 
hsa-mir-3178 hsa-mir-4527 hsa-mir-5701-3 hsa-mir-8061 
hsa-mir-3180-1 hsa-mir-4532 hsa-mir-598-3p hsa-mir-889-3p 
hsa-mir-3180-1-3p hsa-mir-4642 hsa-mir-6126 hsa-mir-934 
hsa-mir-3180-2 hsa-mir-4661-3p hsa-mir-619-5p hsa-mir-937-3p 
hsa-mir-3180-2-3p hsa-mir-4677-3p hsa-mir-627-3p hsa-mir-937-5p 
hsa-mir-3180-3 hsa-mir-4697-3p hsa-mir-627-5p hsa-mir-941-1 
hsa-mir-3180-3-3p hsa-mir-4700-3p hsa-mir-642a-3p hsa-mir-941-2 
hsa-mir-3180-4 hsa-mir-4700-5p hsa-mir-642a-5p hsa-mir-941-3 
hsa-mir-3180-4-3p hsa-mir-4707-5p hsa-mir-6499-5p hsa-mir-941-4 
hsa-mir-3180-5 hsa-mir-4709-3p hsa-mir-6501-5p hsa-mir-941-5 
hsa-mir-3180-5-3p hsa-mir-4709-5p hsa-mir-651-5p hsa-mir-944 
hsa-mir-3195 hsa-mir-4717-3p hsa-mir-6510-3p 
 hsa-mir-3196 hsa-mir-4741 hsa-mir-6511a-1-3p 
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Appendix table 5.5: List of genes regulated by hsa-miR-181a-1-5p 
 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 IRAK1BP1 132 MRPS14 263 SUV39H2 394 SORT1 
2 TOPBP1 133 SRPK2 264 ZNF136 395 SRGN 
3 CSNK1A1 134 BTBD3 265 LRRC8D 396 SSX2IP 
4 ETS1 135 ANKRD1 266 RNMT 397 STAG1 
5 NLK 136 DNAJC7 267 TTPAL 398 STX2 
6 GATA6 137 TMEM257 268 NCOA3 399 TBL1XR1 
7 CDX2 138 SLCO2A1 269 KIF3B 400 TBC1D13 
8 PLAG1 139 HERC3 270 CENPO 401 TBC1D7 
9 UNC5B 140 HMGB2 271 RLIM 402 TFRC 
10 VCAM1 141 TAAR6 272 BCL2 403 TMEM30A 
11 LAPTM4B 142 CFI 273 PROX1 404 TMF1 
12 NOTCH1 143 IDS 274 ZNF846 405 TNRC6B 
13 HMGA2 144 FRA10AC1 275 PPAP2B 406 TSG101 
14 TEF 145 TMEM14A 276 FAM3C 407 TUBB 
15 TUBB2A 146 TAF2 277 PRKCD 408 ULK1 
16 TNPO1 147 DCST1 278 FNDC3B 409 ZBTB4 
17 ZNF23 148 ZNF562 279 RNF187 410 ZNF664 
18 AP3M2 149 COL27A1 280 ZNF597 411 ZNF121 
19 PTPDC1 150 EPHA5 281 PAPD5 412 EN2 
20 CAPRIN2 151 CHL1 282 PEBP1 413 DCAF4 
21 CBX4 152 EYA4 283 PRRC2C 414 PGR 
22 GTPBP3 153 WNT16 284 ARSJ 415 TIMP1 
23 ZNF449 154 CST5 285 CUL5 416 PBX3 
24 SIK2 155 SH3BGRL 286 IPO5 417 COL16A1 
25 TEAD4 156 GPR137B 287 PNRC2 418 ZNF487P 
26 KLHL15 157 OFCC1 288 ZNF616 419 HSP90B1 
27 BRCA1 158 IQCG 289 RCOR1 420 ZNF699 
28 PRRC2B 159 OTX2 290 KIF2C 421 SLC35G3 
29 KIAA0100 160 NKX3-2 291 SPIRE1 422 ZNF667 
30 SOGA2 161 ROPN1L 292 ZNF415 423 ZNF781 
31 MGAT5 162 CCNG1 293 CHD9 424 ZNF788 
32 PPP1R9A 163 NRP1 294 RNF6 425 RAP1B 
33 TNIP1 164 FAM47B 295 PMAIP1 426 E2F5 
34 ZFP36L2 165 FBXO33 296 FKBP1A 427 ZNF669 
35 PGD 166 ATP6V0E1 297 GPR78 428 SCN8A 
36 UCHL1 167 OTUD1 298 KIAA1551 429 SLC35G2 
37 AP1M1 168 BRMS1L 299 TMCC1 430 GOLGA1 
38 GANAB 169 H1F0 300 SPTLC3 431 GNS 
39 PABPC1 170 ARHGAP12 301 SLC25A25 432 GOT1 
40 AKAP12 171 SPRY2 302 ZNF83 433 GOLGA8A 
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41 H2AFY 172 TGFBR3 303 ZNF556 434 GK5 
42 PHPT1 173 GPRIN3 304 MTX3 435 IL1A 
43 TMEM192 174 TRIM2 305 SCAMP2 436 INO80D 
44 HDAC6 175 MAP2K1 306 KLF6 437 HIST1H3D 
45 HUWE1 176 TMED4 307 FOS 438 HECW2 
46 LAMA3 177 PUM1 308 MTMR3 439 EED 
47 UBA2 178 FAM96A 309 FKBP1C 440 EPS15 
48 FAT1 179 FBXO28 310 RPS6KA3 441 FAM58A 
49 DDX27 180 PTGS2 311 MCL1 442 FSD1L 
50 HNRNPAB 181 ANKRD13C 312 XIAP 443 G3BP2 
51 ND2 182 RLF 313 SIRT1 444 ELMSAN1 
52 OCA2 183 LYSMD3 314 RALA 445 GSKIP 
53 PFKFB2 184 CCDC6 315 RNF2 446 C11orf30 
54 SMG1 185 BAG2 316 WHSC1 447 TGFBRAP1 
55 STAG2 186 GPR83 317 KIAA0195 448 TNFRSF11B 
56 RPS8 187 CLUAP1 318 ZNF440 449 TGFBR1 
57 FAM222B 188 INCENP 319 ZNF439 450 PCDHAC2 
58 HOOK3 189 LPGAT1 320 PTPN22 451 PCDHAC1 
59 KCTD2 190 OR11A1 321 PTPN11 452 CCL22 
60 RPL14 191 FKBP10 322 DUSP6 453 CCDC88C 
61 MAZ 192 SMCHD1 323 DUSP5 454 CLCC1 
62 ZEB2 193 NOL4 324 DRAM1 455 CPEB4 
63 PTBP3 194 SIX6 325 PRAP1 456 CPOX 
64 ZNF268 195 S100A1 326 ZNF791 457 APOL6 
65 ELK4 196 PLA2G4C 327 KRBOX4 458 ACYP1 
66 PDK3 197 FAM160A2 328 ZNF253 459 ALDH9A1 
67 KLHL24 198 NUPL1 329 HRAS 460 AFF4 
68 HIGD2A 199 SCD 330 BCL2L11 461 ASB1 
69 ID4 200 H3F3B 331 DDIT4 462 ARRB2 
70 CARM1 201 GATAD2B 332 ATM 463 ARRDC3 
71 LDLR 202 LGALSL 333 HIPK2 464 ATG2B 
72 FOXL1 203 TGIF2 334 ZNF763 465 ATP2B1 
73 ADAM17 204 MOB1A 335 RSF1 466 BAZ2A 
74 ZFAND6 205 SLC35B4 336 ZFP69B 467 PCDHA1 
75 DAZAP2 206 ZNF35 337 ZNF844 468 PCDHA10 
76 ATP8B1 207 PITPNB 338 ZNF780B 469 PCDHA13 
77 RBM25 208 ZNF350 339 TLDC1 470 PCDHA2 
78 ZFP36L1 209 TIAL1 340 AP5M1 471 PCDHA11 
79 AFTPH 210 LCLAT1 341 NCOA7 472 PCDHA12 
80 NOTCH2 211 KIAA1462 342 ZNF266 473 PCDHA5 
81 NFYB 212 RNF34 343 KAT2B 474 PCDHA6 
82 ZNF148 213 ZNF426 344 HFM1 475 PCDHA3 
83 KRAS 214 FSIP1 345 CDKN1B 476 PCDHA4 
84 LBR 215 GSTM2 346 CHMP2B 477 PCDHA7 
85 GIGYF1 216 PTPLAD1 347 ABCG2 478 PCDHA8 
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86 TMEM132B 217 PROSC 348 NPM3 479 PDGFRA 
87 KLHDC5 218 PHOX2A 349 MAN1A2 480 TAB3 
88 C2orf69 219 TCF21 350 LMAN1 481 PDAP1 
89 ATXN7 220 PRR4 351 MRPL34 482 MAPK1IP1L 
90 SEPT2 221 ATF7IP2 352 UBL3 483 BMP3 
91 GNAI3 222 KBTBD3 353 SRGAP1 484 SOX5 
92 TAB2 223 KCTD3 354 PHLDA1 485 MAP3K3 
93 SRSF7 224 FXYD6 355 MOSPD1 486 SMAD2 
94 DDX3X 225 ZNF558 356 PHACTR2 487 MADD 
95 TMEM64 226 TSHR 357 SASH1 488 BMPR2 
96 MOB1B 227 CHRFAM7A 358 PHACTR4 489 MAP4K4 
97 YOD1 228 LRRC17 359 EREG 490 MMP14 
98 SLC37A3 229 RASSF6 360 RGS5 491 MAP3K10 
99 NR6A1 230 CD46 361 TERT 492 PCDHB6 
100 ATP8A1 231 C8A 362 IFNG 493 CDH13 
101 ZNF445 232 ARL6IP6 363 STAT3 494 ACAN 
102 TM9SF3 233 ATG10 364 AHR 495 BLOC1S2 
103 FBXO11 234 WNT2 365 PDIA6 496 PURB 
104 ZNF594 235 NMRK2 366 XPNPEP3 497 RAB2B 
105 PLCL2 236 GCNT1 367 WIF1 498 NIN 
106 PRLR 237 RTEL1-TNFRSF6B 368 TWIST1 499 NMT2 
107 ZNF12 238 ZNF652 369 FKBP14 500 FAM192A 
108 HSPA13 239 PRDX3 370 WDR72 501 NAA50 
109 METAP1 240 ZNF25 371 ZNF829 502 NCAPG 
110 COPS2 241 ENAH 372 MAPK1 503 CD4 
111 NUDT12 242 PCDHB8 373 ZDHHC15 504 MTUS1 
112 SLC7A11 243 WNT3A 374 GJB7 505 PPP3CA 
113 SNAI2 244 PTPRZ1 375 HEPHL1 506 ATG5 
114 C1QTNF9 245 LRRN3 376 EPS8 507 MPP5 
115 FBXO34 246 TUSC1 377 CCNK 508 KMT2E 
116 MOB3B 247 ARF6 378 DGS2 509 PER2 
117 KLRC4 248 TMEM45A 379 ZC3HAV1L 510 PGAP1 
118 TBX4 249 C1orf109 380 PNKD 511 PBRM1 
119 FKBP7 250 PLXDC2 381 NHLRC3 512 OSBPL3 
120 TMPRSS11A 251 TAF15 382 C12orf29 513 KDM5A 
121 UGT3A1 252 LFNG 383 RGS16 514 EFCAB14 
122 GADD45G 253 ZBTB33 384 RHOG 515 KIAA0196 
123 HSD17B3 254 SLC25A37 385 RAN 516 KPNA1 
124 DSCR8 255 CHCHD7 386 RP2 517 DDX52 
125 BPGM 256 RSBN1L 387 SLC7A1 518 DYNC1LI2 
126 AMMECR1 257 ZADH2 388 SLC38A2 519 LPCAT1 
127 USP28 258 ADRBK1 389 SLC19A2 520 LONRF1 
128 KIAA0101 259 ZNF107 390 SLC10A7 521 PHC3 
129 ACOT12 260 FAM13A 391 SIPA1L1 522 PHOX2B 
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130 MTMR12 261 PPP2R5E 392 SHOC2 523 HSPA1B 
131 HEY2 262 FAM73B 393 SMCR8 
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Appendix table 5.6: List of genes regulated by hsa-miR-21-5p 
 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 RASGRP1 146 EPHA4 291 TMEM56 435 TGFBR2 
2 ATRX 147 ELOVL4 292 ZADH2 436 FMOD 
3 LMBR1 148 TBL1XR1 293 DDX3X 437 E2F2 
4 PM20D2 149 ENAH 294 ZNF217 438 RECK 
5 CLIP4 150 TAF5 295 FAM217B 439 SOX5 
6 DMTF1 151 NBEA 296 ZBTB20 440 MTAP 
7 DDX46 152 SESTD1 297 FNBP1 441 TIMP3 
8 FOXN3 153 HPS5 298 ZFYVE16 442 ZCCHC3 
9 NR2C2 154 PIGN 299 DMD 443 RHOB 
10 FBXO3 155 KIAA1551 300 TMX4 444 SERPINB5 
11 GPAM 156 SLAIN2 301 CCT6P1 445 PDCD4 
12 ZNF35 157 CYBRD1 302 UBR3 446 SEPT2 
13 MBNL1 158 RAPH1 303 PTBP3 447 ATXN10 
14 MORC3 159 RRAGC 304 APOLD1 448 SESN1 
15 ZNF367 160 GTF2A1 305 CSNK1A1 449 SOCS5 
16 TMEM245 161 SOX2 306 ACTR2 450 BTG2 
17 MALT1 162 FUBP1 307 NEK1 451 HIPK3 
18 PLEKHA1 163 SNRNP48 308 DYNC1LI2 452 FAM3C 
19 TRPM7 164 TGFB1 309 PTK2 453 FAS 
20 GID4 165 HNRNPH1 310 PAG1 454 SGK3 
21 SUZ12 166 SCAF11 311 SFXN1 455 RP2 
22 SPIN1 167 CERS6 312 HAPLN1 456 CDK6 
23 POLR3B 168 PARP1 313 EIF5 457 GLCCI1 
24 ATP2B4 169 VEGFA 314 GPD2 458 APAF1 
25 CCDC34 170 REV3L 315 SSFA2 459 SLC16A10 
26 PGRMC2 171 TXLNG2P 316 HECTD1 460 FGFRL1 
27 RAB22A 172 MMP2 317 TOP2A 461 PLEKHA8 
28 SASH1 173 GNB4 318 SEC63 462 C10orf137 
29 TRIM2 174 MEIS1 319 STRBP 463 TMEM170A 
30 PHF16 175 KBTBD7 320 PRKCE 464 ATF7IP 
31 ELOVL7 176 RMND5A 321 SLC5A3 465 PER2 
32 LONRF2 177 CPEB3 322 GPD1L 466 MAP2K3 
33 EIF4EBP2 178 CD47 323 VPS13A 467 WSB1 
34 GOLGA4 179 LATS1 324 B3GALNT1 468 RNF6 
35 MTPN 180 UBR5 325 TAF1 469 TCF21 
36 ZMYM2 181 DCAF8 326 MPP5 470 UQCRB 
37 TGFB2 182 WDR7 327 KLHL15 471 SMAD7 
38 RAPGEF6 183 FAM126B 328 DUSP8 472 ZNF460 
39 TRIM33 184 PTGFR 329 LRRC57 473 RPRD2 
40 PRICKLE2 185 PHF20L1 330 PBRM1 474 ERP44 
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41 JPH1 186 PTPN3 331 GXYLT2 475 COL4A1 
42 NAA30 187 ATF2 332 ADNP 476 NTF3 
43 FKBP5 188 EXOC5 333 RPS6KA3 477 FASLG 
44 PROSER1 189 AFTPH 334 PIK3R1 478 SOD3 
45 DDAH1 190 AGO2 335 EPM2A 479 CCL20 
46 SERPINI1 191 ZNF532 336 FIGN 480 DUSP10 
47 ARMCX3 192 PRRC1 337 TSNAX 481 DOCK4 
48 FAM20B 193 NT5C2 338 RAB6C 482 DOCK5 
49 SREK1 194 AKT2 339 LIFR 483 DOCK7 
50 SLC26A2 195 UGGT1 340 TRAPPC2 484 PIAS3 
51 PRKAB2 196 ACBD5 341 LYRM7 485 SP1 
52 AGGF1 197 STAG2 342 CALD1 486 NFKB1 
53 PIK3C2A 198 PRPF39 343 ATAD2B 487 ANP32A 
54 AHSA2 199 EIF2C4 344 SACM1L 488 SMARCA4 
55 IPP 200 TESK2 345 DOCK10 489 PPARA 
56 TMEM2 201 MAP3K1 346 BRCA1 490 SPRY4 
57 MYO9A 202 RAB6A 347 CYP4V2 491 TMEM147 
58 RAI14 203 PURA 348 ETNK1 492 OTUD1 
59 FBXL17 204 OLR1 349 ZNF667 493 PURG 
60 MRPS10 205 KLF9 350 YME1L1 494 CDK2AP1 
61 LAMP2 206 ATMIN 351 PPFIA4 495 CCR1 
62 MOXD1 207 ZYG11B 352 BCAT1 496 TNFAIP3 
63 CASC5 208 TLR4 353 ITSN2 497 PTX3 
64 TET1 209 VPS26A 354 MYCBP2 498 PLAT 
65 RHOQ 210 SLC31A1 355 MRAP2 499 ICAM1 
66 TUBGCP5 211 DLG1 356 PHTF1 500 IL1B 
67 FAXDC2 212 ATP11B 357 CKAP5 501 EGFR 
68 LARS 213 SNRK 358 PARP9 502 ANKRD46 
69 MDM4 214 PLD1 359 CNTRL 503 EIF4A2 
70 ARHGAP21 215 SOWAHC 360 CAPRIN1 504 ISCU 
71 CDK19 216 RSF1 361 NCSTN 505 MEF2C 
72 MUC1 217 CCDC14 362 SMNDC1 506 TIAM1 
73 THOC2 218 PREPL 363 MMP9 507 PPIF 
74 MAP3K2 219 SLC17A5 364 PPM1L 508 TP53BP2 
75 HERPUD2 220 SNX30 365 BCL2 509 TP63 
76 GNAQ 221 FMR1 366 CDC25A 510 TGFBR3 
77 CLCN5 222 MIB1 367 SCRN1 511 DAXX 
78 MKNK2 223 ARID4A 368 CCNG1 512 TOPORS 
79 GTF2I 224 BTBD3 369 PTPDC1 513 HNRNPK 
80 USP7 225 USP47 370 WWC2 514 JMY 
81 PHF17 226 ARHGEF12 371 TNFRSF11B 515 MSH2 
82 RASGRP3 227 PBX1 372 KAT6A 516 MSH6 
83 GAPVD1 228 APPL1 373 FERMT2 517 FOXO3 
84 ESYT2 229 OSBPL3 374 TNPO1 518 BMPR2 
85 TNS3 230 HOXA9 375 MEGF9 519 RASA1 
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86 MON2 231 REV1 376 WNK3 520 PCBP1 
87 ZRANB1 232 WNT5A 377 VASH2 521 SPATS2L 
88 RASEF 233 FBXL2 378 WHSC1L1 522 EIF2S1 
89 PKD2 234 VPS36 379 DCP1A 523 ERBB2 
90 MYEF2 235 RABGAP1 380 FILIP1L 524 TGIF1 
91 PAN3 236 PHACTR2 381 SLK 525 NCOA3 
92 PTAR1 237 SEMA5A 382 HMGB3 526 MYC 
93 SYNE2 238 MTMR9 383 CEP152 527 SETD1B 
94 ANKRD28 239 LIMCH1 384 GLG1 528 FGF12 
95 RSPRY1 240 NUBPL 385 B3GNT5 529 IL12A 
96 OSBPL1A 241 WNK1 386 TOR1AIP2 530 C1orf147 
97 IVNS1ABP 242 RUFY3 387 ALMS1 531 TCEANC2 
98 UTRN 243 SERAC1 388 NETO2 532 RFFL 
99 SRSF11 244 PER3 389 BDH2 533 SECISBP2L 
100 ASRGL1 245 ZNF587 390 SMC1A 534 NFIA 
101 RB1 246 ZNF292 391 PIGX 535 HIF1A 
102 EXOC8 247 DSE 392 SAR1A 536 RNF185 
103 SAMD5 248 AIM1 393 APC 537 SETD2 
104 COBLL1 249 TSHZ3 394 SLMAP 538 CXCL10 
105 PDGFD 250 SRPK2 395 ZBTB38 539 CLU 
106 PFKFB2 251 DCAF10 396 SOCS4 540 TNFRSF10B 
107 ACAT1 252 CEP97 397 FBXO11 541 PATE2 
108 BTBD7 253 PHF20 398 OSR1 542 SIRT2 
109 ZNF326 254 KIFAP3 399 RDH11 543 IGF1R 
110 WHSC1 255 SPG11 400 PELI1 544 ORC4 
111 MOAP1 256 MGA 401 RNF11 545 NAA50 
112 KLHL24 257 STXBP5 402 STAT3 546 MED9 
113 PHIP 258 PTPN14 403 YOD1 547 KRIT1 
114 PALLD 259 NKTR 404 WIBG 548 ITGB8 
115 BOC 260 AKAP9 405 WFS1 549 EPM2AIP1 
116 DAAM1 261 CORO2A 406 TM9SF3 550 GAS5 
117 C20orf194 262 TTC33 407 RTN4 551 RHO 
118 COL5A2 263 AUTS2 408 RPS7 552 NSUN2 
119 TPRG1L 264 NUFIP2 409 PLOD3 553 RNF111 
120 NIN 265 GRPEL2 410 PDHA2 554 RNF103 
121 PPAP2A 266 HS3ST3B1 411 NCAPG 555 SPPL3 
122 C2orf43 267 ELAVL4 412 DERL1 556 SGTB 
123 SGCB 268 ECI2 413 BASP1 557 SET 
124 FANCI 269 E2F3 414 JAG1 558 AP1AR 
125 EDIL3 270 ABCD3 415 REST 559 BNIP2 
126 LPGAT1 271 PKNOX1 416 SPRY2 560 BTN3A3 
127 NIPBL 272 RAB11FIP2 417 BCL6 561 CCR7 
128 DDHD2 273 LCORL 418 CBX4 562 CCL1 
129 DTX3L 274 PURB 419 EIF1AX 563 CENPQ 
130 IREB2 275 ST6GAL1 420 PITHD1 564 DICER1 
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131 MGAT4A 276 KLF5 421 COX20 565 DNAJC16 
132 BAZ1B 277 GPR64 422 C15orf52 566 BCL7A 
133 LIN7C 278 SKP2 423 HIC2 567 PLEKHA2 
134 VPS54 279 KLHDC5 424 GK5 568 GP5 
135 KIAA1715 280 NFAT5 425 FAM136A 569 FRS2 
136 TRIM38 281 FAM46A 426 TPM1 570 KLK2 
137 DDR2 282 RALGPS2 427 C8orf17 571 SATB1 
138 ZBTB8A 283 ZNF207 428 NFIB 572 WWP1 
139 CLOCK 284 SLC9A6 429 FOXN2 573 GDF5 
140 USP34 285 TNRC6B 430 LRRFIP1 574 VHL 
141 GNE 286 KBTBD6 431 MARCKS 575 MYD88 
142 AP3M1 287 MTMR12 432 TGFBI 576 IRAK1 
143 ZBTB47 288 TRIM59 433 PTEN 577 FBXL13 
144 MEF2A 289 SPTLC3 434 E2F1 578 SMN1 
145 HPGD 290 DDX55 
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Appendix table 5.7: List of genes regulated by hsa-miR-22-3p 
 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 TRAF3IP1 35 RCC2 69 CLPTM1L 103 TFRC 
2 ZNF662 36 BTN3A3 70 LBP 104 CYCS 
3 EFR3B 37 SLC2A1 71 FKBP5 105 HIF1A 
4 C5orf24 38 LONP2 72 ALMS1 106 LGALS1 
5 FRAT2 39 C1orf87 73 FUBP1 107 BSG 
6 RAB5B 40 TTC33 74 KCTD12 108 CSF1R 
7 H3F3B 41 INSIG1 75 RPS2 109 BMP6 
8 LRRC1 42 CAMK2N1 76 RPS4X 110 BMPR1B 
9 ZFYVE20 43 TMEM178B 77 RPL24 111 NET1 
10 TBC1D12 44 KCTD10 78 BUB1B 112 TNFRSF10D 
11 BTF3 45 BMP7 79 RPL35A 113 TPD52L2 
12 PRKACA 46 IFT140 80 VAPB 114 BTG1 
13 MAX 47 SRPK1 81 MYO6 115 TIAM1 
14 CSNK2A1 48 RBL1 82 PEX5 116 CTC1 
15 MIS18BP1 49 ESR1 83 SFXN1 117 BRWD3 
16 TBX3 50 PPARA 84 DNHD1 118 DDX6 
17 ARID5B 51 VSNL1 85 GLIS2 119 TMED4 
18 FOXP1 52 DCAF16 86 SPG11 120 PDIK1L 
19 CCNT2 53 CHD9 87 ELP5 121 LRRC20 
20 LEMD3 54 IRF5 88 HSPA1B 122 GINS2 
21 ZNF217 55 HMGB1 89 NUP214 123 YWHAZ 
22 SRSF7 56 SP1 90 RBM39 124 RAB44 
23 E2F2 57 RCOR1 91 RPSA 125 HDAC6 
24 PDHA1 58 PRELID2 92 STX4 126 WWC1 
25 SOGA1 59 C15orf40 93 PIGP 127 HNRNPA3 
26 TSC22D4 60 DDIT4 94 NCOA1 128 CYR61 
27 NR3C1 61 SERBP1 95 BDNF 129 ZNF646 
28 LIN7C 62 TMEM120B 96 HTR2C 130 RMND5A 
29 PIK3C2A 63 ERBB3 97 MAOA 131 WNT1 
30 EDC3 64 ARPC5 98 RGS2 132 CD151 
31 CDK6 65 PTMS 99 ACVR1C 133 TET2 
32 ZNF460 66 TCEAL1 100 SCD 134 CDKN1A 
33 VASN 67 PTEN 101 MYCBP 
  34 RAP2B 68 ZMAT5 102 HDAC4 
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Appendix table 5.8: List of genes regulated by hsa-miR-27b-3p 
 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 RBBP5 98 TMTC1 195 PLA2G2D 292 NRBP1 
2 DAZAP2 99 LMF2 196 MRPS27 293 UBE2D1 
3 CTNND1 100 TSR1 197 PNRC2 294 SGPL1 
4 CSRP2 101 TMEM19 198 DYNLL2 295 ALDOA 
5 TOPBP1 102 PRPF8 199 TMEM254 296 H3F3B 
6 TRUB2 103 UTP14A 200 ABHD17C 297 GNG12 
7 EIF5A2 104 HNRNPF 201 DCAF7 298 EIF5 
8 PKNOX1 105 UBA1 202 KIAA1551 299 NUDT21 
9 CELF1 106 CCND3 203 SPATA13 300 CCNK 
10 MAP1B 107 RPS24 204 AP3B2 301 DDI2 
11 ZNF384 108 KHDRBS1 205 PIGO 302 PLAGL2 
12 RUNX1 109 RAB3B 206 TSEN54 303 MYO1F 
13 LIFR 110 KIAA1211 207 NUS1 304 PISD 
14 RGS6 111 ATP7B 208 TROVE2 305 FAM84B 
15 H3F3C 112 BRAT1 209 NLN 306 SLC26A2 
16 DYRK3 113 GALNT11 210 JMY 307 TMTC3 
17 HOXD11 114 ZNF45 211 EN2 308 RNF139 
18 HOXB3 115 LRIG3 212 KCTD12 309 RNF38 
19 SOS1 116 BAZ2A 213 TARDBP 310 SEC24A 
20 ARL6IP1 117 C5orf51 214 HIST2H2AA3 311 SERTAD3 
21 FZD9 118 RPS15A 215 SRSF1 312 RYBP 
22 TNPO1 119 CALM3 216 KHSRP 313 SGMS1 
23 PAX7 120 UBXN1 217 OLR1 314 CHEK2 
24 ZNF238 121 BDNF-AS 218 ZBTB20 315 SMAD2 
25 USP25 122 NAA50 219 TMEM167A 316 SNX25 
26 HOXA10 123 BUB3 220 TGFBR1 317 TMSB10 
27 SPIB 124 MRPS14 221 CCNT1 318 NECAP1 
28 ADAMTS5 125 PEG10 222 PAX3 319 TPT1 
29 APEX1 126 PITHD1 223 CYP3A4 320 TRIM23 
30 PDHX 127 LDLR 224 VDR 321 UBE2G1 
31 PDIA5 128 SLC25A25 225 ERC1 322 UBR5 
32 APPBP2 129 AKIRIN1 226 AP3D1 323 WDFY1 
33 ALG9 130 FOXJ3 227 MANEA 324 ZFX 
34 ANKRD40 131 MED30 228 FAM217B 325 ZNF627 
35 AP1G1 132 KLHDC3 229 PAIP2 326 BTG2 
36 OTUD4 133 TAOK1 230 RAP1B 327 CFDP1 
37 PPIC 134 ARNTL 231 WEE1 328 ARL5B 
38 SETD1B 135 ZNF175 232 HRK 329 FBXO46 
39 SLC7A2 136 NR2F2 233 EYA4 330 SUCO 
40 NUFIP2 137 LYSMD3 234 EDNRA 331 ACER2 
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41 NRAS 138 LIN54 235 C6orf120 332 SEMA6A 
42 LFNG 139 TIMM10 236 C2orf44 333 ZNF460 
43 NOLC1 140 ICK 237 ZFP36L2 334 MPRIP 
44 NLK 141 HINT1 238 SFXN4 335 ZFP36 
45 NCBP2 142 TXNDC5 239 SFXN1 336 YIPF4 
46 CD2AP 143 ZNF618 240 CYP1B1 337 ZFHX3 
47 THOC3 144 KCTD14 241 TRAPPC2P1 338 TOMM40L 
48 LCOR 145 TMEM68 242 PPARG 339 ZNF106 
49 HNRNPA2B1 146 ITSN2 243 RREB1 340 SLC46A3 
50 DPF1 147 ITCH 244 ADORA2B 341 CREB1 
51 ANKRD2 148 LONRF1 245 SERP1 342 CDH6 
52 EML1 149 ZFP36L1 246 USP46 343 MFF 
53 POGZ 150 ZFP1 247 UGCG 344 PSAP 
54 MDH2 151 GPAM 248 MED13 345 ABCA1 
55 LAPTM4B 152 PPIF 249 ENDOU 346 RNF152 
56 ZMYND11 153 GSE1 250 BNIP3 347 SNRNP27 
57 CUL4B 154 GNPNAT1 251 CRISP2 348 GCSAM 
58 DUSP5 155 WNT9B 252 RMND5A 349 GLCCI1 
59 ZADH2 156 ZNF148 253 CCNYL1 350 IER3 
60 SLC5A6 157 RGPD4 254 LPIN1 351 HMGXB4 
61 CUL1 158 ADD1 255 CPPED1 352 GYS1 
62 HNRNPU 159 EFHD2 256 CAB39L 353 E2F7 
63 NOTCH2 160 HAT1 257 CNN3 354 ELMO1 
64 SLC25A5 161 WASL 258 DPYD 355 FARSA 
65 SEC16A 162 FAM136A 259 THBS1 356 FCHSD2 
66 ANKRD52 163 RAB14 260 SHC1 357 FEM1B 
67 INPPL1 164 PSPC1 261 THBS2 358 SZRD1 
68 TBC1D9 165 FAM73B 262 FOXO1 359 C2CD2L 
69 SNX19 166 FHL2 263 CELF2 360 CCNL2 
70 DDX17 167 FNDC3A 264 GTF2IRD2 361 CPEB4 
71 ZC3H11A 168 KIAA1009 265 TP53INP1 362 PREX1 
72 MTMR3 169 FOXN2 266 SLC25A44 363 ADAR 
73 SLC43A1 170 CARM1 267 SP1 364 ABL2 
74 PRR3 171 PMAIP1 268 PNKD 365 AFF4 
75 PAXBP1 172 TTC3 269 HLA-DRA 366 PLXND1 
76 MAPK9 173 CCNT2 270 TIGD2 367 PHLPP2 
77 C1orf74 174 NOTCH1 271 TMEM91 368 ATP5G3 
78 NPEPPS 175 ZNF800 272 UBXN11 369 NFE2L2 
79 RAPGEF1 176 ST14 273 TMED5 370 NF1 
80 SUPV3L1 177 MMP13 274 TGOLN2 371 KMT2C 
81 HIST2H3A 178 ELL2 275 TGFBR3 372 MIER3 
82 RGMB 179 ID4 276 KRTAP13-2 373 PGM2L1 
83 FASN 180 DYNC2LI1 277 GPATCH11 374 PHC2 
84 KIF1B 181 BMPR2 278 RET 375 PAK2 
85 GNB4 182 CAB39 279 PHB 376 NSD1 
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86 RPL19 183 AGPAT3 280 TOR2A 377 NUP133 
87 ATN1 184 PDK1 281 CCNA2 378 LBR 
88 SRCAP 185 EIF2S2 282 METTL8 379 DERL1 
89 SPAG9 186 SLC6A17 283 TP53INP2 380 MGEA5 
90 RPTOR 187 SMAD4 284 TMBIM6 381 LPCAT1 
91 CTSB 188 OSBPL10 285 MESDC1 382 LMNB2 
92 HIST1H1C 189 DCUN1D4 286 MKNK2 383 LRRC61 
93 CEP192 190 COASY 287 PROX2 384 MED14 
94 NDUFS6 191 HMGN1 288 BAG2 385 VEGFC 
95 DIAPH1 192 NR1D2 289 TXNIP 386 TSPYL1 
96 EHMT2 193 WNK1 290 NGFRAP1 
  97 C8orf4 194 KMT2A 291 NEURL1B 
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Appendix table 5.9: List of genes regulated by hsa-miR-205-5p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 KCTD20 43 DDX5 85 VEGFA 127 TRAF3IP1 
2 MAPK14 44 E2F1 86 BCL9L 128 SERTAD2 
3 TXNL1 45 E2F5 87 CREB1 129 TOLLIP 
4 SPDL1 46 ZEB2 88 SERINC3 130 TMEM55B 
5 TCF20 47 ERBB3 89 HMGB3 131 TMEM123 
6 RAN 48 PRKCE 90 SRD5A1 132 TAF11 
7 RGS6 49 SLC41A1 91 PTEN 133 AFF4 
8 HOXA11 50 SLC7A2 92 ESRRG 134 AFF1 
9 PAPPA-AS1 51 ZEB1 93 PRLR 135 B4GALT5 
10 PRR15 52 PHF8 94 ICK 136 B4GALT6 
11 ACTRT3 53 TMEM201 95 LOH12CR1 137 STK38L 
12 YES1 54 PTPRJ 96 SLC39A14 138 C1orf123 
13 SRC 55 ETNK1 97 BDP1 139 GUCD1 
14 NPRL3 56 XPR1 98 MMD 140 CDK6 
15 NFAT5 57 MRPL44 99 MGLL 141 CDKN2AIPNL 
16 XPOT 58 TM9SF2 100 LYN 142 CLIP1 
17 KCTD16 59 PAIP2B 101 LYSMD3 143 CUL5 
18 TMSB4X 60 NEK9 102 LRRC59 144 C6orf201 
19 PLCXD2 61 NOX5 103 LPCAT1 145 VTI1A 
20 TNFSF8 62 DMXL2 104 MARCKS 146 SLC5A12 
21 SLC25A25 63 ETF1 105 MED13 147 MAML2 
22 C11orf74 64 LAMC1 106 IPO7 148 MAP3K9 
23 GM2A 65 LRRK2 107 PHC2 149 NUDT21 
24 SMNDC1 66 SMIM13 108 PICALM 150 DNAJA1 
25 BAMBI 67 DHCR24 109 PLAGL2 151 CCDC108 
26 LCOR 68 RAB11FIP1 110 NDUFA4 152 SHISA6 
27 TMEM239 69 SLC38A1 111 NDUFB2 153 ACP1 
28 AMOT 70 ANGPTL7 112 NIPA2 154 BCL2 
29 CDK1 71 CTGF 113 NOTCH2 155 NCAPG 
30 SQLE 72 CYR61 114 PANK1 156 KLHL5 
31 CPEB3 73 TP73 115 PARD6B 157 ACSL4 
32 VPS52 74 EGLN2 116 TMEM66 158 BCL6 
33 JMJD1C 75 ERBB2 117 EZR 159 ITGA5 
34 NSF 76 PRRG4 118 ENPP4 160 ACSL1 
35 UBE2Z 77 F2RL2 119 LRRTM4 161 EID2B 
36 YWHAH 78 GOT1 120 KCNJ10 162 TEX35 
37 RBBP4 79 NUFIP2 121 PHLPP2 163 YY1 
38 LRP1 80 IL24 122 YEATS2 164 SMAD1 
39 IMPAD1 81 IL32 123 VAMP1 165 SMAD4 
40 GNAS 82 RNF217 124 RTN3 166 PTPRM 
41 MED1 83 ZNF585B 125 RFX7 167 AR 
42 INPPL1 84 SIGMAR1 126 RAP2B 168 PHF12 
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Appendix table 5.10: List of genes regulated by hsa-miR-92a-1-3p 
 
ID Gene symbol ID Gene symbol ID Gene symbol ID 
Gene 
symbol 
1 ATP6AP1 18 SERINC1 35 TP53 52 GTPBP4 
2 STARD8 19 TJAP1 36 BAK1 53 OPHN1 
3 HOXD13 20 FAS 37 HAND1 54 RPL29 
4 PPP1R12B 21 CREB5 38 KRTAP4-2 55 CIAPIN1 
5 AGO2 22 RFX1 39 POGK 56 ZWINT 
6 LZIC 23 MTHFD1L 40 STEAP3 57 MYC 
7 PTPN14 24 SETD1B 41 TMEM134 58 MRPS11 
8 ARL5B 25 MAZ 42 IQSEC1 59 SLC2A4 
9 HDGF 26 PPP2CA 43 FAM210A 60 PLK1 
10 NKAP 27 CISH 44 RAD51 61 TUBB 
11 MARK2 28 TNFRSF12A 45 PRKAR2A 62 SCAMP3 
12 PPP6R1 29 ZFP30 46 CSTF2 63 TMED10 
13 GTF2A1 30 FAM20B 47 UBB 64 UBE2S 
14 ABHD14A-ACY1 31 BCL11A 48 CACNA2D3 65 DPM2 
15 ACY1 32 UNC5B 49 EEF2 
  16 HIST1H3D 33 PTEN 50 MBLAC2 
  17 BZW1 34 HNRNPUL1 51 DPYSL5 
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Appendix table 5.11: List of genes regulated by hsa-miR-143-3p 
 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 CSRNP2 41 SAMD8 81 PTGS2 121 RPS27 
2 YARS 42 DBT 82 SPTLC2 122 RUNDC1 
3 GALNT6 43 ADAMTS4 83 PAPPA 123 THAP1 
4 MYO6 44 TRIM71 84 PRRC2B 124 C2orf18 
5 KRAS 45 ZNF264 85 CMPK1 125 ZNF440 
6 DNMT3A 46 RRP7A 86 FSCN1 126 C1orf61 
7 TTC38 47 PPP2R5E 87 HRAS 127 DCTN6 
8 CENPP 48 SLC30A9 88 RER1 128 HNF4A 
9 RAB33B 49 MIER3 89 CALM3 129 C1orf50 
10 SFT2D2 50 ZNF277 90 XIAP 130 ENO4 
11 NFYB 51 RPS19 91 COX2 131 OAS3 
12 LRAT 52 MAPK7 92 SECISBP2L 132 PLEKHM3 
13 RBM27 53 FNDC3B 93 COL1A1 133 NUDT3 
14 C2orf15 54 IGFBP5 94 MYCBP 134 GGA2 
15 CREG2 55 GLUL 95 PRR23A 135 ABAT 
16 NFIC 56 HAAO 96 TNF 136 ADH5 
17 NCKAP1 57 IL10RB 97 NR2C2 137 SDC1 
18 USP42 58 SYT7 98 PLEKHA1 138 NAPEPLD 
19 MMP13 59 ELP2 99 NPR1 139 TUBB2A 
20 IER5 60 AKT1 100 UCK2 140 LRIT3 
21 BBC3 61 STOX2 101 KAT7 141 CASP5 
22 PNPO 62 SGPL1 102 IL13RA1 142 OR7D2 
23 COMMD2 63 MYPN 103 YWHAB 143 CTNND1 
24 GJD2 64 SLC2A14 104 DYT10 144 SMAD3 
25 CERS4 65 SLC25A25 105 COL3A1 145 COL5A2 
26 PPIL4 66 FAXC 106 DDX6 146 ERBB3 
27 HYPK 67 FAM120AOS 107 LIMK1 147 PDGFRA 
28 SKAP2 68 BCL2 108 ORAI2 148 MAP3K7 
29 ACOT9 69 MDM2 109 FSD2 149 CHST10 
30 PGLS 70 FAM71F2 110 CCR6 150 MAPK1 
31 BTF3L4 71 VOPP1 111 FGD6 151 COL5A1 
32 ZBTB44 72 TAF1D 112 PHAX 152 RREB1 
33 RAB22A 73 JAG1 113 SLC25A33 153 BRAF 
34 KLK10 74 ZNF607 114 UBE2V2 154 KLF5 
35 TIMM8A 75 ANKRD9 115 GTF2H5 155 CD44 
36 TFPI 76 ZNF573 116 SLC25A16 156 GLRA3 
37 ZC3HAV1L 77 FHIT 117 LRRC2 157 IGF1R 
38 NUBPL 78 SERPINE1 118 ZNF429 
  39 SCN2B 79 HK2 119 IKZF3 
  40 GXYLT1 80 MACC1 120 KIAA0930 
   
 332 Appendices 
Appendix table 5.12: List of genes regulated by hsa-miR-203a-3p 
 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 GATA6 72 RNF141 143 TNF 214 NARS 
2 ARPP19 73 EXOC2 144 SOCS6 215 TMPPE 
3 EXT1 74 WHSC1L1 145 IL24 216 NPPC 
4 DDX3Y 75 FLYWCH2 146 SEC63 217 TSR1 
5 TOR1AIP2 76 GLRX2 147 PRR14L 218 TRPS1 
6 SEMA3D 77 MXRA7 148 DGAT2 219 TRMT5 
7 PDCD10 78 KIAA0408 149 ZUFSP 220 SNAI1 
8 NCL 79 SH3BP4 150 ZNF704 221 NKX2-1 
9 DHX33 80 PI4K2B 151 BIRC5 222 THRAP3 
10 SMAD2 81 PIP5K1A 152 ZNF148 223 TBCEL 
11 DYRK3 82 TOP2A 153 E2F3 224 HNRPDL 
12 SCO1 83 VGLL4 154 PCGF6 225 DAZAP2 
13 KLHL28 84 C15ORF48 155 SLC23A1 226 MTPN 
14 TRIM71 85 CDC42SE2 156 CREB1 227 LCOR 
15 G6PC 86 LCLAT1 157 LINC00598 228 MAPK8 
16 SLAIN2 87 FBXW7 158 TJP2 229 RAPGEF1 
17 C6orf223 88 FOXK2 159 TSC22D2 230 SUMO1 
18 CDH7 89 SON 160 HELZ 231 CLPTM1L 
19 ARID2 90 UVRAG 161 GINS4 232 FOXN3 
20 PIM3 91 GPCPD1 162 CYP20A1 233 CPEB4 
21 PRICKLE2 92 ANP32A 163 KIF1C 234 DLC1 
22 CAND1 93 PARK7 164 PARD6B 235 ARID1A 
23 CALR 94 ABL1 165 MCM9 236 CCSAP 
24 DSCR3 95 IGFBP5 166 GSTO2 237 CCR5 
25 EN2 96 SMCHD1 167 SPATA18 238 GNAS 
26 MAFK 97 FBXL3 168 TRIM4 239 HECTD1 
27 ANKRD13B 98 KIF5B 169 AKT2 240 FRK 
28 KIF13A 99 UBXN2A 170 MMP1 241 SRGAP1 
29 NR2F2 100 MCTP1 171 IL6 242 SLC12A5 
30 PPP1CB 101 ATM 172 DLX5 243 LIFR 
31 FGFR1OP 102 ZNF367 173 E2F1 244 POLR1B 
32 NETO2 103 ZNF652 174 MMP10 245 CERKL 
33 PAX6 104 SNX4 175 RUNX2 246 ARHGEF28 
34 RLIM 105 NUFIP2 176 SMAD4 247 CDKL2 
35 CELF2 106 HEXIM1 177 BMI1 248 NCOA4 
36 LDHA 107 SERTAD3 178 ZEB2 249 LASP1 
37 HNRNPR 108 RMND5A 179 IGF1R 250 JUN 
38 COX20 109 ROCK2 180 PPM1D 251 TRIML2 
39 PRKACB 110 DNTTIP2 181 GDAP1 252 GREM1 
40 ENAH 111 RGS17 182 EDNRA 253 MIDN 
41 PRAMEF7 112 NCALD 183 EYA4 254 HOXA1 
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42 PRAMEF8 113 MAPK9 184 BCL2L2 255 FBXL5 
43 MAR3 114 GABRB1 185 RNF41 256 PDE7A 
44 FYCO1 115 GLIS3 186 LCE1A 257 DUSP5 
45 GAS1 116 PRNP 187 RGL2 258 PLD2 
46 OIT3 117 SOD2 188 GXYLT2 259 ZNF24 
47 MSI2 118 MRO 189 LOH12CR2 260 SIX1 
48 CNNM4 119 CBLL1 190 BMPR1A 261 RAN 
49 SH3GLB1 120 MYD88 191 FAM208A 262 RAPH1 
50 SMURF2 121 SLC44A1 192 UFL1 263 CAV1 
51 ZMYM2 122 SNAI2 193 SZRD1 264 ASAP1 
52 TMEM70 123 GPR156 194 PM20D2 265 VEGFA 
53 ZNF654 124 ZNF451 195 IPMK 266 PRKCA 
54 ZBED3 125 DNAJB6 196 EGLN1 267 FOXK1 
55 SYK 126 CLOCK 197 ABCE1 268 BCL11B 
56 ZNF268 127 CNNM3 198 CDK6 269 BCL7A 
57 SLC39A9 128 ACVR2B 199 SOCS3 270 SMAD9 
58 BTG1 129 WDR77 200 TP63 271 ZEB1 
59 HTR2A 130 TMEM97 201 CADM2 272 RASAL2 
60 ARID3B 131 TRNT1 202 HEPHL1 273 MAP3K13 
61 FMNL2 132 NUDCD1 203 PIK3CA 274 NFYA 
62 SYNM 133 ASPA 204 MBNL1 275 JMY 
63 SPATA13 134 ZCCHC11 205 IFIT1 276 TCF4 
64 KCNJ2 135 DYNLT1 206 ALOX15 277 SRC 
65 BOLA3 136 TPD52L1 207 SERINC1 278 OSBP 
66 NUP50 137 CUL3 208 KIF2A 279 CASK 
67 NAA30 138 IL7 209 HOMEZ 280 CIT 
68 KLHL15 139 RASA2 210 C20orf24 281 CXXC4 
69 ZWINT 140 PEAR1 211 IPO7 282 DNAAF2 
70 GXYLT1 141 STOM 212 RAP2B 
  71 SLC45A4 142 ZNF200 213 PSAT1 
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Appendix table 5.13: List of genes regulated by a pairwise of miRNAs  
 
hsa-miR-181a-1-5p and hsa-miR-21-5p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 AFTPH 16 KLHDC5 31 PHACTR2 46 SEPT2 
2 BCL2 17 KLHL15 32 PTBP3 47 TBL1XR1 
3 BMPR2 18 KLHL24 33 PTPDC1 48 TCF21 
4 BRCA1 19 LPGAT1 34 PURB 49 TGFBR3 
5 BTBD3 20 MPP5 35 RNF6 50 TM9SF3 
6 CBX4 21 MTMR12 36 RP2 51 TNFRSF11B 
7 CCNG1 22 NAA50 37 RPS6KA3 52 TNPO1 
8 CSNK1A1 23 NCAPG 38 RSF1 53 TNRC6B 
9 DDX3X 24 NCOA3 39 SASH1 54 TRIM2 
10 DYNC1LI2 25 NIN 40 SOX5 55 WHSC1 
11 ENAH 26 OSBPL3 41 SPRY2 56 YOD1 
12 FAM3C 27 OTUD1 42 SPTLC3 57 ZADH2 
13 FBXO11 28 PBRM1 43 SRPK2 58 ZNF35 
14 GK5 29 PER2 44 STAG2 59 ZNF667 
15 KIAA1551 30 PFKFB2 45 STAT3 
  
 hsa-miR-181a-1-5p and hsa-miR-22-3p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 CHD9 4 HDAC6 7 SCD 10 TMED4 
2 DDIT4 5 HSPA1B 8 SRSF7 
  3 H3F3B 6 RCOR1 9 TFRC 
  
 hsa-miR-181a-1-5p and hsa-miR-27-3p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 AFF4 12 FAM73B 23 MRPS14 34 SMAD2 
2 BAG2 13 H3F3B 24 MTMR3 35 TGFBR1 
3 BAZ2A 14 ID4 25 NAA50 36 TGFBR3 
4 BMPR2 15 KIAA1551 26 NLK 37 TNPO1 
5 CARM1 16 LAPTM4B 27 NOTCH1 38 TOPBP1 
6 CCNK 17 LBR 28 NOTCH2 39 ZADH2 
7 CPEB4 18 LDLR 29 PMAIP1 40 ZFP36L1 
8 DAZAP2 19 LFNG 30 PNKD 41 ZFP36L2 
9 DUSP5 20 LONRF1 31 PNRC2 42 ZNF148 
10 EN2 21 LPCAT1 32 RAP1B 
  11 EYA4 22 LYSMD3 33 SLC25A25 
  
 hsa-miR-181a-1-5p and hsa-miR-205-5p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 AFF4 5 GOT1 9 NOTCH2 13 ZEB2 
2 BCL2 6 LPCAT1 10 PRLR 
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3 CUL5 7 LYSMD3 11 RAN 
  4 E2F5 8 NCAPG 12 SLC25A25 
  
 hsa-miR-21-5p and hsa-miR-205-5p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 BCL2 5 E2F1 9 MARCKS 13 PRKCE 
2 BCL6 6 ERBB2 10 NCAPG 14 PTEN 
3 CDK6 7 ETNK1 11 NFAT5 15 SMNDC1 
4 CPEB3 8 HMGB3 12 NUFIP2 16 VEGFA 
 hsa-miR-22-3p and hsa-miR-205-5p 
ID Gene symbol ID Gene symbol ID Gene symbol 
 1 CDK6 3 ERBB3 5 RAP2B 
 2 CYR61 4 PTEN 6 TRAF3IP1 
 
 hsa-miR-27b-3p and hsa-miR-205-5p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 AFF4 6 LPCAT1 11 NUFIP2 16 SLC25A25 
2 CREB1 7 LYSMD3 12 PHC2 17 SLC7A2 
3 ICK 8 MED13 13 PHLPP2 18 SMAD4 
4 INPPL1 9 NOTCH2 14 PLAGL2 
  5 LCOR 10 NUDT21 15 RGS6 
  
 hsa-miR-27b-3p and hsa-miR-21-5p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 BMPR2 10 GPAM 19 PITHD1 28 TNPO1 
2 BTG2 11 ITSN2 20 PKNOX1 29 UBR5 
3 DERL1 12 JMY 21 PPIF 30 WNK1 
4 EIF5 13 KIAA1551 22 RMND5A 31 ZADH2 
5 FAM136A 14 LIFR 23 SETD1B 32 ZBTB20 
6 FAM217B 15 MKNK2 24 SFXN1 33 ZNF460 
7 FOXN2 16 NAA50 25 SLC26A2 34 KIAA1551 
8 GLCCI1 17 NUFIP2 26 SP1 
  9 GNB4 18 OLR1 27 TGFBR3 
  
 hsa-miR-27b-3p and hsa-miR-22-3p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 CCNT2 3 KCTD12 5 SFXN1 7 ZNF460 
2 H3F3B 4 RMND5A 6 SP1 
  
 hsa-miR-21-5p and hsa-miR-22-3p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 ALMS1 6 FUBP1 11 PTEN 16 TIAM1 
2 BTN3A3 7 HIF1A 12 RMND5A 17 TTC33 
3 CDK6 8 LIN7C 13 SFXN1 18 ZNF217 
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4 E2F2 9 PIK3C2A 14 SP1 19 ZNF460 
5 FKBP5 10 PPARA 15 SPG11 
  
 hsa-miR-92a-1-3p and hsa-miR-22-3p 
ID Gene symbol 
     1 PTEN 
     
 hsa-miR-92a-1-3p and hsa-miR-21-5p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 AGO2 3 FAS 5 MYC 7 PTPN14 
2 FAM20B 4 GTF2A1 6 PTEN 8 SETD1B 
 hsa-miR-92a-1-3p and hsa-miR-27b-3p 
ID Gene symbol ID Gene symbol 
   1 ARL5B 2 SETD1B 
   
 hsa-miR-92a-1-3p and hsa-miR-205-5p 
ID Gene symbol 
     1 PTEN 
     
 hsa-miR-21-5p and hsa-miR-143-3p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 COL5A2 4 BCL2 7 NUBPL 10 IGF1R 
2 KLF5 5 PLEKHA1 8 SECISBP2L 
  3 NR2C2 6 RAB22A 9 JAG1 
  
 hsa-miR-22-3p and hsa-miR-143-3p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 MYO6 2 ERBB3 3 MYCBP 4 DDX6 
 hsa-miR-27b-3p and hsa-miR-143-3p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 MMP13 3 CTNND1 5 MIER3 7 SLC25A25 
2 CALM3 4 SGPL1 6 RREB1 
  
 hsa-miR-203a-3p and hsa-miR-143-3p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 TRIM71 3 GXYLT1 4 IGFBP5 5 TNF 
2 IGF1R 
      
 hsa-miR-203a-3p and hsa-miR-21-5p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 AKT2 11 ENAH 20 MTPN 29 RMND5A 
2 ANP32A 12 FOXN3 21 MYD88 30 SEC63 
3 BCL7A 13 GXYLT2 22 NAA30 31 SFXN1 
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4 CDK6 14 HECTD1 23 NETO2 32 SLAIN2 
5 CLOCK 15 JMY 24 NUFIP2 33 SP1 
6 COX20 16 KLHL15 25 PM20D2 34 TOP2A 
7 E2F1 17 LIFR 26 PRICKLE2 35 TOR1AIP2 
8 E2F3 18 MBNL1 27 RAPH1 36 TP63 
9 VEGFA 19 WHSC1L1 28 ZMYM2 37 ZNF367 
10 ZNF460 
      
 hsa-miR-203a-3p and hsa-miR-22-3p 
ID Gene symbol ID Gene symbol ID Gene symbol 
 1 CLPTM1L 3 BTG1 5 RMND5A 
 2 RAP2B 4 CDK6 
   
 hsa-miR-203a-3p and hsa-miR-27b-3p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 EYA4 7 SMAD2 13 DAZAP2 19 NR2F2 
2 CPEB4 8 TSR1 14 EN2 20 SMAD4 
3 RAPGEF1 9 DYRK3 15 DUSP5 21 NUFIP2 
4 LCOR 10 ZNF148 16 SZRD1 22 LIFR 
5 SERTAD3 11 CREB1 17 EDNRA 23 JMY 
6 SPATA13 12 CELF2 18 MAPK9 24 RMND5A 
 hsa-miR-203a-3p and hsa-miR-205-5p 
ID Gene symbol ID Gene symbol ID Gene symbol ID Gene symbol 
1 CDK6 5 IL24 9 PARD6B 13 SRC 
2 CREB1 6 IPO7 10 RAN 14 VEGFA 
3 E2F1 7 LCOR 11 RAP2B 15 ZEB1 
4 GNAS 8 NUFIP2 12 SMAD4 16 ZEB2 
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Appendix table 6.1: Calculation of the protein amount to exosome number used 
for treatment on fibroblast. 
 
HaCaT Primary keratinocytes 
Amount of protein  Exosome number Amount of protein Exosome number 
1 µg 57803.46821 1 µg 238095.2381 
10 µg 578034.6821 10 µg 2380952.381 
20 µg 1156069.364 20 µg 4761904.762 
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